,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,75070,3767,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,75070,3767,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,75070,3767,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,75070,3767,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,75070,3767,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,75070,3767,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,179,1,1,,75070,3767,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
7,180,1,1,,75070,3767,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
8,192,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
9,194,1,1,,75070,3767,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
10,200,1,1,,75070,3767,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
11,210,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
12,212,1,1,,75070,3767,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
13,220,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
14,222,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in C57BL/6 mice,Other,,
15,228,1,1,,75070,3767,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Friend Virus Leukemia (Solid) (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
16,248,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
17,278,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  A549 Human Adenocarcinoma of Lung with characteristics of Type II Alveolar Epithelial cells (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
18,280,1,1,,75070,3767,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Amelanotic Melanoma (LOX) (intraperitoneal) in NU/NU BALB/C (nude) mice,Other,,
19,292,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6C3F1 mice,Other,,
20,298,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
21,302,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Madison 109 Lung Carcinoma (intramuscular) in BALB/CM mice,Other,,
22,328,1,1,,75070,3767,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
23,330,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
24,342,1,1,,75070,3767,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
25,357,2,1,,855769,3767,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
26,357,2,1,,11112128,3767,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
27,361,1,2,,855769,3767,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
28,364,1,3,,855769,3767,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
29,368,2,3,,855769,3767,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
30,371,1,1,,855769,3767,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
31,373,1,4,,855769,3767,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
32,374,2,3,,855769,3767,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
33,375,2,3,,855769,3767,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
34,377,1,3,,10321551,3767,Active,42741659.0,5243.0,,,MDR-1,Other,,
35,410,1,5,,11112128,3767,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
36,411,2,1,,855769,3767,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
37,411,2,1,,11112128,3767,Inconclusive,160794.0,,5.0119,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
38,421,1,3,,17389848,3767,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
39,422,1,5,,855769,3767,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
40,425,3,2,,855769,3767,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
41,426,1,2,,17389848,3767,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
42,427,1,1,,17389848,3767,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
43,429,1,5,,855769,3767,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
44,429,1,5,,855769,3767,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
45,430,2,4,,855769,3767,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
46,431,2,4,,855769,3767,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
47,432,2,4,,855769,3767,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
48,433,1,1,,17389848,3767,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
49,434,1,2,,17389848,3767,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
50,435,1,2,,17389848,3767,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
51,436,2,1,,855769,3767,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
52,438,1,4,,855769,3767,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
53,440,3,3,,855769,3767,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
54,441,3,3,,855769,3767,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
55,444,1,1,,855769,3767,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
56,444,1,1,,11112128,3767,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
57,445,3,1,,11112128,3767,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
58,445,3,1,,17389848,3767,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
59,446,1,1,,855769,3767,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
60,446,1,1,,11112128,3767,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
61,447,1,1,,11112128,3767,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
62,448,1,2,,11112128,3767,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
63,449,1,5,,855769,3767,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
64,450,1,2,,855769,3767,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
65,450,1,2,,11112128,3767,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
66,451,1,2,,11112128,3767,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
67,453,2,2,,855769,3767,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
68,454,1,7,,855769,3767,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
69,455,1,7,,855769,3767,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
70,456,1,7,,855769,3767,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
71,457,1,7,,855769,3767,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
72,460,2,2,,855769,3767,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
73,483,1,6,,855769,3767,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
74,485,1,8,,855769,3767,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
75,487,1,2,,855769,3767,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
76,488,2,1,,855769,3767,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
77,501,2,2,,855769,3767,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
78,518,2,6,,855769,3767,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
79,521,2,5,,855769,3767,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
80,522,1,2,,855769,3767,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
81,524,1,3,,855769,3767,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
82,525,1,3,,855769,3767,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
83,526,1,1,,11112128,3767,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
84,527,3,1,,855769,3767,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
85,528,1,4,,855769,3767,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
86,529,1,4,,855769,3767,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
87,530,1,1,,11112128,3767,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
88,530,1,1,,17389848,3767,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
89,538,2,2,,855769,3767,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
90,539,1,2,,855769,3767,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
91,540,1,1,,17389848,3767,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
92,541,1,1,,17389848,3767,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
93,542,1,1,,17389848,3767,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
94,543,1,1,,17389848,3767,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
95,544,2,1,,17389848,3767,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
96,545,1,1,,17389848,3767,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
97,546,1,1,,17389848,3767,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
98,552,1,3,,855769,3767,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
99,555,1,2,,855769,3767,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
100,556,1,3,,855769,3767,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
101,559,2,2,,855769,3767,Inactive,147728.0,,,,RNA polymerase,Screening,,
102,560,1,2,,855769,3767,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
103,561,1,3,,855769,3767,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
104,565,1,4,,855769,3767,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
105,567,1,4,,855769,3767,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
106,568,1,7,,855769,3767,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
107,568,1,7,,855769,3767,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
108,570,1,4,,855769,3767,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
109,571,1,4,,855769,3767,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
110,572,1,5,,855769,3767,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
111,573,1,4,,855769,3767,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
112,574,1,3,,855769,3767,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
113,575,1,4,,855769,3767,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
114,576,1,2,,855769,3767,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
115,577,1,1,,855769,3767,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
116,580,1,5,,855769,3767,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
117,581,2,2,,855769,3767,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
118,583,2,6,,855769,3767,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
119,584,1,3,,11112128,3767,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
120,584,1,3,,17389848,3767,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
121,585,1,4,,11112128,3767,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
122,585,1,4,,17389848,3767,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
123,587,1,5,,855769,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
124,587,1,5,,11112128,3767,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
125,588,1,4,,855769,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
126,588,1,4,,11112128,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
127,589,1,3,,855769,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
128,589,1,3,,11112128,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
129,590,1,3,,855769,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
130,590,1,3,,11112128,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
131,591,1,4,,855769,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
132,591,1,4,,11112128,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
133,592,1,6,,855769,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
134,592,1,6,,11112128,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
135,593,1,4,,855769,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
136,593,1,4,,11112128,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
137,594,1,4,,855769,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
138,594,1,4,,11112128,3767,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
139,595,1,3,,11112128,3767,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
140,595,1,3,,17389848,3767,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
141,596,1,2,,11112128,3767,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
142,596,1,2,,17389848,3767,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
143,597,1,3,,855769,3767,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
144,597,1,3,,11112128,3767,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
145,598,1,4,,855769,3767,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
146,601,1,4,,855769,3767,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
147,602,1,4,,855769,3767,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
148,603,1,2,,11112128,3767,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
149,603,1,2,,17389848,3767,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
150,604,1,3,,855769,3767,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
151,605,1,2,,11112128,3767,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
152,605,1,2,,17389848,3767,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
153,606,1,3,,855769,3767,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
154,606,1,3,,855769,3767,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
155,607,1,3,,11112128,3767,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
156,609,1,2,,855769,3767,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
157,614,1,6,,855769,3767,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
158,615,1,6,,855769,3767,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
159,618,2,6,,855769,3767,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
160,620,2,5,,855769,3767,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
161,622,1,2,,855769,3767,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
162,623,1,3,,855769,3767,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
163,624,1,2,,855769,3767,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
164,625,1,2,,855769,3767,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
165,626,1,3,,855769,3767,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
166,628,2,4,,855769,3767,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
167,629,1,3,,855769,3767,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
168,630,1,1,,855769,3767,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
169,631,1,4,,855769,3767,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
170,631,1,4,,855769,3767,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
171,633,1,3,,855769,3767,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
172,636,1,4,,855769,3767,Inactive,,,,,Modulators of Post-Golgi Transport - 384-well pilot screen,Screening,,
173,637,1,4,,855769,3767,Inactive,,,,,Modulators of Post-Golgi Transport - 1536-well pilot screen,Screening,,
174,639,1,2,,855769,3767,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
175,641,1,4,,855769,3767,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
176,645,1,4,,855769,3767,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
177,648,1,3,,855769,3767,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
178,654,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
179,655,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
180,656,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
181,657,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
182,658,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
183,659,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
184,660,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
185,661,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
186,662,1,1,,11112128,3767,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
187,662,1,1,,17389848,3767,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
188,663,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
189,664,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
190,665,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
191,666,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
192,667,1,1,,17389848,3767,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
193,680,1,10,,855769,3767,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
194,684,1,12,,855769,3767,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
195,686,1,1,,855769,3767,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
196,687,1,17,,855769,3767,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
197,701,1,17,,855769,3767,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
198,708,1,4,,855769,3767,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
199,709,1,2,,855769,3767,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
200,719,1,3,,855769,3767,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
201,731,1,5,,855769,3767,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
202,731,1,5,,855769,3767,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
203,746,1,1,,855769,3767,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
204,750,1,3,,855769,3767,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
205,751,1,3,,855769,3767,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
206,757,1,4,,855769,3767,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
207,758,1,4,,855769,3767,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
208,759,1,4,,855769,3767,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
209,760,1,4,,855769,3767,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
210,761,1,4,,855769,3767,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
211,764,1,4,,855769,3767,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
212,770,1,1,,855769,3767,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
213,771,1,2,,855769,3767,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
214,772,1,2,,855769,3767,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
215,774,1,2,,855769,3767,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
216,775,1,3,,855769,3767,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
217,781,1,1,,855769,3767,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
218,782,1,2,,855769,3767,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
219,782,1,2,,855769,3767,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
220,784,1,4,,855769,3767,Inactive,55584151.0,2629.0,,,Primary Cell Based High Throughput Screening Assay for Enhancers of Beta-Glucosidase Activity,Screening,,
221,793,1,2,,855769,3767,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
222,795,1,1,,855769,3767,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
223,797,1,1,,855769,3767,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
224,798,2,12,,855769,3767,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
225,799,1,5,,855769,3767,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
226,800,2,11,,855769,3767,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
227,803,1,4,,855769,3767,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
228,804,1,3,,855769,3767,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
229,813,1,4,,855769,3767,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
230,817,1,1,,855769,3767,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
231,818,1,2,,855769,3767,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
232,827,1,2,,855769,3767,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
233,828,1,5,,855769,3767,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
234,834,1,3,,855769,3767,Inactive,,,,,C. albicans biofilm killing,Screening,,
235,841,1,1,,855769,3767,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
236,847,1,2,,855769,3767,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
237,861,1,1,,855769,3767,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
238,862,1,2,,855769,3767,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
239,868,1,3,,855769,3767,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
240,871,1,2,,855769,3767,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
241,873,1,13,,855769,3767,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
242,875,1,2,,11112128,3767,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
243,875,1,2,,17389848,3767,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
244,878,1,2,,855769,3767,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
245,880,2,1,,855769,3767,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
246,880,2,1,,855769,3767,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
247,880,2,1,,11112128,3767,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
248,880,2,1,,11112128,3767,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
249,880,2,1,,17389848,3767,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
250,880,2,1,,17389848,3767,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
251,880,2,1,,26746988,3767,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
252,880,2,1,,26746988,3767,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
253,880,2,1,,26751504,3767,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
254,880,2,1,,26751504,3767,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
255,881,2,2,,11112128,3767,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
256,881,2,2,,17389848,3767,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
257,883,1,3,,11112128,3767,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
258,884,1,2,,11112128,3767,Active,13435386.0,1576.0,3.9811,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
259,884,1,2,,17389848,3767,Active,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
260,885,1,2,,11112128,3767,Inactive,13435386.0,1576.0,3.9811,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
261,885,1,2,,17389848,3767,Inactive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
262,886,1,2,,11112128,3767,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
263,886,1,2,,11112128,3767,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
264,886,1,2,,17389848,3767,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
265,886,1,2,,17389848,3767,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
266,887,1,2,,11112128,3767,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
267,887,1,2,,17389848,3767,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
268,889,1,3,,11112128,3767,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
269,889,1,3,,17389848,3767,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
270,891,1,2,,11112128,3767,Inconclusive,40805836.0,1565.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
271,892,1,2,,11112128,3767,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
272,892,1,2,,17389848,3767,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
273,893,1,2,,11112128,3767,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
274,893,1,2,,11112128,3767,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
275,893,1,2,,17389848,3767,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
276,893,1,2,,17389848,3767,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
277,894,2,1,,855769,3767,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
278,894,2,1,,11112128,3767,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
279,894,2,1,,17389848,3767,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
280,894,2,1,,26746988,3767,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
281,898,1,1,,855769,3767,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
282,899,1,2,,11112128,3767,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
283,900,1,3,,11112128,3767,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
284,900,1,3,,17389848,3767,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
285,901,1,2,,11112128,3767,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
286,902,1,2,,11112128,3767,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
287,902,1,2,,17389848,3767,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
288,910,1,2,,17389848,3767,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
289,912,1,2,,11112128,3767,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
290,912,1,2,,17389848,3767,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
291,914,1,3,,855769,3767,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
292,914,1,3,,11112128,3767,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
293,915,1,3,,855769,3767,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
294,915,1,3,,11112128,3767,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
295,920,1,2,,855769,3767,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
296,921,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
297,923,1,2,,11112128,3767,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
298,923,1,2,,17389848,3767,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
299,924,1,2,,11112128,3767,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
300,924,1,2,,17389848,3767,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
301,925,1,2,,11112128,3767,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
302,925,1,2,,17389848,3767,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
303,926,1,2,,11112128,3767,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
304,926,1,2,,17389848,3767,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
305,927,1,3,,11112128,3767,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
306,927,1,3,,17389848,3767,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
307,930,1,2,,17389848,3767,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
308,932,1,4,,855769,3767,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
309,938,1,2,,11112128,3767,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
310,938,1,2,,17389848,3767,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
311,940,1,2,,855769,3767,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
312,940,1,2,,26611787,3767,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
313,946,1,2,,17389848,3767,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
314,947,1,2,,17389848,3767,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
315,948,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
316,950,1,1,,855769,3767,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
317,951,1,1,,855769,3767,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
318,952,1,1,,855769,3767,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
319,955,1,2,,17389848,3767,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
320,960,1,2,,17389848,3767,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
321,961,1,2,,17389848,3767,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
322,962,1,2,,17389848,3767,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
323,963,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
324,964,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
325,965,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
326,966,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
327,967,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
328,968,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
329,969,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
330,970,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
331,971,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
332,972,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
333,973,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
334,974,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
335,975,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
336,976,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
337,977,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
338,978,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
339,979,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
340,980,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
341,981,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
342,982,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
343,983,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
344,984,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
345,985,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
346,986,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
347,987,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
348,988,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
349,989,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
350,993,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
351,994,1,2,,17389848,3767,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
352,995,1,2,,11112128,3767,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
353,995,1,2,,17389848,3767,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
354,1001,2,2,,855769,3767,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
355,1006,1,6,,855769,3767,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
356,1007,1,1,,855769,3767,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
357,1008,1,2,,855769,3767,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
358,1009,1,2,,855769,3767,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
359,1012,1,4,,855769,3767,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
360,1016,1,4,,855769,3767,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
361,1018,2,5,,855769,3767,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
362,1019,1,4,,855769,3767,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
363,1020,1,5,,855769,3767,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
364,1021,1,1,,855769,3767,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
365,1022,1,1,,855769,3767,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
366,1027,1,3,,855769,3767,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
367,1030,2,1,,855769,3767,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
368,1030,2,1,,11112128,3767,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
369,1030,2,1,,17389848,3767,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
370,1030,2,1,,26746988,3767,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
371,1030,2,1,,26751504,3767,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
372,1032,1,2,,855769,3767,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
373,1032,1,2,,855769,3767,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
374,1040,1,2,,855769,3767,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
375,1048,1,1,,855769,3767,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
376,1048,1,1,,855769,3767,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
377,1049,1,1,,855769,3767,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
378,1049,1,1,,855769,3767,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
379,1051,1,1,,855769,3767,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
380,1051,1,1,,855769,3767,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
381,1063,1,1,,855769,3767,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
382,1066,1,2,,855769,3767,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
383,1085,1,1,,855769,3767,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
384,1135,1,3,,855769,3767,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
385,1136,1,3,,855769,3767,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
386,1189,1,5,,48413916,3767,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
387,1191,1,3,,48413916,3767,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Hamster Bioassay Results,Other,,
388,1194,1,3,,48413916,3767,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
389,1195,1,2,,48416132,3767,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
390,1199,1,3,,48413916,3767,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
391,1203,1,3,,855769,3767,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
392,1205,1,4,,48413916,3767,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
393,1208,1,3,,48413916,3767,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
394,1209,2,2,,855769,3767,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
395,1214,1,4,,855769,3767,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
396,1216,1,5,,855769,3767,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
397,1217,1,4,,855769,3767,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
398,1220,2,2,,855769,3767,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
399,1222,1,6,,855769,3767,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
400,1229,1,3,,855769,3767,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
401,1235,1,2,,855769,3767,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
402,1236,1,1,,855769,3767,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
403,1239,1,3,,855769,3767,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
404,1239,1,3,,855769,3767,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
405,1242,1,1,,855769,3767,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
406,1251,1,1,,855769,3767,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
407,1273,1,1,,855769,3767,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
408,1274,1,2,,855769,3767,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
409,1276,1,1,,855769,3767,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
410,1285,1,1,,855769,3767,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
411,1296,1,1,,855769,3767,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
412,1304,1,2,,855769,3767,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
413,1321,1,2,,855769,3767,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
414,1325,1,2,,855769,3767,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
415,1326,1,4,,855769,3767,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
416,1332,1,1,,49698712,3767,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
417,1359,1,4,,855769,3767,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
418,1362,1,2,,855769,3767,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
419,1377,1,1,,855769,3767,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
420,1379,1,2,,855769,3767,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
421,1379,1,2,,11112128,3767,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
422,1379,1,2,,26746988,3767,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
423,1381,1,1,,855769,3767,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
424,1385,2,2,,855769,3767,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
425,1415,1,2,,855769,3767,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
426,1415,1,2,,855769,3767,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
427,1416,1,2,,855769,3767,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
428,1422,1,1,,26611787,3767,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
429,1423,1,2,,855769,3767,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
430,1423,1,2,,855769,3767,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
431,1424,1,1,,855769,3767,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
432,1430,1,1,,855769,3767,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
433,1434,2,3,,855769,3767,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
434,1434,2,3,,855769,3767,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
435,1439,1,1,,855769,3767,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
436,1439,1,1,,855769,3767,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
437,1440,1,1,,855769,3767,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
438,1440,1,1,,855769,3767,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
439,1441,1,1,,855769,3767,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
440,1441,1,1,,855769,3767,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
441,1443,1,3,,855769,3767,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
442,1445,1,1,,855769,3767,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
443,1446,1,3,,855769,3767,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
444,1448,1,3,,855769,3767,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
445,1452,1,1,,855769,3767,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
446,1452,1,1,,11112128,3767,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
447,1452,1,1,,17389848,3767,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
448,1454,1,1,,11112128,3767,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
449,1454,1,1,,26746988,3767,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
450,1456,1,1,,855769,3767,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
451,1457,1,1,,855769,3767,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
452,1457,1,1,,11112128,3767,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
453,1457,1,1,,17389848,3767,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
454,1457,1,1,,26746988,3767,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
455,1457,1,1,,26751504,3767,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
456,1458,1,1,,855769,3767,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
457,1458,1,1,,11112128,3767,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
458,1458,1,1,,17389848,3767,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
459,1458,1,1,,26746988,3767,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
460,1458,1,1,,26751504,3767,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
461,1460,1,3,,855769,3767,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
462,1460,1,3,,26746988,3767,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
463,1460,1,3,,26751504,3767,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
464,1461,1,2,,855769,3767,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
465,1463,1,1,,855769,3767,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
466,1463,1,1,,26746988,3767,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
467,1463,1,1,,26751504,3767,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
468,1466,1,2,,855769,3767,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
469,1467,1,3,,855769,3767,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
470,1467,1,3,,11112128,3767,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
471,1467,1,3,,26746988,3767,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
472,1468,1,1,,855769,3767,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
473,1468,1,1,,26746988,3767,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
474,1468,1,1,,26751504,3767,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
475,1469,1,1,,855769,3767,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
476,1469,1,1,,11112128,3767,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
477,1469,1,1,,17389848,3767,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
478,1469,1,1,,26746988,3767,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
479,1469,1,1,,26751504,3767,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
480,1471,2,1,,11112128,3767,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
481,1471,2,1,,17389848,3767,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
482,1471,2,1,,26746988,3767,Unspecified,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
483,1471,2,1,,26751504,3767,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
484,1476,2,1,,855769,3767,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
485,1476,2,1,,11112128,3767,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
486,1476,2,1,,17389848,3767,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
487,1476,2,1,,26746988,3767,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
488,1477,1,1,,855769,3767,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
489,1477,1,1,,11112128,3767,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
490,1477,1,1,,17389848,3767,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
491,1477,1,1,,26746988,3767,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
492,1477,1,1,,26751504,3767,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
493,1478,2,1,,855769,3767,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
494,1478,2,1,,11112128,3767,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
495,1478,2,1,,17389848,3767,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
496,1478,2,1,,26746988,3767,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
497,1479,1,2,,855769,3767,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
498,1479,1,2,,11112128,3767,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
499,1479,1,2,,17389848,3767,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
500,1479,1,2,,26746988,3767,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
501,1479,1,2,,26751504,3767,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
502,1481,1,2,,855769,3767,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
503,1486,1,3,,855769,3767,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
504,1487,1,1,,855769,3767,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
505,1487,1,1,,11112128,3767,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
506,1490,2,1,,855769,3767,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
507,1490,2,1,,11112128,3767,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
508,1490,2,1,,26746988,3767,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
509,1490,2,1,,26751504,3767,Inconclusive,10954339.0,,50.1187,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
510,1496,1,4,,855769,3767,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
511,1496,1,4,,855769,3767,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
512,1509,1,2,,855769,3767,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
513,1510,1,3,,855769,3767,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
514,1515,1,2,,855769,3767,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
515,1519,1,3,,11112128,3767,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
516,1519,1,3,,26746988,3767,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
517,1527,1,3,,855769,3767,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
518,1529,1,1,,855769,3767,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
519,1530,1,1,,855769,3767,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
520,1531,1,1,,855769,3767,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
521,1556,1,4,,855769,3767,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
522,1565,2,2,,855769,3767,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
523,1566,2,3,,855769,3767,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
524,1578,3,2,,855769,3767,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
525,1580,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
526,1581,1,1,,8149391,3767,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
527,1582,1,1,,8149391,3767,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
528,1583,1,1,,8149391,3767,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
529,1584,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
530,1585,1,1,,8149391,3767,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
531,1586,1,1,,8149391,3767,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
532,1587,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
533,1588,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
534,1589,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
535,1590,1,1,,8149391,3767,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
536,1593,1,1,,8149391,3767,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
537,1594,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
538,1595,1,1,,8149391,3767,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
539,1596,1,1,,8149391,3767,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
540,1597,1,1,,8149391,3767,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
541,1598,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
542,1599,1,1,,8149391,3767,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
543,1600,1,1,,8149391,3767,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
544,1601,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
545,1602,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
546,1603,1,1,,8149391,3767,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
547,1604,1,1,,8149391,3767,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
548,1605,1,1,,8149391,3767,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
549,1606,1,1,,8149391,3767,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
550,1607,1,1,,8149391,3767,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
551,1608,1,1,,8149391,3767,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
552,1609,1,1,,8149391,3767,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
553,1610,1,1,,8149391,3767,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
554,1611,1,1,,8149391,3767,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
555,1612,1,1,,8149391,3767,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
556,1613,1,1,,8149391,3767,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
557,1614,1,1,,8149391,3767,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
558,1616,1,1,,8149391,3767,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
559,1619,1,2,,855769,3767,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
560,1631,3,1,,855769,3767,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
561,1634,3,1,,855769,3767,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
562,1654,2,2,,855769,3767,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
563,1656,2,2,,855769,3767,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
564,1688,1,1,,855769,3767,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
565,1700,1,2,,855769,3767,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
566,1706,1,2,,855769,3767,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
567,1721,1,2,,855769,3767,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
568,1722,1,2,,855769,3767,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
569,1766,1,1,,855769,3767,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
570,1766,1,1,,855769,3767,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
571,1766,1,1,,11112128,3767,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
572,1766,1,1,,11112128,3767,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
573,1766,1,1,,26746988,3767,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
574,1766,1,1,,26746988,3767,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
575,1768,1,1,,855769,3767,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
576,1768,1,1,,855769,3767,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
577,1768,1,1,,11112128,3767,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
578,1768,1,1,,11112128,3767,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
579,1768,1,1,,26746988,3767,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
580,1768,1,1,,26746988,3767,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
581,1775,1,2,,855769,3767,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
582,1776,1,2,,855769,3767,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
583,1777,3,2,,855769,3767,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
584,1778,3,3,,855769,3767,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
585,1779,2,2,,855769,3767,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
586,1789,1,2,,855769,3767,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
587,1800,1,2,,855769,3767,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
588,1817,2,2,,855769,3767,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
589,1822,1,3,,855769,3767,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
590,1825,1,1,,855769,3767,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
591,1845,1,2,,855769,3767,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
592,1850,2,1,,855769,3767,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
593,1851,1,2,,11112128,3767,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
594,1851,1,2,1.0,11112128,3767,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
595,1851,1,2,2.0,11112128,3767,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
596,1851,1,2,3.0,11112128,3767,Active,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
597,1851,1,2,4.0,11112128,3767,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
598,1851,1,2,5.0,11112128,3767,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
599,1861,2,1,,855769,3767,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
600,1862,1,4,,855769,3767,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
601,1863,2,1,,855769,3767,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
602,1865,1,1,,855769,3767,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
603,1865,1,1,,11112128,3767,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
604,1865,1,1,,26746988,3767,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
605,1865,1,1,,26751504,3767,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
606,1867,1,4,,855769,3767,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
607,1868,1,4,,855769,3767,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
608,1870,1,4,,855769,3767,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
609,1873,1,4,,855769,3767,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
610,1887,1,4,,855769,3767,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
611,1903,2,3,,855769,3767,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
612,1948,1,1,,11112128,3767,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
613,1948,1,1,,17389848,3767,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
614,1948,1,1,,26746988,3767,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
615,1961,2,2,,855769,3767,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
616,1984,1,3,,855769,3767,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
617,1986,1,2,,855769,3767,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
618,1996,2,2,,855769,3767,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
619,2006,3,2,,855769,3767,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
620,2006,3,2,,855769,3767,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
621,2006,3,2,,855769,3767,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
622,2012,3,2,,855769,3767,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
623,2013,2,2,,855769,3767,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
624,2014,3,2,,855769,3767,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
625,2016,1,3,,855769,3767,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
626,2023,1,3,,855769,3767,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
627,2025,1,3,,855769,3767,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
628,2029,1,3,,855769,3767,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
629,2052,2,1,,855769,3767,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
630,2058,3,2,,855769,3767,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
631,2066,1,4,,855769,3767,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
632,2071,2,2,,855769,3767,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
633,2073,2,3,,855769,3767,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
634,2073,2,3,,855769,3767,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
635,2094,1,2,,855769,3767,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
636,2094,1,2,,855769,3767,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
637,2094,1,2,,855769,3767,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
638,2099,1,1,,855769,3767,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
639,2100,1,1,,855769,3767,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
640,2101,1,1,,855769,3767,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
641,2101,1,1,,11112128,3767,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
642,2101,1,1,,17389848,3767,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
643,2101,1,1,,26746988,3767,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
644,2101,1,1,,26751504,3767,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
645,2107,1,1,,855769,3767,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
646,2107,1,1,,11112128,3767,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
647,2107,1,1,,17389848,3767,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
648,2107,1,1,,26746988,3767,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
649,2107,1,1,,26751504,3767,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
650,2112,1,1,,855769,3767,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
651,2112,1,1,,11112128,3767,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
652,2112,1,1,,17389848,3767,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
653,2112,1,1,,26746988,3767,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
654,2112,1,1,,26751504,3767,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
655,2120,1,1,,17389848,3767,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
656,2147,1,1,,855769,3767,Inactive,221046486.0,,35.4813,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
657,2147,1,1,,11112128,3767,Inactive,221046486.0,,7.0795,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
658,2147,1,1,,26746988,3767,Inactive,221046486.0,,35.4813,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
659,2205,1,1,,855769,3767,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
660,2221,1,2,,855769,3767,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
661,2242,1,1,,855769,3767,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
662,2280,2,3,,855769,3767,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
663,2288,1,1,,855769,3767,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
664,2289,1,1,,855769,3767,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
665,2314,1,2,,855769,3767,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
666,2314,1,2,,855769,3767,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
667,2315,1,2,,855769,3767,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
668,2315,1,2,,855769,3767,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
669,2326,1,1,,855769,3767,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
670,2380,1,2,,855769,3767,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
671,2417,1,1,,855769,3767,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
672,2435,1,2,,855769,3767,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
673,2445,1,2,,855769,3767,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
674,2451,1,2,,855769,3767,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
675,2451,1,2,,11112128,3767,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
676,2451,1,2,,26746988,3767,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
677,2472,1,2,,855769,3767,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
678,2472,1,2,,11112128,3767,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
679,2472,1,2,,26746988,3767,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
680,2517,2,1,,855769,3767,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
681,2517,2,1,,11112128,3767,Inactive,6980812.0,,1.0,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
682,2517,2,1,,17389848,3767,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
683,2517,2,1,,26746988,3767,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
684,2517,2,1,,26751504,3767,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
685,2520,1,4,,855769,3767,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
686,2521,1,3,,855769,3767,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
687,2523,1,1,,855769,3767,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
688,2524,1,2,,855769,3767,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
689,2528,1,2,,855769,3767,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
690,2528,1,2,,11112128,3767,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
691,2528,1,2,,26746988,3767,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
692,2540,1,2,,855769,3767,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
693,2544,1,2,,855769,3767,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
694,2546,1,1,,855769,3767,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
695,2546,1,1,,11112128,3767,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
696,2546,1,1,,17389848,3767,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
697,2546,1,1,,26746988,3767,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
698,2549,1,1,,855769,3767,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
699,2549,1,1,,11112128,3767,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
700,2549,1,1,,17389848,3767,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
701,2549,1,1,,26746988,3767,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
702,2549,1,1,,26751504,3767,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
703,2551,1,1,,855769,3767,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
704,2551,1,1,,11112128,3767,Inconclusive,188536040.0,19885.0,14.1254,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
705,2551,1,1,,17389848,3767,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
706,2551,1,1,,26746988,3767,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
707,2557,1,3,,855769,3767,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
708,2563,1,1,,855769,3767,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
709,2599,1,2,,855769,3767,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
710,2606,1,2,,855769,3767,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
711,2629,1,1,,855769,3767,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
712,2662,2,1,,855769,3767,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
713,2674,1,1,,855769,3767,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
714,2675,1,1,,855769,3767,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
715,2676,1,2,,855769,3767,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
716,2685,1,1,,855769,3767,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
717,2690,1,2,,855769,3767,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
718,2706,1,1,,855769,3767,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
719,2716,1,1,,855769,3767,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
720,2732,1,1,,855769,3767,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
721,2751,2,2,,855769,3767,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
722,2796,1,4,,855769,3767,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
723,2797,1,2,,855769,3767,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
724,2805,2,2,,855769,3767,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
725,2806,2,2,,855769,3767,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
726,2825,1,2,,855769,3767,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
727,22293,4,4,,103168230,3767,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
728,26304,4,4,,103168230,3767,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
729,29360,4,3,,103168230,3767,Inconclusive,,,,,Ionization constant (pKa),Other,10891117.0,
730,29811,4,3,,103168230,3767,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
731,40838,6,7,,103168230,3767,Inconclusive,120758.0,289606.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
732,40838,6,7,,103168230,3767,Inconclusive,120761.0,24947.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
733,40838,6,7,,103168230,3767,Inconclusive,120763.0,140675.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
734,40838,6,7,,103168230,3767,Inconclusive,120764.0,29707.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
735,40838,6,7,,103168230,3767,Inconclusive,120769.0,25450.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
736,40838,6,7,,103168230,3767,Inconclusive,120782.0,140674.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
737,40838,6,7,,103168230,3767,Inconclusive,120788.0,29709.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
738,40838,6,7,,103168230,3767,Inconclusive,120790.0,79211.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
739,40838,6,7,,103168230,3767,Inconclusive,232127.0,29708.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
740,40838,6,7,,103168230,3767,Inconclusive,544363.0,29689.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
741,40838,6,7,,103168230,3767,Inconclusive,3023821.0,81658.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
742,40838,6,7,,103168230,3767,Inconclusive,13959374.0,65191.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
743,40838,6,7,,103168230,3767,Inconclusive,51317298.0,29705.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
744,40838,6,7,,103168230,3767,Inconclusive,52000955.0,24922.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
745,40838,6,7,,103168230,3767,Inconclusive,52000957.0,25451.0,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
746,40838,6,7,,103168230,3767,Inconclusive,81902501.0,,,,Percent inhibition of [3H]- Diazepam binding to GABA-A Benzodiazepine receptor of rat frontal cortex membranes (ND = no data),Other,2985785.0,
747,71452,6,7,,103168230,3767,Inconclusive,120758.0,289606.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
748,71452,6,7,,103168230,3767,Inconclusive,120761.0,24947.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
749,71452,6,7,,103168230,3767,Inconclusive,120763.0,140675.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
750,71452,6,7,,103168230,3767,Inconclusive,120764.0,29707.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
751,71452,6,7,,103168230,3767,Inconclusive,120769.0,25450.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
752,71452,6,7,,103168230,3767,Inconclusive,120782.0,140674.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
753,71452,6,7,,103168230,3767,Inconclusive,120788.0,29709.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
754,71452,6,7,,103168230,3767,Inconclusive,120790.0,79211.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
755,71452,6,7,,103168230,3767,Inconclusive,232127.0,29708.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
756,71452,6,7,,103168230,3767,Inconclusive,544363.0,29689.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
757,71452,6,7,,103168230,3767,Inconclusive,3023821.0,81658.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
758,71452,6,7,,103168230,3767,Inconclusive,13959374.0,65191.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
759,71452,6,7,,103168230,3767,Inconclusive,51317298.0,29705.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
760,71452,6,7,,103168230,3767,Inconclusive,52000955.0,24922.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
761,71452,6,7,,103168230,3767,Inconclusive,52000957.0,25451.0,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
762,71452,6,7,,103168230,3767,Inconclusive,81902501.0,,,,Displacement of [3H]- muscimol from GABA-A receptor from rat cerebellum membrane (ND = no data),Other,2985785.0,
763,73512,6,4,,103168230,3767,Inconclusive,,,,,Percent of enzyme inhibition by Gamma-amino-N-butyrate transaminase assay method; ND means no data,Other,2985785.0,
764,74655,3,7,,103168230,3767,Unspecified,,,,,Percent of enzyme inhibition by Glutamate decarboxylase assay method,Other,2985785.0,
765,103849,10,1,,103168230,3767,Active,,,,,Minimum inhibitory concentration against Mycobacterium tuberculosis H37Rv (ATCC 27294) in BACTEC 6A medium,Other,11334565.0,
766,104011,7,2,,103168230,3767,Unspecified,,,,,Activity against Mycobacterium tuberculosis (H37Rv) using the standard BACTEC radiometric growth assay,Other,10966749.0,
767,104797,6,2,,103168230,3767,Unspecified,,,100.0,CC50,Cytotoxicity of compound against mock-infected MT-4 cells was evaluated by MTT assay,Confirmatory,15006398.0,
768,117754,3,4,,103168230,3767,Unspecified,,,,,Antitubercular activity (12.5 mg/kg) in the 31-day murine mice model,Other,7310807.0,
769,117760,3,4,,103168230,3767,Unspecified,,,,,Antitubercular activity (3.1 mg/kg) in the 31-day murine mice model,Other,7310807.0,
770,117765,3,4,,103168230,3767,Unspecified,,,,,Antitubercular activity (6.25 mg/kg) in the 31-day murine mice model,Other,7310807.0,
771,143104,7,1,,103168230,3767,Active,,,1.3,MIC50,In vitro anti-mycobacterial activity against streptomycin resistant Mycobacterium tuberculosis ATCC 35820 was determined,Confirmatory,15006398.0,
772,143106,6,2,,103168230,3767,Unspecified,,,,,Minimal inhibitory activity of compound against Mycobacterium tuberculosis H37Rv,Other,15189042.0,
773,143110,7,2,,103168230,3767,Active,,,,,"In vitro anti-mycobacterial activity against Mycobacterium tuberculosis ATCC 27294, determined by the MTT method",Other,15006398.0,
774,143111,7,2,,103168230,3767,Active,,,,,"In vitro anti-mycobacterial activity against Mycobacterium tuberculosis C.I. 1104, determined by the MTT method",Other,15006398.0,
775,143113,7,2,,103168230,3767,Active,,,,,In vitro anti-mycobacterial activity against ethambutol resistant Mycobacterium tuberculosis ATCC 35837 determined by the MTT method,Other,15006398.0,
776,143115,7,2,,103168230,3767,Unspecified,,,,,In vitro anti-mycobacterial activity against pirazynamide resistant Mycobacterium tuberculosis ATCC 35828 determined by the MTT method,Other,15006398.0,
777,143117,7,2,,103168230,3767,Unspecified,,,,,In vitro anti-mycobacterial activity against streptomycin resistant Mycobacterium tuberculosis ATCC 35820 determined by the MTT method,Other,15006398.0,
778,143262,3,3,,103168230,3767,Unspecified,,,,,"Minimum inhibitory concentration against Mycobacterium tuberculosis var. bovis strain at 310K, with value expressed as pMIC i.e. -log of MIC (ug/mL).",Other,15239654.0,
779,143412,6,2,,103168230,3767,Unspecified,,,,,Growth inhibitory activity against Mycobacterium tuberculosis H37R,Other,12773043.0,
780,143435,10,1,,103168230,3767,Unspecified,,,,,In vitro anti-mycobacterial activity against Mycobacterium tuberculosis strain H37Rv,Other,12139444.0,
781,143695,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium (NIHJ1605),Other,14611838.0,
782,143696,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium NIHJ1605,Other,14611839.0,
783,143701,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CIP 103317,Other,9873650.0,
784,143715,6,2,,103168230,3767,Unspecified,,,,,In vitro antibacterial activity against Mycobacterium avium 103317,Other,10571160.0,
785,143721,6,2,,103168230,3767,Unspecified,,,,,In vitro cytotoxicity against Mycobacterium avium (CIP 103317) was determined,Other,9873376.0,
786,143722,9,1,,103168230,3767,Unspecified,,,,,In vitro inhibition of Mycobacterium Avium growth after 14 days culture.,Other,12392731.0,
787,143841,9,1,,103168230,3767,Unspecified,,,,,In vitro inhibition of Mycobacterium Avium (My 330/88) growth after 21 days culture.,Other,12392731.0,
788,143856,6,2,,103168230,3767,Active,,,,,The compound was tested for its ability to inhibit the growth of Mycobacterium avium; Resistant,Other,10843212.0,
789,143871,7,1,,103168230,3767,Active,,,1.4,MIC50,In vitro anti-mycobacterial activity against Mycobacterium avium complex was determined,Confirmatory,15006398.0,
790,143872,7,2,,103168230,3767,Active,,,,,In vitro anti-mycobacterial activity against Mycobacterium smegmatis determined by the MTT method,Other,15006398.0,
791,144016,7,1,,103168230,3767,Unspecified,,,100.0,MIC50,In vitro anti-mycobacterial activity against Mycobacterium fortuitum was determined,Confirmatory,15006398.0,
792,144021,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium gordonae CIP 6427,Other,9873650.0,
793,144023,6,2,,103168230,3767,Unspecified,,,,,In vitro antibacterial activity against Mycobacterium gordonae 6427,Other,10571160.0,
794,144025,6,2,,103168230,3767,Unspecified,,,,,In vitro cytotoxicity against Mycobacterium gordonae (CIP 6427) was determined,Other,9873376.0,
795,144030,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium intracellular (ATCC 1954 E-3),Other,14611838.0,
796,144031,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium intracellular ATCC 1954 E-3,Other,14611839.0,
797,144139,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium intracellular.,Other,3934384.0,
798,144143,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii (ATCC12478),Other,14611838.0,
799,144144,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii ATCC 12478,Other,14611839.0,
800,144146,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium kansasii,Other,3934384.0,
801,144147,9,1,,103168230,3767,Unspecified,,,,,In vitro inhibition of Mycobacterium Kansasi (My 235/80) growth after 14 days culture.,Other,12392731.0,
802,144148,9,1,,103168230,3767,Unspecified,,,,,In vitro inhibition of Mycobacterium Kansasi (My 235/80) growth after 21 days culture.,Other,12392731.0,
803,144149,9,1,,103168230,3767,Unspecified,,,,,In vitro inhibition of Mycobacterium Kansasi (My 235/80) growth after 7 days culture.,Other,12392731.0,
804,144150,9,1,,103168230,3767,Active,,,,,In vitro inhibition of Mycobacterium Kansasi (My 6 509/96) growth after 14 days culture.,Other,12392731.0,
805,144151,9,1,,103168230,3767,Active,,,,,In vitro inhibition of Mycobacterium Kansasi (My 6 509/96) growth after 21 days culture.,Other,12392731.0,
806,144152,9,1,,103168230,3767,Active,,,,,In vitro inhibition of Mycobacterium Kansasi (My 6 509/96) growth after 7 days culture.,Other,12392731.0,
807,144295,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium marinum CIP 6423,Other,9873650.0,
808,144297,6,2,,103168230,3767,Unspecified,,,,,In vitro antibacterial activity against Mycobacterium marinum 6423,Other,10571160.0,
809,144298,6,2,,103168230,3767,Unspecified,,,,,In vitro cytotoxicity against Mycobacterium marinum (CIP 6423) was determined,Other,9873376.0,
810,144442,6,2,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity was determined against Mycobacterium smegmatis SANK75075,Other,14611839.0,
811,144444,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis CIP 103599.,Other,9873650.0,
812,144445,6,2,,103168230,3767,Unspecified,,,,,In vitro antibacterial activity against Mycobacterium smegmatis 103599,Other,10571160.0,
813,144448,6,2,,103168230,3767,Unspecified,,,,,In vitro cytotoxicity against Mycobacterium smegmatis CIP (103599) was determined,Other,9873376.0,
814,144564,7,1,,103168230,3767,Active,,,1.8,MIC50,In vitro anti-mycobacterial activity against Mycobacterium smegmatis was determined,Confirmatory,15006398.0,
815,144566,7,2,,103168230,3767,Active,,,,,In vitro anti-mycobacterial activity against Mycobacterium smegmatis determined by the MTT method,Other,15006398.0,
816,144572,6,3,,103168230,3767,Unspecified,,,,,The compound was tested for its ability to inhibit the growth of Mycobacterium tuberculosis strain H37Rv; Sensitive,Other,10843212.0,
817,144574,6,3,,103168230,3767,Active,,,,,The compound was tested for its ability to inhibit the growth of Mycobacterium tuberculosis strain H6/99; Resistant,Other,10843212.0,
818,144578,5,1,,103168230,3767,Unspecified,,,,,Ability to inhibit 100%growth against Mycobacterium tuberculosis H37Rv in Youman's medium,Other,2509708.0,
819,144579,5,1,,103168230,3767,Unspecified,,,,,Ability to inhibit 100%growth against Mycobacterium tuberculosis H37Rv in Youman's medium with 10% bovine serum,Other,2509708.0,
820,144581,5,1,,103168230,3767,Unspecified,,,,,Ability to inhibit 100%growth against Mycobacterium tuberculosis strain no: 22443 in Youman's medium.,Other,2509708.0,
821,144582,5,1,,103168230,3767,Unspecified,,,,,Ability to inhibit 100%growth against Mycobacterium tuberculosis strain no: 312 in Youman's medium.,Other,2509708.0,
822,144583,5,1,,103168230,3767,Unspecified,,,,,Ability to inhibit partial growth (50+/-10%) against Mycobacterium tuberculosis H37Rv in Youman's medium,Other,2509708.0,
823,144584,5,1,,103168230,3767,Unspecified,,,,,Ability to inhibit partial growth (50+/-10%) against Mycobacterium tuberculosis H37Rv in Youman's medium with 10% bovine serum,Other,2509708.0,
824,144587,5,1,,103168230,3767,Unspecified,,,,,Ability to inhibit partial growth (50+/-10%) against Mycobacterium tuberculosis strain no: 22443 in Youman's medium,Other,2509708.0,
825,144588,5,1,,103168230,3767,Unspecified,,,,,Ability to inhibit partial growth (50+/-10%) against Mycobacterium tuberculosis strain no: 312 in Youman's medium,Other,2509708.0,
826,144734,3,3,,103168230,3767,Unspecified,,,,,"In vitro inhibition of Mycobacterium tuberculosis H37Rv, determined at 0.2 ug/mL",Other,15189042.0,
827,144735,3,3,,103168230,3767,Unspecified,,,,,"In vitro inhibition of Mycobacterium tuberculosis H37Rv, determined at 2 ug/mL",Other,15189042.0,
828,144736,3,3,,103168230,3767,Unspecified,,,,,"In vitro inhibition of Mycobacterium tuberculosis H37Rv, determined at 20 ug/mL",Other,15189042.0,
829,144883,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis,Other,12657257.0,
830,144887,6,2,,103168230,3767,Unspecified,,,,,Compound was evaluated for in vitro anti-mycobacterial activity against Mycobacterium tuberculosis,Other,8576910.0,
831,145020,6,2,,103168230,3767,Unspecified,,,,,In vitro anti-mycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,11212096.0,
832,145022,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CIP 103471,Other,9873650.0,
833,145023,6,2,,103168230,3767,Unspecified,,,,,Compound was tested for inhibitory activity against Mycobacterium tuberculosis H37Rv ATCC 27294 and the activity is expressed as minimum inhibitory concentration (MIC).,Other,9632376.0,
834,145128,8,1,,103168230,3767,Active,,,,,Compound was tested in vitro for growth inhibition activity against Mycobacterium tuberculosis H37Rv in Bactec 12B media.,Other,9871552.0,
835,145129,8,1,,103168230,3767,Active,,,,,Compound was tested in vitro for growth inhibition activity against Mycobacterium tuberculosis H37Rv in Bactec 6A media.,Other,9871552.0,
836,145132,6,2,,103168230,3767,Unspecified,,,,,In vitro antibacterial activity against Mycobacterium tuberculosis 103471,Other,10571160.0,
837,145142,6,2,,103168230,3767,Unspecified,,,,,"In vitro antimicrobacterial activity to inhibit 90% of Mycobacterium tuberculosis H37Rv (Rifampin and Isoniazid susceptible ATCC 27294 strain), relative to that of controls",Other,10762047.0,
838,145144,6,2,,103168230,3767,Unspecified,,,,,In vitro minimum inhibitory concentration against Mycobacterium tuberculosis CIP 103471 was determined,Other,9873376.0,
839,145145,9,1,,103168230,3767,Active,,,,,In vitro inhibition of Mycobacterium Tuberculosis (My 331/88) growth after 14 days culture.,Other,12392731.0,
840,145146,9,1,,103168230,3767,Active,,,,,In vitro inhibition of Mycobacterium Tuberculosis (My 331/88) growth after 21 days culture.,Other,12392731.0,
841,145281,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against Mycobacterium tuberculosis using microplate alamar blue assay,Other,12729658.0,
842,145295,6,2,,103168230,3767,Unspecified,,,,,Tested for antibacterial activity against Mycobacterium tuberculosis H37Rv isonicotinic acid hydrazide-resistant strain,Other,3934384.0,
843,145296,6,2,,103168230,3767,Unspecified,,,,,Tested for antibacterial activity against Mycobacterium tuberculosis H37Rv kanamycin resistant strain,Other,3934384.0,
844,145297,6,2,,103168230,3767,Unspecified,,,,,Tested for antibacterial activity against Mycobacterium tuberculosis H37Rv streptomycin resistant strain,Other,3934384.0,
845,145298,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv.,Other,3934384.0,
846,145300,7,1,,103168230,3767,Active,,,0.09,MIC50,In vitro anti-mycobacterial activity against Mycobacterium tuberculosis ATCC 27294 was determined,Confirmatory,15006398.0,
847,145301,7,1,,103168230,3767,Active,,,0.06,MIC50,In vitro anti-mycobacterial activity against Mycobacterium tuberculosis C.I. 1104 was determined,Confirmatory,15006398.0,
848,145303,7,1,,103168230,3767,Active,,,0.2,MIC50,In vitro anti-mycobacterial activity against ethambutol resistant Mycobacterium tuberculosis ATCC 35837 was determined,Confirmatory,15006398.0,
849,145305,7,1,,103168230,3767,Active,,,0.1,MIC50,In vitro anti-mycobacterial activity against pirazynamide resistant Mycobacterium tuberculosis ATCC 35828 was determined,Confirmatory,15006398.0,
850,159987,8,2,,103168230,3767,Active,,,10.0,IC50,Effect on plasma amine oxidase (0.1 uM) after 15 min of incubation at pH 7.2,Confirmatory,3127589.0,
851,159988,8,2,,103168230,3767,Active,,,10.0,IC50,Effect on plasma amine oxidase (0.1 uM) after 30 min of incubation at pH 7.2,Confirmatory,3127589.0,
852,159989,8,2,,103168230,3767,Unspecified,,,100.0,IC50,Effect on plasma amine oxidase (0.1 uM) after 0 min of incubation at pH 7.2,Confirmatory,3127589.0,
853,159990,8,2,,103168230,3767,Active,,,5.0,IC50,Effect on plasma amine oxidase (0.1 uM) after 60 min of incubation at pH 7.2,Confirmatory,3127589.0,
854,183966,3,3,,103168230,3767,Unspecified,,,,,Brain mitochondrial activity measured at 0 min of incubation at 1 uM concentration,Other,3127589.0,
855,183967,3,3,,103168230,3767,Unspecified,,,,,Brain mitochondrial activity measured at 0 min of incubation at 10 uM concentration,Other,3127589.0,
856,183968,3,3,,103168230,3767,Unspecified,,,,,Brain mitochondrial activity measured at 0 min of incubation at 100 uM concentration,Other,3127589.0,
857,183969,3,3,,103168230,3767,Unspecified,,,,,Brain mitochondrial activity measured at 120 min of incubation at 1 uM concentration,Other,3127589.0,
858,183970,3,3,,103168230,3767,Unspecified,,,,,Brain mitochondrial activity measured at 120 min of incubation at 10 uM concentration,Other,3127589.0,
859,183971,3,3,,103168230,3767,Unspecified,,,,,Brain mitochondrial activity measured at 120 min of incubation at 100 uM concentration,Other,3127589.0,
860,210952,5,4,,103168230,3767,Inconclusive,,,,,In vitro inhibition of translocase I; Not determined.,Other,14611839.0,
861,216526,5,1,,103168230,3767,Unspecified,,,,,Minimal toxic dose that induced a reduction of 50% of cell growth in Vero cell line infected with Mycobacterium tuberculosis CIP 103471,Other,9873376.0,
862,217175,9,1,,103168230,3767,Unspecified,,,,IC50,In vitro cytotoxicity against VERO cell line,Confirmatory,12139444.0,
863,217188,5,1,,103168230,3767,Unspecified,,,,,In vitro cytotoxicity against VERO cells.,Other,9873650.0,
864,217726,6,2,,103168230,3767,Unspecified,,,,,Compound was tested for its cytotoxicity on Vero cells,Other,10762047.0,
865,218066,5,1,,103168230,3767,Unspecified,,,,,In vitro cytotoxicity against vero cells,Other,10571160.0,
866,244746,5,1,,103168230,3767,Unspecified,,,,,In vitro antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis strain,Other,15863306.0,
867,244758,5,2,,103168230,3767,Inconclusive,,,,,In vitro antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis strain; nd= not determined,Other,15863306.0,
868,244759,5,1,,103168230,3767,Unspecified,,,,,In vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv in broth cluture infected with macrophages,Other,15863306.0,
869,244763,5,1,,103168230,3767,Unspecified,,,,,Minimum bactericidal required against isoniazid resistant Mycobacterium tuberculosis was determined in monolayers of mouse bone marrow macrophages,Other,15501030.0,
870,244764,5,1,,103168230,3767,Unspecified,,,,,Minimum bactericidal concentration required against Mycobacterium tuberculosis H37Rv strain was determined in monolayers of mouse bone marrow macrophages,Other,15501030.0,
871,245017,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration tested against Mycobacterium avium ATCC 49601,Other,15780634.0,
872,245018,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against Mycobacterium avium ATCC 49601,Other,15780635.0,
873,245026,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against isoniazid-resistant Mycobacterium tuberculosis strain,Other,15863306.0,
874,245086,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against Mycobacterium tuberculosis H37Rv ATCC 27294,Other,15745799.0,
875,245139,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration tested against Mycobacterium intracellular ATCC 13950,Other,15780634.0,
876,245140,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against Mycobacterium intracellular ATCC 13950,Other,15780635.0,
877,245207,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration tested against Mycobacterium tuberculosis H37Rv ATCC 27294,Other,15780634.0,
878,245208,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against Mycobacterium tuberculosis H37Rv ATCC 27294,Other,15780635.0,
879,245289,5,2,,103168230,3767,Inconclusive,,,,,Minimum inhibitory concentration against ethambutol-resistant Mycobacterium tuberculosis strain; nd= not determined,Other,15863306.0,
880,245294,5,2,,103168230,3767,Inconclusive,,,,,In vitro antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis strain; nd= not determined,Other,15863306.0,
881,245333,5,2,,103168230,3767,Inconclusive,,,,,In vitro antimycobacterial activity against ethionamide-resistant Mycobacterium tuberculosis strain; nd= not determined,Other,15863306.0,
882,245343,5,2,,103168230,3767,Inconclusive,,,,,In vitro antimycobacterial activity against thiacetazone resistant Mycobacterium tuberculosis strain; nd= not determined,Other,15863306.0,
883,245396,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against Mycobacterium tuberculosis H37Rv pFPCA1 in green fluorescent protein microplate assay,Other,16005211.0,
884,245416,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against resistant Mycobacterium tuberculosis clinical isolates; N=9; Range=8-16,Other,15745799.0,
885,245447,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against sensitive Mycobacterium tuberculosis clinical isolates; N=9; Range = 0.12-0.25,Other,15745799.0,
886,245485,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration tested against Mycobacterium tuberculosis resistant clinical isolates; Range 8->16 ug/mL,Other,15780634.0,
887,245490,6,2,,103168230,3767,Unspecified,,,,,In vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv in broth cluture infected with macrophages; Range 0.025-0.05,Other,15863306.0,
888,245520,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against Mycobacterium tuberculosis resistant clinical isolates; Range: 8->16 ug/ml,Other,15780635.0,
889,245536,5,2,,103168230,3767,Inconclusive,,,,,In vitro antimycobacterial activity against Mycobacterium tuberculosis Erdman in broth cluture infected with macrophages;nd = not determined,Other,15863306.0,
890,245556,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration tested against Mycobacterium tuberculosis sensitive clinical isolates; Range 0.125-0.25 ug/ml,Other,15780634.0,
891,245565,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibitory concentration against Mycobacterium tuberculosis sensitive clinical isolates; Range: 0.125-0.25 ug/ml,Other,15780635.0,
892,245631,6,2,,103168230,3767,Unspecified,,,,,Minimum inhibition concentration required against isoniazid resistant Mycobacterium tuberculosis was determined in monolayers of mouse bone marrow macrophages,Other,15501030.0,
893,246790,5,1,,103168230,3767,Unspecified,,,,,Effective concentration required for the reduction in colony forming units (CFU) at seven days compared to drug free controls,Other,15863306.0,
894,246798,5,1,,103168230,3767,Unspecified,,,,,Effective concentration required to reduce CFU of Mycobacterium tuberculosis Erdman (ATCC 35801) strain was determined in monolayers of mouse bone marrow macrophages,Other,15501030.0,
895,246804,5,1,,103168230,3767,Unspecified,,,,,Effective concentration required for the reduction in colony forming units (CFU) at seven days compared to drug free controls,Other,15863306.0,
896,246807,5,1,,103168230,3767,Unspecified,,,,,Effective concentration required to reduce CFU of Mycobacterium tuberculosis Erdman (ATCC 35801) strain was determined in monolayers of mouse bone marrow macrophages,Other,15501030.0,
897,249391,5,1,,103168230,3767,Unspecified,,,,,In vitro minimum inhibitory concentration dissolved in DMSO against Mycobacterium bovis BCG using BACTEC 460 radiometric system,Other,16002282.0,
898,249486,3,3,,103168230,3767,Inconclusive,,,,,Ratio of effective concentration required for the reduction in colony forming units (CFU) at seven days compared to drug free controls to that of MIC against Mycobacterium tuberculosis Erdman;nd= not determined,Other,15863306.0,
899,250178,3,4,,103168230,3767,Unspecified,,,,,Viable Mycobacterium tuberculosis in lungs of infected Mice after an 8-day drug treatment; Dose is 25 mg/kg,Other,15456272.0,
900,250191,3,4,,103168230,3767,Unspecified,,,,,Viable Mycobacterium tuberculosis in spleen of infected Mice after an 8-day drug treatment; Dose is 25 mg/kg,Other,15456272.0,
901,251156,3,3,,103168230,3767,Unspecified,,,,,Effective concentration required compared to that of Minimum inhibition concentration required against Mycobacterium tuberculosis H37Rv strain was determined; Range is 0.6-1.2,Other,15501030.0,
902,251783,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity of compound against Mycobacterium tuberculosis H37Rv at 0.05 ug/mL,Other,15225698.0,
903,252818,3,4,,103168230,3767,Unspecified,,,,,Selective index of IC50 of Vero Cells to that of MIC of Mycobacterium tuberculosis H37Rv,Other,15863306.0,
904,253855,3,3,,103168230,3767,Unspecified,,,,,LogP against Mycobacterium tuberculosis [H37Rv stain],Other,16115763.0,
905,255498,8,1,,103168230,3767,Active,,,,,In vitro minimal inhibitory concentration against Mycobacterium tuberculosis [H37Rv stain],Other,16115763.0,
906,255821,6,2,,103168230,3767,Unspecified,,,45.57,IC50,In vitro inhibitory concentration against Mycobacterium tuberculosis [H37Rv stain],Confirmatory,16115763.0,
907,256076,3,4,,103168230,3767,Unspecified,,,,,Log CFU in lungs of mice infected with H37Rv stain of Mycobacterium tuberculosis after administration at 25 mg/Kg,Other,16115763.0,
908,256825,6,2,,103168230,3767,Unspecified,,,,,Activity against Mycobacterium tuberculosis in the absence of mouse serum,Other,16366608.0,
909,256826,6,2,,103168230,3767,Unspecified,,,,,Activity against Mycobacterium tuberculosis H37Rv in presence of 10% mouse serum,Other,16366608.0,
910,256827,6,2,,103168230,3767,Unspecified,,,,,"Maximum concentration in female C57BL/6 mice administered with 300 mg/kg, po",Other,16366608.0,
911,256828,4,3,,103168230,3767,Inconclusive,,,,,"Tmax in female C57BL/6 mice administered with 300 mg/kg, po",Other,16366608.0,
912,256829,4,3,,103168230,3767,Inconclusive,,,,,"Half life in female C57BL/6 mice administered with 300 mg/kg, po",Other,16366608.0,
913,256830,3,3,,103168230,3767,Unspecified,,,,,"Oral bioavailability in female C57BL/6 mice administered with 300 mg/kg, po",Other,16366608.0,
914,256831,3,4,,103168230,3767,Unspecified,,,,,Viable number of Mycobacterium tuberculosis colonies in lungs of infected mice after 9 days of administration of 300 mg/kg,Other,16366608.0,
915,257538,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by agar microdilution technique,Other,16171992.0,
916,257539,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by standard BACTEC radiometric growth assay,Other,16171992.0,
917,259160,9,1,,103168230,3767,Inconclusive,,,,MIC50,Inhibitory activity against Mycobacterium tuberculosis H37Rv,Confirmatory,16392788.0,
918,260115,3,4,,103168230,3767,Unspecified,,,,,Toxicity towards human mononuclear leucocytes at 1 mM,Other,16298528.0,
919,260456,6,2,,103168230,3767,Unspecified,,,454.7,IC50,Inhibition of mammalian Vero cell viability at 6.25 and 62.5 ug/ml by MTT assay,Confirmatory,16303302.0,
920,260457,8,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv,Other,16303302.0,
921,260458,8,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against INH-resistant Mycobacterium tuberculosis,Other,16303302.0,
922,264989,3,3,,103168230,3767,Unspecified,,,,,Reduction in CFU in C57BL/6 mouse infected with 10^5 CFU of Mycobacterium tuberculosis H37Rv at 10 mg/kg after 20 days,Other,16722620.0,
923,265977,7,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against Vero cell line,Other,16759086.0,
924,265978,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,16759086.0,
925,265979,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis,Other,16759086.0,
926,265985,3,3,,103168230,3767,Unspecified,,,,,"Activity against Mycobacterium tuberculosis H37Rv infected in CD1 mouse assessed as decrease in bacterial load relative to control in lung at 25 mg/kg, ip",Other,16759086.0,
927,265987,3,4,,103168230,3767,Unspecified,,,,,"Activity against Mycobacterium tuberculosis H37Rv infected in CD1 mouse assessed as decrease in bacterial load relative to control in spleen at 25 mg/kg, ip",Other,16759086.0,
928,268908,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis 103471,Other,16884306.0,
929,268909,5,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against Vero cell line,Other,16884306.0,
930,268910,3,4,,103168230,3767,Unspecified,,,,,"Protection index, cytotoxicity against Vero cell line/antibacterial activity against Mycobacterium tuberculosis 103471",Other,16884306.0,
931,268911,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium avium,Other,16884306.0,
932,268912,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium marinum,Other,16884306.0,
933,268913,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis,Other,16884306.0,
934,269240,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,16725324.0,
935,269241,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis by agar dilution method,Other,16725324.0,
936,270287,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by BACTEC-460 radiometric assay at 6.25 ug/ml,Other,16784842.0,
937,270289,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against INH-resistant Mycobacterium tuberculosis by agar dilution method at 6.25 ug/ml,Other,16784842.0,
938,270291,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by BACTEC-460 radiometric assay,Other,16784842.0,
939,270292,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against INH-resistant Mycobacterium tuberculosis by agar dilution method,Other,16784842.0,
940,271342,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv,Other,16870429.0,
941,275904,9,5,,103168230,3767,Inconclusive,81669991.0,,,Ki,Inhibition of Mycobacterium tuberculosis MbtA by [32P]PPi-ATP exchange assay,Confirmatory,17181146.0,
942,275905,7,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv,Other,17181146.0,
943,275906,7,1,,103168230,3767,Inconclusive,,,,,Inhibitory activity against Yersinia pseudotuberculosis ATCC 6902,Other,17181146.0,
944,279782,3,3,,103168230,3767,Active,,,,,"Clearance of Mycobacterium tuberculosis H37Rv in BALB/c mouse lung at 25 mg/kg, po five times/week after 1 month relative to control",Other,17145791.0,
945,279783,3,4,,103168230,3767,Active,,,,,"Clearance of Mycobacterium tuberculosis H37Rv in BALB/c mouse spleen at 25 mg/kg, po five times/week after 1 month relative to control",Other,17145791.0,
946,283235,3,3,,103168230,3767,Unspecified,,,,,"Reduction of bacterial counts in Mycobacterium tuberculosis H37Rv infected Swiss mouse lung at 25 mg/kg, po for 5 days/week after 1 month",Other,17178794.0,
947,283236,3,3,,103168230,3767,Unspecified,,,,,"Reduction of bacterial counts in Mycobacterium tuberculosis H37Rv infected Swiss mouse lung at 25 mg/kg, po for 5 days/week after 2 months",Other,17178794.0,
948,283244,3,3,,103168230,3767,Active,,,,,"Reduction of lung lesions in Mycobacterium tuberculosis H37Rv infected Swiss mouse at 25 mg/kg, po for 5 days/week after 2 months",Other,17178794.0,
949,285159,8,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days,Other,17210775.0,
950,285160,8,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days,Other,17210775.0,
951,285161,8,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay,Other,17210775.0,
952,285162,8,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days,Other,17210775.0,
953,287082,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate Alamar Blue assay,Other,17480099.0,
954,287114,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,17007966.0,
955,287741,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,17306980.0,
956,287744,9,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 331/88 after 14 days,Other,17306980.0,
957,287745,9,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium 330/88 after 14 days,Other,17306980.0,
958,287746,9,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days,Other,17306980.0,
959,287747,9,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days,Other,17306980.0,
960,287748,9,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 331/88 after 21 days,Other,17306980.0,
961,287749,9,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium 330/88 after 21 days,Other,17306980.0,
962,287750,9,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days,Other,17306980.0,
963,287751,9,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days,Other,17306980.0,
964,287752,9,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days,Other,17306980.0,
965,287753,9,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days,Other,17306980.0,
966,287809,9,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis My 331/88 after 14 days,Other,17321746.0,
967,287810,9,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis My 331/88 after 21 days,Other,17321746.0,
968,287811,9,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium avium My 330/88 after 14 days,Other,17321746.0,
969,287812,9,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium avium My 330/88 after 21 days,Other,17321746.0,
970,287813,9,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium kansasii My 235/80 after 7 days,Other,17321746.0,
971,287814,9,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium kansasii My 235/80 after 14 days,Other,17321746.0,
972,287815,9,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium kansasii My 235/80 after 21 days,Other,17321746.0,
973,287816,9,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium kansasii My 6509/96 after 7 days,Other,17321746.0,
974,287817,9,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium kansasii My 6509/96 after 14 days,Other,17321746.0,
975,287818,9,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium kansasii My 6509/96 after 21 days,Other,17321746.0,
976,289147,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,17562368.0,
977,289148,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against drug-sensitive Mycobacterium tuberculosis CIBIN 687 isolates,Other,17562368.0,
978,289149,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against drug-sensitive Mycobacterium tuberculosis CIBIN 650 isolates,Other,17562368.0,
979,289150,10,1,,103168230,3767,Active,,,,,Antimycobacterial activity against streptomycin and isoniazid-resistant Mycobacterium tuberculosis CIBIN 675 isolates,Other,17562368.0,
980,289151,8,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against streptomycin, isoniazid, rifampicin, pyrazinamide-resistant Mycobacterium tuberculosis CIBIN 234 isolates",Other,17562368.0,
981,289152,8,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against streptomycin, isoniazid, ethambutol-resistant Mycobacterium tuberculosis CIBIN 112 isolates",Other,17562368.0,
982,289153,6,2,,103168230,3767,Active,,,39.8,IC50,Cytotoxicity against Vero cells,Confirmatory,17562368.0,
983,289154,6,2,,103168230,3767,Unspecified,,,,,Toxicity against non-adherent human PBMC,Other,17562368.0,
984,289155,6,2,,103168230,3767,Unspecified,,,,,Toxicity against adherent human PBMC,Other,17562368.0,
985,289156,3,5,,103168230,3767,Unspecified,,,,,Survival of adherent human PBMC at 100 ug/mL,Other,17562368.0,
986,289701,6,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis str. MC2 155 after 24 hrs by broth dilution method,Other,17112641.0,
987,289703,3,5,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis str. MC2 155 after 24 hrs at 1 ug/ml by broth dilution method,Other,,
988,290253,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,17276683.0,
989,290254,6,2,,103168230,3767,Unspecified,,,455.77,IC50,Cytotoxicity against Vero cells after 72 hrs by MTT assay,Confirmatory,17276683.0,
990,292287,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
991,292288,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Enterobacter aerogenes after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
992,292289,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Proteus vulgaris ATCC 49132 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
993,292290,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 13048 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
994,292291,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Salmonella Typhimurium after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
995,292292,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 14990 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
996,292293,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
997,292294,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
998,292295,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity Listeria monocytogenes ATCC 15313 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
999,292296,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity Streptococcus pyogenes ATCC 19615 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
1000,292297,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity Streptococcus pneumoniae ATCC 49619 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
1001,292298,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity Enterococcus faecalis ATCC 29212 after 16 to 20 hrs by broth microdilution method,Other,17602465.0,
1002,292302,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against drug-resistant Mycobacterium tuberculosis H37Rv at 1mg/mL by BACTEC assay,Other,17602465.0,
1003,294759,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv after 2 weeks by broth dilution method,Other,17331717.0,
1004,294760,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium avium 724S after 2 weeks by broth dilution method,Other,17331717.0,
1005,294761,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus after 2 weeks by broth dilution method,Other,17331717.0,
1006,294762,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 873 after 2 weeks by broth dilution method,Other,17331717.0,
1007,294763,10,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 906 after 2 weeks by broth dilution method,Other,17331717.0,
1008,294764,10,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 908 after 2 weeks by broth dilution method,Other,17331717.0,
1009,294765,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 910 after 2 weeks by broth dilution method,Other,17331717.0,
1010,296297,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method using double dilution technique,Other,17467984.0,
1011,296298,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis by agar dilution method using double dilution technique,Other,17467984.0,
1012,297110,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv after 18 hrs by agar plate dilution method,Other,17658779.0,
1013,297111,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv after 18 hrs by agar plate dilution method,Other,17658779.0,
1014,297112,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against rifampicin-resistant Mycobacterium tuberculosis H37Rv after 18 hrs by agar plate dilution method,Other,17658779.0,
1015,297113,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG Tokyo after 18 hrs by agar plate dilution method,Other,17658779.0,
1016,297114,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium avium Flamingo after 18 hrs by agar plate dilution method,Other,17658779.0,
1017,297115,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium intracellular ATCC 15984 after 18 hrs by agar plate dilution method,Other,17658779.0,
1018,297116,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium aurum after 18 hrs by agar plate dilution method,Other,17658779.0,
1019,297117,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium fortuitum NIHJ1615 after 18 hrs by agar plate dilution method,Other,17658779.0,
1020,297118,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis Takeo after 18 hrs by agar plate dilution method,Other,17658779.0,
1021,301998,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,17888665.0,
1022,301999,6,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against Vero cells after 48 hrs by XTT method,Other,17888665.0,
1023,302000,3,4,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for Vero cells to MIC of Mycobacterial tuberculosis H37Rv",Other,17888665.0,
1024,302004,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at MIC,Other,17888665.0,
1025,303464,6,2,,103168230,3767,Unspecified,,,455.8,IC50,Cytotoxicity against Vero cells after 72 hrs by MTT assay,Confirmatory,17960928.0,
1026,303465,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,17960928.0,
1027,303466,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multi-drug-resistant Mycobacterium tuberculosis by agar dilution method,Other,17960928.0,
1028,303467,8,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium smegmatis by agar dilution method,Other,17960928.0,
1029,303469,3,3,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse assessed as lung bacterial count at 25 mg/kg, ip after 35 days post infection",Other,17960928.0,
1030,303471,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse assessed as spleen bacterial count at 25 mg/kg, ip after 35 days post infection",Other,17960928.0,
1031,303654,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis ATTC 27294 after 5 days by MABA assay,Other,17967538.0,
1032,305979,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis mc2155 after 48 hrs by microdilution resazurin assay,Other,17208445.0,
1033,305980,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by microdilution resazurin assay,Other,17208445.0,
1034,306130,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,17239593.0,
1035,307104,3,3,,103168230,3767,Active,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv at 0.05 ug/mL after 21 days,Other,17368035.0,
1036,309184,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv by nitrate reductase assay,Other,17692520.0,
1037,309276,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by MABA assay,Other,17764933.0,
1038,309277,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by Agar dilution method,Other,17764933.0,
1039,309703,9,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay,Other,17851083.0,
1040,310321,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,17933535.0,
1041,310322,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method,Other,17933535.0,
1042,310323,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method,Other,17933535.0,
1043,310488,6,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis by microbroth dilution method,Other,17937983.0,
1044,310489,7,2,,103168230,3767,Inconclusive,,,,,Solubility at pH 6.0 by shake-flask method,Other,17937983.0,
1045,310490,7,2,,103168230,3767,Inconclusive,,,,,Solubility at pH 7.4 by shake-flask method,Other,17937983.0,
1046,310491,4,5,,103168230,3767,Inconclusive,,,,,Stability in rat liver microsomes after 90 mins,Other,17937983.0,
1047,310492,4,3,,103168230,3767,Inconclusive,,,,,Protein binding in rat,Other,17937983.0,
1048,310493,3,3,,103168230,3767,Unspecified,,,,,Antituberculosis activity in Mycobacterium tuberculosis infected rat assessed as reduction of colony formation,Other,17937983.0,
1049,311448,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra by alamar blue microplate assay,Other,17844996.0,
1050,311487,6,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,17845001.0,
1051,315581,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,17997304.0,
1052,316438,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis ATCC 2729411 by Almar blue assay,Other,18068364.0,
1053,316444,6,2,,103168230,3767,Unspecified,,,455.8,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,18068979.0,
1054,316445,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,18068979.0,
1055,316446,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis by agar dilution method,Other,18068979.0,
1056,316447,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method,Other,18068979.0,
1057,316450,3,3,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse lungs assessed as viable organisms at 25 mg/kg, ip after 35 days relative to control",Other,18068979.0,
1058,316452,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse spleen assessed as viable organisms at 25 mg/kg, ip after 35 days relative to control",Other,18068979.0,
1059,318919,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,18304818.0,
1060,318920,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method,Other,18304818.0,
1061,318921,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 by agar dilution method,Other,18304818.0,
1062,318922,6,2,,103168230,3767,Unspecified,,,455.8,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,18304818.0,
1063,318926,3,3,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in lung at 25 mg/kg, ip after 10 days",Other,18304818.0,
1064,318927,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 25 mg/kg, ip after 10 days",Other,18304818.0,
1065,319147,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,18338841.0,
1066,325108,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 0.1 ug/ml after 1 week by BACTED460 method,Other,17438054.0,
1067,325109,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 0.1 ug/ml after 2 weeks by BACTED460 method,Other,17438054.0,
1068,325110,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 0.1 ug/ml after 3 weeks by BACTED460 method,Other,17438054.0,
1069,325111,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 0.1 ug/ml after 4 weeks by BACTED460 method,Other,17438054.0,
1070,325112,6,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 0.4 ug/ml after 1 week by BACTED460 method,Other,17438054.0,
1071,325113,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 0.4 ug/ml after 2 weeks by BACTED460 method,Other,17438054.0,
1072,325114,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 0.4 ug/ml after 3 weeks by BACTED460 method,Other,17438054.0,
1073,325115,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 0.4 ug/ml after 4 weeks by BACTED460 method,Other,17438054.0,
1074,325120,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB7 isolate at 0.1 ug/ml after 1 week,Other,17438054.0,
1075,325121,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB7 isolate at 0.1 ug/ml after 2 weeks,Other,17438054.0,
1076,325122,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB7 isolate at 0.1 ug/ml after 3 weeks,Other,17438054.0,
1077,325123,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB7 isolate at 0.1 ug/ml after 4 weeks,Other,17438054.0,
1078,325124,6,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB7 isolate at 0.4 ug/ml after 1 week,Other,17438054.0,
1079,325125,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB7 isolate at 0.4 ug/ml after 2 weeks,Other,17438054.0,
1080,325126,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB7 isolate at 0.4 ug/ml after 3 weeks,Other,17438054.0,
1081,325127,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB7 isolate at 0.4 ug/ml after 4 weeks,Other,17438054.0,
1082,325128,6,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB19 isolate at 0.1 ug/ml after 1 week,Other,17438054.0,
1083,325129,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB19 isolate at 0.1 ug/ml after 2 weeks,Other,17438054.0,
1084,325130,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB19 isolate at 0.1 ug/ml after 3 weeks,Other,17438054.0,
1085,325131,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB19 isolate at 0.1 ug/ml after 4 weeks,Other,17438054.0,
1086,325132,6,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB19 isolate at 0.4 ug/ml after 1 week,Other,17438054.0,
1087,325133,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB19 isolate at 0.4 ug/ml after 2 weeks,Other,17438054.0,
1088,325134,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB19 isolate at 0.4 ug/ml after 3 weeks,Other,17438054.0,
1089,325135,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB19 isolate at 0.4 ug/ml after 4 weeks,Other,17438054.0,
1090,325136,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB20 isolate at 0.1 ug/ml after 1 week,Other,17438054.0,
1091,325137,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB20 isolate at 0.1 ug/ml after 2 weeks,Other,17438054.0,
1092,325138,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB20 isolate at 0.1 ug/ml after 3 weeks,Other,17438054.0,
1093,325139,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB20 isolate at 0.1 ug/ml after 4 weeks,Other,17438054.0,
1094,325140,6,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB20 isolate at 0.4 ug/ml after 1 week,Other,17438054.0,
1095,325141,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB20 isolate at 0.4 ug/ml after 2 weeks,Other,17438054.0,
1096,325142,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB20 isolate at 0.4 ug/ml after 3 weeks,Other,17438054.0,
1097,325143,7,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis TB20 isolate at 0.4 ug/ml after 4 weeks,Other,17438054.0,
1098,325144,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv subculture 1 with wild type katG mutation,Other,17438054.0,
1099,325145,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv subculture 3 with katG D329H mutant,Other,17438054.0,
1100,325146,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv subculture 4 with wild type katG mutation in presence of catalase activity,Other,17438054.0,
1101,325147,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv subculture 5 with wild type katG mutation in absence of catalase activity,Other,17438054.0,
1102,325148,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv subculture 6 with katG W328R mutant,Other,17438054.0,
1103,325149,3,4,,103168230,3767,Active,,,,,Stability in BACTEC medium at 37 degC upto 4 weeks,Other,17438054.0,
1104,325852,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,18078756.0,
1105,325853,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis by agar dilution method,Other,18078756.0,
1106,325854,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 by agar dilution method,Other,18078756.0,
1107,325855,6,2,,103168230,3767,Unspecified,,,455.8,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,18078756.0,
1108,325870,3,3,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in lungs at 25 mg/kg, ip after 10 days",Other,18078756.0,
1109,325871,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 25 mg/kg, ip after 10 days",Other,18078756.0,
1110,326162,6,2,,103168230,3767,Unspecified,,,1800.0,IC50,Antimalarial activity against Plasmodium falciparum Dd2 expressing katG,Confirmatory,17567585.0,
1111,326163,6,2,,103168230,3767,Unspecified,,,1800.0,IC50,Antimalarial activity against Plasmodium falciparum Dd2,Confirmatory,17567585.0,
1112,326164,6,2,,103168230,3767,Unspecified,,,1800.0,IC50,Antimalarial activity against Plasmodium falciparum Dd2 with pLN-hrp3-katG-V5 insertion at attB site,Confirmatory,17567585.0,
1113,326165,6,2,,103168230,3767,Unspecified,,,1200.0,IC50,Antimalarial activity against Plasmodium falciparum 3D7 expressing katG,Confirmatory,17567585.0,
1114,326166,6,2,,103168230,3767,Unspecified,,,1200.0,IC50,Antimalarial activity against Plasmodium falciparum 3D7,Confirmatory,17567585.0,
1115,326167,6,2,,103168230,3767,Unspecified,,,1200.0,IC50,Antimalarial activity against Plasmodium falciparum 3D7 with pLN-hrp3-katG-V5 insertion at attB site,Confirmatory,17567585.0,
1116,327687,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,18179177.0,
1117,333430,7,2,,103168230,3767,Active,,,,IC50,Antitubercular activity against Mycobacterium tuberculosis H37Ra ATCC 25177 after 4 days by microtiter plate alamar blue technique,Confirmatory,15497961.0,
1118,333828,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 6841 after 72 hrs by MTT assay,Other,15620264.0,
1119,333829,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium phlei ATCC 11758 after 72 hrs by MTT assay,Other,15620264.0,
1120,333830,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium aurum after 120 hrs by MTT assay,Other,15620264.0,
1121,333831,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 after 72 hrs by MTT assay,Other,15620264.0,
1122,333960,3,3,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis at 20 ug/disk by disk diffusion assay,Other,9392889.0,
1123,333961,3,3,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis at 10 ug/disk by disk diffusion assay,Other,9392889.0,
1124,333962,3,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium avium at 100 ug/disk by disk diffusion assay,Other,9392889.0,
1125,333963,3,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium avium at 20 ug/disk by disk diffusion assay,Other,9392889.0,
1126,333964,3,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium avium at 10 ug/disk by disk diffusion assay,Other,9392889.0,
1127,336137,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by Microplate Alamar Blue Assay,Other,12350163.0,
1128,336490,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis by microdilution method,Other,12444676.0,
1129,344011,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis MC2 155 under aerobic condition after 24 hrs by MTT method,Other,18556206.0,
1130,344012,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis MC2 155 under hypoxic condition after 96 hrs by MTT method,Other,18556206.0,
1131,344013,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium bovis BCG under aerobic condition after 7 days by MTT method,Other,18556206.0,
1132,344014,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium bovis BCG under hypoxic condition after 14 days by MTT method,Other,18556206.0,
1133,344015,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra under aerobic condition after 7 days by MTT method,Other,18556206.0,
1134,344016,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra under hypoxic condition after 14 days by MTT method,Other,18556206.0,
1135,344826,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium bovis BCG by alamar blue assay,Other,18926698.0,
1136,345803,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 4 days by microplate alamar blue assay,Other,18977145.0,
1137,345804,6,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against HEK293 cells after 72 hrs by MTT assay,Other,18977145.0,
1138,345805,3,10,,103168230,3767,Inconclusive,399889.0,100730517.0,,,Antagonist activity at guinea pig ileum histamine H1 receptor at 0.3 x 10'4 M,Other,18977145.0,
1139,348342,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampin and isoniazid-susceptible Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by Alamar blue assay,Other,17923172.0,
1140,349544,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 21 to 28 days by two fold agar dilution method,Other,19299129.0,
1141,352247,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 14 days,Other,19403314.0,
1142,352248,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 21 days,Other,19403314.0,
1143,352249,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 14 days,Other,19403314.0,
1144,352250,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 21 days,Other,19403314.0,
1145,352251,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 7 days,Other,19403314.0,
1146,352252,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 14 days,Other,19403314.0,
1147,352253,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 21 days,Other,19403314.0,
1148,352254,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 7 days,Other,19403314.0,
1149,352255,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 14 days,Other,19403314.0,
1150,352256,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 21 days,Other,19403314.0,
1151,353147,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 3 days by radiometric method,Other,19285414.0,
1152,353148,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 4 days by radiometric method,Other,19285414.0,
1153,353149,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 5 days by radiometric method,Other,19285414.0,
1154,353150,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 6 days by radiometric method,Other,19285414.0,
1155,353151,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 7 days by radiometric method,Other,19285414.0,
1156,353152,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 8 days by radiometric method,Other,19285414.0,
1157,353153,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 9 days by radiometric method,Other,19285414.0,
1158,353154,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 6.25 ug/mL after 7 to 9 days by radiometric method,Other,19285414.0,
1159,355266,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 21 days by broth microdilution method,Other,9428161.0,
1160,355395,3,3,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis at 100 ug/disk by disk diffusion assay,Other,9392889.0,
1161,355724,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra,Other,12713411.0,
1162,355908,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,12762815.0,
1163,356042,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by Microplate Alamar Blue Assay,Other,12828479.0,
1164,357312,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra by microplate Alamar blue assay,Other,11520217.0,
1165,358264,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis,Other,11678665.0,
1166,359198,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,11277765.0,
1167,362953,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,18714980.0,
1168,362954,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method,Other,18714980.0,
1169,362955,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 by agar dilution method,Other,18714980.0,
1170,362956,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 35801 infected in CD1 mouse assessed as bacterial load in lungs at 25 mg/kg, ip after 10 days",Other,18714980.0,
1171,362957,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 25 mg/kg, ip after 10 days",Other,18714980.0,
1172,363986,5,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis mc2 155 after 48 hrs by microdilution resazurin assay,Other,18752967.0,
1173,363987,5,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by microdilution resazurin assay,Other,18752967.0,
1174,364834,4,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis ATCC 14468 assessed as zone of inhibition diameter at 1 mg/mL after 48 hrs by Kirby-Bauer disk diffusion assay,Other,18678487.0,
1175,364835,4,3,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 assessed as zone of inhibition diameter at 1 mg/mL after 24 hrs by Kirby-Bauer disk diffusion assay,Other,18678487.0,
1176,364836,4,3,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as zone of inhibition diameter at 1 mg/mL after 24 hrs by Kirby-Bauer disk diffusion assay,Other,18678487.0,
1177,364837,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis ATCC 14468 after 48 hrs visualized by MTT analyzed by broth microdilution assay,Other,18678487.0,
1178,364838,7,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs visualized by MTT analyzed by broth microdilution assay,Other,18678487.0,
1179,364839,7,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs visualized by MTT analyzed by broth microdilution assay,Other,18678487.0,
1180,366951,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 21 days by broth dilution assay,Other,18207286.0,
1181,369297,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis H37Rv,Other,10879539.0,
1182,369298,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against mono-rifampin-resistant Mycobacterium tuberculosis TN675,Other,10879539.0,
1183,369299,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN913,Other,10879539.0,
1184,369300,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against mono-rifampin-resistant Mycobacterium tuberculosis TN994,Other,10879539.0,
1185,369301,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN1008,Other,10879539.0,
1186,369302,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN1040,Other,10879539.0,
1187,369303,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN1051,Other,10879539.0,
1188,369304,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN1082,Other,10879539.0,
1189,369305,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN2351,Other,10879539.0,
1190,369306,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN2524,Other,10879539.0,
1191,369307,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN3183,Other,10879539.0,
1192,369308,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN3979,Other,10879539.0,
1193,369309,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN4259,Other,10879539.0,
1194,369332,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis TN1037,Other,10879539.0,
1195,369333,3,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against log phase recombinant Mycobacterium tuberculosis H37Rv-lux with plasmid MV361 at 10 ug/ml incubated for 7 days assessed as bacterial count after 4 days,Other,10879539.0,
1196,369334,3,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against log phase recombinant Mycobacterium tuberculosis H37Rv-lux with plasmid MV361 at 10 ug/ml incubated for 7 days assessed as bacterial count,Other,10879539.0,
1197,369763,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected Swiss mouse assessed as spleen weight at 25 mg/kg 5 times weekly for 4 weeks,Other,15591164.0,
1198,369764,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected Swiss mouse assessed as reduction of bacterial count in spleen at 25 mg/kg 5 times weekly for 4 weeks,Other,15591164.0,
1199,369884,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected Swiss mouse assessed as reduction of bacterial count in lungs at 25 mg/kg 5 times weekly for 4 weeks,Other,15591164.0,
1200,370069,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 14 days,Other,17132069.0,
1201,370070,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35838 after 14 days,Other,17132069.0,
1202,370071,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35822 after 14 days,Other,17132069.0,
1203,370072,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35837 after 14 days,Other,17132069.0,
1204,370073,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35820 after 14 days,Other,17132069.0,
1205,370074,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35812 after 14 days,Other,17132069.0,
1206,370083,6,2,,103168230,3767,Unspecified,,,,,Inhibition of fatty acid synthesis in Mycobacterium bovis BCG after 60 mins,Other,17132069.0,
1207,370084,6,2,,103168230,3767,Unspecified,,,,,Inhibition of alpha-mycolic acid synthesis in Mycobacterium bovis BCG after 60 mins,Other,17132069.0,
1208,370085,6,2,,103168230,3767,Unspecified,,,,,Inhibition of methoxy-mycolic acid synthesis in Mycobacterium bovis BCG after 60 mins,Other,17132069.0,
1209,370086,6,2,,103168230,3767,Unspecified,,,,,Inhibition of keto-mycolic acid synthesis in Mycobacterium bovis BCG after 60 mins,Other,17132069.0,
1210,370107,5,1,,103168230,3767,Unspecified,,,,,"Plasma concentration in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po after 0.083 hrs",Other,17132069.0,
1211,370108,5,1,,103168230,3767,Unspecified,,,,,"Plasma concentration in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po after 0.25 hrs",Other,17132069.0,
1212,370109,5,1,,103168230,3767,Unspecified,,,,,"Plasma concentration in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po after 0.5 hrs",Other,17132069.0,
1213,370110,5,1,,103168230,3767,Unspecified,,,,,"Plasma concentration in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po after 1 hr",Other,17132069.0,
1214,370111,5,1,,103168230,3767,Unspecified,,,,,"Plasma concentration in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po after 2 hrs",Other,17132069.0,
1215,370112,5,1,,103168230,3767,Unspecified,,,,,"Plasma concentration in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po after 4 hrs",Other,17132069.0,
1216,370239,6,2,,103168230,3767,Unspecified,,,,,"Cmax in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po",Other,17132069.0,
1217,370240,7,1,,103168230,3767,Unspecified,,,,,"AUC (0 to t) in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po",Other,17132069.0,
1218,370241,3,4,,103168230,3767,Unspecified,,,,,"Tmax in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po",Other,17132069.0,
1219,370242,3,4,,103168230,3767,Unspecified,,,,,"Half life in Mycobacterium bovis BCG infected tuberculosis mouse model at 10 mg/kg, po",Other,17132069.0,
1220,370250,3,5,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis Kurono infected ICR mouse assessed as viable lung bacterial count at 1.25 mg/kg, po administered once daily measured after 28 days",Other,17132069.0,
1221,370251,3,5,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis Kurono infected ICR mouse assessed as viable lung bacterial count at 2.5 mg/kg, po administered once daily measured after 28 days",Other,17132069.0,
1222,370252,3,5,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis Kurono infected ICR mouse assessed as viable lung bacterial count at 5 mg/kg, po administered once daily measured after 28 days",Other,17132069.0,
1223,370253,3,5,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis Kurono infected ICR mouse assessed as viable lung bacterial count at 10 mg/kg, po administered once daily measured after 28 days",Other,17132069.0,
1224,370254,3,5,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis Kurono infected ICR mouse assessed as viable lung bacterial count at 20 mg/kg, po administered once daily measured after 28 days",Other,17132069.0,
1225,370262,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis Kurono infected ICR mouse assessed as reduction in viable lung bacterial count at 5 mg/kg, po administered once daily measured after 28 days",Other,17132069.0,
1226,370269,6,2,,103168230,3767,Unspecified,,,,,"Cmax in human at 300 mg, po",Other,17132069.0,
1227,370270,7,2,,103168230,3767,Unspecified,,,,,"AUC (0 to t) in human at 300 mg, po",Other,17132069.0,
1228,373111,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 14 days by micromethod,Other,18694614.0,
1229,373112,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 21 days by micromethod,Other,18694614.0,
1230,373113,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 7 days by micromethod,Other,18694614.0,
1231,373114,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 14 days by micromethod,Other,18694614.0,
1232,373115,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 21 days by micromethod,Other,18694614.0,
1233,373116,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days by micromethod,Other,18694614.0,
1234,373117,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by micromethod,Other,18694614.0,
1235,373118,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by micromethod,Other,18694614.0,
1236,373119,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 14 days by micromethod,Other,18694614.0,
1237,373120,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 21 days by micromethod,Other,18694614.0,
1238,374030,3,3,,103168230,3767,Active,,,,,"Antimicrobial activity against 3 weeks old culture of Mycobacterium tuberculosis H37Rv assessed as 1:16 serum inhibitory titers treated with blood from 25 mg/kg, po dosed Swiss mouse collected after 1 hrs",Other,17876006.0,
1239,374033,8,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv,Other,17876006.0,
1240,374036,6,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv assessed as drug concentration required to kill 99% of the inoculum,Other,17876006.0,
1241,374075,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 24 hrs by agar microdilution method,Other,18952325.0,
1242,376993,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by alamar blue assay,Other,16724857.0,
1243,376994,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against drug-susceptible Mycobacterium tuberculosis isolate by alamar blue assay,Other,16724857.0,
1244,376995,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against isoniazid-resistant Mycobacterium tuberculosis isolate by alamar blue assay,Other,16724857.0,
1245,376996,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Mycobacterium tuberculosis isolate by alamar blue assay,Other,16724857.0,
1246,377083,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by Alamar blue assay,Other,15730240.0,
1247,377923,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Ra by Microplate Alamar blue assay,Other,16792425.0,
1248,378814,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,17067151.0,
1249,378857,6,2,,103168230,3767,Unspecified,,,,,Antimalarial activity against multidrug-resistant Plasmodium falciparum K1,Other,17067157.0,
1250,378983,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,16441071.0,
1251,382876,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv micro-dilution Resazurin assay,Other,18321714.0,
1252,384791,3,3,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 6.25 ug/ml by alamar blue assay,Other,17714832.0,
1253,384792,6,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against HEK293 cells by MTT assay,Other,17714832.0,
1254,392376,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay,Other,19081718.0,
1255,392599,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19131245.0,
1256,392600,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method,Other,19131245.0,
1257,392601,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium microti MTCC 1727 by agar dilution method,Other,19131245.0,
1258,392602,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium fortuitum MTCC 951 by agar dilution method,Other,19131245.0,
1259,392603,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium phlei MTCC 1724 by agar dilution method,Other,19131245.0,
1260,392604,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium vaccae MTCC 997 by agar dilution method,Other,19131245.0,
1261,392605,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii MTCC 3058 by agar dilution method,Other,19131245.0,
1262,392606,6,2,,103168230,3767,Unspecified,,,455.8,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,19131245.0,
1263,392607,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against log-phase culture of Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19131245.0,
1264,392608,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against 6-week-starved culture of Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19131245.0,
1265,392609,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against log-phase culture of Mycobacterium smegmatis ATCC 14468 by agar dilution method,Other,19131245.0,
1266,392610,8,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against 6-week-starved culture of Mycobacterium smegmatis ATCC 14468 by agar dilution method,Other,19131245.0,
1267,392819,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 21 days by agar proportion method,Other,19162489.0,
1268,394143,8,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,18502542.0,
1269,394144,8,1,,103168230,3767,Active,,,,,Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method,Other,18502542.0,
1270,394145,8,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method,Other,18502542.0,
1271,394146,6,2,,103168230,3767,Unspecified,,,455.8,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,18502542.0,
1272,394148,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in lungs at 25 mg/kg, ip administered 10 days postinfection for 10 days measured after 35 days of infection",Other,18502542.0,
1273,394291,3,4,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 25 mg/kg, ip administered 10 days postinfection for 10 days measured after 35 days of infection",Other,18502542.0,
1274,398142,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by Microplate Alamar blue assay,Other,19427791.0,
1275,400590,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 4 days by microplate alamar blue assay,Other,15043440.0,
1276,402572,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by alamar blue assay,Other,15217275.0,
1277,402722,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,16038559.0,
1278,404304,3,10,,103168230,3767,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
1279,404969,3,3,,103168230,3767,Unspecified,,,,,Half life in human with NAT2 single nucleotide polymorphic mutant with fast acetylating activity,Other,17438043.0,
1280,404970,3,3,,103168230,3767,Unspecified,,,,,Half life in human with NAT2 single nucleotide polymorphic mutant with slow acetylating activity,Other,17438043.0,
1281,404971,8,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Ra,Other,17438043.0,
1282,404972,3,4,,103168230,3767,Unspecified,,,,,AUC (0 to 24 hrs)/MIC ratio in Mycobacterium tuberculosis infected mouse model,Other,17438043.0,
1283,404973,8,1,,103168230,3767,Unspecified,,,,,Effect on mutation frequency of Mycobacterium tuberculosis H37Ra assessed as mutation prevention concentration,Other,17438043.0,
1284,404974,3,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis in mouse assessed as microbial kill activity,Other,17438043.0,
1285,404975,3,3,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Ra assessed as early bactericidal activity,Other,17438043.0,
1286,404976,3,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Ra assessed as microbial kill activity,Other,17438043.0,
1287,406205,6,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis,Other,17485499.0,
1288,408343,3,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis ATCC 14468 assessed as inhibition zone diameter at 500 mg/mL after 24 hrs by Kirby-Bauer disk diffusion assay,Other,18450455.0,
1289,408344,7,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Escherichia coli ATCC 23722 after 36 hrs visualized by MTT staining by broth macrodilution assay,Other,18450455.0,
1290,408345,7,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 36 hrs visualized by MTT staining by broth macrodilution assay,Other,18450455.0,
1291,408346,6,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis ATCC 14468 after 36 hrs visualized by MTT staining by broth macrodilution assay,Other,18450455.0,
1292,408869,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolates by agar dilution method,Other,18494459.0,
1293,408870,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis,Other,18494459.0,
1294,408871,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampicin-resistant Mycobacterium tuberculosis,Other,18494459.0,
1295,408872,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CIP 103317,Other,18494459.0,
1296,408873,3,4,,103168230,3767,Unspecified,,,,,"Protection index, ratio of MNTD50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis 103471",Other,18494459.0,
1297,408874,5,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 5 days,Other,18494459.0,
1298,408875,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 103471,Other,18494459.0,
1299,408877,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,18494459.0,
1300,408878,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis CIP 103599,Other,18494459.0,
1301,408879,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium marinum CIP 6423,Other,18494459.0,
1302,409954,4,9,,103168230,3767,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
1303,409956,4,9,,103168230,3767,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
1304,410232,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by radiometric respiratory technique,Other,18952418.0,
1305,414454,8,1,,103168230,3767,Active,,,,,Antitubercular activity against rifampin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay,Other,19271749.0,
1306,414458,8,1,,103168230,3767,Active,,,,,Antitubercular activity against replicating form of Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay,Other,19271749.0,
1307,414459,8,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against non replicating persistent form of Mycobacterium tuberculosis H37Rv ATCC 27294 after 10 days by LORA,Other,19271749.0,
1308,414460,6,2,,103168230,3767,Unspecified,,,128.0,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by Cell titer assay,Confirmatory,19271749.0,
1309,414461,8,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay,Other,19271749.0,
1310,414462,8,1,,103168230,3767,Active,,,,,Antitubercular activity against streptomycin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay,Other,19271749.0,
1311,417660,5,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 6.25 ug/mL by radiometric method,Other,19285414.0,
1312,417661,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 1 day by radiometric method,Other,19285414.0,
1313,417662,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth index at 6.25 ug/mL after 2 days by radiometric method,Other,19285414.0,
1314,419344,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 weeks,Other,18538450.0,
1315,420027,8,1,,103168230,3767,Unspecified,,,,IC50,Antimycobacterial activity against rifampicin/isoniazid-susceptible Mycobacterium tuberculosis H37Rv ATCC 27294 by BACTEC 460 radiometric method,Confirmatory,19022537.0,
1316,420982,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium bovis BCG Pasteur after 6 days by microdilution resazurin assay,Other,19232450.0,
1317,420983,5,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by microdilution resazurin assay,Other,19232450.0,
1318,420984,7,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay,Other,19232450.0,
1319,420986,3,4,,103168230,3767,Inactive,,,,,Antibacterial activity against Escherichia coli CIP188631 after 24 hrs by twofold serial dilution method,Other,19232450.0,
1320,421756,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium fortuitum after 72 hrs,Other,19093848.0,
1321,421757,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis after 72 hrs,Other,19093848.0,
1322,421758,7,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Mycobacterium smegmatis mc2 2700 after 72 hrs,Other,19093848.0,
1323,421759,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium phlei after 72 hrs,Other,19093848.0,
1324,421760,7,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus SA1199B overexpressing NorA efflux pump after 72 hrs,Other,19093848.0,
1325,421761,7,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against tetracycline-effluxing Staphylococcus aureus XU212 after 72 hrs,Other,19093848.0,
1326,421762,7,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus EMRSA15 after 72 hrs,Other,19093848.0,
1327,421787,3,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in GKO C57BL/6 mouse assessed as bacterial number in lung at 25 mg/kg/day administered 14 days postinfection via oral gavage for nine consecutive days measured on day 24 postinfection,Other,19093848.0,
1328,421788,3,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in GKO C57BL/6 mouse assessed as bacterial number in spleen at 25 mg/kg/day administered 14 days postinfection via oral gavage for nine consecutive days measured on day 24 postinfection,Other,19093848.0,
1329,423417,8,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra after 4 days by microplate alamar blue assay,Other,19265430.0,
1330,425023,7,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,19368377.0,
1331,425189,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,19403307.0,
1332,425190,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multi drug-resistant Mycobacterium tuberculosis,Other,19403307.0,
1333,426145,3,3,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv assessed as parasite growth inhibition at 25 ug/ml after 4 days by microplate alamar blue assay,Other,19548690.0,
1334,426315,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 24 hrs by microplate alamar Blue assay,Other,19555123.0,
1335,427230,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra by green fluorescent protein microplate assay,Other,19456117.0,
1336,427245,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 6.25 ug/mL by BACTEC 460 radiometric assay,Other,19457676.0,
1337,427284,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by microdilution resazurin assay,Other,19467603.0,
1338,427285,3,3,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at 5 ug/disk by microdilution resazurin assay,Other,19467603.0,
1339,429086,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolates from tuberculosis patient assessed as percent resistant isolates at 0.2 ug/ml by absolute-concentration method,Other,18070968.0,
1340,429090,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolates from tuberculosis patient assessed as percent sensitive isolates at 0.2 ug/ml by absolute-concentration method,Other,18070968.0,
1341,429094,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolates from tuberculosis patient assessed as percent specific isolates at 0.2 ug/ml by absolute-concentration method,Other,18070968.0,
1342,429374,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 21 days by agar proportion method,Other,19371979.0,
1343,430079,10,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay,Other,19620006.0,
1344,430083,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate UC0801 by microplate alamar blue assay,Other,19620006.0,
1345,430084,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate UC0802 by microplate alamar blue assay,Other,19620006.0,
1346,430085,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate UC0803 by microplate alamar blue assay,Other,19620006.0,
1347,430086,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate UC0804 by microplate alamar blue assay,Other,19620006.0,
1348,432680,8,1,,103168230,3767,Active,,,,,Antimycobacterial against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19524332.0,
1349,432681,8,1,,103168230,3767,Active,,,,,Antimycobacterial against multidrug resistant Mycobacterium tuberculosis by agar dilution method,Other,19524332.0,
1350,432682,8,1,,103168230,3767,Active,,,,,Antimycobacterial against Mycobacterium smegmatis MC2 by agar dilution method,Other,19524332.0,
1351,433905,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar microdilution assay,Other,19272678.0,
1352,433906,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 5 days by microplate alamar blue assay,Other,19272678.0,
1353,434955,1,2,,855769,3767,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1354,434962,1,2,,855769,3767,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1355,434973,1,3,,855769,3767,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1356,434989,1,1,,855769,3767,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1357,435003,1,3,,855769,3767,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1358,435022,2,2,,855769,3767,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1359,435030,1,2,,855769,3767,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1360,435030,1,2,,855769,3767,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1361,436604,3,4,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis infected in C57BL/6 mouse assessed reduction in colony forming units per lung at 25 mg/kg administered for 2 days after 24 hrs post-infection measured after 3 days by short course therapy (Rvb=6.37 +/- 0.24 logCFU/lung),Other,19524330.0,
1362,436605,8,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by broth dilution method,Other,19524330.0,
1363,436607,10,1,,103168230,3767,Unspecified,,,,,Bacteriostatic activity in Mycobacterium tuberculosis Erdman infected in mouse macrophages assessed as reduction of colony forming units after 7 days,Other,19524330.0,
1364,436608,10,1,,103168230,3767,Unspecified,,,,,Bactericidal activity in Mycobacterium tuberculosis Erdman infected in mouse macrophages assessed as reduction of colony forming units after 7 days,Other,19524330.0,
1365,436609,3,3,,103168230,3767,Unspecified,,,,,Ratio of EC90 for Mycobacterium tuberculosis Erdman to MIC for Mycobacterium tuberculosis H37Rv,Other,19524330.0,
1366,436610,8,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis Erdman by broth dilution method,Other,19524330.0,
1367,436611,3,4,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis infected in CD1 mouse assessed colony forming units per lung at 25 mg/kg administered 5 days a week for 4 weeks after 1 week post-infection by long course therapy (Rvb=8.80 +/- 0.18 logCFU/lung),Other,19524330.0,
1368,436612,3,3,,103168230,3767,Unspecified,,,,,Toxicity in C57BL/6 mouse assessed as overt toxicity,Other,19524330.0,
1369,436613,7,1,,103168230,3767,Unspecified,,,,,Toxicity in C57BL/6 mouse assessed as maximum tolerance dose,Other,19524330.0,
1370,436614,3,4,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis infected in C57BL/6 mouse assessed reduction in colony forming units per lung at 25 mg/kg administered for 2 days after 24 hrs post-infection measured after 3 days by short course therapy (Rvb=6.51 +/- 0.13 logCFU/lung),Other,19524330.0,
1371,436697,7,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by BACTEC radiometric respiratory technique,Other,19535178.0,
1372,437278,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as reduction in relative light units at 0.05 ug/ml after 72 hrs by LRP assay,Other,19464085.0,
1373,437279,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as reduction in relative light units at 0.5 ug/ml after 72 hrs by LRP assay,Other,19464085.0,
1374,437280,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as reduction in relative light units at 5 ug/ml after 72 hrs by LRP assay,Other,19464085.0,
1375,437281,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as reduction in relative light units at 10 ug/ml after 72 hrs by LRP assay,Other,19464085.0,
1376,437282,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis at 0.05 ug/ml after 72 hrs by LRP assay,Other,19464085.0,
1377,437283,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis at 0.5 ug/ml after 72 hrs by LRP assay,Other,19464085.0,
1378,437284,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis at 5 ug/ml after 72 hrs by LRP assay,Other,19464085.0,
1379,437285,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis at 10 ug/ml after 72 hrs by LRP assay,Other,19464085.0,
1380,437286,5,2,,103168230,3767,Unspecified,,,59579.9,IC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as reduction in relative light units after 72 hrs by LRP assay,Confirmatory,19464085.0,
1381,437746,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 30 days by agar microdilution method,Other,19846238.0,
1382,437961,8,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 28 days by agar dilution method,Other,19853329.0,
1383,438556,6,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv replicating form by alamar blue assay,Other,19757815.0,
1384,438557,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against non replicating persistent form of Mycobacterium tuberculosis H37Rv after 10 days by low oxygen recovery assay,Other,19757815.0,
1385,438558,5,2,,103168230,3767,Unspecified,,,128.0,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs,Confirmatory,19757815.0,
1386,439870,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay,Other,19817445.0,
1387,439871,7,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs,Other,19817445.0,
1388,440729,3,5,,103168230,3767,Inactive,,,,,Antimycobacterial activity against 30 day old non-replicating dormant cultures of Mycobacterium tuberculosis H37Rv assessed as reduction of bacterial viability measured after 11 days by resazurin reduction assay,Other,19827833.0,
1389,440732,3,5,,103168230,3767,Inactive,,,,,Antimycobacterial activity against 30 day old non-replicating dormant cultures of Mycobacterium tuberculosis H37Rv assessed as revival of bacterial viability exposed for 11 days measured after 30 days post exposure by resazurin reduction assay,Other,19827833.0,
1390,440893,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19781824.0,
1391,440894,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis by agar dilution method,Other,19781824.0,
1392,440895,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium smegmatis MC2 by agar dilution method,Other,19781824.0,
1393,442657,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19942326.0,
1394,442658,8,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method,Other,19942326.0,
1395,442659,8,2,,103168230,3767,Unspecified,,,455.8,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,19942326.0,
1396,442662,4,3,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in lungs at 25 mg/kg, ip administered 10 days postinfection for 10 days measured after 35 days of infection (Rvb=7.99 +/- 0.16 log CFU)",Other,19942326.0,
1397,442663,4,3,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 25 mg/kg, ip administered 10 days postinfection for 10 days measured after 35 days of infection (Rvb=9.02 +/- 0.21 log CFU)",Other,19942326.0,
1398,445210,7,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv by broth dilution method,Other,19828313.0,
1399,445285,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG str. Tokyo 172 by broth dilution method,Other,19828313.0,
1400,445286,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium avium 724S by broth dilution method,Other,19828313.0,
1401,445287,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium avium SmO by broth dilution method,Other,19828313.0,
1402,445288,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis by broth dilution method,Other,19828313.0,
1403,445289,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus by broth dilution method,Other,19828313.0,
1404,445290,7,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Escherichia coli by broth dilution method,Other,19828313.0,
1405,445329,5,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against human THP1 cells,Other,19828313.0,
1406,445330,5,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,19828313.0,
1407,445331,5,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against human MRC5 cells,Other,19828313.0,
1408,445332,3,3,,103168230,3767,Unspecified,,,,,Selectivity for Mycobacterium tuberculosis H37Rv over human THP1 cells,Other,19828313.0,
1409,445333,3,4,,103168230,3767,Unspecified,,,,,Selectivity for Mycobacterium tuberculosis H37Rv over human A549 cells,Other,19828313.0,
1410,445334,3,4,,103168230,3767,Unspecified,,,,,Selectivity for Mycobacterium tuberculosis H37Rv over human MRC5 cells,Other,19828313.0,
1411,446149,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis H37Rv after 16 to 24 hrs by microplate alamar,Other,20000577.0,
1412,446150,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv after 16 to 24 hrs by microplate alamar,Other,20000577.0,
1413,446151,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis H37Rv after 16 to 24 hrs by microplate alamar,Other,20000577.0,
1414,446152,6,2,,103168230,3767,Unspecified,,,,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs,Confirmatory,20000577.0,
1415,446153,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv expressing pFCA-luxAB after 10 days by low-oxygen recovery assay,Other,20000577.0,
1416,446154,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 16 to 24 hrs by microplate alamar,Other,20000577.0,
1417,448702,7,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 21 days by broth dilution assay,Other,19589626.0,
1418,449435,10,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis XDR infected in MDBK by BACTEC analysis,Other,19679378.0,
1419,449728,1,2,,855769,3767,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1420,449762,1,2,,855769,3767,Inconclusive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1421,449763,1,3,,855769,3767,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1422,453816,7,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 16 to 24 hrs by microplate alamar blue assay,Other,19783449.0,
1423,454541,7,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis,Other,19900810.0,
1424,454542,7,1,,103168230,3767,Active,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis,Other,19900810.0,
1425,456894,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by resazurin assay,Other,20056418.0,
1426,456895,6,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 155 ATCC 19420 after 7 days by resazurin assay,Other,20056418.0,
1427,456896,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 19542 after 7 days by resazurin assay,Other,20056418.0,
1428,456897,3,3,,103168230,3767,Unspecified,,,,,Inhibition of Mycobacterium membrane bound ATP synthase,Other,20056418.0,
1429,456898,6,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Other,20056418.0,
1430,457436,7,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at pH 6.8 by microplate alamar blue assay,Other,20022500.0,
1431,457437,7,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at pH 6 by microplate alamar blue assay,Other,20022500.0,
1432,457888,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 331/88 after 14 days by micromethod,Other,20060303.0,
1433,457889,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 331/88 after 21 days by micromethod,Other,20060303.0,
1434,457890,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium 330/88 after 14 days by micromethod,Other,20060303.0,
1435,458154,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium 330/88 after 21 days by micromethod,Other,20060303.0,
1436,458155,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days by micromethod,Other,20060303.0,
1437,458156,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days by micromethod,Other,20060303.0,
1438,458158,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by micromethod,Other,20060303.0,
1439,458159,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by micromethod,Other,20060303.0,
1440,458160,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 7357/98 after 14 days by micromethod,Other,20060303.0,
1441,458161,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 7357/98 after 21 days by micromethod,Other,20060303.0,
1442,458162,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 9449/06 after 14 days by micromethod,Other,20060303.0,
1443,458163,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 9449/06 after 21 days by micromethod,Other,20060303.0,
1444,458164,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 2092/05 after 14 days by micromethod,Other,20060303.0,
1445,458165,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 2092/05 after 21 days by micromethod,Other,20060303.0,
1446,458166,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate Praha 1 after 14 days by micromethod,Other,20060303.0,
1447,458167,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate Praha 1 after 21 days by micromethod,Other,20060303.0,
1448,458168,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate Praha 128 after 14 days by micromethod,Other,20060303.0,
1449,458169,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate Praha 128 after 21 days by micromethod,Other,20060303.0,
1450,458170,5,2,,103168230,3767,Unspecified,,,100.0,EC50,Toxicity against human HCT8 cells after 72 hrs by XTT assay,Confirmatory,20060303.0,
1451,458171,3,4,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of EC50 for human HCT8 cells to MIC for Mycobacterium tuberculosis isolates",Other,20060303.0,
1452,458172,3,4,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of EC50 for human HCT8 cells to MIC for multidrug-resistant Mycobacterium tuberculosis isolates",Other,20060303.0,
1453,461171,7,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate Alamar blue assay,Other,20045640.0,
1454,461172,7,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by low-oxygen-recovery assay,Other,20045640.0,
1455,463073,1,2,,855769,3767,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1456,463075,1,1,,855769,3767,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1457,463079,1,2,,855769,3767,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1458,463082,1,1,,855769,3767,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1459,463104,1,2,,855769,3767,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1460,463115,1,1,,855769,3767,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1461,463141,1,2,,855769,3767,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1462,463187,1,1,,855769,3767,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1463,463189,1,1,,855769,3767,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1464,463190,1,2,,855769,3767,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1465,463193,1,1,,855769,3767,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1466,463195,1,2,,855769,3767,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1467,463210,1,2,,855769,3767,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1468,463212,1,1,,855769,3767,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1469,463254,1,1,,855769,3767,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1470,463977,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 24 hrs by broth microdilution method,Other,20034708.0,
1471,463978,3,3,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at MIC after 24 hrs by broth microdilution method,Other,20034708.0,
1472,464198,7,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by radiometric method,Other,20035557.0,
1473,464199,7,1,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Mycobacterium smegmatis MC2 155 by microplate dilution method,Other,20035557.0,
1474,464201,7,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in human U937 cells by radiometric method,Other,20035557.0,
1475,464202,4,3,,103168230,3767,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in human U937 cells at MBC by radiometric method,Other,20035557.0,
1476,464203,5,2,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human U937 cells,Confirmatory,20035557.0,
1477,464245,7,1,,103168230,3767,Active,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Ra after 4 days by Alamar blue assay,Other,20038128.0,
1478,465092,6,2,,103168230,3767,Inconclusive,,,,IC50,Antibacterial activity against methicillin-resistant Staphylococcus aureus by modified NCCLS method,Confirmatory,20337497.0,
1479,465093,6,2,,103168230,3767,Inconclusive,,,,IC50,Antibacterial activity against Mycobacterium intracellular by after 4 days alamar blue assay,Confirmatory,20337497.0,
1480,465094,6,2,,103168230,3767,Active,,,,IC50,Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 4 days by alamar blue assay,Confirmatory,20337497.0,
1481,465565,7,1,,103168230,3767,Active,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin microtiter assay,Other,20138519.0,
1482,465566,5,2,,103168230,3767,Unspecified,,,5833.5,CC50,Cytotoxicity against african green monkey Vero C1008 cells after 72 hrs by MTT assay,Confirmatory,20138519.0,
1483,465569,3,4,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero C1008 cells assessed as cell viability at 125 ug/ml after 72 hrs by MTT assay,Other,20138519.0,
1484,465570,3,4,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero C1008 cells assessed as cell viability at 62.5 ug/ml after 72 hrs by MTT assay,Other,20138519.0,
1485,465571,3,4,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero C1008 cells assessed as cell viability at 31.25 ug/ml after 72 hrs by MTT assay,Other,20138519.0,
1486,465572,3,4,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero C1008 cells assessed as cell viability at 2000 ug/ml after 72 hrs by MTT assay,Other,20138519.0,
1487,465573,3,4,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero C1008 cells assessed as cell viability at 1000 ug/ml after 72 hrs by MTT assay,Other,20138519.0,
1488,467612,3,6,,103168230,3767,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
1489,467613,5,3,,103168230,3767,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
1490,468244,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate Alamar blue assay,Other,19627125.0,
1491,470175,6,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra after 4 days by microplate alamar blue assay,Other,19943622.0,
1492,470208,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 4 days by almar blue assay,Other,19663417.0,
1493,470810,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19879757.0,
1494,470811,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis by agar dilution method,Other,19879757.0,
1495,470812,6,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Other,19879757.0,
1496,474485,3,4,,103168230,3767,Inconclusive,,,,,"Lipophilicity, log D of the compound",Other,20205479.0,
1497,474486,3,5,,103168230,3767,Unspecified,,,,,Plasma protein binding in baboon,Other,20205479.0,
1498,474498,3,4,,103168230,3767,Unspecified,,,,,Biodistribution in ip dosed cat brain,Other,20205479.0,
1499,474499,5,1,,103168230,3767,Unspecified,,,,,"Biodistribution in human CSF at 8.5 mg/kg, po after 2 hrs",Other,20205479.0,
1500,474500,5,1,,103168230,3767,Unspecified,,,,,"Biodistribution in human CSF at 108.7 mg, po after 1 hr",Other,20205479.0,
1501,476043,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19850377.0,
1502,476702,6,3,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 4 weeks by agar slant proportion method,Other,20304645.0,
1503,476929,3,3,,103168230,3767,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
1504,478490,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 6.25 ug/ml by BACTEC 460,Other,20137835.0,
1505,478535,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 21 days by broth dilution assay,Other,20149496.0,
1506,479635,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 1 ug/ml after 6 days by microplate alamar blue assay,Other,20420370.0,
1507,479638,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 6 days by microplate alamar blue assay,Other,20420370.0,
1508,479642,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis H37Rv at 1 ug/ml by radiometric BACTEC assay,Other,20420370.0,
1509,479646,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv at 2 ug/ml by radiometric BACTEC assay,Other,20420370.0,
1510,479650,3,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 2.5 ug/ml after 4 days,Other,20420370.0,
1511,484649,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,20434911.0,
1512,484735,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis under aerobic condition,Other,20483615.0,
1513,484736,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis under dormancy-inducing hypoxic condition,Other,20483615.0,
1514,484737,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium bovis BCG under aerobic condition,Other,20483615.0,
1515,484738,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium bovis BCG under dormancy-inducing hypoxic condition,Other,20483615.0,
1516,484739,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv under aerobic condition,Other,20483615.0,
1517,484740,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv under dormancy-inducing hypoxic condition,Other,20483615.0,
1518,485270,1,1,,855769,3767,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1519,485272,1,1,,855769,3767,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1520,485273,2,1,,855769,3767,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1521,485275,1,3,,855769,3767,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1522,485281,1,1,,855769,3767,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1523,485281,1,1,,11112128,3767,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1524,485290,1,1,,855769,3767,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1525,485290,1,1,,11112128,3767,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1526,485290,1,1,,17389848,3767,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1527,485290,1,1,,26746988,3767,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1528,485290,1,1,,26751504,3767,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1529,485294,1,1,,855769,3767,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1530,485297,1,1,,855769,3767,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1531,485298,1,1,,855769,3767,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1532,485313,1,2,,855769,3767,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1533,485314,1,1,,855769,3767,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1534,485341,1,1,,855769,3767,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1535,485344,1,1,,855769,3767,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1536,485346,1,1,,855769,3767,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1537,485346,1,1,,855769,3767,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1538,485347,1,2,,855769,3767,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1539,485349,1,1,,855769,3767,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1540,485350,1,2,,92124073,3767,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1541,485350,1,2,,92124987,3767,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1542,485353,2,1,,855769,3767,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1543,485358,1,1,,855769,3767,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1544,485360,1,1,,855769,3767,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1545,485364,1,1,,855769,3767,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1546,485367,1,2,,855769,3767,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1547,487838,6,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 48 hrs by green fluorescent protein-based assay,Other,20537903.0,
1548,487839,6,2,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium fortuitum after 48 hrs by microtiter plate method,Other,20537903.0,
1549,487840,6,2,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium kansasii after 48 hrs by microtiter plate method,Other,20537903.0,
1550,487841,6,2,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium chelonae after 48 hrs by microtiter plate method,Other,20537903.0,
1551,487842,6,2,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium avium after 48 hrs by microtiter plate method,Other,20537903.0,
1552,487843,6,2,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium intracellular after 48 hrs by microtiter plate method,Other,20537903.0,
1553,488806,1,2,,855769,3767,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1554,488837,1,1,,855769,3767,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1555,488839,1,1,,49718175,3767,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1556,488839,1,1,,49718175,3767,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1557,488847,1,3,,855769,3767,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1558,488862,1,1,,855769,3767,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1559,488862,1,1,,49718175,3767,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1560,488890,1,2,,855769,3767,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1561,488895,1,2,,855769,3767,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1562,488895,1,2,,49718175,3767,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1563,488896,1,1,,49718175,3767,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1564,488899,1,1,,49718175,3767,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1565,488965,1,2,,855769,3767,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1566,488965,1,2,,49718175,3767,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1567,488966,1,1,,49718175,3767,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1568,489030,2,1,,855769,3767,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1569,489031,2,1,,855769,3767,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1570,489305,6,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 2 weeks by microbroth dilution method,Other,20542692.0,
1571,489306,3,4,,103168230,3767,Inactive,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv ATCC 27294 in stationary phase culture at pH 5.8 up to 200 ug/ml after 3 days followed by washout from day 4 to week 4 by microbroth dilution method,Other,20542692.0,
1572,489570,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 14 days by microdilution method,Other,20226572.0,
1573,489571,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 21 days by microdilution method,Other,20226572.0,
1574,489572,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 14 days by microdilution method,Other,20226572.0,
1575,489573,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 21 days by microdilution method,Other,20226572.0,
1576,489574,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 14 days by microdilution method,Other,20226572.0,
1577,489575,7,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 21 days by microdilution method,Other,20226572.0,
1578,489576,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by microdilution method,Other,20226572.0,
1579,489577,7,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by microdilution method,Other,20226572.0,
1580,490423,3,3,,103168230,3767,Inactive,,,,,Cytoprotective activity against 4HNE-induced cytotoxicity in HMEC1 cells at 25 uM by MTT assay,Other,20403645.0,
1581,492947,1,1,,855769,3767,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1582,492953,1,1,,49718175,3767,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1583,492956,1,1,,49718175,3767,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1584,492967,1,2,,92124987,3767,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1585,492967,1,2,,99301158,3767,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1586,492972,1,1,,49718175,3767,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1587,493005,1,1,,49718175,3767,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1588,493008,1,1,,49718175,3767,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1589,493008,1,1,,49718175,3767,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1590,493008,1,1,,49718175,3767,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1591,493008,1,1,,49718175,3767,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1592,493011,1,1,,855769,3767,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1593,493012,1,1,,855769,3767,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1594,493014,1,1,,855769,3767,Inconclusive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1595,493027,1,2,,49718175,3767,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1596,493027,1,2,,49718175,3767,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1597,493033,1,2,,92124073,3767,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1598,493033,1,2,,92124987,3767,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1599,493035,1,2,,49718175,3767,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1600,493035,1,2,,49718175,3767,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1601,493036,1,2,,855769,3767,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1602,493056,1,1,,855769,3767,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1603,493084,1,1,,855769,3767,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1604,493087,1,1,,49718175,3767,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1605,493091,1,1,,49718175,3767,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1606,493098,1,1,,49718175,3767,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1607,493131,1,1,,49718175,3767,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1608,493140,1,1,,103914042,3767,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1609,493160,1,1,,49718175,3767,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1610,493162,1,2,,99301158,3767,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1611,493187,1,2,,49718175,3767,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1612,493244,1,1,,49718175,3767,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1613,493244,1,1,,49718175,3767,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1614,493244,1,1,,49718175,3767,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1615,493244,1,1,,49718175,3767,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1616,493951,4,2,,103168230,3767,Unspecified,,,455.73,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,20615698.0,
1617,493952,6,1,,103168230,3767,Active,,,,,Antimicrobial activity aagainst Mycobacterium tuberculosis ATCC 14468 in log phase by agar dilution method,Other,20615698.0,
1618,493953,6,1,,103168230,3767,Active,,,,,Antimicrobial activity aagainst Mycobacterium sp. Mc2 in log phase assessed as inhibition of growth,Other,20615698.0,
1619,493954,6,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity aagainst Mycobacterium tuberculosis ATCC 14468 in starved phase by agar dilution method,Other,20615698.0,
1620,493955,6,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity aagainst Mycobacterium sp. Mc2 in presence of acetate,Other,20615698.0,
1621,494207,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 24 hrs after 4 weeks,Other,20452706.0,
1622,494208,5,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against Vero cells after 24 hrs by MTS assay,Other,20452706.0,
1623,494209,5,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against mouse BMDM after 48 hrs by MTS assay,Other,20452706.0,
1624,494491,6,1,,103168230,3767,Active,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days using resazurin dye by broth microdilution assay,Other,20537437.0,
1625,494492,6,1,,103168230,3767,Active,,,,,Antituberculosis activity against multi drug-resistant Mycobacterium tuberculosis after 7 days using resazurin dye by broth microdilution assay,Other,20537437.0,
1626,494493,2,3,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis at MIC concentration after 7 days using resazurin dye by broth microdilution assay,Other,20537437.0,
1627,494988,2,3,,103168230,3767,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema administered orally at dose equivalent to 70 mg/kg ibuprofen after 4 hrs,Other,20643545.0,
1628,494990,2,3,,103168230,3767,Unspecified,,,,,Analgesic activity in po dosed mouse assessed as decrease in tail flick tendency after 4 hrs by tail flick test,Other,20643545.0,
1629,494991,2,3,,103168230,3767,Unspecified,,,,,Gastrointestinal toxicity in rat assessed as ulcerogenic index administered orally at dose equivalent to 210 mg/kg ibuprofen,Other,20643545.0,
1630,494993,2,5,,103168230,3767,Unspecified,,,,,Gastrointestinal toxicity in rat liver assessed as ulcerogenic activity-related malonaldehyde level per 100 mg of tissue administered orally at dose equivalent to 210 mg/kg ibuprofen (RVb = 3.26 nmol),Other,20643545.0,
1631,494995,4,1,,103168230,3767,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on serum SGOT level (Rvb = 143.71 +/- 1.1 U/mL),Other,20643545.0,
1632,494996,4,1,,103168230,3767,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on serum SGPT level (Rvb = 32.46 +/- 0.76 U/mL),Other,20643545.0,
1633,494997,4,1,,103168230,3767,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on serum alkaline phosphatase level (Rvb = 12.17 +/- 0.16 U/mL),Other,20643545.0,
1634,494998,6,1,,103168230,3767,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on total serum protein level (Rvb = 1.72+/- 0.02 g/dl),Other,20643545.0,
1635,494999,6,1,,103168230,3767,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on total albumin level (Rvb = 1.63 +/- 0.02 g/dl),Other,20643545.0,
1636,495232,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against wild type Mycobacterium tuberculosis 210 after 4 weeks,Other,19822701.0,
1637,495233,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis NJT210CGG harboring embB497 CAG-CGG(Gln-Arg) mutation in embB gene after 4 weeks,Other,19822701.0,
1638,495234,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against wild type Mycobacterium tuberculosis NJT210CGG-CAG after 4 weeks,Other,19822701.0,
1639,495235,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis NJT210GCC harboring embB406 GGC-GCC(Gly-Ala) mutation in embB gene after 4 weeks,Other,19822701.0,
1640,495236,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis NJT210GAC harboring embB406 GGC-GAC(Gly-Asp) mutation in embB gene after 4 weeks,Other,19822701.0,
1641,495237,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis NJT210TGC harboring embB406 GGC-TGC(Gly-Cys) mutation in embB gene after 4 weeks,Other,19822701.0,
1642,495474,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis NJT210TCC harboring embB406 GGC-TCC(Gly-Ser) mutation in embB gene after 4 weeks,Other,19822701.0,
1643,499888,5,4,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra after 6 days by microplate alamar blue assay,Other,20718497.0,
1644,499895,2,3,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium bovis BCG at 1 ug/ml after 6 days by microplate alamar blue assay,Other,20718497.0,
1645,499896,5,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium bovis BCG after 6 days by microplate alamar blue assay,Other,20718497.0,
1646,499901,2,5,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra at 1 ug/ml after 6 days by microplate alamar blue assay,Other,20718497.0,
1647,504299,6,3,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by green fluorescent protein-based fluorescent assay,Other,20815366.0,
1648,504326,1,2,,49718175,3767,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1649,504326,1,2,,49718175,3767,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1650,504327,1,1,,855769,3767,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1651,504327,1,1,,11112128,3767,Inconclusive,153791535.0,2648.0,15.8489,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1652,504329,1,1,,49718175,3767,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1653,504332,1,1,,855769,3767,Inconclusive,168985070.0,,22.3872,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1654,504332,1,1,,11112128,3767,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1655,504333,1,1,,855769,3767,Inconclusive,6683500.0,29994.0,89.1251,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1656,504339,1,1,,49718175,3767,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1657,504357,1,1,,49718175,3767,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1658,504357,1,1,,49718175,3767,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1659,504411,1,1,,49718175,3767,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1660,504414,1,1,,49718175,3767,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1661,504414,1,1,,49718175,3767,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1662,504423,1,1,,49718175,3767,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1663,504441,1,1,,49718175,3767,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1664,504444,1,1,,49718175,3767,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1665,504454,1,3,,49718175,3767,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1666,504459,1,3,,855769,3767,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
1667,504462,1,1,,49718175,3767,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1668,504466,1,1,,855769,3767,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1669,504467,1,1,,855769,3767,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1670,504490,1,2,,49718175,3767,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1671,504523,1,1,,49718175,3767,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1672,504523,1,1,,49718175,3767,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1673,504541,1,1,,855769,3767,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1674,504558,1,1,,49718175,3767,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1675,504577,2,2,,49718175,3767,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1676,504582,2,1,,855769,3767,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1677,504582,2,1,,49718175,3767,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1678,504594,1,1,,855769,3767,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1679,504600,1,2,,855769,3767,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1680,504621,1,1,,49718175,3767,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1681,504634,1,1,,49718175,3767,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1682,504648,1,1,,49718175,3767,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1683,504651,1,1,,855769,3767,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1684,504652,1,1,,855769,3767,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1685,504660,1,1,,855769,3767,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1686,504690,1,3,,49718175,3767,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1687,504692,2,2,,49718175,3767,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1688,504700,1,1,,49718175,3767,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1689,504700,1,1,,49718175,3767,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1690,504706,1,1,,855769,3767,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1691,504707,1,1,,49718175,3767,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1692,504707,1,1,,49718175,3767,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1693,504720,1,1,,49718175,3767,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1694,504734,1,1,,49718175,3767,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1695,504766,2,1,,49718175,3767,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1696,504770,1,2,,92124073,3767,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1697,504775,1,1,,49718175,3767,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1698,504803,1,1,,49718175,3767,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1699,504810,1,2,,855769,3767,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1700,504812,1,2,,855769,3767,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1701,504832,1,1,,855769,3767,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1702,504834,1,1,,855769,3767,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1703,504842,1,1,,855769,3767,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1704,504845,1,1,,49718175,3767,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1705,504847,1,1,,11112128,3767,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1706,504847,1,1,,49718175,3767,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1707,504865,1,1,,11112128,3767,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1708,504884,1,2,,49718175,3767,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1709,504891,1,1,,49718175,3767,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1710,504894,1,1,,49718175,3767,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1711,504897,1,2,,121269825,3767,Active,,,0.294,Average IC90,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media using Purified and Synthesized Compounds (6),Confirmatory,,
1712,504898,1,2,,121269825,3767,Active,,,0.46,Average IC90,A High Throughput Confirmatory Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in the absence of Glycerol using Purified and Synthesized Compounds (5),Confirmatory,,
1713,504901,1,2,,121269825,3767,Active,,,37.61,Average IC90,A High Throughput Confirmatory Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in the absence of Glycerol using Purified and Synthesized Compounds (6),Confirmatory,,
1714,504903,1,2,,121269825,3767,Active,,,0.32,Average IC90,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media using Purified and Synthesized Compounds (5),Confirmatory,,
1715,504909,1,2,,121269825,3767,Inactive,,,,Average CC50,A Cell Based Secondary Assay To Explore Vero Cell Cytotoxicity of Purified and Synthesized Compounds that Inhibit Mycobacterium Tuberculosis (5),Confirmatory,,
1716,504910,1,2,,121269825,3767,Inactive,,,,Average CC50,A Cell Based Secondary Assay to Explore Cytotoxicity in HepG2 Cells of Compounds that Modulate Mycobacterium tuberculosis in Media Containing Glycerol versus Media without Glycerol (4),Confirmatory,,
1717,504911,1,2,,121269825,3767,Inactive,,,,Average CC50,A Cell Based Secondary Assay to Explore Cytotoxicity in THP-1 Cells of Compounds that Modulate Mycobacterium tuberculosis in Media Containing Glycerol versus Media without Glycerol (4),Confirmatory,,
1718,504937,1,2,,49718175,3767,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1719,509426,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic katG315 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1720,509427,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic inhA-15 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1721,509428,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic ahpC-10 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1722,509429,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic ahpC-6 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1723,509430,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic ahpC-12 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1724,509431,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic ahpC-39 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1725,509432,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic inhA-8 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1726,509433,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic ahpC-9 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1727,509434,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic inhA25 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1728,509435,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic ahpC-32 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1729,509436,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic ahpC-15 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1730,509437,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic katG295 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1731,509438,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic katG299 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1732,509439,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug resistant Mycobacterium tuberculosis containing phenotypic katG322 mutation assessed as cumulative microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1733,509513,5,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 6 weeks,Other,20576327.0,
1734,509514,5,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis H37Rv after 6 weeks,Other,20576327.0,
1735,509515,4,2,,103168230,3767,Unspecified,,,130.5,IC50,Cytotoxicity against african green monkey Vero after 72 hrs by MTT assay,Confirmatory,20576327.0,
1736,509516,2,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse lung at 25 mg/kg, iv after 6 weeks",Other,20576327.0,
1737,509628,1,3,,103168230,3767,Unspecified,,,,,"Antibacterial activity against Mycobacterium tuberculosis containing phenotypic rpoB513,katG315,inhA-15,ahpC-10,ahpC-6 mutation assessed as microbial sensitivity by phenotypic drug susceptibility testing",Other,20008778.0,
1738,509629,1,3,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis containing phenotypic embB306 mutation assessed as microbial sensitivity by phenotypic drug susceptibility testing,Other,20008778.0,
1739,509681,2,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse spleen at 25 mg/kg, iv after 6 weeks",Other,20576327.0,
1740,515080,5,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 24 hrs by microtiter alamar blue assay,Other,20691508.0,
1741,515141,5,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium intracellular ATCC 35743 after 48 hrs by agar dilution method,Other,20696500.0,
1742,515142,5,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium xenopi ATCC 14470 after 48 hrs by agar dilution method,Other,20696500.0,
1743,515143,5,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium chelonae ATCC 35751 after 48 hrs by agar dilution method,Other,20696500.0,
1744,515144,5,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis ATCC 35797 after 48 hrs by agar dilution method,Other,20696500.0,
1745,515166,4,2,,103168230,3767,Active,,,7.8,IC50,Antimycobacterial activity against Mycobacterium smegmatis after 24 hrs by MTT assay,Confirmatory,20696503.0,
1746,515167,4,2,,103168230,3767,Active,,,0.3,IC50,Antimycobacterial activity against Mycobacterium tuberculosis after 24 hrs by MTT assay,Confirmatory,20696503.0,
1747,515917,6,1,,103168230,3767,Active,,,,,Antibacterial activity against rifampicin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay,Other,20833056.0,
1748,515918,6,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against isoniazid-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay,Other,20833056.0,
1749,515919,6,1,,103168230,3767,Active,,,,,Antibacterial activity against streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay,Other,20833056.0,
1750,515920,6,1,,103168230,3767,Active,,,,,Antibacterial activity against kanamycin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay,Other,20833056.0,
1751,515921,6,1,,103168230,3767,Active,,,,,Antibacterial activity against clofazimine-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay,Other,20833056.0,
1752,517147,3,4,,103168230,3767,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at 6.25 ug/ml by microplate alamar blue assay,Other,20813528.0,
1753,517148,5,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by twofold dilution method,Other,20813528.0,
1754,517149,1,5,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv",Other,20813528.0,
1755,520099,2,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis Erdman injected into gamma interferon gene knockout C57BL/6 mouse assessed as bacterial load in lung of mouse at 25 mg/kg measured 9 days post drug treatment,Other,18268091.0,
1756,520102,2,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis Erdman injected into gamma interferon gene knockout C57BL/6 mouse assessed as bacterial load in spleen of mouse at 25 mg/kg measured 9 days post drug treatment,Other,18268091.0,
1757,520104,3,1,,103168230,3767,Unspecified,,,,,"Oral bioavailability in mouse at 25 mg/kg, po measured after 30 mins",Other,18268091.0,
1758,520106,3,1,,103168230,3767,Unspecified,,,,,"Oral bioavailability in mouse at 25 mg/kg, po measured after 2 hrs",Other,18268091.0,
1759,520108,2,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at assessed as growth inhibition at 10 mg/kg following 24 days oxygen depletion by Wayne method relative to control,Other,18268091.0,
1760,520113,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by alamar blue assay,Other,18268091.0,
1761,523290,2,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in B6 mouse assessed as 2 log reduction in bacterial burden in lungs orally treated in water upto 8 days,Other,20160054.0,
1762,523294,2,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in B6 mouse assessed as lowest concentration to reduce bacterial burden in lungs to level of reduction achieved with higher doses orally treated in water upto 8 days,Other,20160054.0,
1763,526269,6,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by resazurin microtiter assay,Other,20850299.0,
1764,526270,4,2,,103168230,3767,Unspecified,,,500.0,CC50,Toxicity in African green monkey Vero cells,Confirmatory,20850299.0,
1765,528952,1,4,,103168230,3767,Unspecified,,,,,"Bactericidal activity against Mycobacterium tuberculosis in pulmonary tuberculosis patient assessed as reduction in sputum bacterial count at 300 mg/kg, po once daily measured after 1 day",Other,18505852.0,
1766,528953,1,4,,103168230,3767,Unspecified,,,,,"Bactericidal activity against Mycobacterium tuberculosis in pulmonary tuberculosis patient assessed as reduction in sputum bacterial count at 300 mg/kg, po once daily measured after 2 days",Other,18505852.0,
1767,528954,1,4,,103168230,3767,Unspecified,,,,,"Bactericidal activity against Mycobacterium tuberculosis in pulmonary tuberculosis patient assessed as reduction in sputum bacterial count at 300 mg/kg, po once daily measured after 3 days",Other,18505852.0,
1768,528955,1,4,,103168230,3767,Unspecified,,,,,"Bactericidal activity against Mycobacterium tuberculosis in pulmonary tuberculosis patient assessed as reduction in sputum bacterial count at 300 mg/kg, po once daily measured after 4 days",Other,18505852.0,
1769,528956,1,4,,103168230,3767,Unspecified,,,,,"Bactericidal activity against Mycobacterium tuberculosis in pulmonary tuberculosis patient assessed as reduction in sputum bacterial count at 300 mg/kg, po once daily measured after 5 days",Other,18505852.0,
1770,528957,1,4,,103168230,3767,Unspecified,,,,,"Bactericidal activity against Mycobacterium tuberculosis in pulmonary tuberculosis patient assessed as reduction in sputum bacterial count at 300 mg/kg, po once daily measured after 6 days",Other,18505852.0,
1771,528958,1,4,,103168230,3767,Unspecified,,,,,"Bactericidal activity against Mycobacterium tuberculosis in pulmonary tuberculosis patient assessed as reduction in sputum bacterial count at 300 mg/kg, po once daily measured after 7 days",Other,18505852.0,
1772,528963,1,4,,103168230,3767,Unspecified,,,,,"Bactericidal activity against Mycobacterium tuberculosis in pulmonary tuberculosis patient assessed as reduction in sputum bacterial count at 300 mg/kg, po once daily measured on day 8 after starting standard TB therapy",Other,18505852.0,
1773,529098,1,4,,103168230,3767,Unspecified,,,,,"Toxicity in pulmonary tuberculosis patient assessed as hemoptysis at 300 mg/kg, po once daily",Other,18505852.0,
1774,529102,1,4,,103168230,3767,Unspecified,,,,,"Cardiotoxicity in pulmonary tuberculosis patient assessed as increase in QT interval at 300 mg/kg, po once daily for 7 days",Other,18505852.0,
1775,529521,2,3,,103168230,3767,Active,,,,,Antimycobacterial activity against ethambutol-susceptible and rifampin-resistant Mycobacterium tuberculosis isolate NJT30167 expressing embB codon 306 ATG assessed as bacterial growth rate at sub MIC compound concentration by radiometric Bactec 460TB method,Other,18378710.0,
1776,529522,2,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate NJT210 expressing embB codon 306 CTG mutant assessed as bacterial growth rate at 0.03 ug/ml by radiometric Bactec 460TB method,Other,18378710.0,
1777,529523,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against ethambutol resistant Mycobacterium tuberculosis isolate NJT210EMB-R-C3 assessed as bacterial colony formation at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1778,529524,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against ethambutol resistant Mycobacterium tuberculosis isolate NJT210EMB-R-C2 assessed as bacterial colony formation at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1779,529525,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against ethambutol resistant Mycobacterium tuberculosis isolate NJT210EMB-R-C1 assessed as bacterial colony formation at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1780,529526,5,2,,103168230,3767,Inconclusive,,,,,"Antimycobacterial activity against rifampin, ethambutol resistant Mycobacterium tuberculosis isolate A2558 at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1781,529527,5,2,,103168230,3767,Inconclusive,,,,,"Antimycobacterial activity against rifampin, ethambutol resistant Mycobacterium tuberculosis isolate 5041 at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1782,529528,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against rifampin, ethambutol resistant Mycobacterium tuberculosis isolate NJT30167 expressing embB codon 306 ATG mutant at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1783,529529,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against rifampin, ethambutol resistant Mycobacterium tuberculosis isolate 30167 at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1784,529530,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol resistant Mycobacterium tuberculosis isolate NJT5310 expressing embB codon 306 ATG-GTG mutant at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1785,529531,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol resistant Mycobacterium tuberculosis isolate NJT5310 expressing embB codon 306 ATG-CTG mutant at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1786,529532,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol resistant Mycobacterium tuberculosis isolate NJT5310 expressing embB codon 306 ATG-ATC mutant at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1787,529533,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol resistant Mycobacterium tuberculosis isolate NJT5310 expressing embB codon 306 ATG-ATA mutant at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1788,529534,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol resistant Mycobacterium tuberculosis isolate NJT5310 expressing embB codon 306 ATG mutant at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1789,529535,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol resistant Mycobacterium tuberculosis isolate 5310 at 37 degC after 3 to 4 weeks by radiometric Bactec 460TB method",Other,18378710.0,
1790,529536,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate NJT210 expressing embB codon 306 CTG-ATG mutant at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1791,529537,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate NJT210 expressing embB codon 306 ATC-ATG mutant at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1792,529538,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate NJT210 expressing embB codon 306 GTG mutant at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1793,529539,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate NJT210 expressing embB codon 306 CTG mutant at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1794,529540,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate NJT210 expressing embB codon 306 ATC mutant at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1795,529541,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate NJT210 expressing embB codon 306 ATA mutant at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1796,529542,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate 210 at 37 degC after 10 to 11 days by radiometric Bactec 460TB method,Other,18378710.0,
1797,529543,2,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate NJT210 expressing embB codon 306 CTG mutant assessed as bacterial growth rate at 0.04 ug/ml by radiometric Bactec 460TB method,Other,18378710.0,
1798,532022,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 14 days determined according to CFU count by bioluminescence method,Other,20421401.0,
1799,532023,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 7 days determined according to CFU count by bioluminescence method,Other,20421401.0,
1800,532956,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis ATCC 35802,Other,20516287.0,
1801,532957,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 1,Other,20516287.0,
1802,532958,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 2,Other,20516287.0,
1803,532959,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 3,Other,20516287.0,
1804,532960,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 4,Other,20516287.0,
1805,532961,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 5,Other,20516287.0,
1806,532962,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 6,Other,20516287.0,
1807,532963,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 7,Other,20516287.0,
1808,532964,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against streptomycin-resistant Mycobacterium tuberculosis isolate 8,Other,20516287.0,
1809,532965,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Mycobacterium tuberculosis isolate 9,Other,20516287.0,
1810,532966,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against quinolone-resistant Mycobacterium tuberculosis isolate 10,Other,20516287.0,
1811,532967,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against quinolone-resistant Mycobacterium tuberculosis isolate 11,Other,20516287.0,
1812,532968,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against quinolone-resistant Mycobacterium tuberculosis isolate 12,Other,20516287.0,
1813,532969,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis isolate 13 isolated from Beijing,Other,20516287.0,
1814,532970,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 14,Other,20516287.0,
1815,532971,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against isoniazid-resistant Mycobacterium tuberculosis isolate 15,Other,20516287.0,
1816,532972,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 16,Other,20516287.0,
1817,532973,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 17,Other,20516287.0,
1818,532974,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 18,Other,20516287.0,
1819,532975,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Mycobacterium tuberculosis isolate 19,Other,20516287.0,
1820,532976,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against multidrug drug-resistant Mycobacterium tuberculosis isolate 20,Other,20516287.0,
1821,534419,5,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG-Connaught,Other,18955515.0,
1822,534421,5,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG-Denmark,Other,18955515.0,
1823,534422,5,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG-japan,Other,18955515.0,
1824,534424,5,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG-Pasteur,Other,18955515.0,
1825,534426,3,1,,103168230,3767,Unspecified,,,,,Drug level in human serum at 10 mg/kg,Other,18955515.0,
1826,535772,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium ulcerans 1059 agar dilution method,Other,20421401.0,
1827,535773,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K carrying the luxAB gene under the hsp60 promoter agar dilution method,Other,20421401.0,
1828,535775,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 14 days determined according to RLU count by real-time luminescence method,Other,20421401.0,
1829,535776,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 7 days determined according to RLU count by real-time luminescence method,Other,20421401.0,
1830,535819,2,2,,103168230,3767,Unspecified,,,,,AUC (0 to 24 hrs) in guinea pig at 30 mg/kg,Other,18694944.0,
1831,535825,1,3,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in bacterial load at 30 mg/kg,Other,18694944.0,
1832,535826,1,4,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig spleen assessed as reduction in bacterial load at 30 mg/kg,Other,18694944.0,
1833,535827,1,3,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in bacteria induced progression of inflammation at 30 mg/kg after 4 weeks by histological analysis relative to control,Other,18694944.0,
1834,535828,1,3,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in development of new secondary lesions at 30 mg/kg after 4 weeks by histological analysis relative to control,Other,18694944.0,
1835,535915,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 21 days by broth dilution assay,Other,20797808.0,
1836,538838,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 30 days by agar microdilution method,Other,21041091.0,
1837,538989,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 14 days by microdilution method,Other,21044844.0,
1838,538990,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 21 days by microdilution method,Other,21044844.0,
1839,538991,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 14 days by microdilution method,Other,21044844.0,
1840,538992,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 21 days by microdilution method,Other,21044844.0,
1841,538993,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 14 days by microdilution method,Other,21044844.0,
1842,538994,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 21 days by microdilution method,Other,21044844.0,
1843,538995,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by microdilution method,Other,21044844.0,
1844,538996,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by microdilution method,Other,21044844.0,
1845,539118,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,20970331.0,
1846,539834,6,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21071220.0,
1847,540173,2,4,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as reduction of relative light unit at 1 ug/ml after 72 hrs by luciferase reporter phage assay relative to control,Other,20822833.0,
1848,540174,1,3,,103168230,3767,Unspecified,,,,,Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis assessed as reduction of relative light unit at 1 ug/ml after 72 hrs by luciferase reporter phage assay relative to control,Other,20822833.0,
1849,540175,2,4,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as reduction of relative light unit at 2 ug/ml after 72 hrs by luciferase reporter phage assay relative to control,Other,20822833.0,
1850,540176,1,3,,103168230,3767,Unspecified,,,,,Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis assessed as reduction of relative light unit at 2 ug/ml after 72 hrs by luciferase reporter phage assay relative to control,Other,20822833.0,
1851,540209,4,3,,103168230,3767,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1852,540210,4,3,,103168230,3767,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1853,540211,2,5,,103168230,3767,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1854,540212,4,3,,103168230,3767,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1855,540213,4,3,,103168230,3767,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1856,540253,1,1,,49718175,3767,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1857,540253,1,1,,49718175,3767,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1858,540253,1,1,,49718175,3767,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1859,540256,1,2,,855769,3767,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1860,540263,1,1,,49718175,3767,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1861,540263,1,1,,49718175,3767,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1862,540267,1,1,,49718175,3767,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1863,540275,1,1,,855769,3767,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1864,540276,1,2,,855769,3767,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1865,540276,1,2,,11112128,3767,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1866,540276,1,2,,17389848,3767,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1867,540276,1,2,,26746988,3767,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1868,540276,1,2,,26746989,3767,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1869,540276,1,2,,26751504,3767,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1870,540276,1,2,,49718175,3767,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1871,540276,1,2,,50100374,3767,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1872,540277,1,1,,855769,3767,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1873,540295,1,1,,49718175,3767,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1874,540299,1,2,,92124073,3767,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1875,540299,1,2,,92124987,3767,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1876,540303,1,1,,49718175,3767,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1877,540303,1,1,,49718175,3767,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1878,540303,1,1,,49718175,3767,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1879,540308,1,1,,49718175,3767,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1880,540317,1,1,,49718175,3767,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1881,540336,1,1,,855769,3767,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1882,540336,1,1,,855769,3767,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1883,540336,1,1,,49718175,3767,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1884,540336,1,1,,49718175,3767,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1885,540364,1,2,,49718175,3767,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1886,545232,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days by micromethod,Other,20937542.0,
1887,545233,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days by micromethod,Other,20937542.0,
1888,545234,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium avium 330/88 after 14 days by micromethod,Other,20937542.0,
1889,545235,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium avium 330/88 after 21 days by micromethod,Other,20937542.0,
1890,545236,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days by micromethod,Other,20937542.0,
1891,545237,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days by micromethod,Other,20937542.0,
1892,545238,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days by micromethod,Other,20937542.0,
1893,545239,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days by micromethod,Other,20937542.0,
1894,545240,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by micromethod,Other,20937542.0,
1895,545241,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by micromethod,Other,20937542.0,
1896,545242,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 357/2005 after 14 days by micromethod,Other,20937542.0,
1897,545243,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 357/2005 after 21 days by micromethod,Other,20937542.0,
1898,545244,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 53/2009 after 14 days by micromethod,Other,20937542.0,
1899,545245,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 53/2009 after 21 days by micromethod,Other,20937542.0,
1900,545246,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against extensively drug resistant Mycobacterium tuberculosis Praha 1 after 14 days by micromethod,Other,20937542.0,
1901,545247,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against extensively drug resistant Mycobacterium tuberculosis Praha 1 after 21 days by micromethod,Other,20937542.0,
1902,545248,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against extensively drug resistant Mycobacterium tuberculosis Praha 131 after 14 days by micromethod,Other,20937542.0,
1903,545249,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against extensively drug resistant Mycobacterium tuberculosis Praha 131 after 21 days by micromethod,Other,20937542.0,
1904,545250,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 362/1998 after 14 days by micromethod,Other,20937542.0,
1905,545251,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 362/1998 after 21 days by micromethod,Other,20937542.0,
1906,545252,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 14 days by micromethod,Other,20937542.0,
1907,545253,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 21 days by micromethod,Other,20937542.0,
1908,545987,2,4,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by Microdilution Resazurin assay,Other,20961671.0,
1909,545988,2,3,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium bovis BCG after 6 days by Microdilution Resazurin assay,Other,20961671.0,
1910,545989,4,2,,103168230,3767,Unspecified,,,100.0,IC50,Cytotoxicity against african green monkey Vero cells assessed as cell growth after 48 hrs by hemocytometry,Confirmatory,20961671.0,
1911,546032,2,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in swiss mouse assessed as increase mouse survival at 25 mg/kg, po qd for 28 days measured on day 30 relative to control",Other,20970222.0,
1912,546033,2,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in swiss mouse assessed as increase in mean survival time at 25 mg/kg, po qd for 28 days measured on day 30 relative to control",Other,20970222.0,
1913,546247,2,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in swiss mouse assessed as increase mouse survival at 25 mg/kg, po qd for 28 days measured on day 40 relative to control",Other,20970222.0,
1914,547623,2,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in swiss mouse assessed as increase in mean survival time at 25 mg/kg, po qd for 28 days measured on day 40",Other,20970222.0,
1915,547819,4,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis by agar dilution method,Other,20828886.0,
1916,548358,5,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,20932607.0,
1917,551505,1,4,,103168230,3767,Inconclusive,,,,,Cytotoxicity against human MRC5 cells assessed as metabolic active cells at 100 uM after 72 hrs by XTT assay relative to control,Other,21106378.0,
1918,551507,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 6841 after 72 hrs by broth microtiter dilution method,Other,21106378.0,
1919,551508,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium phlei ATCC 19249 after 72 hrs by broth microtiter dilution method,Other,21106378.0,
1920,559690,4,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug-resistant Mycobacterium tuberculosis clinical isolates,Other,19451293.0,
1921,563689,5,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Ra by broth microdilution method,Other,19704125.0,
1922,563690,5,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Ra by by 7H9 broth dilution method,Other,19704125.0,
1923,563691,5,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Ra by by BACTEC method,Other,19704125.0,
1924,563693,5,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Ra by by 7H10 agar plate method,Other,19704125.0,
1925,563695,5,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against rifampin-resistant Mycobacterium tuberculosis H37Ra,Other,19704125.0,
1926,563696,5,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against isoniazid-resistant Mycobacterium tuberculosis H37Ra,Other,19704125.0,
1927,563697,5,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against ethambutol-resistant Mycobacterium tuberculosis H37Ra,Other,19704125.0,
1928,563698,5,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against pyrazinamide-resistant Mycobacterium tuberculosis H37Ra,Other,19704125.0,
1929,565228,5,3,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium chelonae ATCC 35752 by resazurine microtiter assay,Other,19581465.0,
1930,565229,5,3,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium chelonae ATCC 35752 harboring pZS01 carrying mspA gene by resazurine microtiter assay,Other,19581465.0,
1931,565230,5,3,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium chelonae 9917 by resazurine microtiter assay,Other,19581465.0,
1932,565231,5,3,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium chelonae 9917 harboring pZS01 carrying mspA gene by resazurine microtiter assay,Other,19581465.0,
1933,566037,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis CMCC 93202 after 72 hrs by serial double dilution technique,Other,21146257.0,
1934,566038,6,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by serial double dilution technique,Other,21146257.0,
1935,566039,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 09710 after 7 days by serial double dilution technique,Other,21146257.0,
1936,566040,4,2,,103168230,3767,Unspecified,,,6282.8,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat,Confirmatory,21146257.0,
1937,566041,1,5,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 27294",Other,21146257.0,
1938,566905,6,3,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of bacterial growth in log phase by agar dilution method,Other,21093117.0,
1939,566906,6,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of bacterial growth in dormant phase,Other,21093117.0,
1940,567906,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21237641.0,
1941,569255,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,21232949.0,
1942,569256,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium bovis BCG str. Tokyo 172,Other,21232949.0,
1943,569258,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium subsp. hominissuis 104,Other,21232949.0,
1944,569259,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium subsp. avium ATCC 2529I,Other,21232949.0,
1945,569260,4,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus,Other,21232949.0,
1946,569261,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 873,Other,21232949.0,
1947,569262,5,3,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH5alpha,Other,21232949.0,
1948,571668,2,3,,103168230,3767,Unspecified,,,,,Cmax in 10'6 human THP1 cells at 3 ug/ml after 10 mins by HPLC,Other,18591268.0,
1949,571669,2,3,,103168230,3767,Unspecified,,,,,Cmax in 10'6 human THP1 cells at 3 ug/ml administered as microparticles after 10 mins by HPLC,Other,18591268.0,
1950,571670,5,1,,103168230,3767,Unspecified,,,,,Elimination rate constant in human THP1 cells at 3 ug/ml after 10 mins by HPLC,Other,18591268.0,
1951,571671,5,1,,103168230,3767,Unspecified,,,,,Elimination rate constant in human THP1 cells at 3 ug/ml administered as microparticles after 10 mins by HPLC,Other,18591268.0,
1952,571672,3,2,,103168230,3767,Unspecified,,,,,Cmax in 10'6 mouse alveolar macrophages at 4 to 5 mg/kg administered as inhalable dose measured 6 hrs postinhalation by HPLC,Other,18591268.0,
1953,571673,3,2,,103168230,3767,Unspecified,,,,,"Cmax in 10'6 mouse alveolar macrophages at 4 to 5 mg/kg, iv measured after 4 hrs by HPLC",Other,18591268.0,
1954,571674,5,2,,103168230,3767,Unspecified,,,,,"Plasma concentration in BALB/c mouse at 4 to 5 mg/kg, iv administered as single bolus dose by HPLC",Other,18591268.0,
1955,571675,5,2,,103168230,3767,Unspecified,,,,,Plasma concentration in BALB/c mouse at 4 to 5 mg/kg administered as inhalable bolus dose by HPLC,Other,18591268.0,
1956,571676,4,1,,103168230,3767,Unspecified,,,,,"AUC (OBS) in BALB/c mouse serum at 4 to 5 mg/kg, iv administered as single bolus dose by HPLC",Other,18591268.0,
1957,571677,4,1,,103168230,3767,Unspecified,,,,,AUC (OBS) in BALB/c mouse serum at 4 to 5 mg/kg administered as inhalable bolus dose by HPLC,Other,18591268.0,
1958,571678,2,4,,103168230,3767,Unspecified,,,,,"Half life in BALB/c mouse serum at 4 to 5 mg/kg, iv administered as single bolus dose by HPLC",Other,18591268.0,
1959,571679,2,4,,103168230,3767,Unspecified,,,,,Half life in BALB/c mouse serum at 4 to 5 mg/kg administered as inhalable bolus dose by HPLC,Other,18591268.0,
1960,571680,4,1,,103168230,3767,Unspecified,,,,,"Volume of distribution in BALB/c mouse at 4 to 5 mg/kg, iv administered as single bolus dose by HPLC",Other,18591268.0,
1961,571681,4,1,,103168230,3767,Unspecified,,,,,Volume of distribution in BALB/c mouse at 4 to 5 mg/kg administered as inhalable bolus dose by HPLC,Other,18591268.0,
1962,571682,3,2,,103168230,3767,Unspecified,,,,,"Clearance in BALB/c mouse at 4 to 5 mg/kg, iv administered as single bolus dose by HPLC",Other,18591268.0,
1963,571683,3,2,,103168230,3767,Unspecified,,,,,Clearance in BALB/c mouse at 4 to 5 mg/kg administered as inhalable bolus dose by HPLC,Other,18591268.0,
1964,572889,2,4,,103168230,3767,Unspecified,,,,,"Antibacterial activity against Mycobacterium tuberculosis Erdman infected in gamma interferon gene knockout C57BL/6 mouse assessed as bacterial load in lung at 25 mg/kg, po administered 18 days postinfection for 9 days measured on day 24 (Rvb= 4.47+/-0.12 log CFU)",Other,18625764.0,
1965,572890,2,4,,103168230,3767,Unspecified,,,,,"Antibacterial activity against Mycobacterium tuberculosis Erdman infected in gamma interferon gene knockout C57BL/6 mouse assessed as bacterial load in spleen at 25 mg/kg, po administered 18 days postinfection for 9 days measured on day 24 (Rvb= 6.57+/-0.17 log CFU)",Other,18625764.0,
1966,572894,2,4,,103168230,3767,Unspecified,,,,,"Antibacterial activity against Mycobacterium tuberculosis Erdman infected in gamma interferon gene knockout C57BL/6 mouse assessed as log reduction in bacterial load in lung at 25 mg/kg, po administered 18 days postinfection for 9 days measured on day 24 relative to control",Other,18625764.0,
1967,572895,2,4,,103168230,3767,Unspecified,,,,,"Antibacterial activity against Mycobacterium tuberculosis Erdman infected in gamma interferon gene knockout C57BL/6 mouse assessed as log reduction in bacterial load in spleen at 25 mg/kg, po administered 18 days postinfection for 9 days measured on day 24 relative to control",Other,18625764.0,
1968,574582,2,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 obtained from sputum of patient at 0.1 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1969,574588,2,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 obtained from pus of patient at 0.1 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1970,574783,2,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2403 obtained from sputum of patient at 0.1 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1971,574789,2,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 obtained from sputum of patient at 0.1 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1972,574795,2,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 obtained from sputum of patient at 0.1 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1973,574801,2,3,,103168230,3767,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 obtained from sputum of patient at 0.1 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1974,574806,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method",Other,20713679.0,
1975,574807,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method",Other,20713679.0,
1976,574808,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method",Other,20713679.0,
1977,574809,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method",Other,20713679.0,
1978,574810,5,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method",Other,20713679.0,
1979,574811,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method,Other,20713679.0,
1980,576904,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 by broth microdilution method,Other,20566771.0,
1981,576905,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5089 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv1484 InhA gene by broth microdilution method,Other,20566771.0,
1982,576906,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5097 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2763c DfrA gene by broth microdilution method,Other,20566771.0,
1983,576907,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv3248c SahH gene by broth microdilution method,Other,20566771.0,
1984,576908,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0753c MmsA gene by broth microdilution method,Other,20566771.0,
1985,576909,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv1187 RocA gene by broth microdilution method,Other,20566771.0,
1986,576910,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0155 PntAA gene by broth microdilution method,Other,20566771.0,
1987,576911,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2623 universal stress protein gene by broth microdilution method,Other,20566771.0,
1988,576912,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv1996 universal stress protein gene by broth microdilution method,Other,20566771.0,
1989,576913,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0468 FadB2 gene by broth microdilution method,Other,20566771.0,
1990,576914,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2691 CeoB/TrKA gene by broth microdilution method,Other,20566771.0,
1991,576915,2,3,,103168230,3767,Inactive,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0091 Mtn/Sah gene by broth microdilution method,Other,20566771.0,
1992,576916,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2858c Aldc gene by broth microdilution method,Other,20566771.0,
1993,576917,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv1059 unknown gene by broth microdilution method,Other,20566771.0,
1994,576918,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0926c unknown gene by broth microdilution method,Other,20566771.0,
1995,576919,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv3777 probable oxidoreductase gene by broth microdilution method,Other,20566771.0,
1996,576920,2,3,,103168230,3767,Inactive,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2971 probable oxidoreductase gene by broth microdilution method,Other,20566771.0,
1997,576921,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2766 FabG5 gene by broth microdilution method,Other,20566771.0,
1998,576922,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2671 RibD gene by broth microdilution method,Other,20566771.0,
1999,576923,1,3,,103168230,3767,Unspecified,,,,,Ratio of MIC for Mycobacterium smegmatis overexpressing dfrA gene to MIC for wild-type Mycobacterium smegmatis,Other,20566771.0,
2000,576924,2,3,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5072 overexpressing dhfr gene assessed as growth inhibition at 10 ug/ml,Other,20566771.0,
2001,576925,2,3,,103168230,3767,Inactive,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5071 overexpressing InhA gene assessed as growth inhibition at 10 ug/ml,Other,20566771.0,
2002,576926,2,3,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5072 overexpressing dhfr gene assessed as growth inhibition at 120 ug/ml,Other,20566771.0,
2003,576927,2,3,,103168230,3767,Inactive,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5071 overexpressing InhA gene assessed as growth inhibition at 120 ug/ml,Other,20566771.0,
2004,576928,2,3,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5069 assessed as growth inhibition at 50 ug/ml,Other,20566771.0,
2005,576929,2,3,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5069 assessed as growth inhibition at 150 ug/ml,Other,20566771.0,
2006,576930,2,3,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5071 overexpressing InhA gene assessed as growth inhibition at 50 ug/ml,Other,20566771.0,
2007,576931,2,3,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium smegmatis MC2 5071 overexpressing InhA gene assessed as growth inhibition at 150 ug/ml,Other,20566771.0,
2008,576932,5,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against wild-type Mycobacterium tuberculosis H37Rv by MTT assay,Other,20566771.0,
2009,576933,2,4,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv harboring pMV261::dfrA plasmid by MTT assay,Other,20566771.0,
2010,576934,2,4,,103168230,3767,Inactive,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv harboring pMV261::InhA plasmid by MTT assay,Other,20566771.0,
2011,576935,2,4,,103168230,3767,Unspecified,,,,,Ratio of MIC for Mycobacterium tuberculosis H37RV harboring pMV261::InhA plasmid to MIC for wild-type Mycobacterium tuberculosis H37Rv,Other,20566771.0,
2012,576936,6,5,,103168230,3767,Active,803341899.0,,0.001,Ki,Inhibition of Mycobacterium tuberculosis dihydrofolate reductase,Confirmatory,20566771.0,
2013,576937,1,3,,103168230,3767,Inactive,,,,,Antimicrobial activity against Escherichia coli expressing katG and dfrA gene,Other,20566771.0,
2014,580321,5,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 5 days by tetrazolium microplate assay,Other,21334900.0,
2015,580322,4,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate after 5 days by tetrazolium microplate assay,Other,21334900.0,
2016,587940,6,1,,103168230,3767,Active,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 7 days by MTT assay,Other,21309577.0,
2017,587941,4,2,,103168230,3767,Unspecified,,,3649.0,IC50,Cytotoxicity against human THP1 cells after 72 hrs by MTT assay,Confirmatory,21309577.0,
2018,587942,1,4,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for human THP1 cells to MIC for Mycobacterium tuberculosis H37Rv",Other,21309577.0,
2019,587943,6,1,,103168230,3767,Active,,,,,Antituberculosis activity against Mycobacterium tuberculosis MYC5165 harboring InhA mutant gene after 7 days by MTT assay,Other,21309577.0,
2020,587944,6,1,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis 1400 harboring KatG mutant gene after 7 days by MTT assay,Other,21309577.0,
2021,588209,2,3,,103168230,3767,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2022,588210,2,4,,103168230,3767,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2023,588211,2,3,,103168230,3767,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2024,588212,2,3,,103168230,3767,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2025,588213,2,3,,103168230,3767,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2026,588214,2,3,,103168230,3767,Active,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2027,588215,2,3,,103168230,3767,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2028,588216,2,3,,103168230,3767,Active,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2029,588217,2,3,,103168230,3767,Active,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2030,588218,2,3,,103168230,3767,Active,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2031,588219,2,3,,103168230,3767,Active,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2032,588220,2,3,,103168230,3767,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
2033,588334,1,1,,49718175,3767,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2034,588335,1,1,,49718175,3767,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2035,588342,1,1,,855769,3767,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2036,588352,1,2,,49718175,3767,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2037,588354,1,1,,49718175,3767,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2038,588358,1,2,,49718175,3767,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2039,588368,1,2,,855769,3767,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2040,588391,1,1,,49718175,3767,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2041,588405,1,1,,49718175,3767,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2042,588413,1,2,,49718175,3767,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2043,588436,1,1,,855769,3767,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2044,588436,1,1,,49718175,3767,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2045,588453,1,1,,49718175,3767,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2046,588456,1,1,,49718175,3767,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2047,588458,1,1,,49718175,3767,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2048,588459,1,2,,855769,3767,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2049,588459,1,2,,855769,3767,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2050,588459,1,2,,855769,3767,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2051,588460,1,2,,855769,3767,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2052,588460,1,2,,855769,3767,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2053,588460,1,2,,855769,3767,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2054,588461,1,2,,855769,3767,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2055,588461,1,2,,855769,3767,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2056,588461,1,2,,855769,3767,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2057,588473,1,1,,49718175,3767,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2058,588473,1,1,,49718175,3767,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2059,588475,1,2,,49718175,3767,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2060,588475,1,2,,49718175,3767,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2061,588478,1,2,,124800826,3767,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2062,588489,1,1,,49718175,3767,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2063,588492,1,1,,49718175,3767,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2064,588493,1,2,,49718175,3767,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2065,588497,1,2,,49718175,3767,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2066,588497,1,2,,49718175,3767,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2067,588497,1,2,,49718175,3767,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2068,588499,1,3,,49718175,3767,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2069,588499,1,3,,49718175,3767,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2070,588499,1,3,,49718175,3767,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2071,588501,1,2,,49718175,3767,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2072,588501,1,2,,49718175,3767,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2073,588501,1,2,,49718175,3767,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2074,588506,1,2,,855769,3767,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2075,588513,1,1,,17389848,3767,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2076,588514,1,1,,17389848,3767,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2077,588515,1,1,,17389848,3767,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2078,588516,1,1,,17389848,3767,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2079,588519,1,2,,92124073,3767,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2080,588519,1,2,,92124987,3767,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2081,588526,1,1,,17389848,3767,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2082,588527,1,1,,17389848,3767,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2083,588532,1,1,,17389848,3767,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2084,588533,1,1,,17389848,3767,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2085,588534,1,1,,17389848,3767,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2086,588535,1,1,,17389848,3767,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2087,588536,1,1,,17389848,3767,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2088,588537,1,1,,17389848,3767,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2089,588541,1,1,,17389848,3767,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2090,588543,1,1,,17389848,3767,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2091,588544,1,1,,17389848,3767,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2092,588545,1,1,,17389848,3767,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2093,588546,1,1,,17389848,3767,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2094,588547,1,1,,17389848,3767,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2095,588549,1,1,,49718175,3767,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2096,588550,1,1,,855769,3767,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2097,588579,1,1,,11112128,3767,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2098,588579,1,1,,49718175,3767,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2099,588579,1,1,,124881930,3767,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2100,588579,1,1,,124881932,3767,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2101,588590,1,1,,49718175,3767,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2102,588591,1,1,,49718175,3767,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2103,588621,1,1,,49718175,3767,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2104,588664,1,2,,49718175,3767,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2105,588664,1,2,,49718175,3767,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2106,588674,1,2,,855769,3767,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2107,588674,1,2,,49718175,3767,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2108,588685,1,1,,855769,3767,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2109,588689,1,1,,49718175,3767,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2110,588692,2,1,,49718175,3767,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2111,588726,1,2,,49718175,3767,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2112,588727,1,1,,49718175,3767,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2113,588795,1,1,,49718175,3767,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2114,588814,1,3,,49718175,3767,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2115,588819,1,4,,49718175,3767,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2116,588834,2,1,,17389848,3767,Inconclusive,325651834.0,3757.0,35.4813,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2117,588850,1,1,,49718175,3767,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2118,588852,1,3,,49718175,3767,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2119,588855,1,1,,49718175,3767,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2120,588856,1,1,,49718175,3767,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2121,589055,1,10,,103168230,3767,Unspecified,117250.0,1571.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP2E1",Other,,
2122,589165,3,7,,103168230,3767,Unspecified,116241312.0,1576.0,,Ki,Mechanism based inhibition of human cytochrome P450 3A4 was evaluated using S-mephenytoin,Confirmatory,16248836.0,
2123,589218,3,7,,103168230,3767,Unspecified,117144.0,1544.0,,Ki,Mechanism based inhibition of human cytochrome P450 1A2 measured by phenacetin O-deethylation (POD),Confirmatory,16248836.0,
2124,589229,3,7,,103168230,3767,Unspecified,308153612.0,1548.0,,Ki,Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation,Confirmatory,16248836.0,
2125,589250,3,7,,103168230,3767,Unspecified,60416369.0,1557.0,,Ki,Mechanism based inhibition of human cytochrome P450 2C19 evaluated using Tolbutamide,Confirmatory,16248836.0,
2126,589253,3,7,,103168230,3767,Unspecified,117225.0,1558.0,,Ki,Mechanism based inhibition of human cytochrome P450 2C8 measured by paclitaxel hydroxylation using a recombinant system,Confirmatory,16248836.0,
2127,589254,3,7,,103168230,3767,Unspecified,117225.0,1558.0,,Ki,Mechanism based inhibition of human cytochrome P450 2C8 using human liver microsomes,Confirmatory,16248836.0,
2128,589638,4,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21320779.0,
2129,589639,4,1,,103168230,3767,Active,,,,,Antimicrobial activity against multidrug-resisntat Mycobacterium tuberculosis by agar dilution method,Other,21320779.0,
2130,589640,3,2,,103168230,3767,Unspecified,,,455.73,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,21320779.0,
2131,590140,4,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay,Other,21376591.0,
2132,590141,4,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by LORA assay,Other,21376591.0,
2133,590862,1,4,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv,Other,21429744.0,
2134,594787,4,1,,103168230,3767,Active,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21498077.0,
2135,594795,4,1,,103168230,3767,Active,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21507635.0,
2136,594923,1,3,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium vanbaalenii assessed as growth inhibition at 30 uM after 72 hrs by microplate reader,Other,21397998.0,
2137,594925,1,3,,103168230,3767,Active,,,,,Antibacterial activity against Rhodococcus opacus assessed as growth inhibition at 50 uM after 72 hrs by microplate reader,Other,21397998.0,
2138,594930,3,2,,103168230,3767,Active,,,15.0,IC50,Antibacterial activity against Mycobacterium tuberculosis assessed as inhibition of cell growth after 24 hrs,Confirmatory,21397998.0,
2139,595428,4,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,21341709.0,
2140,598739,1,4,,103168230,3767,Unspecified,,,,,"Selectivity index, Ratio of CC50 for african green monkey Vero cells to IC90 for Mycobacterium tuberculosis H37Rv ATCC 27294",Other,21570839.0,
2141,598740,4,2,,103168230,3767,Active,,,,IC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate Alamar blue assay,Confirmatory,21570839.0,
2142,598779,3,2,,103168230,3767,Unspecified,,,500.0,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by Cell titer Glo luminescent cell viability assay,Confirmatory,21570839.0,
2143,599009,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21592801.0,
2144,599246,4,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 after 3 days by MTT assay,Other,21429630.0,
2145,599247,4,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis mc2155 after 3 days by MTT assay,Other,21429630.0,
2146,599272,4,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 6841 after 3 days by MTT assay,Other,21429630.0,
2147,599273,4,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium phlei ATCC 11758 after 3 days by MTT assay,Other,21429630.0,
2148,599274,1,4,,103168230,3767,Inconclusive,,,,,Cytotoxicity against human MRC5 cells assessed as cell viability at 100 uM after 72 hrs by XTT assay,Other,21429630.0,
2149,599275,1,4,,103168230,3767,Inconclusive,,,,,Cytotoxicity against human MRC5 cells assessed as cell viability at 30 uM after 72 hrs by XTT assay,Other,21429630.0,
2150,599556,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay,Other,21450375.0,
2151,600827,4,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by resazurin method,Other,21489660.0,
2152,600828,4,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 19420 after 7 days by resazurin method,Other,21489660.0,
2153,600829,4,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 19542 after 7 days by resazurin method,Other,21489660.0,
2154,600830,1,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as inhibition of bacterial growth at 1 to 100 ug/ml after 7 days by resazurin method,Other,21489660.0,
2155,602123,1,1,,49718175,3767,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2156,602141,1,1,,49718175,3767,Active,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2157,602162,1,1,,49718175,3767,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2158,602163,1,1,,49718175,3767,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2159,602179,1,2,,49718175,3767,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2160,602229,1,1,,49718175,3767,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2161,602233,1,1,,49718175,3767,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2162,602244,1,2,,49718175,3767,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2163,602247,1,2,,49718175,3767,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2164,602248,1,2,,49718175,3767,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2165,602250,1,2,,49718175,3767,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2166,602252,1,1,,49718175,3767,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2167,602252,1,1,,49718175,3767,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2168,602261,1,1,,49718175,3767,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2169,602274,1,2,,49718175,3767,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2170,602276,1,1,,855769,3767,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
2171,602277,1,1,,855769,3767,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
2172,602281,1,1,,49718175,3767,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2173,602281,1,1,,49718175,3767,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2174,602310,1,2,,49718175,3767,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2175,602313,1,1,,49718175,3767,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2176,602314,1,2,,92124073,3767,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2177,602314,1,2,,92124987,3767,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2178,602329,1,1,,49718175,3767,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2179,602332,1,1,,11112128,3767,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2180,602332,1,1,,49718175,3767,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2181,602332,1,1,,124881930,3767,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2182,602332,1,1,,124881932,3767,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2183,602332,1,1,,124881933,3767,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2184,602340,1,2,,49718175,3767,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2185,602342,2,1,,49718175,3767,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2186,602346,1,1,,855769,3767,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2187,602346,1,1,,49718175,3767,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2188,602363,1,1,,855769,3767,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2189,602363,1,1,,49718175,3767,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2190,602393,1,1,,855769,3767,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2191,602393,1,1,,49718175,3767,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2192,602396,1,2,,49718175,3767,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2193,602399,1,2,,49718175,3767,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2194,602405,1,1,,49718175,3767,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2195,602410,1,1,,49718175,3767,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2196,602429,1,1,,49718175,3767,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2197,602438,1,1,,49718175,3767,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2198,602440,1,1,,49718175,3767,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2199,602449,1,2,,49718175,3767,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2200,602481,1,1,,49718175,3767,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2201,603129,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 24 hrs by tetrazolium microplate assay,Other,21419633.0,
2202,603130,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate 02TBDM039EP097 after 24 hrs by tetrazolium microplate assay,Other,21419633.0,
2203,603726,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 28 days by agar dilution method,Other,21641797.0,
2204,603735,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21641799.0,
2205,603876,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against non-replicating Mycobacterium tuberculosis H37Rv ATCC 27294 incubated 10 days under anaerobic condition measured after 28 hrs of recovery in air by luciferase based low oxygen recovery assay,Other,21546135.0,
2206,603879,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against replicating Mycobacterium tuberculosis H37Rv ATCC 27294 after 1 week by microplate alamar blue assay,Other,21546135.0,
2207,604174,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,21665469.0,
2208,609619,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21733688.0,
2209,609620,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis by agar dilution method,Other,21733688.0,
2210,609928,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 30 days by agar microdilution method,Other,21737274.0,
2211,609932,1,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in mouse bone marrow macrophages assessed as intracellular growth inhibition after 4 days,Other,21737274.0,
2212,609933,2,3,,103168230,3767,Unspecified,,,,,Inhibition of albino rat intestine alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 100 uM,Other,21737274.0,
2213,610801,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 4 days by MABA assay,Other,21546254.0,
2214,610802,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv transfected with pFPCA-luxAB grown under anaerobic condition for 10 days followed by 24 hrs incubation under aerobic condition by LORA assay,Other,21546254.0,
2215,613195,4,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by MTT assay,Other,21712145.0,
2216,613617,1,4,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv at 250 ug/mL after 24 hrs by Lowenstein-Jensen method,Other,21741732.0,
2217,613618,3,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 24 hrs by Lowenstein-Jensen method,Other,21741732.0,
2218,613871,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against active log phase Mycobacterium smegmatis ATCC 14468 by agar dilution method,Other,21840711.0,
2219,613872,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against active log phase Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21840711.0,
2220,613873,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against 6-weeks nutrient starved phase cultures of Mycobacterium smegmatis ATCC 14468 treated for 7 days measured after 4 weeks by agar dilution method,Other,21840711.0,
2221,613874,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against 6-weeks nutrient starved phase cultures of Mycobacterium tuberculosis H37Rv treated for 7 days measured after 4 weeks by agar dilution method,Other,21840711.0,
2222,613878,3,2,,103168230,3767,Unspecified,,,455.73,CC50,Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,21840711.0,
2223,613880,3,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 7 days by microbroth dilution method,Other,21840723.0,
2224,614136,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 4 days by MABA assay,Other,21824772.0,
2225,616691,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 4 weeks by agar proportion method,Other,21764184.0,
2226,616692,1,4,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as growth inhibition at 10 times MIC after 24 hrs by MTS assay,Other,21764184.0,
2227,616693,1,5,,103168230,3767,Unspecified,,,,,Cytotoxicity against mouse BMDM cells assessed as growth inhibition at 10 times MIC after 24 hrs by MTS assay,Other,21764184.0,
2228,616696,1,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in Swiss mouse infected assessed as mouse survival at 25 mg/kg/day, po for 28 days measured on day 30 post infection",Other,21764184.0,
2229,616698,1,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in Swiss mouse infected assessed as mean survival time of mouse at 25 mg/kg/day, po for 28 days measured on day 30 post infection",Other,21764184.0,
2230,616700,1,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in Swiss mouse infected assessed as mouse survival at 25 mg/kg/day, po for 28 days measured on day 40 post infection",Other,21764184.0,
2231,616702,1,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in Swiss mouse infected assessed as mean survival time of mouse survival at 28 mg/kg/day, po for 28 days measured on day 40 post infection",Other,21764184.0,
2232,616791,1,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in Swiss mouse assessed as inhibition of viable bacterial counts in lungs at 25 mg/kg, po for 28 days measured on day 30 post infection",Other,21764184.0,
2233,616918,1,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis pSMT1 infected in mouse J774A.1 ATCC TIB-67 cells assessed as viable bacterial count at 0.125 ug/ml for 4 days followed by 3 days incubation in drug-free medium by luciferase reporter gene assay,Other,21807506.0,
2234,616940,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 2 weeks by BACTEC 460 radiometric method,Other,21807509.0,
2235,617025,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis after 2 weeks by BACTEC 460 radiometric method,Other,21807509.0,
2236,617280,6,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by Microplate Alamar blue assay,Other,21776985.0,
2237,617850,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against drug sensitive Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate Alamar blue assay,Other,21859082.0,
2238,617851,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis CIBIN/UMF15:99 isolate by microplate Alamar blue assay,Other,21859082.0,
2239,618417,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 28 days by agar dilution method,Other,21723649.0,
2240,618737,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 4 weeks by agar dilution assay,Other,21783364.0,
2241,618758,4,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 9 days by resazurin reduction assay,Other,21820768.0,
2242,618760,4,1,,103168230,3767,Active,,,,,Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822 harboring Ser-315-Tri mutation in katG gene after 9 days by resazurin reduction assay,Other,21820768.0,
2243,619381,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by colony forming unit determination,Other,21855181.0,
2244,619382,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis A8 241 after 28 days by colony forming unit determination,Other,21855181.0,
2245,619383,1,4,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 27294",Other,21855181.0,
2246,619384,1,4,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to MIC for multidrug-resistant Mycobacterium tuberculosis A8 241",Other,21855181.0,
2247,619385,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNTC 330/88 after 14 days,Other,21855181.0,
2248,619386,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNTC 330/88 after 21 days,Other,21855181.0,
2249,619387,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC My 235/80 after 7 days,Other,21855181.0,
2250,619388,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC My 235/80 after 14 days,Other,21855181.0,
2251,619389,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC My 235/80 after 21 days,Other,21855181.0,
2252,619390,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC 6509/96 after 7 days,Other,21855181.0,
2253,619391,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC 6509/96 after 14 days,Other,21855181.0,
2254,619392,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC 6509/96 after 21 days,Other,21855181.0,
2255,619393,3,2,,103168230,3767,Unspecified,,,1000.0,IC50,Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay,Confirmatory,21855181.0,
2256,619394,3,2,,103168230,3767,Unspecified,,,4670.0,IC50,Cytotoxicity against human PBMC measured after overnight incubation by MTT assay,Confirmatory,21855181.0,
2257,619395,3,4,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay,Confirmatory,21855181.0,
2258,619448,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis H37Rv after 28 days by agar dilution method,Other,21855182.0,
2259,619608,4,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,21839549.0,
2260,620088,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by resazurin assay,Other,21880400.0,
2261,620089,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis ATCC 19420 after 7 days by resazurin assay,Other,21880400.0,
2262,620090,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium fortuitum ATCC 19542 after 7 days by resazurin assay,Other,21880400.0,
2263,620091,1,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by resazurin assay,Other,21880400.0,
2264,621894,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay,Other,21919533.0,
2265,623578,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis ATCC 12051 after 5 days by microbroth dilution antibiotic susceptibility assay,Other,21978379.0,
2266,623579,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium diernhoferi ATCC 19340 after 5 days by microbroth dilution antibiotic susceptibility assay,Other,21978379.0,
2267,623580,3,2,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against vancomycin-resistant Enterococcus faecium Ef 379 after 22 hrs by microbroth dilution antibiotic susceptibility assay,Other,21978379.0,
2268,623581,3,2,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 22 hrs by microbroth dilution antibiotic susceptibility assay,Other,21978379.0,
2269,623585,3,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against 5 x 10'4 inoculum per tube Mycobacterium tuberculosis H37Rv after 24 hrs by Lowenstein-Jensen method,Other,21981980.0,
2270,623633,4,1,,103168230,3767,Active,,,,,Antituberculosis activity against 10'7 cfu/mL Mycobacterium tuberculosis H37Rv after 28 days,Other,21937152.0,
2271,623645,1,4,,103168230,3767,Unspecified,,,,,Antituberculosis activity against 5 x 10'4 bacilli per tube Mycobacterium tuberculosis H37Rv assessed as growth inhibition at 0.20 ug/mL incubated for 24 hrs measured after 28 days,Other,21981980.0,
2272,623870,1,1,,49718175,3767,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2273,623870,1,1,,49718175,3767,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2274,623877,1,1,,49718175,3767,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2275,623901,1,1,,49718175,3767,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2276,624030,1,2,,124881933,3767,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2277,624037,1,3,,49718175,3767,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2278,624038,1,3,,49718175,3767,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2279,624040,1,3,,49718175,3767,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2280,624125,1,4,,49718175,3767,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2281,624126,1,3,,49718175,3767,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2282,624127,1,2,,49718175,3767,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2283,624168,1,1,,49718175,3767,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2284,624169,1,1,,49718175,3767,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2285,624170,1,1,,49718175,3767,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2286,624170,1,1,,124881933,3767,Inactive,71051501.0,2744.0,31.6228,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2287,624171,1,1,,49718175,3767,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2288,624172,1,1,,49718175,3767,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2289,624172,1,1,,124881933,3767,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2290,624173,1,3,,49718175,3767,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2291,624173,1,3,,124881933,3767,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2292,624178,1,1,,49718175,3767,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2293,624202,1,1,,49718175,3767,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2294,624204,1,2,,49718175,3767,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2295,624246,1,1,,49718175,3767,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2296,624256,1,2,,49718175,3767,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2297,624263,1,1,,49718175,3767,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2298,624263,1,1,,49718175,3767,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2299,624267,1,2,,49718175,3767,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2300,624267,1,2,,49718175,3767,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2301,624268,1,3,,49718175,3767,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2302,624288,1,1,,49718175,3767,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2303,624296,1,1,,855769,3767,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2304,624296,1,1,,49718175,3767,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2305,624297,1,1,,855769,3767,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2306,624297,1,1,,49718175,3767,Inconclusive,7705682.0,51053.0,0.7943,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2307,624304,1,2,,49718175,3767,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2308,624330,1,2,,49718175,3767,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2309,624349,1,2,,92124073,3767,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2310,624349,1,2,,92124987,3767,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2311,624349,1,2,,92307469,3767,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2312,624349,1,2,,92308852,3767,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2313,624349,1,2,,121362444,3767,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2314,624349,1,2,,121362658,3767,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2315,624352,1,1,,49718175,3767,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2316,624354,1,1,,49718175,3767,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2317,624377,1,1,,49718175,3767,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2318,624414,1,1,,49718175,3767,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2319,624415,1,2,,49718175,3767,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2320,624416,1,1,,49718175,3767,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2321,624417,1,1,,49718175,3767,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2322,624418,1,1,,49718175,3767,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2323,624463,1,1,,49718175,3767,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2324,624464,1,1,,49718175,3767,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2325,624465,1,1,,49718175,3767,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2326,624466,1,3,,49718175,3767,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2327,624467,1,1,,49718175,3767,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2328,624483,1,1,,49718175,3767,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2329,625144,5,5,,103168230,3767,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2330,625145,4,7,,103168230,3767,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2331,625146,5,5,,103168230,3767,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2332,625147,4,7,,103168230,3767,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2333,625148,4,7,,103168230,3767,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2334,625149,4,7,,103168230,3767,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2335,625150,5,5,,103168230,3767,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2336,625151,4,7,,103168230,3767,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2337,625152,4,7,,103168230,3767,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2338,625153,4,7,,103168230,3767,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2339,625154,4,7,,103168230,3767,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2340,625155,4,7,,103168230,3767,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2341,625156,1,9,,103168230,3767,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2342,625157,6,2,,103168230,3767,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2343,625158,3,4,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2344,625159,5,5,,103168230,3767,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2345,625160,1,9,,103168230,3767,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2346,625161,4,7,,103168230,3767,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2347,625162,4,7,,103168230,3767,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2348,625163,4,7,,103168230,3767,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2349,625164,1,6,,103168230,3767,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2350,625165,3,4,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2351,625166,3,4,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2352,625167,5,5,,103168230,3767,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2353,625168,4,7,,103168230,3767,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2354,625169,1,6,,103168230,3767,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2355,625170,3,4,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2356,625171,4,7,,103168230,3767,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2357,625172,4,7,,103168230,3767,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2358,625173,5,5,,103168230,3767,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2359,625174,5,5,,103168230,3767,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2360,625175,5,5,,103168230,3767,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2361,625176,1,9,,103168230,3767,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2362,625177,5,5,,103168230,3767,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2363,625178,5,5,,103168230,3767,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2364,625179,1,9,,103168230,3767,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2365,625180,5,5,,103168230,3767,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2366,625181,5,5,,103168230,3767,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2367,625182,5,5,,103168230,3767,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2368,625183,5,5,,103168230,3767,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2369,625184,5,5,,103168230,3767,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2370,625185,5,5,,103168230,3767,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2371,625186,5,5,,103168230,3767,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2372,625187,5,5,,103168230,3767,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2373,625188,1,9,,103168230,3767,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2374,625189,1,7,,103168230,3767,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2375,625190,4,5,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2376,625191,4,7,,103168230,3767,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2377,625192,4,7,,103168230,3767,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2378,625193,5,5,,103168230,3767,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2379,625194,4,7,,103168230,3767,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2380,625195,4,7,,103168230,3767,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2381,625196,5,6,,103168230,3767,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2382,625197,3,4,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2383,625198,4,7,,103168230,3767,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2384,625199,4,7,,103168230,3767,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2385,625200,4,7,,103168230,3767,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2386,625201,4,7,,103168230,3767,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2387,625202,4,7,,103168230,3767,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2388,625203,4,7,,103168230,3767,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2389,625204,4,7,,103168230,3767,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2390,625205,4,7,,103168230,3767,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2391,625206,4,7,,103168230,3767,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2392,625207,4,7,,103168230,3767,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2393,625208,5,5,,103168230,3767,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2394,625209,4,7,,103168230,3767,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2395,625210,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2396,625211,1,6,,103168230,3767,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2397,625212,3,4,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2398,625213,4,7,,103168230,3767,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2399,625214,1,9,,103168230,3767,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2400,625215,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2401,625216,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2402,625217,4,7,,103168230,3767,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2403,625218,4,7,,103168230,3767,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2404,625219,3,4,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2405,625220,4,7,,103168230,3767,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2406,625221,4,7,,103168230,3767,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2407,625222,4,7,,103168230,3767,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2408,625223,4,7,,103168230,3767,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2409,625224,3,4,,103168230,3767,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2410,625225,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2411,625226,4,7,,103168230,3767,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2412,625227,4,7,,103168230,3767,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2413,625228,4,7,,103168230,3767,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2414,625229,5,5,,103168230,3767,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2415,625230,1,6,,103168230,3767,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2416,625231,4,7,,103168230,3767,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2417,625232,1,9,,103168230,3767,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2418,625233,4,7,,103168230,3767,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2419,625234,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2420,625235,4,7,,103168230,3767,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2421,625236,5,5,,103168230,3767,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2422,625237,4,7,,103168230,3767,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2423,625238,4,7,,103168230,3767,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2424,625239,4,7,,103168230,3767,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2425,625240,1,9,,103168230,3767,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2426,625241,4,7,,103168230,3767,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2427,625242,4,7,,103168230,3767,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2428,625243,5,5,,103168230,3767,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2429,625244,5,5,,103168230,3767,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2430,625245,5,5,,103168230,3767,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2431,625246,1,9,,103168230,3767,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2432,625247,5,5,,103168230,3767,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2433,625248,5,5,,103168230,3767,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2434,625249,5,5,,103168230,3767,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2435,625250,5,5,,103168230,3767,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2436,625251,5,5,,103168230,3767,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2437,625252,4,7,,103168230,3767,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2438,625253,4,7,,103168230,3767,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2439,625254,4,7,,103168230,3767,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2440,625255,4,7,,103168230,3767,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2441,625256,4,7,,103168230,3767,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2442,625257,4,7,,103168230,3767,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2443,625258,4,7,,103168230,3767,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2444,625259,4,7,,103168230,3767,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2445,625260,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2446,625261,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2447,625262,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2448,625263,4,7,,103168230,3767,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2449,625264,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2450,625265,1,6,,103168230,3767,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2451,625266,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2452,625267,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2453,625268,4,2,,103168230,3767,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2454,625268,4,2,,103168230,3767,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2455,625268,4,2,,103168230,3767,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2456,625268,4,2,,103168230,3767,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2457,625269,4,7,,103168230,3767,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2458,625270,4,7,,103168230,3767,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2459,625271,5,5,,103168230,3767,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2460,625272,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2461,625273,4,6,,103168230,3767,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2462,625274,1,6,,103168230,3767,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2463,625275,3,4,,103168230,3767,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2464,625276,1,3,,103168230,3767,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI,Other,21624500.0,
2465,625279,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2466,625280,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2467,625281,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2468,625282,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2469,625283,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2470,625284,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2471,625285,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2472,625286,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2473,625287,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2474,625288,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2475,625289,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2476,625290,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2477,625291,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2478,625292,1,3,,103168230,3767,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2479,625336,3,2,,103168230,3767,Unspecified,,,456.0,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,21978838.0,
2480,625337,4,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by two fold serial dilution method,Other,21978838.0,
2481,625338,4,1,,103168230,3767,Active,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis by two fold serial dilution method,Other,21978838.0,
2482,625488,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 24 hrs by microplate alamar blue assay,Other,21982497.0,
2483,625489,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against rifampicin and isoniazid-resistant Mycobacterium tuberculosis isolate 2199 after 24 hrs by microplate alamar blue assay,Other,21982497.0,
2484,625633,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNTC My 331/88 ATCC 27294 after 14 days,Other,22018878.0,
2485,625690,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNTC My 331/88 ATCC 27294 after 21 days,Other,22018878.0,
2486,625691,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNTC My 330/88 after 14 days,Other,22018878.0,
2487,625692,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNTC My 330/88 after 21 days,Other,22018878.0,
2488,625693,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC My 335/80 after 7 days,Other,22018878.0,
2489,625694,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC My 335/80 after 14 days,Other,22018878.0,
2490,625695,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNTC My 335/80 after 21 days,Other,22018878.0,
2491,625696,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 isolate after 7 days,Other,22018878.0,
2492,625697,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 isolate after 14 days,Other,22018878.0,
2493,625698,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 isolate after 21 days,Other,22018878.0,
2494,625699,3,2,,103168230,3767,Unspecified,,,1000.0,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,22018878.0,
2495,625700,3,2,,103168230,3767,Unspecified,,,4670.0,IC50,Cytotoxicity against human PBMC by MTT assay,Confirmatory,22018878.0,
2496,626867,3,2,,103168230,3767,Active,,,,,Antimicrobial activity against replicating Mycobacterium tuberculosis after 8 days by micro plate alamar blue assay,Other,21903392.0,
2497,626868,3,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against non-replicating Mycobacterium tuberculosis after 11 days by luminescence based low oxygen recovery assay,Other,21903392.0,
2498,626917,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 using compound level ranging from 1 to 100 ug/mL after 7 days by resazurin reduction test,Other,21907466.0,
2499,626918,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 ATCC 19420 using compound level ranging from 1 to 100 ug/mL after 7 days by resazurin reduction test,Other,21907466.0,
2500,626919,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 19542 using compound level ranging from 1 to 100 ug/mL after 7 days by resazurin reduction test,Other,21907466.0,
2501,626920,1,4,,103168230,3767,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv ATCC 27294 using compound level ranging from 1 to 100 ug/mL after 7 days by resazurin reduction test,Other,21907466.0,
2502,626921,3,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampicin and ethambuto-resistant Mycobacterium tuberculosis using compound level ranging from 0.3125 to 5 ug/mL after 7 days by resazurin reduction test",Other,21907466.0,
2503,626922,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 using compound level ranging from 0.3125 to 5 ug/mL after 7 days by resazurin reduction test,Other,21907466.0,
2504,626923,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 ATCC 19420 using compound level ranging from 0.3125 to 5 ug/mL after 7 days by resazurin reduction test,Other,21907466.0,
2505,626924,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 19542 using compound level ranging from 0.3125 to 5 ug/mL after 7 days by resazurin reduction test,Other,21907466.0,
2506,628413,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin based microdilution assay,Other,21917452.0,
2507,628414,3,2,,103168230,3767,Unspecified,,,1459.85,CC50,Cytotoxicity against african green monkey Vero C1008 cells after 72 hrs by MTT assay,Confirmatory,21917452.0,
2508,630083,3,2,,103168230,3767,Active,,,,IC50,Antimycobacterial activity Mycobacterium tuberculosis H37Rv after 6 days by MTT colorimetric assay,Confirmatory,21975068.0,
2509,630991,3,2,,103168230,3767,Active,,,0.07,IC50,Antimicrobial activity against Mycobacterium tuberculosis H37Rv in GASTD medium after 10 days by spectrophotometric analysis,Confirmatory,21940166.0,
2510,630992,3,2,,103168230,3767,Active,,,0.09,IC50,Antimicrobial activity against Mycobacterium tuberculosis H37Rv in GASTD medium supplemented with 100 uM FeCl3 after 10 days by spectrophotometric analysis,Confirmatory,21940166.0,
2511,630993,1,4,,103168230,3767,Unspecified,,,,,Ratio of IC50 for Mycobacterium tuberculosis H37Rv in GASTD medium supplemented with 100 uM FeCl3 to IC50 for Mycobacterium tuberculosis H37Rv in Fe-deficient GASTD medium,Other,21940166.0,
2512,630994,1,4,,103168230,3767,Unspecified,,,,,Ratio of MIC90 for Mycobacterium tuberculosis H37Rv in GASTD medium supplemented with 100 uM FeCl3 to MIC90 for Mycobacterium tuberculosis H37Rv in Fe-deficient GASTD medium,Other,21940166.0,
2513,631056,1,4,,103168230,3767,Active,,,,,Bactericidal activity against Mycobacterium tuberculosis H37Rv in GASTD medium at 2 times MIC after 30 days by colony counting,Other,21940166.0,
2514,632212,3,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,22061642.0,
2515,632573,3,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar double dilution technique,Other,22071303.0,
2516,632574,3,2,,103168230,3767,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis by agar double dilution technique,Other,22071303.0,
2517,634038,3,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv by twofold serial dilution method,Other,22153872.0,
2518,634039,3,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against drug-sensitive Mycobacterium tuberculosis isolate Spec. 210 by twofold serial dilution method,Other,22153872.0,
2519,634040,3,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against multidrug-resistant Mycobacterium tuberculosis isolate Spec. 192 by twofold serial dilution method,Other,22153872.0,
2520,634537,4,1,,103168230,3767,Active,,,0.03,MIC50,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as intracellular ATP level after 5 days by luminescence assay,Confirmatory,22088956.0,
2521,634538,3,3,,103168230,3767,Inconclusive,,,,CC50,Cytotoxicity against hamster BHK21 cells after 5 days,Confirmatory,22088956.0,
2522,634539,3,2,,103168230,3767,Inconclusive,,,,CC50,Cytotoxicity against human HepG2 cells after 5 days,Confirmatory,22088956.0,
2523,634540,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against clinical isolate of Mycobacterium tuberculosis TN675 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2524,634541,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN913 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2525,634607,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against clinical isolate Mycobacterium tuberculosis TN994 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2526,634608,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1008 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2527,634609,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1037 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2528,634610,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1040 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2529,634611,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1051 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2530,634612,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1082 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2531,634613,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN2351 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2532,634614,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN2524 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2533,634615,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN3183 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2534,634616,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN3979 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2535,634617,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN4259 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2536,634618,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis AH9584 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2537,634619,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis BE11677 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2538,634620,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis E8133 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2539,634621,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis W4 assessed as intracellular ATP level after 5 days by luminescence assay,Other,22088956.0,
2540,636829,3,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by green fluorescent protein microplate assay,Other,21995505.0,
2541,637042,4,1,,103168230,3767,Active,,,0.54,MIC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv expressing pSMT1 after 1 to 7 days by luminescent assay,Confirmatory,22182928.0,
2542,637044,5,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human HepG2/C3A cells after 24 hrs by neutral red uptake assay,Confirmatory,22182928.0,
2543,637045,1,4,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human HepG2/C3A cells to MIC50 for Mycobacterium tuberculosis H37Rv",Other,22182928.0,
2544,638435,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by Resazurin microtiter assay,Other,22079026.0,
2545,640405,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by two fold agar dilution method,Other,22197387.0,
2546,640406,3,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis by two fold agar dilution method,Other,22197387.0,
2547,640418,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 to 11 days by microdilution method,Other,22197389.0,
2548,640419,1,4,,103168230,3767,Unspecified,,,,,Growth inhibition of human HepG2 cells at 20 uM after 48 hrs by MTT assay,Other,22197389.0,
2549,640420,1,4,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium bovis BCG infected in BALB/c mouse assessed as log reduction in CFU in lungs at 25 mg/kg, po qd administered 48 hrs post infection for 6 weeks measured after 6 weeks (Rvb = 4.64+/-0.17 log10CFU)",Other,22197389.0,
2550,640421,1,5,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium bovis BCG infected in BALB/c mouse assessed as log reduction in CFU in spleen at 25 mg/kg, po qd administered 48 hrs post infection for 6 weeks measured after 6 weeks (Rvb = 4.79+/-0.25 log10CFU)",Other,22197389.0,
2551,641634,1,4,,103168230,3767,Inactive,,,,,Antibacterial activity against Bordetella bronchiseptica ATCC 10580 at 1 mg/ml after 24 hrs by agar well diffusion method,Other,22119127.0,
2552,641635,1,4,,103168230,3767,Inactive,,,,,Antibacterial activity against Enterobacter aerogenes ATCC 13048 at 1 mg/ml after 24 hrs by agar well diffusion method,Other,22119127.0,
2553,641636,1,4,,103168230,3767,Inactive,,,,,Antibacterial activity against Salmonella typhi ATCC 6539 at 1 mg/ml after 24 hrs by agar well diffusion method,Other,22119127.0,
2554,641637,1,4,,103168230,3767,Inactive,,,,,Antibacterial activity against Escherichia coli ATCC 15224 at 1 mg/ml after 24 hrs by agar well diffusion method,Other,22119127.0,
2555,641638,1,4,,103168230,3767,Inactive,,,,,Antibacterial activity against Micrococcus luteus ATCC 10240 at 1 mg/ml after 24 hrs by agar well diffusion method,Other,22119127.0,
2556,641639,1,4,,103168230,3767,Inactive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 6538 at 1 mg/ml after 24 hrs by agar well diffusion method,Other,22119127.0,
2557,641640,1,4,,103168230,3767,Active,,,,,Antioxidant activity against OH-radical-induced oxidative Escherichia coli pBR322 damage at 10 to 1000 ug/ml incubated for 1 hr in dark by agarose gel electrophoresis,Other,22119127.0,
2558,641645,3,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against brine shrimps after 24 hr,Other,22119127.0,
2559,641646,1,4,,103168230,3767,Unspecified,,,,,Binding affinity to chicken blood dsDNA assessed as shift in Ep/mv at 1 x 10 '-3 M at pH 4.7 by cyclic voltammetry,Other,22119127.0,
2560,641647,1,4,,103168230,3767,Unspecified,,,,,Binding affinity to chicken blood dsDNA assessed as shift in Ep/mv at 1 x 10 '-3 M at pH 7.4 by cyclic voltammetry,Other,22119127.0,
2561,641648,1,4,,103168230,3767,Unspecified,,,,,Binding affinity to chicken blood dsDNA assessed as decrease in current at 1 x 10 '-3 M at pH 4.7 by cyclic voltammetry,Other,22119127.0,
2562,641649,1,4,,103168230,3767,Unspecified,,,,,Binding affinity to chicken blood dsDNA assessed as decrease in current at 1 x 10 '-3 M at pH 7.4 by cyclic voltammetry,Other,22119127.0,
2563,642346,1,4,,103168230,3767,Active,,,,,Binding affinity to chicken blood dsDNA assessed as hyperchromic effect at 1.1 x 10 '-4 M at pH 4.7 by UV-spectroscopy,Other,22119127.0,
2564,642347,1,4,,103168230,3767,Active,,,,,Binding affinity to chicken blood dsDNA assessed as hyperchromic effect at 1.1 x 10 '-4 M at pH 7.4 by UV-spectroscopy,Other,22119127.0,
2565,642348,2,1,,103168230,3767,Unspecified,,,,,Binding affinity to chicken blood dsDNA at pH 4.7 by UV-spectroscopy,Other,22119127.0,
2566,642349,2,1,,103168230,3767,Unspecified,,,,,Binding affinity to chicken blood dsDNA at pH 7.4 by UV-spectroscopy,Other,22119127.0,
2567,642350,2,1,,103168230,3767,Unspecified,,,,,Binding affinity to chicken blood dsDNA at pH 4.7 by cyclic voltammetry,Other,22119127.0,
2568,642351,2,1,,103168230,3767,Unspecified,,,,,Binding affinity to chicken blood dsDNA at pH 7.4 by cyclic voltammetry,Other,22119127.0,
2569,643449,6,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by ten-fold serial dilution method,Other,22128803.0,
2570,644238,4,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 16 to 24 hrs by microplate alamar blue assay,Other,22264895.0,
2571,644317,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin assay,Other,22280817.0,
2572,644318,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis ATCC 19420 after 7 days by resazurin assay,Other,22280817.0,
2573,644319,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium fortuitum ATCC 19542 after 7 days by resazurin assay,Other,22280817.0,
2574,644320,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Multidrug-resistant Mycobacterium tuberculosis after 7 days by resazurin assay,Other,22280817.0,
2575,644321,1,4,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 7 days by resazurin assay,Other,22280817.0,
2576,644364,4,2,,103168230,3767,Active,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 7 to 14 days by twofold serial broth dilution method,Other,22285027.0,
2577,644431,1,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv harboring pSMT1 encoding Vibrio harveyi luxAB gene at 10 uM after 7 days by luminometric analysis,Other,22301215.0,
2578,644432,1,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv harboring pSMT1 encoding Vibrio harveyi luxAB gene at 1 uM after 7 days by luminometric analysis,Other,22301215.0,
2579,644433,1,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv harboring pSMT1 encoding Vibrio harveyi luxAB gene at 0.1 uM after 7 days by luminometric analysis,Other,22301215.0,
2580,644434,4,1,,103168230,3767,Active,,,0.465,MIC50,Antibacterial activity against Mycobacterium tuberculosis H37Rv harboring pSMT1 encoding Vibrio harveyi luxAB gene after 7 days by luminometric analysis,Confirmatory,22301215.0,
2581,644435,3,3,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human HepG2/C3A cells after 24 hrs by neutral red assay,Confirmatory,22301215.0,
2582,644438,1,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv harboring pSMT1 encoding Vibrio harveyi luxAB gene infected in mouse J774.A1 cells at 2 uM after 5 days by luminometric analysis,Other,22301215.0,
2583,644439,1,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv harboring pSMT1 encoding Vibrio harveyi luxAB gene infected in mouse J774.A1 cells at 1 uM after 5 days by luminometric analysis,Other,22301215.0,
2584,644440,1,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv harboring pSMT1 encoding Vibrio harveyi luxAB gene infected in mouse J774.A1 cells at 0.5 uM after 5 days by luminometric analysis,Other,22301215.0,
2585,645537,3,2,,103168230,3767,Active,,,,,Antitubercular activity against rifampicin-resistant Mycobacterium tuberculosis by microbroth dilution assay,Other,21691438.0,
2586,645538,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis by microbroth dilution assay,Other,21691438.0,
2587,645539,3,2,,103168230,3767,Active,,,,,Antitubercular activity against kanamycin-resistant Mycobacterium tuberculosis by microbroth dilution assay,Other,21691438.0,
2588,645540,3,2,,103168230,3767,Active,,,,,Antitubercular activity against streptomycin-resistant Mycobacterium tuberculosis by microbroth dilution assay,Other,21691438.0,
2589,646114,4,1,,103168230,3767,Active,,,,,Antitubercular activity against multi-drug-resistant Mycobacterium tuberculosis H37Rv clinical isolate after 28 days by 10 fold serial dilution method,Other,22277278.0,
2590,649473,3,2,,103168230,3767,Active,,,,IC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by MTT assay,Confirmatory,22361273.0,
2591,649474,3,2,,103168230,3767,Active,,,,IC50,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis MYC5165 after 6 days by MTT assay,Confirmatory,22361273.0,
2592,649717,3,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv by REMA method,Other,22365752.0,
2593,649892,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days,Other,22365879.0,
2594,649895,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days,Other,22365879.0,
2595,649896,4,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 14 days",Other,22365879.0,
2596,649897,4,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 21 days",Other,22365879.0,
2597,649898,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days,Other,22365879.0,
2598,649899,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days,Other,22365879.0,
2599,649900,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days,Other,22365879.0,
2600,649901,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days,Other,22365879.0,
2601,649902,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days,Other,22365879.0,
2602,649903,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days,Other,22365879.0,
2603,650748,3,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by microplate alamar blue assay,Other,22325950.0,
2604,651550,1,1,,49718175,3767,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2605,651560,1,1,,49718175,3767,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2606,651572,1,2,,49718175,3767,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2607,651582,1,1,,49718175,3767,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2608,651602,1,1,,49718175,3767,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2609,651602,1,1,,49718175,3767,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2610,651602,1,1,,49718175,3767,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2611,651610,2,1,,49718175,3767,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2612,651631,4,1,,144207189,3767,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2613,651631,4,1,,144208565,3767,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2614,651631,4,1,,144210513,3767,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2615,651632,4,1,,144207189,3767,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2616,651632,4,1,,144208565,3767,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2617,651632,4,1,,144210513,3767,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2618,651633,4,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2619,651633,4,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2620,651633,4,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2621,651634,4,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2622,651634,4,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2623,651634,4,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2624,651635,1,3,,11112128,3767,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2625,651635,1,3,,49718175,3767,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2626,651636,1,1,,49718175,3767,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2627,651640,1,1,,49718175,3767,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2628,651644,1,1,,49718175,3767,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2629,651647,1,1,,49718175,3767,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2630,651654,1,1,,49718175,3767,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2631,651658,1,1,,49718175,3767,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2632,651660,1,1,,49718175,3767,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2633,651661,2,1,,49718175,3767,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2634,651687,1,1,,49718175,3767,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2635,651699,1,1,,49718175,3767,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2636,651699,1,1,,49718175,3767,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2637,651702,1,2,,49718175,3767,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2638,651704,2,1,,49718175,3767,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2639,651710,1,1,,49718175,3767,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2640,651711,2,1,,49718175,3767,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2641,651718,1,2,,49718175,3767,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2642,651719,1,2,,49718175,3767,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
2643,651723,1,1,,49718175,3767,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2644,651724,1,1,,49718175,3767,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2645,651725,1,1,,49718175,3767,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2646,651741,1,1,,17389848,3767,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2647,651743,1,1,,17389848,3767,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2648,651749,1,1,,17389848,3767,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2649,651751,1,1,,17389848,3767,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2650,651754,1,1,,17389848,3767,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2651,651755,1,1,,17389848,3767,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2652,651757,1,1,,17389848,3767,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2653,651758,1,1,,17389848,3767,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2654,651768,1,2,,49718175,3767,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2655,651777,1,1,,17389848,3767,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2656,651778,1,1,,17389848,3767,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2657,651800,1,1,,49718175,3767,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2658,651802,1,1,,17389848,3767,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2659,651819,1,1,,49718175,3767,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2660,651820,1,1,,855769,3767,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2661,651820,1,1,,49718175,3767,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2662,651821,2,4,,49718175,3767,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2663,651828,1,2,,92308852,3767,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2664,651828,1,2,,121362444,3767,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2665,651838,1,1,,17389848,3767,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2666,651838,1,1,1.0,17389848,3767,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2667,651838,1,1,2.0,17389848,3767,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2668,651838,1,1,3.0,17389848,3767,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2669,651838,1,1,4.0,17389848,3767,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2670,651838,1,1,5.0,17389848,3767,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2671,651838,1,1,6.0,17389848,3767,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2672,651838,1,1,7.0,17389848,3767,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2673,651838,1,1,8.0,17389848,3767,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2674,651957,1,1,,49718175,3767,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2675,651958,1,1,,49718175,3767,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2676,651965,1,1,,49718175,3767,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2677,651999,1,1,,49718175,3767,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2678,652010,1,1,,49718175,3767,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2679,652017,1,1,,49718175,3767,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2680,652025,1,1,,49718175,3767,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2681,652039,1,1,,49718175,3767,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2682,652048,1,2,,49718175,3767,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2683,652048,1,2,,144207189,3767,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2684,652051,1,1,,49718175,3767,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2685,652051,1,1,,144207189,3767,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2686,652054,1,1,,49718175,3767,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2687,652067,1,4,,49718175,3767,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2688,652104,1,1,,49718175,3767,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2689,652105,1,1,,49718175,3767,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2690,652106,1,1,,49718175,3767,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2691,652115,1,1,,49718175,3767,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2692,652126,1,3,,49718175,3767,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2693,652154,1,1,,49718175,3767,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2694,652162,2,1,,49718175,3767,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2695,652163,1,1,,49718175,3767,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2696,652197,1,1,,49718175,3767,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2697,652257,1,1,,49718175,3767,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2698,653493,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis at 15 nmol/disc after 24 hrs by paper disc diffusion method,Other,22405649.0,
2699,653494,1,2,,103168230,3767,Inactive,,,,,Antimycobacterial activity against Mycobacterium smegmatis assessed as viability at 10 uM after 1 hr by resazurin test,Other,22405649.0,
2700,653495,1,2,,103168230,3767,Inactive,,,,,Antimycobacterial activity against Mycobacterium smegmatis assessed as viability at 20 uM after 5 to 12 hrs by resazurin test,Other,22405649.0,
2701,653498,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis,Other,22405649.0,
2702,653499,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis,Other,22405649.0,
2703,656227,2,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2704,656228,2,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2705,656229,2,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2706,656230,2,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, streptomycin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2707,656231,2,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2708,656232,2,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2709,656233,2,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, ethambutol-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2710,657783,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against drug-susceptible Mycobacterium tuberculosis H37Rv measured 24 hrs post dose by microplate alamar blue assay,Other,22503208.0,
2711,657784,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 44 from Chinese tuberculosis patient measured 24 hrs post dose by microplate alamar blue assay,Other,22503208.0,
2712,657785,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 83 from Chinese tuberculosis patient measured 24 hrs post dose by microplate alamar blue assay,Other,22503208.0,
2713,657786,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 164 from Chinese tuberculosis patient measured 24 hrs post dose by microplate alamar blue assay,Other,22503208.0,
2714,657787,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 431 from Chinese tuberculosis patient measured 24 hrs post dose by microplate alamar blue assay,Other,22503208.0,
2715,657788,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis isolate 926 from Chinese tuberculosis patient measured 24 hrs post dose by microplate alamar blue assay,Other,22503208.0,
2716,657972,5,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,22440626.0,
2717,657974,1,3,,103168230,3767,Unspecified,,,,,Cytotoxicity against human HepG2 cells at 20 to 25 uM after 48 hrs by MTT assay,Other,22440626.0,
2718,657975,2,2,,103168230,3767,Unspecified,,,,,"AUC (0 to t) in Wistar rat at 50 mg/kg, po administered as single dose",Other,22440626.0,
2719,657976,2,2,,103168230,3767,Unspecified,,,,,"Cmax in Wistar rat at 50 mg/kg, po administered as single dose",Other,22440626.0,
2720,657977,1,3,,103168230,3767,Unspecified,,,,,"Tmax in Wistar rat at 50 mg/kg, po administered as single dose",Other,22440626.0,
2721,657978,1,3,,103168230,3767,Unspecified,,,,,Oral bioavailability in Wistar rat at 50 mg/kg administered as single dose,Other,22440626.0,
2722,657979,2,2,,103168230,3767,Unspecified,,,,,"AUC (0 to t) in Wistar rat at 10 mg/kg, iv administered as single bolus dose",Other,22440626.0,
2723,657980,2,2,,103168230,3767,Unspecified,,,,,"Cmax in Wistar rat at 10 mg/kg, iv administered as single bolus dose",Other,22440626.0,
2724,657981,1,3,,103168230,3767,Unspecified,,,,,"Elimination rate constant in Wistar rat at 10 mg/kg, iv administered as single bolus dose",Other,22440626.0,
2725,657982,1,3,,103168230,3767,Unspecified,,,,,"Half life in Wistar rat at 10 mg/kg, iv administered as single bolus dose",Other,22440626.0,
2726,657983,1,3,,103168230,3767,Unspecified,,,,,"Volume of distribution in Wistar rat at 10 mg/kg, iv administered as single bolus dose",Other,22440626.0,
2727,657984,2,2,,103168230,3767,Unspecified,,,,,"Plasma clearance in Wistar rat at 10 mg/kg, iv administered as single bolus dose",Other,22440626.0,
2728,658437,2,4,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis mc2 155 after 72 hrs by MTT assay,Other,22459211.0,
2729,658539,3,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 after 72 hrs by MTT assay,Other,21899267.0,
2730,658540,3,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 6841 after 72 hrs by MTT assay,Other,21899267.0,
2731,658541,3,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 2700 expressing Mycobacterium tuberculosis fatty acid synthase 1 gene after 72 hrs by MTT assay,Other,21899267.0,
2732,658542,3,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium phlei ATCC 11758 after 72 hrs by MTT assay,Other,21899267.0,
2733,661399,2,4,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra,Other,22522007.0,
2734,661402,1,6,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Ra infected in gamma interferon-knockout mouse assessed as reduction in lung CFU load at 25 mg/kg, po BID dosage beginning at 15 post infection for 9 days (Rvb = 8.86 +/- 0.02 log10CFU)",Other,22522007.0,
2735,661404,1,6,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Ra infected in gamma interferon-knockout mouse assessed as reduction in spleen CFU load at 25 mg/kg, po BID dosage beginning at 15 post infection for 9 days (Rvb = 7.30 +/- 0.09 log10CFU)",Other,22522007.0,
2736,662304,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 28 days,Other,22572576.0,
2737,662996,1,3,,103168230,3767,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv at 0.2 ug/mL,Other,22607678.0,
2738,664308,2,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv by BACTEC MGIT method,Other,22516426.0,
2739,664309,1,3,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv at 6.25 ug/ml by BACTEC MGIT method,Other,22516426.0,
2740,665277,3,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 28 days by agar dilution method,Other,22575534.0,
2741,665278,3,1,,103168230,3767,Active,,,,,"Antitubercular activity against isoniazid, rifampicin and ethambutol-resistant Mycobacterium tuberculosis clinical isolate after 28 days by agar dilution method",Other,22575534.0,
2742,665339,2,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 1 days by radiometric growth assay,Other,22578509.0,
2743,665340,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 1 ug/mL assessed as growth index after 3 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2744,665341,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 1 ug/mL assessed as growth index after 4 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2745,665343,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 1 ug/mL assessed as growth index after 7 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2746,665344,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 1 ug/mL assessed as growth index after 10 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2747,665345,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 0.5 ug/mL assessed as growth index after 3 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2748,665346,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 0.5 ug/mL assessed as growth index after 4 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2749,665347,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 0.5 ug/mL assessed as growth index after 5 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2750,665348,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 0.5 ug/mL assessed as growth index after 7 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2751,665350,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 0.1 ug/mL assessed as growth index after 3 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2752,665351,1,3,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv at 0.1 ug/mL assessed as growth index after 4 days by radiometric growth assay (Rvb = 210 growth index),Other,22578509.0,
2753,665365,1,3,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at 1 ug/mL by radiometric growth assay,Other,22578509.0,
2754,665366,1,3,,103168230,3767,Inactive,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate at 1 ug/mL by radiometric growth assay,Other,22578509.0,
2755,665367,1,3,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at 10 ug/mL by radiometric growth assay,Other,22578509.0,
2756,665368,1,3,,103168230,3767,Inactive,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate at 10 ug/mL by radiometric growth assay,Other,22578509.0,
2757,666966,1,3,,103168230,3767,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv at 6.25 ug/mL after 12 to 28 days relative to control,Other,22652224.0,
2758,669186,2,2,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv in aerobic conditions after 7 days by microplate-based alamar blue assay,Other,22452568.0,
2759,669187,2,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv in anaerobic conditions after 11 days by luminescnece-based low-oxygen recovery assay,Other,22452568.0,
2760,669488,3,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,22449006.0,
2761,669834,2,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate alamar blue assay,Other,22449052.0,
2762,669835,2,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against non-replicating Mycobacterium tuberculosis H37Rv ATCC 27294 by low oxygen recovery assay,Other,22449052.0,
2763,669844,2,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv by microplate alamar blue assay,Other,22449052.0,
2764,669845,2,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against rifampicin-resistant Mycobacterium tuberculosis H37Rv by microplate alamar blue assay,Other,22449052.0,
2765,670244,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microbroth dilution method,Other,22633120.0,
2766,670326,1,5,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth at 0.1 ug/ml incubated for 6 days by MABA method,Other,22664188.0,
2767,670861,2,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as minimum concentration required to inhibit 90% growth after 1 week by fluorescence-based microplate Alamar Blue assay,Other,22726932.0,
2768,670862,2,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against non-replicating Mycobacterium tuberculosis assessed as minimum concentration required to inhibit 90% growth after 10 days under anaerobic condition by luciferase-based low-oxygen recovery assay,Other,22726932.0,
2769,670863,2,2,,103168230,3767,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay,Other,22726932.0,
2770,671455,1,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of microbial growth at 1 ug/ml by radiometric-BACTEC assay,Other,22664188.0,
2771,674504,2,3,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by alamar blue broth microdilution assay,Other,22749825.0,
2772,674505,2,3,,103168230,3767,Active,,,,,Antimycobacterial activity against INH-resistant Mycobacterium tuberculosis by alamar blue broth microdilution assay,Other,22749825.0,
2773,674506,2,3,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Other,22749825.0,
2774,674914,3,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by Lowenstein-Jensen slope method,Other,22832312.0,
2775,678712,1,8,,103168230,3767,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
2776,678713,1,8,,103168230,3767,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
2777,678714,1,8,,103168230,3767,Unspecified,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2778,678715,1,8,,103168230,3767,Unspecified,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2779,678716,1,8,,103168230,3767,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
2780,678717,1,8,,103168230,3767,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
2781,678721,1,5,,103168230,3767,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
2782,678722,1,5,,103168230,3767,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
2783,679795,1,7,,103168230,3767,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Branched DNA assay in vivo SD rat, liver",Other,12065443.0,
2784,683315,2,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 by microbroth dilution method,Other,22939698.0,
2785,683316,2,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 by microbroth dilution method,Other,22939698.0,
2786,683317,2,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 by microbroth dilution method,Other,22939698.0,
2787,683318,2,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv by microbroth dilution method,Other,22939698.0,
2788,683319,2,4,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Mycobacterium smegmatis MC2 155 by microbroth dilution method,Other,22939698.0,
2789,683320,2,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug-resistant Mycobacterium tuberculosis 164 by microbroth dilution method,Other,22939698.0,
2790,683321,2,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against drug-resistant Mycobacterium tuberculosis 926 by microbroth dilution method,Other,22939698.0,
2791,683322,2,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microbroth dilution method,Other,22939698.0,
2792,683323,2,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against multidrug-resistant Morganella morganii 07-09 by microbroth dilution method,Other,22939698.0,
2793,683324,2,2,,103168230,3767,Inconclusive,,,,,Antibacterial activity against Escherichia coli ATCC 25922 by microbroth dilution method,Other,22939698.0,
2794,683325,2,2,,103168230,3767,Inconclusive,,,,,Antifungal activity against Candida albicans ATCC 10231 by microbroth dilution method,Other,22939698.0,
2795,683685,2,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay,Other,23064162.0,
2796,683686,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 10 days by low oxygen recovery assay,Other,23064162.0,
2797,683687,2,2,,103168230,3767,Inconclusive,,,,,Kinetic solubility of the compound at pH 7.4,Other,23064162.0,
2798,684287,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 after 14 days by micromethod,Other,22907036.0,
2799,684288,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 after 21 days by micromethod,Other,22907036.0,
2800,684289,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium My 330/88 after 14 days by micromethod,Other,22907036.0,
2801,684290,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium My 330/88 after 21 days by micromethod,Other,22907036.0,
2802,684291,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 7 days by micromethod,Other,22907036.0,
2803,684292,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 14 days by micromethod,Other,22907036.0,
2804,684293,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 21 days by micromethod,Other,22907036.0,
2805,684294,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii My 6509/96 clinical isolate after 7 days by micromethod,Other,22907036.0,
2806,684295,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii My 6509/96 clinical isolate after 14 days by micromethod,Other,22907036.0,
2807,684296,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii My 6509/96 clinical isolate after 21 days by micromethod,Other,22907036.0,
2808,684999,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 331/88 after 14 days by micromethod,Other,22960697.0,
2809,685000,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 331/88 after 21 days by micromethod,Other,22960697.0,
2810,685001,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid resistance Mycobacterium avium 330/88 after 14 days by micromethod,Other,22960697.0,
2811,685002,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid resistance Mycobacterium avium 330/88 after 21 days by micromethod,Other,22960697.0,
2812,685003,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 clinical isolate after 7 days by micromethod,Other,22960697.0,
2813,685004,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid resistance Mycobacterium kansasii 225/80 after 7 days by micromethod,Other,22960697.0,
2814,685005,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid resistance Mycobacterium kansasii 225/80 after 14 days by micromethod,Other,22960697.0,
2815,685006,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid resistance Mycobacterium kansasii 225/80 after 21 days by micromethod,Other,22960697.0,
2816,685007,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 clinical isolate after 14 days by micromethod,Other,22960697.0,
2817,685008,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 clinical isolate after 21 days by micromethod,Other,22960697.0,
2818,686940,1,1,,49718175,3767,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2819,686964,1,1,,49718175,3767,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2820,686970,1,2,,49718175,3767,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2821,686971,1,2,,49718175,3767,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2822,686977,2,1,,49698712,3767,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2823,686978,1,1,,49718175,3767,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2824,686978,1,1,,124881930,3767,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2825,686978,1,1,,124881932,3767,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2826,686978,1,1,,144207189,3767,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2827,686979,1,1,,49718175,3767,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2828,686979,1,1,,124881930,3767,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2829,686979,1,1,,124881932,3767,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2830,686979,1,1,,144207189,3767,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2831,686992,2,1,,49718175,3767,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2832,686996,1,1,,49718175,3767,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2833,687014,1,1,,49718175,3767,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2834,687016,1,1,,49718175,3767,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2835,689221,2,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 culture in GAS media after 7 days by microplate alamar blue assay,Other,22391032.0,
2836,689222,2,2,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 culture in GAST media after 7 days by microplate alamar blue assay,Other,22391032.0,
2837,689223,2,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 culture in 7H12 media after 7 days by microplate alamar blue assay,Other,22391032.0,
2838,689224,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium against recombinant Mycobacterium tuberculosis H37Rv expressing luxAB incubated for 10 days in anaerobic condition followed by incubation for 28 hrs in aerobic condition by LORA assay,Other,22391032.0,
2839,689225,2,2,,103168230,3767,Unspecified,,,128.0,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiter assay,Confirmatory,22391032.0,
2840,689770,2,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate SRI after 5 days by resazurin-based microplate assay,Other,22691154.0,
2841,689771,2,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate ITR after 7 days by luminescence spectrometry,Other,22691154.0,
2842,689772,2,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv incubated for 10 days in anaerobic condition followed by 48 hrs incubation in aerobic condition by LORA assay,Other,22691154.0,
2843,689773,2,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay,Other,22691154.0,
2844,689774,1,2,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of CC50 for Vero cells to MIC90 for Mycobacterium tuberculosis H37Rv isolate SRI",Other,22691154.0,
2845,690778,2,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin microtiter assay,Other,22967765.0,
2846,694227,2,2,,103168230,3767,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Other,23062712.0,
2847,694231,3,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv under anaerobic condition by BACTEC method,Other,23062712.0,
2848,694357,1,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv under anaerobic condition assessed as growth inhibition at 0.1 ug/ml by BACTEC method,Other,23062712.0,
2849,694365,1,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis MS-115 under anaerobic condition assessed as growth inhibition at 0.1 ug/ml by BACTEC method,Other,23062712.0,
2850,694774,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampicin-resistant Mycobacterium tuberculosis ATCC 35338 after 7 days by resazurin microtitre assay,Other,23000294.0,
2851,694775,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822 after 7 days by resazurin microtitre assay,Other,23000294.0,
2852,694779,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pan-susceptible Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by resazurin microtitre assay,Other,23000294.0,
2853,697342,2,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv,Other,23046964.0,
2854,698819,1,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis infected in human assessed as log reduction of bacterial count at 400 mg, qd measured up to 7 days",Other,22421275.0,
2855,698996,1,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis infected in human assessed as log reduction of bacterial count at 300 mg, qd measured up to 2 days",Other,22421275.0,
2856,699539,1,7,,103168230,3767,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2857,699540,1,7,,103168230,3767,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2858,699541,1,7,,103168230,3767,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2859,700527,2,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampicin and ethambutol-resistant Mycobacterium tuberculosis at 0.3125 to 5 ug/mL after 7 days by Resazurin assay",Other,21920636.0,
2860,700528,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 19542 at 0.3125 to 5 ug/mL after 7 days by Resazurin assay,Other,21920636.0,
2861,700529,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 19420 at 0.3125 to 5 ug/mL after 7 days by Resazurin assay,Other,21920636.0,
2862,700530,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 0.3125 to 5 ug/mL after 7 days by Resazurin assay,Other,21920636.0,
2863,700531,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by Resazurin assay,Other,21920636.0,
2864,700537,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 19420 at 1 to 100 ug/mL after 7 days by Resazurin assay,Other,21920636.0,
2865,700538,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 19542 at 1 to 100 ug/mL after 7 days by Resazurin assay,Other,21920636.0,
2866,700539,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 1 to 100 ug/mL after 7 days by Resazurin assay,Other,21920636.0,
2867,717304,1,2,,103168230,3767,Unspecified,,,,,"Antitubercular activity against streptomycin, isoniazid, rifampicin,ethambutol-resistant Mycobacterium tuberculosis clinical isolate assessed as reduction in RLU at 0.5 ug/mL after 72 hrs by luciferase reporter phage assay",Other,23122523.0,
2868,717308,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as reduction in RLU at 0.5 ug/mL after 72 hrs by luciferase reporter phage assay,Other,23122523.0,
2869,717596,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,23151429.0,
2870,717690,2,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Other,23122863.0,
2871,717691,2,2,,103168230,3767,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis by agar dilution method,Other,23122863.0,
2872,717692,2,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,23122863.0,
2873,718130,2,4,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis str. MC2 155 by broth dilution method,Other,23205944.0,
2874,718939,1,2,,103168230,3767,Active,,,,,Antitubercular activity against non-culturable Mycobacterium tuberculosis assessed as reduction in dormant cell viability at 10 ug/mL measured for 7 days by MPN assay,Other,23137434.0,
2875,718942,1,4,,103168230,3767,Inconclusive,,,,,Cytotoxicity against HEK293T cells assessed as cellular growth at 100 uM by MTT assay,Other,23137434.0,
2876,719007,1,4,,103168230,3767,Inconclusive,,,,,Cytotoxicity against HEK293T cells assessed as cellular growth at 25 uM by MTT assay,Other,23137434.0,
2877,719008,3,1,,103168230,3767,Active,,,,,Antitubercular activity against log phase culture of Mycobacterium tuberculosis H37Rv ATCC 27294 by agar dilution method,Other,23137434.0,
2878,719022,2,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against log-phase Mycobacterium kansasii CIT11/06 assessed as growth inhibition after 5 days by alamar blue assay,Other,23140987.0,
2879,720504,1,1,,49718175,3767,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2880,720508,1,1,,49718175,3767,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2881,720509,1,1,,49718175,3767,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2882,720511,1,1,,49718175,3767,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2883,720516,2,1,,144207189,3767,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2884,720516,2,1,,144208565,3767,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2885,720516,2,1,,144210513,3767,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2886,720532,1,1,,11112128,3767,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2887,720532,1,1,,124881930,3767,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2888,720532,1,1,,124881932,3767,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2889,720532,1,1,,144207189,3767,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2890,720533,1,1,,11112128,3767,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2891,720533,1,1,,124881930,3767,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2892,720533,1,1,,124881932,3767,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2893,720533,1,1,,144207189,3767,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2894,720542,1,2,,49718175,3767,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2895,720543,1,1,,49718175,3767,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2896,720551,1,2,,49718175,3767,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2897,720552,2,1,,144207189,3767,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2898,720552,2,1,,144208565,3767,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2899,720552,2,1,,144210513,3767,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2900,720553,1,2,,49718175,3767,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2901,720554,1,3,,121362444,3767,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2902,720579,2,1,,49718175,3767,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2903,720579,2,1,,124881930,3767,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2904,720579,2,1,,124881932,3767,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2905,720580,1,1,,49718175,3767,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2906,720580,1,1,,124881930,3767,Inconclusive,222762.0,3707576.0,3.1623,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2907,720580,1,1,,124881932,3767,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2908,720582,1,1,,49718175,3767,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2909,720596,1,1,,49718175,3767,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2910,720634,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2911,720634,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2912,720634,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2913,720635,2,1,,144207189,3767,Inconclusive,,,13.3332,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2914,720635,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2915,720635,2,1,,144210513,3767,Inconclusive,,,1.8126,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2916,720636,1,1,,17389848,3767,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2917,720637,2,1,,144207189,3767,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2918,720637,2,1,,144208565,3767,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2919,720637,2,1,,144210513,3767,Inconclusive,,,3.4143,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2920,720641,1,2,,92307469,3767,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2921,720641,1,2,,92308852,3767,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2922,720647,1,2,,49718175,3767,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2923,720648,1,1,,49718175,3767,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2924,720652,1,1,,17389848,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2925,720653,1,1,,17389848,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2926,720659,1,1,,17389848,3767,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2927,720674,2,2,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2928,720674,2,2,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2929,720674,2,2,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2930,720675,2,2,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2931,720675,2,2,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2932,720675,2,2,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2933,720678,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2934,720678,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2935,720678,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2936,720679,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2937,720679,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2938,720679,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2939,720680,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2940,720680,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2941,720680,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2942,720681,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2943,720681,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2944,720681,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2945,720682,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2946,720682,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2947,720682,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2948,720683,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2949,720683,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2950,720683,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2951,720684,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2952,720684,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2953,720684,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2954,720685,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2955,720685,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2956,720685,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2957,720686,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2958,720686,2,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2959,720686,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2960,720687,2,2,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2961,720687,2,2,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2962,720687,2,2,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2963,720691,4,1,,144207189,3767,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2964,720691,4,1,,144208565,3767,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2965,720691,4,1,,144210513,3767,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2966,720692,3,1,,144207189,3767,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2967,720692,3,1,,144208565,3767,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2968,720692,3,1,,144210513,3767,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2969,720693,3,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2970,720693,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2971,720693,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2972,720700,1,4,,49718175,3767,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2973,720702,1,1,,49718175,3767,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2974,720704,1,4,,49718175,3767,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2975,720707,1,2,,49718175,3767,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2976,720708,1,2,,49718175,3767,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2977,720709,1,2,,49718175,3767,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2978,720711,1,2,,49718175,3767,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2979,720717,1,3,,92124073,3767,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2980,720717,1,3,,92124987,3767,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2981,720717,1,3,,92307469,3767,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2982,720717,1,3,,92308852,3767,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2983,720719,2,1,,144207189,3767,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2984,720719,2,1,,144208565,3767,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2985,720719,2,1,,144210513,3767,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2986,720725,2,1,,144207189,3767,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2987,720725,2,1,,144208565,3767,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2988,720725,2,1,,144210513,3767,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2989,721559,1,2,,103168230,3767,Inconclusive,,,,,"Lipophilicity, log K of the compound in methanol-water mixture by HPLC analysis",Other,23237840.0,
2990,721560,3,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,23237840.0,
2991,721561,1,2,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis H37Rv CNCTC My 331/88",Other,23237840.0,
2992,721562,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 152/73 after 10 to 14 days by microdilution panel method,Other,23237840.0,
2993,721563,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 80/72 after 10 to 14 days by microdilution panel method,Other,23237840.0,
2994,721564,4,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 10 to 14 days by microdilution panel method,Other,23237840.0,
2995,721565,4,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv CNCTC My 331/88 after 10 to 14 days by microdilution panel method,Other,23237840.0,
2996,721633,1,2,,103168230,3767,Active,,,2.6,IC50,Antimycobacterial activity against Mycobacterium vanbaalenii incubated up to 24 hrs,Confirmatory,23314046.0,
2997,721634,1,2,,103168230,3767,Active,,,,,Growth inhibition of Mycobacterium vanbaalenii at 50 uM after 18 hrs,Other,23314046.0,
2998,721635,1,2,,103168230,3767,Active,,,,,Growth inhibition of Mycobacterium smegmatis at 100 uM after 24 hrs,Other,23314046.0,
2999,724312,1,4,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as growth inhibition after 8 days by XTT reduction menadione assay,Other,23265877.0,
3000,725312,1,2,,103168230,3767,Inactive,,,,,Inhibition of human Flag-tagged LEDGF interaction to His6-tagged HIV1 integrase expressed in Escherichia coli BL21 (DE3) at 1000 uM preincubated for 20 mins measured after 1 hr by AlphaScreen proximity luminescent assay,Other,23306052.0,
3001,725967,1,4,,103168230,3767,Inconclusive,,,,,Cytotoxicity against HEK293T cells assessed as growth inhibition at 50 uM by MTT assay relative to control,Other,23391589.0,
3002,725968,1,4,,103168230,3767,Inconclusive,,,,,Cytotoxicity against HEK293T cells assessed as growth inhibition at 25 uM by MTT assay relative to control,Other,23391589.0,
3003,725969,2,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition by NCCLS agar dilution method,Other,23391589.0,
3004,725971,1,6,,103168230,3767,Inconclusive,614134358.0,886016.0,,,Inhibition of Mycobacterium tuberculosis CysK1 using O-acetyl-L-serine as substrate assessed as L-cycteine formation at 100 uM after 5 mins by spectrophotometric analysis relative to control,Other,23391589.0,
3005,729921,1,2,,103168230,3767,Unspecified,,,100.0,IC50,Cytotoxicity against mouse bone marrow derived macrophage assessed as growth inhibition after 48 hrs by MTS assay,Confirmatory,23454512.0,
3006,729922,1,2,,103168230,3767,Unspecified,,,100.0,IC50,Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 24 hrs by MTS assay,Confirmatory,23454512.0,
3007,729923,2,1,,103168230,3767,Active,,,,,Antitubercular activity Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 4 weeks,Other,23454512.0,
3008,730805,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 0.2 ug/ml,Other,23414843.0,
3009,733054,1,3,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Other,23352268.0,
3010,733061,1,3,,103168230,3767,Active,,,,EC50,Antitubercular activity against Mycobacterium tuberculosis H37Rv by BacTiter-Gl Microbial Cell Viability assay,Confirmatory,23352268.0,
3011,733062,1,3,,103168230,3767,Unspecified,,,,EC50,Antitubercular activity against Mycobacterium tuberculosis H37Rv by microdilution alamar Blue broth assay,Confirmatory,23352268.0,
3012,733449,1,2,,103168230,3767,Unspecified,,,150.0,IC50,Trypanosomicidal activity against axenic epimastigote stage of Trypanosoma cruzi Tulahuen 2 assessed as growth inhibition,Confirmatory,23202852.0,
3013,733452,1,2,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse J774.1 cells to MIC for Mycobacterium tuberculosis H37Rv",Other,23202852.0,
3014,733453,1,2,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse J774.1 cells to MIC for multidrug-resistant Mycobacterium tuberculosis clinical isolate",Other,23202852.0,
3015,733454,1,3,,103168230,3767,Unspecified,,,400.0,IC50,Cytotoxicity against mouse J774.1 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,23202852.0,
3016,733455,2,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate assessed as growth inhibition after 5 days by MTT assay,Other,23202852.0,
3017,733456,2,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 5 days by MTT assay,Other,23202852.0,
3018,738683,1,2,,103168230,3767,Unspecified,,,,,"Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in BALB/c mouse assessed as log10 reduction of bacterial growth in lungs at 25 mg/kg, po administered 6 days a week for 30 days starting from 2 days post infection relative to untreated control",Other,23474387.0,
3019,739420,1,2,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells by microplate Alamar Blue assay,Confirmatory,23611124.0,
3020,739421,1,2,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate Alamar Blue assay,Other,23611124.0,
3021,743012,3,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3022,743012,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3023,743012,3,1,,144210513,3767,Inconclusive,,,28.7277,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3024,743014,3,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3025,743014,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3026,743014,3,1,,144210513,3767,Inconclusive,,,28.7277,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3027,743015,3,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3028,743015,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3029,743015,3,1,,144210513,3767,Inconclusive,,,28.7277,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3030,743033,3,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3031,743033,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3032,743033,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3033,743035,2,1,,144207189,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3034,743035,2,1,,144208565,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3035,743035,2,1,,144210513,3767,Inconclusive,124375976.0,367.0,23.0196,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3036,743036,2,1,,144207189,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3037,743036,2,1,,144208565,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3038,743036,2,1,,144210513,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3039,743040,3,1,,144207189,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3040,743040,3,1,,144208565,3767,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3041,743040,3,1,,144210513,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3042,743041,3,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3043,743041,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3044,743041,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3045,743042,3,1,,144207189,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3046,743042,3,1,,144208565,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3047,743042,3,1,,144210513,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3048,743053,2,1,,144207189,3767,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3049,743053,2,1,,144208565,3767,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3050,743053,2,1,,144210513,3767,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3051,743054,2,1,,144207189,3767,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3052,743054,2,1,,144208565,3767,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3053,743054,2,1,,144210513,3767,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3054,743063,2,1,,144207189,3767,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3055,743063,2,1,,144208565,3767,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3056,743063,2,1,,144210513,3767,Inconclusive,124375976.0,367.0,21.7319,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3057,743064,3,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3058,743064,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3059,743064,3,1,,144210513,3767,Inconclusive,,,11.4367,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3060,743065,3,1,,144207189,3767,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3061,743065,3,1,,144208565,3767,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3062,743065,3,1,,144210513,3767,Inactive,399498506.0,24831.0,11.4367,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3063,743066,3,1,,144207189,3767,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3064,743066,3,1,,144208565,3767,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3065,743066,3,1,,144210513,3767,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3066,743067,2,1,,144207189,3767,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3067,743067,2,1,,144208565,3767,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3068,743067,2,1,,144210513,3767,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3069,743069,2,1,,144207189,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3070,743069,2,1,,144208565,3767,Inactive,348019627.0,2099.0,21.9474,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3071,743069,2,1,,144210513,3767,Inactive,348019627.0,2099.0,23.0196,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3072,743074,2,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3073,743074,2,1,,144208565,3767,Inconclusive,,,21.9474,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3074,743074,2,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3075,743075,2,1,,144207189,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3076,743075,2,1,,144208565,3767,Inactive,348019627.0,2099.0,55.1293,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3077,743075,2,1,,144210513,3767,Inactive,348019627.0,2099.0,18.2851,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3078,743077,2,1,,144207189,3767,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3079,743077,2,1,,144208565,3767,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3080,743077,2,1,,144210513,3767,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3081,743078,2,1,,144207189,3767,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3082,743078,2,1,,144208565,3767,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3083,743078,2,1,,144210513,3767,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3084,743079,3,1,,144207189,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3085,743079,3,1,,144208565,3767,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3086,743079,3,1,,144210513,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3087,743080,3,1,,144207189,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3088,743080,3,1,,144208565,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3089,743080,3,1,,144210513,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3090,743081,3,1,,144207189,3767,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3091,743081,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3092,743081,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3093,743083,3,1,,144207189,3767,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3094,743083,3,1,,144208565,3767,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3095,743083,3,1,,144210513,3767,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3096,743084,3,1,,144207189,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3097,743084,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3098,743084,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3099,743085,3,1,,144207189,3767,Active,51095037.0,196.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3100,743085,3,1,,144208565,3767,Inconclusive,51095037.0,196.0,1.2234,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3101,743085,3,1,,144210513,3767,Inconclusive,51095037.0,196.0,10.193,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3102,743086,3,1,,144207189,3767,Inconclusive,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3103,743086,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3104,743086,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3105,743091,2,1,,144207189,3767,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3106,743091,2,1,,144208565,3767,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3107,743091,2,1,,144210513,3767,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3108,743094,3,1,,144207189,3767,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3109,743094,3,1,,144208565,3767,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3110,743094,3,1,,144210513,3767,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3111,743122,2,1,,144207189,3767,Active,51095037.0,196.0,7.942080000000001,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3112,743122,2,1,,144208565,3767,Active,51095037.0,196.0,27.3893,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3113,743122,2,1,,144210513,3767,Active,51095037.0,196.0,0.5731930000000001,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3114,743126,1,1,,49718175,3767,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3115,743139,2,1,,144207189,3767,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3116,743139,2,1,,144208565,3767,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3117,743139,2,1,,144210513,3767,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3118,743140,2,1,,144207189,3767,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3119,743140,2,1,,144208565,3767,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3120,743140,2,1,,144210513,3767,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3121,743191,3,1,,144208565,3767,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3122,743191,3,1,,144210513,3767,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3123,743191,3,1,,170466877,3767,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3124,743194,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3125,743194,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3126,743194,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3127,743199,2,1,,144208565,3767,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3128,743199,2,1,,144210513,3767,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3129,743199,2,1,,170466877,3767,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3130,743202,4,1,,144208565,3767,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3131,743202,4,1,,144210513,3767,Inconclusive,20149576.0,4780.0,2.0338,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3132,743202,4,1,,170466877,3767,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3133,743203,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3134,743203,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3135,743203,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3136,743209,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3137,743209,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3138,743209,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3139,743210,4,1,,144208565,3767,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3140,743210,4,1,,144210513,3767,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3141,743210,4,1,,170466877,3767,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3142,743211,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3143,743211,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3144,743211,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3145,743212,3,1,,144208565,3767,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3146,743212,3,1,,144210513,3767,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3147,743212,3,1,,170466877,3767,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3148,743213,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3149,743213,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3150,743213,3,1,,170466877,3767,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3151,743215,3,1,,144208565,3767,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3152,743215,3,1,,144210513,3767,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3153,743215,3,1,,170466877,3767,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3154,743217,3,1,,144208565,3767,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3155,743217,3,1,,144210513,3767,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3156,743217,3,1,,170466877,3767,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3157,743218,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3158,743218,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3159,743218,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3160,743219,3,1,,144208565,3767,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3161,743219,3,1,,144210513,3767,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3162,743219,3,1,,170466877,3767,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3163,743220,3,1,,144208565,3767,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3164,743220,3,1,,144210513,3767,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3165,743220,3,1,,170466877,3767,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3166,743221,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3167,743221,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3168,743221,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3169,743222,3,1,,144208565,3767,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3170,743222,3,1,,144210513,3767,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3171,743222,3,1,,170466877,3767,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3172,743223,3,1,,144208565,3767,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3173,743223,3,1,,144210513,3767,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3174,743223,3,1,,170466877,3767,Inconclusive,216409708.0,7421.0,0.19,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3175,743224,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3176,743224,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3177,743224,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3178,743225,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3179,743225,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3180,743225,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3181,743226,2,1,,144208565,3767,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3182,743226,2,1,,144210513,3767,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3183,743226,2,1,,170466877,3767,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3184,743227,2,1,,144208565,3767,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3185,743227,2,1,,144210513,3767,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3186,743227,2,1,,170466877,3767,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3187,743228,3,1,,144208565,3767,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3188,743228,3,1,,144210513,3767,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3189,743228,3,1,,170466877,3767,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3190,743238,1,1,,49718175,3767,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3191,743239,2,1,,144208565,3767,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3192,743239,2,1,,144210513,3767,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3193,743239,2,1,,170466877,3767,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3194,743240,2,1,,144208565,3767,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3195,743240,2,1,,144210513,3767,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3196,743240,2,1,,170466877,3767,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3197,743241,2,1,,144208565,3767,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3198,743241,2,1,,144210513,3767,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3199,743241,2,1,,170466877,3767,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3200,743242,2,1,,144208565,3767,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3201,743242,2,1,,144210513,3767,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3202,743242,2,1,,170466877,3767,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3203,743244,1,1,,144207189,3767,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3204,743247,1,2,,49718175,3767,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3205,743255,1,1,,49718175,3767,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3206,743266,1,2,,49718175,3767,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3207,743268,1,1,,172080636,3767,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
3208,743269,1,1,,49718175,3767,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3209,743269,1,1,,49718175,3767,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3210,743270,1,1,,172080636,3767,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3211,743271,1,1,,172080636,3767,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
3212,743272,1,1,,172080636,3767,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
3213,743279,1,2,,49718175,3767,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3214,743287,1,1,,49718175,3767,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
3215,743288,1,1,,17389848,3767,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3216,743292,1,1,,17389848,3767,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3217,743344,1,1,,174006260,3767,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3218,743345,1,1,,174006260,3767,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3219,743346,1,1,,174006260,3767,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
3220,743347,1,1,,174006260,3767,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3221,743397,1,1,,49718175,3767,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3222,743398,1,1,,49718175,3767,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3223,745299,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 12 to 28 days by Lowenstein-Jensen method,Other,23567957.0,
3224,745300,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition at 250 ug/mL after 12 to 28 days by Lowenstein-Jensen method relative to control,Other,23567957.0,
3225,746724,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774.A1 cells at 1 MOI assessed as intracellular bacterial growth inhibition at 0.1 uM after 1 hr by luciferase reporter gene assay relative to control,Other,23567963.0,
3226,746725,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774.A1 cells at 1 MOI assessed as intracellular bacterial growth inhibition at 1 uM after 1 hr by luciferase reporter gene assay relative to control,Other,23567963.0,
3227,746726,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774.A1 cells at 1 MOI assessed as intracellular bacterial growth inhibition at 10 uM after 1 hr by luciferase reporter gene assay relative to control,Other,23567963.0,
3228,746730,1,1,,103168230,3767,Active,,,0.39,MIC50,Antimycobacterial activity against Mycobacterium ulcerans 1615 assessed as growth inhibition after 6 days by luciferase reporter gene assay,Confirmatory,23567963.0,
3229,746731,1,1,,103168230,3767,Active,,,0.1,MIC50,Antimycobacterial activity against Mycobacterium avium subsp. paratuberculosis ATCC 19698 assessed as growth inhibition after 6 days by luciferase reporter gene assay,Confirmatory,23567963.0,
3230,746732,1,1,,103168230,3767,Active,,,0.1,MIC50,Antimycobacterial activity against Mycobacterium avium subsp. avium ATCC 15769 assessed as growth inhibition after 6 days by luciferase reporter gene assay,Confirmatory,23567963.0,
3231,746733,1,1,,103168230,3767,Active,,,0.1,MIC50,Antimycobacterial activity against Mycobacterium bovis AN5 assessed as growth inhibition after 6 days by luciferase reporter gene assay,Confirmatory,23567963.0,
3232,746734,1,1,,103168230,3767,Active,,,0.1,MIC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 6 days by luciferase reporter gene assay,Confirmatory,23567963.0,
3233,746737,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 0.1 uM after 6 days by luciferase reporter gene assay relative to control,Other,23567963.0,
3234,746738,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 1 uM after 6 days by luciferase reporter gene assay relative to control,Other,23567963.0,
3235,746739,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 10 uM after 6 days by luciferase reporter gene assay relative to control,Other,23567963.0,
3236,753835,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Bacille Calmette-Guerin,Other,23668986.0,
3237,754932,1,1,,103168230,3767,Inconclusive,,,,,"Lipophilicity, log K of the compound by HPLC analysis",Other,23659859.0,
3238,754934,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 152/73 assessed as growth inhibition after 14 days by microdilution method,Other,23659859.0,
3239,754935,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 80/72 assessed as growth inhibition after 14 days by microdilution method,Other,23659859.0,
3240,754936,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 assessed as growth inhibition after 14 days by microdilution method,Other,23659859.0,
3241,754937,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 14 days by microdilution method,Other,23659859.0,
3242,758266,1,1,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 12 to 28 days by Lowenstein-Jensen method,Other,23747804.0,
3243,758267,1,1,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition at 250 ug/ml after 12 to 28 days by Lowenstein-Jensen method relative to control,Other,23747804.0,
3244,760170,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv expressing pCHERRY3 after 4 days by plate format assay,Other,23930153.0,
3245,765104,3,1,,103168230,3767,Inactive,,,,,"Bacteriostatic activity against rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide-resistant Mycobacterium tuberculosis MS-115 assessed as growth inhibition",Other,23891229.0,
3246,765105,1,2,,103168230,3767,Inactive,,,,,"Bacteriostatic activity against rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide-resistant Mycobacterium tuberculosis MS-115 assessed as growth inhibition at 2 to 200 ug/mL relative to control",Other,23891229.0,
3247,765112,3,1,,103168230,3767,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition,Other,23891229.0,
3248,765268,1,1,,103168230,3767,Unspecified,,,,,T>MIC in Mycobacterium tuberculosis infected mouse,Other,23910985.0,
3249,765269,1,1,,103168230,3767,Unspecified,,,,,fT>MIC in Mycobacterium tuberculosis infected mouse,Other,23910985.0,
3250,765270,1,2,,103168230,3767,Unspecified,,,,,AUC/MIC in Mycobacterium tuberculosis infected mouse,Other,23910985.0,
3251,765271,1,1,,103168230,3767,Unspecified,,,,,fAUC/MIC in Mycobacterium tuberculosis infected mouse,Other,23910985.0,
3252,765272,1,1,,103168230,3767,Unspecified,,,,,Cmax/MIC in Mycobacterium tuberculosis infected mouse,Other,23910985.0,
3253,765273,1,1,,103168230,3767,Unspecified,,,,,fCmax/MIC in Mycobacterium tuberculosis infected mouse,Other,23910985.0,
3254,765960,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 27294",Other,23886691.0,
3255,765962,1,1,,103168230,3767,Unspecified,,,100.0,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,23886691.0,
3256,765963,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by microdilution plate assay,Other,23886691.0,
3257,765964,1,3,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microplate alamar blue assay,Other,23886691.0,
3258,767539,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis assessed as growth inhibition at 0.3125 to 5 ug/mL by resazurin assay,Other,23942420.0,
3259,767540,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 19542 assessed as growth inhibition at 0.3125 to 5 ug/mL by resazurin assay,Other,23942420.0,
3260,767541,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 19420 assessed as growth inhibition at 0.3125 to 5 ug/mL by resazurin assay,Other,23942420.0,
3261,767542,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition at 0.3125 to 5 ug/mL by resazurin assay,Other,23942420.0,
3262,767543,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum ATCC 19542 assessed as growth inhibition at 1 to 100 ug/mL by resazurin assay,Other,23942420.0,
3263,767544,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 19420 assessed as growth inhibition at 1 to 100 ug/mL by resazurin assay,Other,23942420.0,
3264,767545,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition at 1 to 100 ug/mL by resazurin assay,Other,23942420.0,
3265,768269,1,1,,103168230,3767,Unspecified,,,,,Cell cycle arrest in human HCT8 cells assessed as accumulation at G2/M phase at 50 ug/mL after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 13.83%),Other,23823011.0,
3266,768272,1,1,,103168230,3767,Unspecified,,,,,Cell cycle arrest in human HCT8 cells assessed as accumulation at S phase at 50 ug/mL after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 39.43%),Other,23823011.0,
3267,768276,1,1,,103168230,3767,Unspecified,,,,,Induction of apoptosis in human HCT8 cells assessed as viable cells at 50 ug/mL after 24 hrs by Annexin V-FITC and propidium iodide staining-based flow cytometric analysis (Rvb = 87.7%),Other,23823011.0,
3268,768278,1,1,,103168230,3767,Unspecified,,,,,Induction of apoptosis in human HCT8 cells assessed as early apoptotic cells at 50 ug/mL after 24 hrs by Annexin V-FITC and propidium iodide staining-based flow cytometric analysis (Rvb = 1.57%),Other,23823011.0,
3269,768280,1,1,,103168230,3767,Unspecified,,,,,Induction of apoptosis in human HCT8 cells assessed as late apoptotic cells at 50 ug/mL after 24 hrs by Annexin V-FITC and propidium iodide staining-based flow cytometric analysis (Rvb = 2.97%),Other,23823011.0,
3270,768283,1,1,,103168230,3767,Unspecified,,,,,Induction of apoptosis in human HCT8 cells assessed as necrotic cells at 50 ug/mL after 24 hrs by Annexin V-FITC and propidium iodide staining-based flow cytometric analysis (Rvb = 7.73%),Other,23823011.0,
3271,768284,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Acinetobacter baumannii 247 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3272,768285,1,1,,103168230,3767,Active,,,,,Antibacterial activity against Acinetobacter baumannii 192 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3273,768287,1,1,,103168230,3767,Active,,,,,Antibacterial activity against Acinetobacter baumannii 135 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3274,768288,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Acinetobacter baumannii 125 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3275,768289,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Acinetobacter baumannii 122 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3276,768290,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Enterococcus faecalis 2920 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3277,768292,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Pseudomonas aeruginosa 1144 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3278,768293,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Pseudomonas aeruginosa 165 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3279,768294,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3280,768295,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Klebsiella pneumoniae 1756 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3281,768296,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Escherichia coli 1777 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3282,768297,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Proteus mirabilis 1751 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3283,768298,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Morganella morganii 2810 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3284,768299,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Citrobacter koseri 1742 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3285,768300,1,1,,103168230,3767,Active,,,,,Antibacterial activity against Enterobacter cloacae 1845 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3286,768301,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Staphylococcus aureus assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3287,768302,1,1,,103168230,3767,Inactive,,,,,Antibacterial activity against Staphylococcus hominis 1813 assessed as growth inhibition at 1 mg/mL after 24 hrs by agar-disk diffusion technique,Other,23823011.0,
3288,768303,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis after 8 days by micro plate Alamar Blue assay,Other,23823011.0,
3289,768304,1,2,,103168230,3767,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 0.1 mg/mL after 30 mins under dark conditions by spectrophotometric analysis relative to control,Other,23823011.0,
3290,768305,1,1,,103168230,3767,Unspecified,,,,,Decrease in NAT1 gene expression in human HCT8 cells at 50 ug/mL after 24 hrs by RT-PCR analysis,Other,23823011.0,
3291,768308,1,1,,103168230,3767,Unspecified,,,,,Cell cycle arrest in human HCT8 cells assessed as accumulation at G0/G1 phase at 50 ug/mL after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 46.43%),Other,23823011.0,
3292,768309,1,1,,103168230,3767,Unspecified,,,,,Decrease in NAT2 gene expression in human HCT8 cells at 50 ug/mL after 24 hrs by RT-PCR analysis,Other,23823011.0,
3293,768663,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium fortuitum PCM 672 assessed as growth inhibition after 48 hrs by microplate Alamar blue assay,Other,23850103.0,
3294,768853,1,3,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 6 weeks,Other,,
3295,768854,1,3,,103168230,3767,Unspecified,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis after 6 weeks,Other,,
3296,769004,1,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,,
3297,770315,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,23953191.0,
3298,771922,1,3,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 28 days by agar dilution method,Other,,
3299,774190,1,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay,Confirmatory,24079882.0,
3300,774191,1,1,,103168230,3767,Unspecified,,,,,Antitubecular activity against Mycobacterium tuberculosis H37Pv assessed as growth inhibition by low oxygen recovery assay,Other,24079882.0,
3301,774192,1,1,,103168230,3767,Unspecified,,,,,Antitubecular activity against Mycobacterium tuberculosis H37Pv assessed as growth inhibition after 4 days by microplate Alamar blue assay,Other,24079882.0,
3302,774292,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC90 for Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate Alamar blue assay",Other,24087924.0,
3303,774293,1,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS-PMS assay,Other,24087924.0,
3304,774294,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against cycloserine-resistant Mycobacterium tuberculosis ATCC 35826,Other,24087924.0,
3305,774295,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against kanamycin-resistant Mycobacterium tuberculosis ATCC 35827,Other,24087924.0,
3306,774296,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis ATCC 35820,Other,24087924.0,
3307,774297,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822,Other,24087924.0,
3308,774298,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis ATCC 35838,Other,24087924.0,
3309,774300,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate Alamar blue assay,Other,24087924.0,
3310,774413,1,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of cell viability measured on day 8 by XTT assay in presence of menadione,Other,24117130.0,
3311,774597,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 expressing luciferase reporter gene infected in mouse J774 macrophages assessed as intracellular growth inhibition at 0.5 uM after 4 days by luminometry relative to untreated control,Other,23850570.0,
3312,774598,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 expressing luciferase reporter gene infected in mouse J774 macrophages assessed as intracellular growth inhibition at 1 uM after 4 days by luminometry relative to untreated control,Other,23850570.0,
3313,774599,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 expressing luciferase reporter gene infected in mouse J774 macrophages assessed as intracellular growth inhibition at 2 uM after 4 days by luminometry relative to untreated control,Other,23850570.0,
3314,774600,1,1,,103168230,3767,Inconclusive,,,,,"Therapeutic index, ratio of IC50 for human HepG2/C3A cells to GI50 for Mycobacterium tuberculosis H37Rv ATCC 27294",Other,23850570.0,
3315,774601,1,2,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human HepG2/C3A cells after 24 hrs by neutral red dye uptake assay,Confirmatory,23850570.0,
3316,774602,1,1,,103168230,3767,Active,,,0.01,GI50,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 expressing luciferase reporter gene assessed as growth inhibition after 6 days by luminometry,Confirmatory,23850570.0,
3317,774603,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 expressing luciferase reporter gene assessed as reduction in bacterial count after 6 days by luminometry,Other,23850570.0,
3318,774604,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 expressing luciferase reporter gene assessed as growth inhibition at 0.1 uM after 6 days by luminometry relative to control,Other,23850570.0,
3319,774605,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 expressing luciferase reporter gene assessed as growth inhibition at 1 uM after 6 days by luminometry relative to control,Other,23850570.0,
3320,774606,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 expressing luciferase reporter gene assessed as growth inhibition at 10 uM after 6 days by luminometry relative to control,Other,23850570.0,
3321,774992,1,2,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human GM637 cells after 4 days by WST-1 assay,Confirmatory,24016834.0,
3322,774993,1,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human HCT116 cells after 4 days by WST-1 assay,Confirmatory,24016834.0,
3323,774994,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 21 days by micro-broth dilution method,Other,24016834.0,
3324,775552,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii DSM 44162 after 7 days,Other,24045008.0,
3325,775553,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium marinum CAMP 5644 after 21 days,Other,24045008.0,
3326,775554,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 700084 after 3 days,Other,24045008.0,
3327,775853,3,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by micro plate alamar blue assay,Other,24074842.0,
3328,775976,1,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 28 days by agar dilution method,Other,24077526.0,
3329,775978,1,5,,103168230,3767,Unspecified,614101224.0,885459.0,,,"Inhibition of Mycobacterium tuberculosis pantothenate synthetase cloned in Escherichia coli BL21 (DE3) using ATP, beta-alanine, pantoic acid as substrate assessed as NAD+ production at 100 uM measured every 12 secs for 120 secs by spectrophotometric analysis relative to control",Other,24077526.0,
3330,776427,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 5 days by broth microdilution method,Other,24095750.0,
3331,777340,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 24 hrs by agar microdilution method,Other,24900592.0,
3332,779946,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 700084 after 3 days by two-fold serial dilution method,Other,24075143.0,
3333,779947,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii DSM 44162 after 7 days by two-fold serial dilution method,Other,24075143.0,
3334,779948,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium marinum CAMP 5644 after 21 days by two-fold serial dilution method,Other,24075143.0,
3335,780281,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC90 for Mycobacterium tuberculosis H37Rv",Other,24084159.0,
3336,780282,1,1,,103168230,3767,Unspecified,,,128.0,IC50,Cytotoxicity against african green monkey Vero cells by tetrazolium dye reduction assay,Confirmatory,24084159.0,
3337,780283,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by MABA assay,Other,24084159.0,
3338,780667,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of CC50 for African green monkey Vero C1008 cells to MIC for Mycobacterium tuberculosis H37Rv",Other,24095091.0,
3339,780668,1,2,,103168230,3767,Unspecified,,,1470.0,CC50,Cytotoxicity against African green monkey Vero C1008 cells after 72 hrs by MTT assay,Confirmatory,24095091.0,
3340,780669,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as parasite growth inhibition after 7 days by resazurin microtitre assay,Other,24095091.0,
3341,780895,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampicin-resistant Mycobacterium tuberculosis ATCC 35338 harboring rpoB His-526-Tir gene mutant after 7 days by REMA assay,Other,24103427.0,
3342,780896,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis 1896HF harboring inhA mutant after 7 days by REMA assay,Other,24103427.0,
3343,780897,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822 harboring katG mutant after 7 days by REMA assay,Other,24103427.0,
3344,780898,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by REMA assay,Other,24103427.0,
3345,809771,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/12,Other,,
3346,809772,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/12,Other,,
3347,809773,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/12,Other,,
3348,809774,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/12,Other,,
3349,809775,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/12,Other,,
3350,809776,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/12,Other,,
3351,809777,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/12,Other,,
3352,809778,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/13,Other,,
3353,809779,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/13,Other,,
3354,809780,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/13,Other,,
3355,809781,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/13,Other,,
3356,809782,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/13,Other,,
3357,809783,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/13,Other,,
3358,809784,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/13,Other,,
3359,809785,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/13,Other,,
3360,809786,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/13,Other,,
3361,809787,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/13,Other,,
3362,809788,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/13,Other,,
3363,809789,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/13,Other,,
3364,809790,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/13,Other,,
3365,809791,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/13,Other,,
3366,809792,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/13,Other,,
3367,809793,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/13,Other,,
3368,809794,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/13,Other,,
3369,809795,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/14,Other,,
3370,809796,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/14,Other,,
3371,809797,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/14,Other,,
3372,809798,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/14,Other,,
3373,809799,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/14,Other,,
3374,809800,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/14,Other,,
3375,809809,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/7,Other,,
3376,809810,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/7,Other,,
3377,809811,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/7,Other,,
3378,809812,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/7,Other,,
3379,809813,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/7,Other,,
3380,809814,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/8,Other,,
3381,809815,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/8,Other,,
3382,809816,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/8,Other,,
3383,809817,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/8,Other,,
3384,809818,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/8,Other,,
3385,809819,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/8,Other,,
3386,809820,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/8,Other,,
3387,809821,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/8,Other,,
3388,809822,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/8,Other,,
3389,809823,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/8,Other,,
3390,809824,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/8,Other,,
3391,809825,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/8,Other,,
3392,809826,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/8,Other,,
3393,809827,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/8,Other,,
3394,809828,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/8,Other,,
3395,809829,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/8,Other,,
3396,809830,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/8,Other,,
3397,809831,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/9,Other,,
3398,809832,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/9,Other,,
3399,809833,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/9,Other,,
3400,809834,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/9,Other,,
3401,809835,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/9,Other,,
3402,809836,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/9,Other,,
3403,809837,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/9,Other,,
3404,809838,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/9,Other,,
3405,809839,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/9,Other,,
3406,809840,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/9,Other,,
3407,809841,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/9,Other,,
3408,809842,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/9,Other,,
3409,809843,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/9,Other,,
3410,809844,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/9,Other,,
3411,809845,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/9,Other,,
3412,809846,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/9,Other,,
3413,810160,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/14,Other,,
3414,810161,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/14,Other,,
3415,810162,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/14,Other,,
3416,810163,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/14,Other,,
3417,810164,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/14,Other,,
3418,810165,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/14,Other,,
3419,810166,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/14,Other,,
3420,810167,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/14,Other,,
3421,810168,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/14,Other,,
3422,810169,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/14,Other,,
3423,810170,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/14,Other,,
3424,810171,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/15,Other,,
3425,810172,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/15,Other,,
3426,810173,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/15,Other,,
3427,810174,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/15,Other,,
3428,810175,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/15,Other,,
3429,810176,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/15,Other,,
3430,810205,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/9,Other,,
3431,810206,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/10,Other,,
3432,810207,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/10,Other,,
3433,810208,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/10,Other,,
3434,810209,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/10,Other,,
3435,810210,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/10,Other,,
3436,810211,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/10,Other,,
3437,810212,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/10,Other,,
3438,810213,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/10,Other,,
3439,810214,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/10,Other,,
3440,810840,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/10,Other,,
3441,810841,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/10,Other,,
3442,810842,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/10,Other,,
3443,810843,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/10,Other,,
3444,810844,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/10,Other,,
3445,810845,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/10,Other,,
3446,810846,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/10,Other,,
3447,810847,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/10,Other,,
3448,810848,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/11,Other,,
3449,810849,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/11,Other,,
3450,810850,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/11,Other,,
3451,810851,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/11,Other,,
3452,810852,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/11,Other,,
3453,810853,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/11,Other,,
3454,810854,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/11,Other,,
3455,810855,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/11,Other,,
3456,810856,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/11,Other,,
3457,810857,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/11,Other,,
3458,810858,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/11,Other,,
3459,810859,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/11,Other,,
3460,810860,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/11,Other,,
3461,810861,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/11,Other,,
3462,810862,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/11,Other,,
3463,810863,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/11,Other,,
3464,810864,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/11,Other,,
3465,810865,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/12,Other,,
3466,810866,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/12,Other,,
3467,810867,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/12,Other,,
3468,810868,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/12,Other,,
3469,810869,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/12,Other,,
3470,810870,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/12,Other,,
3471,810871,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/12,Other,,
3472,810872,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/12,Other,,
3473,810873,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/12,Other,,
3474,810874,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/12,Other,,
3475,810875,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/12,Other,,
3476,810876,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/12,Other,,
3477,810877,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/12,Other,,
3478,810878,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/12,Other,,
3479,811205,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/12,Other,,
3480,811206,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/12,Other,,
3481,811207,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/12,Other,,
3482,811208,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/13,Other,,
3483,811209,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/13,Other,,
3484,811210,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/13,Other,,
3485,811211,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/13,Other,,
3486,811212,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/13,Other,,
3487,811363,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/15,Other,,
3488,811364,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/15,Other,,
3489,811365,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/15,Other,,
3490,811366,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/15,Other,,
3491,811367,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/15,Other,,
3492,811368,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/15,Other,,
3493,811369,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/15,Other,,
3494,811370,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/15,Other,,
3495,811371,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/15,Other,,
3496,811372,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/15,Other,,
3497,811373,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/15,Other,,
3498,811374,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/16,Other,,
3499,811375,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/16,Other,,
3500,811376,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/16,Other,,
3501,811377,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/16,Other,,
3502,811378,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/16,Other,,
3503,811379,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/16,Other,,
3504,811380,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/16,Other,,
3505,811381,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/16,Other,,
3506,811382,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/16,Other,,
3507,811634,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/9,Other,,
3508,811635,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/9,Other,,
3509,811725,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/16,Other,,
3510,811726,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/16,Other,,
3511,811727,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/16,Other,,
3512,811728,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/16,Other,,
3513,811729,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/16,Other,,
3514,811730,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/16,Other,,
3515,811731,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/16,Other,,
3516,811732,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/16,Other,,
3517,811733,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/17,Other,,
3518,811734,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/17,Other,,
3519,811735,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/17,Other,,
3520,811736,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/17,Other,,
3521,811737,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/17,Other,,
3522,811738,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/17,Other,,
3523,811739,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/17,Other,,
3524,811740,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/17,Other,,
3525,811741,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/17,Other,,
3526,811742,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/17,Other,,
3527,811743,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/17,Other,,
3528,811744,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/17,Other,,
3529,811745,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/17,Other,,
3530,811746,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/17,Other,,
3531,811747,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/17,Other,,
3532,811748,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/17,Other,,
3533,811749,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/17,Other,,
3534,811750,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/18,Other,,
3535,811751,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/18,Other,,
3536,811949,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/9,Other,,
3537,811950,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/9,Other,,
3538,811951,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/9,Other,,
3539,811952,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/9,Other,,
3540,811953,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/9,Other,,
3541,811954,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/9,Other,,
3542,811955,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/9,Other,,
3543,811956,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/9,Other,,
3544,811957,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/9,Other,,
3545,811958,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/9,Other,,
3546,811959,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/9,Other,,
3547,811960,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/9,Other,,
3548,812325,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/13,Other,,
3549,812326,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/13,Other,,
3550,812327,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/13,Other,,
3551,812328,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/13,Other,,
3552,812329,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/13,Other,,
3553,812330,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/13,Other,,
3554,812331,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/13,Other,,
3555,812332,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/13,Other,,
3556,812333,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/13,Other,,
3557,812334,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/13,Other,,
3558,812335,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/13,Other,,
3559,812336,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/13,Other,,
3560,812337,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/14,Other,,
3561,812338,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/14,Other,,
3562,812339,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/14,Other,,
3563,812340,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/14,Other,,
3564,812341,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/14,Other,,
3565,812342,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/14,Other,,
3566,812343,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/14,Other,,
3567,812344,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/14,Other,,
3568,812345,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/14,Other,,
3569,812346,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/14,Other,,
3570,812347,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/14,Other,,
3571,812348,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/14,Other,,
3572,812349,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/14,Other,,
3573,812350,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/14,Other,,
3574,812351,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/14,Other,,
3575,812352,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/14,Other,,
3576,812353,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/14,Other,,
3577,812354,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/15,Other,,
3578,812355,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/15,Other,,
3579,812671,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/15,Other,,
3580,812672,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/15,Other,,
3581,812673,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/15,Other,,
3582,812674,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/15,Other,,
3583,812675,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/15,Other,,
3584,812676,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/15,Other,,
3585,812677,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/15,Other,,
3586,812678,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/15,Other,,
3587,812679,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/15,Other,,
3588,812680,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/15,Other,,
3589,812681,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/15,Other,,
3590,812682,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/15,Other,,
3591,812683,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/15,Other,,
3592,812684,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/15,Other,,
3593,812685,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/15,Other,,
3594,812686,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/16,Other,,
3595,812687,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/16,Other,,
3596,812842,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/18,Other,,
3597,812843,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/18,Other,,
3598,812844,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/18,Other,,
3599,812845,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/18,Other,,
3600,812846,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/18,Other,,
3601,812847,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/18,Other,,
3602,812848,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/18,Other,,
3603,812849,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/18,Other,,
3604,812850,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/18,Other,,
3605,812851,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/18,Other,,
3606,812852,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/18,Other,,
3607,813166,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/18,Other,,
3608,813167,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/18,Other,,
3609,813168,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/18,Other,,
3610,813169,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/18,Other,,
3611,813170,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/19,Other,,
3612,813171,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/19,Other,,
3613,813172,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/19,Other,,
3614,813173,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/19,Other,,
3615,813174,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/19,Other,,
3616,813175,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/19,Other,,
3617,813176,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/19,Other,,
3618,813177,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/19,Other,,
3619,813178,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/19,Other,,
3620,813179,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/19,Other,,
3621,813180,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/19,Other,,
3622,813181,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/19,Other,,
3623,813182,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/19,Other,,
3624,813183,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/19,Other,,
3625,813184,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/19,Other,,
3626,813185,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/19,Other,,
3627,813186,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/19,Other,,
3628,813187,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/20,Other,,
3629,813188,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/20,Other,,
3630,813189,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/20,Other,,
3631,813190,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/20,Other,,
3632,813191,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/20,Other,,
3633,813192,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/20,Other,,
3634,813193,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/20,Other,,
3635,813194,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/20,Other,,
3636,813195,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/20,Other,,
3637,813196,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/20,Other,,
3638,813197,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/20,Other,,
3639,813198,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/20,Other,,
3640,813199,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/20,Other,,
3641,813200,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/20,Other,,
3642,813201,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/20,Other,,
3643,813774,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/16,Other,,
3644,813775,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/16,Other,,
3645,813776,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/16,Other,,
3646,813777,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/16,Other,,
3647,813778,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/16,Other,,
3648,813779,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/16,Other,,
3649,813780,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/16,Other,,
3650,813781,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/16,Other,,
3651,813782,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/16,Other,,
3652,813783,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/16,Other,,
3653,813784,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/16,Other,,
3654,813785,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/16,Other,,
3655,813786,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/16,Other,,
3656,813787,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/16,Other,,
3657,813788,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/16,Other,,
3658,814208,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/9,Other,,
3659,814209,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/9,Other,,
3660,814210,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/9,Other,,
3661,814211,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/10,Other,,
3662,814212,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/10,Other,,
3663,814213,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/10,Other,,
3664,814214,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/10,Other,,
3665,814215,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/10,Other,,
3666,814216,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/10,Other,,
3667,814217,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/10,Other,,
3668,814218,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/10,Other,,
3669,814219,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/10,Other,,
3670,814220,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/10,Other,,
3671,814221,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/10,Other,,
3672,814222,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/10,Other,,
3673,814223,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/10,Other,,
3674,814224,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/10,Other,,
3675,814225,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/10,Other,,
3676,814226,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/10,Other,,
3677,814227,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/10,Other,,
3678,814228,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/11,Other,,
3679,814229,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/11,Other,,
3680,814230,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/11,Other,,
3681,814231,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/11,Other,,
3682,814232,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/11,Other,,
3683,814233,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/11,Other,,
3684,814234,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/11,Other,,
3685,814235,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/11,Other,,
3686,814236,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/11,Other,,
3687,814237,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/11,Other,,
3688,814238,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 61/11,Other,,
3689,814239,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 61/11,Other,,
3690,814240,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 61/11,Other,,
3691,814241,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 61/11,Other,,
3692,814242,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 61/11,Other,,
3693,814243,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/11,Other,,
3694,814244,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/11,Other,,
3695,814245,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 61/12,Other,,
3696,814246,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 61/12,Other,,
3697,814247,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 61/12,Other,,
3698,814292,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 61/20,Other,,
3699,814293,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 61/20,Other,,
3700,814562,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 61/12,Other,,
3701,814563,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 61/12,Other,,
3702,814564,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 61/12,Other,,
3703,814565,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 61/12,Other,,
3704,814566,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 61/12,Other,,
3705,814567,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 61/12,Other,,
3706,814568,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 61/12,Other,,
3707,814606,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/5,Other,,
3708,814607,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/5,Other,,
3709,814608,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/5,Other,,
3710,814609,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/5,Other,,
3711,814610,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/5,Other,,
3712,814611,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/5,Other,,
3713,814612,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/5,Other,,
3714,814613,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/5,Other,,
3715,814614,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/5,Other,,
3716,814615,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/5,Other,,
3717,814616,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/5,Other,,
3718,814617,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/5,Other,,
3719,814618,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/5,Other,,
3720,814619,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/5,Other,,
3721,814620,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/5,Other,,
3722,814621,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/5,Other,,
3723,814622,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/5,Other,,
3724,814623,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/6,Other,,
3725,814624,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/6,Other,,
3726,814625,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/6,Other,,
3727,814626,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/6,Other,,
3728,814627,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/6,Other,,
3729,814628,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/6,Other,,
3730,814629,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/6,Other,,
3731,814630,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/6,Other,,
3732,814631,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/6,Other,,
3733,814632,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/6,Other,,
3734,814633,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/6,Other,,
3735,814634,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/6,Other,,
3736,814635,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 629/6,Other,,
3737,814636,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 629/6,Other,,
3738,814637,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 629/6,Other,,
3739,814638,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 629/6,Other,,
3740,814639,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 629/6,Other,,
3741,814640,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 629/7,Other,,
3742,814641,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 629/7,Other,,
3743,814642,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 629/7,Other,,
3744,814643,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 629/7,Other,,
3745,814644,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 629/7,Other,,
3746,814645,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 629/7,Other,,
3747,814646,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 629/7,Other,,
3748,814647,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 629/7,Other,,
3749,814648,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 629/7,Other,,
3750,814649,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 629/7,Other,,
3751,814650,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 629/7,Other,,
3752,814651,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 629/7,Other,,
3753,906425,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/7,Other,,
3754,906426,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/7,Other,,
3755,906427,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/7,Other,,
3756,906428,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/7,Other,,
3757,906429,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/7,Other,,
3758,906430,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/7,Other,,
3759,906431,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/7,Other,,
3760,906432,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/7,Other,,
3761,906433,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/7,Other,,
3762,906434,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/7,Other,,
3763,906435,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/7,Other,,
3764,906436,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/8,Other,,
3765,906437,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/8,Other,,
3766,906438,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/8,Other,,
3767,906439,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/8,Other,,
3768,906440,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/8,Other,,
3769,906441,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/8,Other,,
3770,906442,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/8,Other,,
3771,906443,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/8,Other,,
3772,906444,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/8,Other,,
3773,906445,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/8,Other,,
3774,906446,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/8,Other,,
3775,906447,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/8,Other,,
3776,906448,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/8,Other,,
3777,906449,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/8,Other,,
3778,906450,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/8,Other,,
3779,906451,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/8,Other,,
3780,906452,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/8,Other,,
3781,906453,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/8,Other,,
3782,906454,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/8,Other,,
3783,906455,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/8,Other,,
3784,906456,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/8,Other,,
3785,906457,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/9,Other,,
3786,906458,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/9,Other,,
3787,906459,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/9,Other,,
3788,906460,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/9,Other,,
3789,906461,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/9,Other,,
3790,906462,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/9,Other,,
3791,906463,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/9,Other,,
3792,906464,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/9,Other,,
3793,906465,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/9,Other,,
3794,906466,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/9,Other,,
3795,906467,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/9,Other,,
3796,906468,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/9,Other,,
3797,906469,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/9,Other,,
3798,906504,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/16,Other,,
3799,906505,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/16,Other,,
3800,906506,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/16,Other,,
3801,906507,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/16,Other,,
3802,906508,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/16,Other,,
3803,906509,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/16,Other,,
3804,906510,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/16,Other,,
3805,906511,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/16,Other,,
3806,906586,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/9,Other,,
3807,906587,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/9,Other,,
3808,906588,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/9,Other,,
3809,906648,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/14,Other,,
3810,906649,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/14,Other,,
3811,906650,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/14,Other,,
3812,906651,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/14,Other,,
3813,906652,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/14,Other,,
3814,906653,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/14,Other,,
3815,906654,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/14,Other,,
3816,906655,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/14,Other,,
3817,906656,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/14,Other,,
3818,906657,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/14,Other,,
3819,906658,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/14,Other,,
3820,906659,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/14,Other,,
3821,906660,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/15,Other,,
3822,906661,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/15,Other,,
3823,906662,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/15,Other,,
3824,906663,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/15,Other,,
3825,906664,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/15,Other,,
3826,906665,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/15,Other,,
3827,906666,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/15,Other,,
3828,906667,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/15,Other,,
3829,906668,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/15,Other,,
3830,906669,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/15,Other,,
3831,906670,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/15,Other,,
3832,906671,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/15,Other,,
3833,906672,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/15,Other,,
3834,906673,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/15,Other,,
3835,906674,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/15,Other,,
3836,906675,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/15,Other,,
3837,906676,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/15,Other,,
3838,906677,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/15,Other,,
3839,906678,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/15,Other,,
3840,906774,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/15,Other,,
3841,906775,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/15,Other,,
3842,906776,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/16,Other,,
3843,906777,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/16,Other,,
3844,906778,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/16,Other,,
3845,906779,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/16,Other,,
3846,906780,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/16,Other,,
3847,906781,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/16,Other,,
3848,906782,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/16,Other,,
3849,906783,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/16,Other,,
3850,906784,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/16,Other,,
3851,906785,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/16,Other,,
3852,906786,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/16,Other,,
3853,906787,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/16,Other,,
3854,906788,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/16,Other,,
3855,906789,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/16,Other,,
3856,906976,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/16,Other,,
3857,906977,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/16,Other,,
3858,906978,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/16,Other,,
3859,906979,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/16,Other,,
3860,906980,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/16,Other,,
3861,906981,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/16,Other,,
3862,906982,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/16,Other,,
3863,906983,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/17,Other,,
3864,906984,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/17,Other,,
3865,906985,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/17,Other,,
3866,906986,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/17,Other,,
3867,906987,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/17,Other,,
3868,906988,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/17,Other,,
3869,906989,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/17,Other,,
3870,906990,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/17,Other,,
3871,906991,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/17,Other,,
3872,906992,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/17,Other,,
3873,906993,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/17,Other,,
3874,906994,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/17,Other,,
3875,906995,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/17,Other,,
3876,906996,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/17,Other,,
3877,906997,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/17,Other,,
3878,906998,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/17,Other,,
3879,906999,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/17,Other,,
3880,907009,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/9,Other,,
3881,907010,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/9,Other,,
3882,907011,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/9,Other,,
3883,907012,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/9,Other,,
3884,907013,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/9,Other,,
3885,907014,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/10,Other,,
3886,907015,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/10,Other,,
3887,907016,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/10,Other,,
3888,907017,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/10,Other,,
3889,907018,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/10,Other,,
3890,907019,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/10,Other,,
3891,907020,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/10,Other,,
3892,907021,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/10,Other,,
3893,907022,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/10,Other,,
3894,907023,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/10,Other,,
3895,907024,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/10,Other,,
3896,907025,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/10,Other,,
3897,907026,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/10,Other,,
3898,907027,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/10,Other,,
3899,907028,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/10,Other,,
3900,907029,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/10,Other,,
3901,907030,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/10,Other,,
3902,907031,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/10,Other,,
3903,907032,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/10,Other,,
3904,907033,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/10,Other,,
3905,907034,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/10,Other,,
3906,907035,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/11,Other,,
3907,907036,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/11,Other,,
3908,907037,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/11,Other,,
3909,907038,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/11,Other,,
3910,907039,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/11,Other,,
3911,907040,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/11,Other,,
3912,907041,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/11,Other,,
3913,907042,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/11,Other,,
3914,907043,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/11,Other,,
3915,907044,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/11,Other,,
3916,907045,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/11,Other,,
3917,907152,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/17,Other,,
3918,907153,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/17,Other,,
3919,907154,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/17,Other,,
3920,907155,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/17,Other,,
3921,907156,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/18,Other,,
3922,907157,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/18,Other,,
3923,907158,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/18,Other,,
3924,907159,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/18,Other,,
3925,907160,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/18,Other,,
3926,907161,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/18,Other,,
3927,907162,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/18,Other,,
3928,907163,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/18,Other,,
3929,907164,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/18,Other,,
3930,907165,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/18,Other,,
3931,907166,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/18,Other,,
3932,907167,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/18,Other,,
3933,907168,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/18,Other,,
3934,907169,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/18,Other,,
3935,907170,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/18,Other,,
3936,907171,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/18,Other,,
3937,907172,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/18,Other,,
3938,907173,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/18,Other,,
3939,907174,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/18,Other,,
3940,907175,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/11,Other,,
3941,907176,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/11,Other,,
3942,907177,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/11,Other,,
3943,907178,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/11,Other,,
3944,907179,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/11,Other,,
3945,907180,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/11,Other,,
3946,907181,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/11,Other,,
3947,907182,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/11,Other,,
3948,907183,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/11,Other,,
3949,907184,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/11,Other,,
3950,907185,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/12,Other,,
3951,907241,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/9,Other,,
3952,907242,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/9,Other,,
3953,907243,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/9,Other,,
3954,907244,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/9,Other,,
3955,907245,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/9,Other,,
3956,907246,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/9,Other,,
3957,907247,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/9,Other,,
3958,907248,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/9,Other,,
3959,907249,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/9,Other,,
3960,907250,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/9,Other,,
3961,907251,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/9,Other,,
3962,907252,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/9,Other,,
3963,907253,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/9,Other,,
3964,907254,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/9,Other,,
3965,907255,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/9,Other,,
3966,907256,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/9,Other,,
3967,907257,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/9,Other,,
3968,907258,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/9,Other,,
3969,907259,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/9,Other,,
3970,907260,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/9,Other,,
3971,907569,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/18,Other,,
3972,907570,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/18,Other,,
3973,907571,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/19,Other,,
3974,907572,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/19,Other,,
3975,907573,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/19,Other,,
3976,907574,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/19,Other,,
3977,907575,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/19,Other,,
3978,907576,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/19,Other,,
3979,907577,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/19,Other,,
3980,907578,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/19,Other,,
3981,907579,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/19,Other,,
3982,907580,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/19,Other,,
3983,907581,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/19,Other,,
3984,907582,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/19,Other,,
3985,907583,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/19,Other,,
3986,907584,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/19,Other,,
3987,907601,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/12,Other,,
3988,907602,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/12,Other,,
3989,907603,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/12,Other,,
3990,907604,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/12,Other,,
3991,907605,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/12,Other,,
3992,907606,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/12,Other,,
3993,907607,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/12,Other,,
3994,907608,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/12,Other,,
3995,907609,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/12,Other,,
3996,907610,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/12,Other,,
3997,907611,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/12,Other,,
3998,907612,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/12,Other,,
3999,907613,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/12,Other,,
4000,907614,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/12,Other,,
4001,907615,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/12,Other,,
4002,907616,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/12,Other,,
4003,907617,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/12,Other,,
4004,907618,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/12,Other,,
4005,907619,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/12,Other,,
4006,907620,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/12,Other,,
4007,907621,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/13,Other,,
4008,907622,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/13,Other,,
4009,907623,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/13,Other,,
4010,907624,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/13,Other,,
4011,907625,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/13,Other,,
4012,907626,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/13,Other,,
4013,907627,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/13,Other,,
4014,907628,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/13,Other,,
4015,907630,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/13,Other,,
4016,907676,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/9,Other,,
4017,907677,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/10,Other,,
4018,907678,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/10,Other,,
4019,907679,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/10,Other,,
4020,907680,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/10,Other,,
4021,907727,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/19,Other,,
4022,907728,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/19,Other,,
4023,907729,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/19,Other,,
4024,907730,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/19,Other,,
4025,907731,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/19,Other,,
4026,907732,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/19,Other,,
4027,907733,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/19,Other,,
4028,907734,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/20,Other,,
4029,907735,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/20,Other,,
4030,907736,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/20,Other,,
4031,907737,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/20,Other,,
4032,907738,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/20,Other,,
4033,907739,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/20,Other,,
4034,907740,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/20,Other,,
4035,907741,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/20,Other,,
4036,907742,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/20,Other,,
4037,907743,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/20,Other,,
4038,907744,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/20,Other,,
4039,907745,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/20,Other,,
4040,907746,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/20,Other,,
4041,907747,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/20,Other,,
4042,907748,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/20,Other,,
4043,907749,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/20,Other,,
4044,907750,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/20,Other,,
4045,907751,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/20,Other,,
4046,907752,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/20,Other,,
4047,907753,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/20,Other,,
4048,907754,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/20,Other,,
4049,907755,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/5,Other,,
4050,907756,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/5,Other,,
4051,907757,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/5,Other,,
4052,907758,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/13,Other,,
4053,907759,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/13,Other,,
4054,907760,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/13,Other,,
4055,907761,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/13,Other,,
4056,907762,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/13,Other,,
4057,907763,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/13,Other,,
4058,907764,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/13,Other,,
4059,907765,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/13,Other,,
4060,907766,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/13,Other,,
4061,907767,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/13,Other,,
4062,907768,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/13,Other,,
4063,907769,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/13,Other,,
4064,907770,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/14,Other,,
4065,907771,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/14,Other,,
4066,907772,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/14,Other,,
4067,907773,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/14,Other,,
4068,907774,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/14,Other,,
4069,907775,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/14,Other,,
4070,907776,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/14,Other,,
4071,907823,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/10,Other,,
4072,907824,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/10,Other,,
4073,907825,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/10,Other,,
4074,907826,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/10,Other,,
4075,907827,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/10,Other,,
4076,907828,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/10,Other,,
4077,907829,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/10,Other,,
4078,907830,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/10,Other,,
4079,907831,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/10,Other,,
4080,907832,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/10,Other,,
4081,907833,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/10,Other,,
4082,907834,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/10,Other,,
4083,907835,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/10,Other,,
4084,907836,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/10,Other,,
4085,907837,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/10,Other,,
4086,907838,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/10,Other,,
4087,907839,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/10,Other,,
4088,907840,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/11,Other,,
4089,907841,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/11,Other,,
4090,907842,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/11,Other,,
4091,907843,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/11,Other,,
4092,907844,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/11,Other,,
4093,907845,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/11,Other,,
4094,907846,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/11,Other,,
4095,907847,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/11,Other,,
4096,907848,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/11,Other,,
4097,907849,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/11,Other,,
4098,907850,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/11,Other,,
4099,907851,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/11,Other,,
4100,907852,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/11,Other,,
4101,907853,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/11,Other,,
4102,907854,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/11,Other,,
4103,907855,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/11,Other,,
4104,907856,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/11,Other,,
4105,907857,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/11,Other,,
4106,907858,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/11,Other,,
4107,907859,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/11,Other,,
4108,907860,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/11,Other,,
4109,907861,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/12,Other,,
4110,907862,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/12,Other,,
4111,907863,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/12,Other,,
4112,907864,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/12,Other,,
4113,908172,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/5,Other,,
4114,908173,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/5,Other,,
4115,908174,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/5,Other,,
4116,908175,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/5,Other,,
4117,908176,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/5,Other,,
4118,908177,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/5,Other,,
4119,908178,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/5,Other,,
4120,908179,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/5,Other,,
4121,908206,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/14,Other,,
4122,908207,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/14,Other,,
4123,908208,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/14,Other,,
4124,908209,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/14,Other,,
4125,908210,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/14,Other,,
4126,908211,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/14,Other,,
4127,908212,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/14,Other,,
4128,908213,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/14,Other,,
4129,908214,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/14,Other,,
4130,908215,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/14,Other,,
4131,908216,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/14,Other,,
4132,908217,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/14,Other,,
4133,908218,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/14,Other,,
4134,908219,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/14,Other,,
4135,908220,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/15,Other,,
4136,908221,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/15,Other,,
4137,908222,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/15,Other,,
4138,908223,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/15,Other,,
4139,908224,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/15,Other,,
4140,908225,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/15,Other,,
4141,908305,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/5,Other,,
4142,908306,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/5,Other,,
4143,908307,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/5,Other,,
4144,908308,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/5,Other,,
4145,908309,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/5,Other,,
4146,908310,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/5,Other,,
4147,908311,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/5,Other,,
4148,908312,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/5,Other,,
4149,908313,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/5,Other,,
4150,908314,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/5,Other,,
4151,908315,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/6,Other,,
4152,908316,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/6,Other,,
4153,908317,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/6,Other,,
4154,908318,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/6,Other,,
4155,908319,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/6,Other,,
4156,908320,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/6,Other,,
4157,908321,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/6,Other,,
4158,908322,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/6,Other,,
4159,908323,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/6,Other,,
4160,908324,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/6,Other,,
4161,908325,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/6,Other,,
4162,908326,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/6,Other,,
4163,908327,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/6,Other,,
4164,908328,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/6,Other,,
4165,908329,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/6,Other,,
4166,908330,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/6,Other,,
4167,908331,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/6,Other,,
4168,908332,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/6,Other,,
4169,908333,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/6,Other,,
4170,908334,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/6,Other,,
4171,908335,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/6,Other,,
4172,908336,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/7,Other,,
4173,908337,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/7,Other,,
4174,908338,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/7,Other,,
4175,908339,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/7,Other,,
4176,908340,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/7,Other,,
4177,908341,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/7,Other,,
4178,908342,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/7,Other,,
4179,908343,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/7,Other,,
4180,908344,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/7,Other,,
4181,908345,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/7,Other,,
4182,908346,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/15,Other,,
4183,908347,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/15,Other,,
4184,908348,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/15,Other,,
4185,908349,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/15,Other,,
4186,908350,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/15,Other,,
4187,908351,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/15,Other,,
4188,908352,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/15,Other,,
4189,908353,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 629/15,Other,,
4190,908354,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 629/15,Other,,
4191,908355,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 629/15,Other,,
4192,908356,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 629/15,Other,,
4193,908357,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 629/15,Other,,
4194,908358,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 629/15,Other,,
4195,908359,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 629/15,Other,,
4196,908360,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 629/15,Other,,
4197,908361,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 629/16,Other,,
4198,908362,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 629/16,Other,,
4199,908363,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 629/16,Other,,
4200,908364,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 629/16,Other,,
4201,908365,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 629/16,Other,,
4202,908366,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 629/16,Other,,
4203,908367,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 629/16,Other,,
4204,908368,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 629/16,Other,,
4205,908369,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 629/16,Other,,
4206,908370,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 629/16,Other,,
4207,908371,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 629/16,Other,,
4208,908372,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 629/16,Other,,
4209,908373,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 629/16,Other,,
4210,908388,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/12,Other,,
4211,908389,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/12,Other,,
4212,908390,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/12,Other,,
4213,908391,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/12,Other,,
4214,908392,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/12,Other,,
4215,908393,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/12,Other,,
4216,908394,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/12,Other,,
4217,908395,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/12,Other,,
4218,908396,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/12,Other,,
4219,908397,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/12,Other,,
4220,908398,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/12,Other,,
4221,908399,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/12,Other,,
4222,908400,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/12,Other,,
4223,908401,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/12,Other,,
4224,908402,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/12,Other,,
4225,908403,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/12,Other,,
4226,908404,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/12,Other,,
4227,908405,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/13,Other,,
4228,908406,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/13,Other,,
4229,908407,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/13,Other,,
4230,908408,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/13,Other,,
4231,908409,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/13,Other,,
4232,908410,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/13,Other,,
4233,908411,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/13,Other,,
4234,908412,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/13,Other,,
4235,908413,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/13,Other,,
4236,908414,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 61/13,Other,,
4237,908415,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 61/13,Other,,
4238,908416,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 61/13,Other,,
4239,908417,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 61/13,Other,,
4240,908418,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 61/13,Other,,
4241,908419,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 61/13,Other,,
4242,908420,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 61/13,Other,,
4243,908421,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 61/13,Other,,
4244,908422,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 61/13,Other,,
4245,908423,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 61/13,Other,,
4246,908424,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 61/13,Other,,
4247,908425,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 61/13,Other,,
4248,908426,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 61/14,Other,,
4249,908427,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 61/14,Other,,
4250,908428,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 61/14,Other,,
4251,908493,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 61/14,Other,,
4252,908494,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 61/14,Other,,
4253,908495,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 61/14,Other,,
4254,908496,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 61/14,Other,,
4255,908497,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 61/14,Other,,
4256,908498,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 61/14,Other,,
4257,930254,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020729,Other,,
4258,930255,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020729,Other,,
4259,930256,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020729,Other,,
4260,930257,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020729,Other,,
4261,930258,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020729",Other,,
4262,930887,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020729,Other,,
4263,930888,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020729,Other,,
4264,930889,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020729,Other,,
4265,930890,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020729,Other,,
4266,930891,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020729,Other,,
4267,930892,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020729,Other,,
4268,930893,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020729,Other,,
4269,930894,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020729,Other,,
4270,930895,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020729,Other,,
4271,930896,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020729,Other,,
4272,930897,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020729,Other,,
4273,930898,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020729,Other,,
4274,930899,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020729,Other,,
4275,930900,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020729,Other,,
4276,944119,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020729,Other,,
4277,944120,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020729,Other,,
4278,944121,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020729,Other,,
4279,944122,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020729,Other,,
4280,944123,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020729,Other,,
4281,944124,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020729,Other,,
4282,944125,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020729,Other,,
4283,944126,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020729",Other,,
4284,944127,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020729,Other,,
4285,944128,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020729,Other,,
4286,944129,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020729,Other,,
4287,944130,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020729,Other,,
4288,944131,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020729,Other,,
4289,944761,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020729,Other,,
4290,944762,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020729,Other,,
4291,944763,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020729,Other,,
4292,944764,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020729,Other,,
4293,944765,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020729,Other,,
4294,944766,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020729,Other,,
4295,953026,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020729,Other,,
4296,953027,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020729,Other,,
4297,953028,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020729,Other,,
4298,953029,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020729,Other,,
4299,955011,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020729,Other,,
4300,955012,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020729,Other,,
4301,955013,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020729,Other,,
4302,955014,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020729,Other,,
4303,955015,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020729,Other,,
4304,955016,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020729,Other,,
4305,955017,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020729,Other,,
4306,955018,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020729,Other,,
4307,955019,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020729,Other,,
4308,955020,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020729,Other,,
4309,955021,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020729,Other,,
4310,955022,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020729,Other,,
4311,955023,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020729,Other,,
4312,955024,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020729,Other,,
4313,955025,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020729,Other,,
4314,973961,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020729,Other,,
4315,973962,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020729,Other,,
4316,973963,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020729,Other,,
4317,973964,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020729,Other,,
4318,973965,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020729,Other,,
4319,973966,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020729,Other,,
4320,973967,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020729,Other,,
4321,973968,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020729,Other,,
4322,973969,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020729,Other,,
4323,973970,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020729,Other,,
4324,973971,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020729,Other,,
4325,973972,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020729,Other,,
4326,973973,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020729,Other,,
4327,973974,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020729,Other,,
4328,973975,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020729,Other,,
4329,973976,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020729,Other,,
4330,973977,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020729,Other,,
4331,973978,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020729,Other,,
4332,973979,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020729,Other,,
4333,977599,1,1,,103168230,3767,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4334,977602,1,2,,103168230,3767,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4335,996356,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: CVD040520",Other,,
4336,996357,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: CVD040520",Other,,
4337,996358,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: CVD040520,Other,,
4338,996359,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: CVD040520",Other,,
4339,996360,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: CVD040520",Other,,
4340,996361,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: CVD040520",Other,,
4341,996945,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: CVD040520",Other,,
4342,996946,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: CVD040520",Other,,
4343,996947,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: CVD040520",Other,,
4344,996948,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: CVD040520",Other,,
4345,996949,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: CVD040520",Other,,
4346,996950,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: CVD040520",Other,,
4347,996951,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: CVD040520",Other,,
4348,996952,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: CVD040520",Other,,
4349,996953,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: CVD040520,Other,,
4350,996954,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: CVD040520",Other,,
4351,996955,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020729",Other,,
4352,996956,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020729",Other,,
4353,996957,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020729",Other,,
4354,996958,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020729",Other,,
4355,996959,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020729",Other,,
4356,996960,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020729,Other,,
4357,996961,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020729",Other,,
4358,996962,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020729,Other,,
4359,996963,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020729",Other,,
4360,996964,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020729",Other,,
4361,996965,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020729",Other,,
4362,996966,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020729",Other,,
4363,996967,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020729",Other,,
4364,996968,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020729",Other,,
4365,996969,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020729",Other,,
4366,996970,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020729",Other,,
4367,996971,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
4368,996972,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020729",Other,,
4369,996973,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020729",Other,,
4370,996974,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020729",Other,,
4371,996975,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020729",Other,,
4372,996976,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020729",Other,,
4373,996977,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020729",Other,,
4374,996978,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020729",Other,,
4375,999421,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020729",Other,,
4376,999422,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020729",Other,,
4377,999423,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020729",Other,,
4378,999424,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020729",Other,,
4379,999425,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020729,Other,,
4380,999426,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020729,Other,,
4381,999427,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020729",Other,,
4382,999428,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020729",Other,,
4383,999429,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020729",Other,,
4384,999430,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020729,Other,,
4385,999431,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
4386,999432,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020729",Other,,
4387,999433,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020729",Other,,
4388,999434,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020729",Other,,
4389,999435,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020729,Other,,
4390,999436,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
4391,999437,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020729",Other,,
4392,999438,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020729",Other,,
4393,999439,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020729",Other,,
4394,999440,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020729",Other,,
4395,999441,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020729",Other,,
4396,999442,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020729",Other,,
4397,999443,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020729",Other,,
4398,999444,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020729",Other,,
4399,999445,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
4400,999446,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020729,Other,,
4401,999447,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020729",Other,,
4402,999448,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020729",Other,,
4403,999449,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020729,Other,,
4404,999450,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020729",Other,,
4405,999451,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020729",Other,,
4406,999452,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020729",Other,,
4407,999453,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020729",Other,,
4408,999454,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020729",Other,,
4409,999455,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020729",Other,,
4410,1003756,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: CVD040520",Other,,
4411,1003757,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: CVD040520",Other,,
4412,1003758,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: CVD040520",Other,,
4413,1003759,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: CVD040520",Other,,
4414,1003760,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: CVD040520",Other,,
4415,1004345,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: CVD040520",Other,,
4416,1004346,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: CVD040520",Other,,
4417,1004347,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: CVD040520",Other,,
4418,1004348,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: CVD040520",Other,,
4419,1004349,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: CVD040520",Other,,
4420,1004350,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: CVD040520",Other,,
4421,1004351,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: CVD040520,Other,,
4422,1004352,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: CVD040520",Other,,
4423,1004353,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: CVD040520",Other,,
4424,1004354,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: CVD040520",Other,,
4425,1004355,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: CVD040520",Other,,
4426,1004356,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: CVD040520",Other,,
4427,1004357,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: CVD040520",Other,,
4428,1004358,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: CVD040520",Other,,
4429,1004359,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: CVD040520",Other,,
4430,1004360,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: CVD040520",Other,,
4431,1004361,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: CVD040520",Other,,
4432,1004362,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: CVD040520",Other,,
4433,1004363,1,3,,103168230,3767,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: CVD040520,Other,,
4434,1004364,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: CVD040520",Other,,
4435,1004365,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: CVD040520",Other,,
4436,1004366,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: CVD040520",Other,,
4437,1004367,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: CVD040520",Other,,
4438,1004368,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: CVD040520",Other,,
4439,1004369,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: CVD040520",Other,,
4440,1004370,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: CVD040520",Other,,
4441,1004371,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: CVD040520",Other,,
4442,1004372,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: CVD040520",Other,,
4443,1004373,1,3,,103168230,3767,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: intraperitoneal | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: CVD040520",Other,,
4444,1049153,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/10,Other,,
4445,1049154,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/11,Other,,
4446,1049155,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/11,Other,,
4447,1049156,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/11,Other,,
4448,1049157,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/11,Other,,
4449,1049158,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/11,Other,,
4450,1049159,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/12,Other,,
4451,1049160,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/12,Other,,
4452,1049161,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/12,Other,,
4453,1049162,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/12,Other,,
4454,1049163,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/12,Other,,
4455,1049164,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/13,Other,,
4456,1049165,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/13,Other,,
4457,1049166,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/13,Other,,
4458,1049167,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/13,Other,,
4459,1049168,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/13,Other,,
4460,1049169,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/14,Other,,
4461,1049170,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/14,Other,,
4462,1049171,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/14,Other,,
4463,1049172,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/14,Other,,
4464,1049173,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/14,Other,,
4465,1049174,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/15,Other,,
4466,1049175,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/15,Other,,
4467,1049176,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/15,Other,,
4468,1049177,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/15,Other,,
4469,1049178,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/15,Other,,
4470,1049179,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/16,Other,,
4471,1049180,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/16,Other,,
4472,1049181,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/16,Other,,
4473,1050019,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/16,Other,,
4474,1050020,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/16,Other,,
4475,1050388,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/9,Other,,
4476,1050389,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/9,Other,,
4477,1050390,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/9,Other,,
4478,1050391,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/9,Other,,
4479,1050392,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/9,Other,,
4480,1050393,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/10,Other,,
4481,1050394,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/10,Other,,
4482,1050395,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/10,Other,,
4483,1050396,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/10,Other,,
4484,1050397,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/10,Other,,
4485,1050398,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/11,Other,,
4486,1050399,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/11,Other,,
4487,1050400,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/11,Other,,
4488,1050401,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/11,Other,,
4489,1050402,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/11,Other,,
4490,1050403,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/12,Other,,
4491,1050404,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/12,Other,,
4492,1050405,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/12,Other,,
4493,1050406,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/12,Other,,
4494,1050407,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/12,Other,,
4495,1050408,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/13,Other,,
4496,1050409,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/13,Other,,
4497,1050410,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/13,Other,,
4498,1050411,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/13,Other,,
4499,1051188,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/13,Other,,
4500,1051189,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/14,Other,,
4501,1051384,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/14,Other,,
4502,1051385,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/14,Other,,
4503,1051386,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/14,Other,,
4504,1051387,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/14,Other,,
4505,1051388,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/15,Other,,
4506,1051389,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/15,Other,,
4507,1051390,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/15,Other,,
4508,1051391,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/15,Other,,
4509,1051392,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/15,Other,,
4510,1051393,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/16,Other,,
4511,1051394,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/16,Other,,
4512,1051395,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/16,Other,,
4513,1051396,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/16,Other,,
4514,1051397,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/16,Other,,
4515,1051398,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/17,Other,,
4516,1051399,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/17,Other,,
4517,1051400,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/17,Other,,
4518,1051401,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/17,Other,,
4519,1051402,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/17,Other,,
4520,1051403,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/18,Other,,
4521,1051404,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/18,Other,,
4522,1051405,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/18,Other,,
4523,1051406,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/18,Other,,
4524,1051407,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/18,Other,,
4525,1051408,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/19,Other,,
4526,1051409,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/19,Other,,
4527,1051410,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/19,Other,,
4528,1051411,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/19,Other,,
4529,1051412,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/19,Other,,
4530,1051413,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 61/20,Other,,
4531,1051414,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 61/20,Other,,
4532,1051415,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 61/20,Other,,
4533,1051416,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 61/20,Other,,
4534,1051417,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 61/20,Other,,
4535,1051418,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/5,Other,,
4536,1051419,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/5,Other,,
4537,1051420,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/5,Other,,
4538,1051421,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/5,Other,,
4539,1051422,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/5,Other,,
4540,1051423,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/6,Other,,
4541,1051424,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/6,Other,,
4542,1051425,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/6,Other,,
4543,1051426,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/6,Other,,
4544,1051427,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/6,Other,,
4545,1051428,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/7,Other,,
4546,1053052,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/7,Other,,
4547,1053053,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/7,Other,,
4548,1053054,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/7,Other,,
4549,1053055,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/7,Other,,
4550,1053056,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/8,Other,,
4551,1053057,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/8,Other,,
4552,1053058,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/8,Other,,
4553,1053059,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/8,Other,,
4554,1053060,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/8,Other,,
4555,1053061,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/9,Other,,
4556,1053062,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/9,Other,,
4557,1053063,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/9,Other,,
4558,1053064,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/9,Other,,
4559,1053065,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 629/9,Other,,
4560,1053066,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 629/10,Other,,
4561,1053067,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 629/10,Other,,
4562,1053068,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 629/10,Other,,
4563,1053069,1,2,,103168230,3767,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 629/10,Other,,
4564,1053175,2,1,,178127225,3767,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
4565,1053188,2,1,,49718175,3767,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4566,1053197,1,1,,49718175,3767,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
4567,1053479,3,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv expressing inhA G96V mutant assessed as parasite growth inhibition after 7 days by Alamar Blue assay,Other,24107081.0,
4568,1053480,3,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv expressing inhA M103L mutant assessed as parasite growth inhibition after 7 days by Alamar Blue assay,Other,24107081.0,
4569,1053481,3,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv expressing inhA M103I mutant assessed as parasite growth inhibition after 7 days by Alamar Blue assay,Other,24107081.0,
4570,1053500,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as parasite growth inhibition after 7 days by Alamar Blue assay,Other,24107081.0,
4571,1053501,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis,Other,24107081.0,
4572,1054051,1,1,,103168230,3767,Active,,,0.33,MIC50,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by three-fold serial dilution assay,Confirmatory,24090347.0,
4573,1054534,1,2,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,24140916.0,
4574,1054541,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin microtitre assay,Other,24140916.0,
4575,1055746,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 155 ATCC 14468 after 32 hrs by turbidimetry,Other,24189497.0,
4576,1055935,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis harboring luxABCDE under hypoxic condition after 10 days by MABA assay in presence of 10% fetal bovine serum,Other,24224794.0,
4577,1055936,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis harboring luxABCDE under hypoxic condition after 10 days by MABA assay in presence of 4% bovine serum albumin,Other,24224794.0,
4578,1055937,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv under normoxic condition after 7 days by MABA assay in presence of 10% fetal bovine serum,Other,24224794.0,
4579,1055938,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv under normoxic condition after 7 days by MABA assay in presence of 4% bovine serum albumin,Other,24224794.0,
4580,1055953,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 700084 under normoxic condition after 72 hrs by MABA assay,Other,24224794.0,
4581,1055954,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against capreomycin-resistant Mycobacterium tuberculosis under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4582,1055955,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against cycloserine-resistant Mycobacterium tuberculosis ATCC 35826 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4583,1055956,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4584,1055957,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against kanamycin-resistant Mycobacterium tuberculosis ATCC 35827 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4585,1055958,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4586,1055959,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis ATCC 35838 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4587,1055960,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis ATCC 35820 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4588,1055961,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X005319 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4589,1055962,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X005282 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4590,1055963,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X004439 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4591,1055964,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X004244 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4592,1055965,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X003899 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4593,1055966,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X001354 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4594,1055967,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis harboring luxABCDE under hypoxic condition after 10 days by MABA assay,Other,24224794.0,
4595,1055969,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv under normoxic condition after 7 days by MABA assay,Other,24224794.0,
4596,1057527,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity in Mycobacterium tuberculosis H37Rv after 5 days by Alamar Blue assay,Other,24169232.0,
4597,1058222,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by BacTiter-Glo method,Other,24200931.0,
4598,1058223,1,1,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium avium,Other,24200931.0,
4599,1058224,1,1,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium intracellulare,Other,24200931.0,
4600,1058225,1,1,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium chelonae,Other,24200931.0,
4601,1058226,1,1,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium kansasii,Other,24200931.0,
4602,1058227,1,1,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium fortuitum,Other,24200931.0,
4603,1059231,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis,Other,24246731.0,
4604,1059234,1,1,,103168230,3767,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,24246731.0,
4605,1060592,1,2,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human GM637 cells after 4 days by WST-1 assay,Confirmatory,24269516.0,
4606,1060593,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 21 days by micro-broth dilution method,Other,24269516.0,
4607,1060595,1,2,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human HCT116 cells after 4 days by WST-1 assay,Confirmatory,24269516.0,
4608,1060900,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as parasite growth inhibition after 28 days by agar dilution method,Other,24292337.0,
4609,1060918,1,2,,103168230,3767,Unspecified,,,450.0,IC50,Cytotoxicity against african green monkey Vero cells by MTT assay,Confirmatory,24292339.0,
4610,1060919,1,2,,103168230,3767,Unspecified,,,450.0,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,24292339.0,
4611,1060920,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate alamar blue assay,Other,24292339.0,
4612,1061090,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as parasite growth inhibition after 28 days by agar dilution method,Other,24314670.0,
4613,1061098,1,1,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against Staphylococcus aureus,Other,24314672.0,
4614,1061099,1,1,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against Escherichia coli,Other,24314672.0,
4615,1061100,1,1,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against Candida albicans,Other,24314672.0,
4616,1061101,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv in presence of 10% FBS,Other,24314672.0,
4617,1061102,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium smegmatis,Other,24314672.0,
4618,1061103,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv in presence of 4% BSA,Other,24314672.0,
4619,1061104,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by low oxygen recovery assay,Other,24314672.0,
4620,1061105,1,2,,103168230,3767,Unspecified,,,100.0,IC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,24314672.0,
4621,1061106,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in african green monkey Vero cells,Other,24314672.0,
4622,1061123,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv-CV-Lux AB after 10 days by low oxygen recovery assay,Other,24315189.0,
4623,1061124,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 4 days by microplate Alamar blue assay,Other,24315189.0,
4624,1062056,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 1 to 100 ug/ml after 7 days by resazurin assay,Other,24361479.0,
4625,1062057,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against multi drug-resistant Mycobacterium tuberculosis after 7 days by resazurin assay,Other,24361479.0,
4626,1062058,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis (MC2) ATCC 19420 after 7 days by resazurin assay,Other,24361479.0,
4627,1062059,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by resazurin assay,Other,24361479.0,
4628,1062066,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium fortuitum ATCC 19542 after 7 days by resazurin assay,Other,24361479.0,
4629,1063299,1,1,,103168230,3767,Active,,,,,Antitubercular activity against capreomycin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 16 to 24 hrs by microplate-Alamar Blue assay,Other,24333612.0,
4630,1063300,1,1,,103168230,3767,Active,,,,,Antitubercular activity against moxifloxacin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 16 to 24 hrs by microplate-Alamar Blue assay,Other,24333612.0,
4631,1063301,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 16 to 24 hrs by microplate-Alamar Blue assay,Other,24333612.0,
4632,1063302,1,1,,103168230,3767,Active,,,,,Antitubercular activity against rifampin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 16 to 24 hrs by microplate-Alamar Blue assay,Other,24333612.0,
4633,1063305,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 16 to 24 hrs by microplate-Alamar Blue assay,Other,24333612.0,
4634,1063941,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifamycin, streptomycin, ethambutol and ofloxacin, clofazimine-resistant Mycobacterium tuberculosis Praha 4 after 21 days",Other,24369840.0,
4635,1063942,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifamycin, streptomycin, ethambutol and ofloxacin, clofazimine-resistant Mycobacterium tuberculosis Praha 4 after 14 days",Other,24369840.0,
4636,1063968,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifamycin, streptomycin, ethambutol, clofazimine, ofloxacin, gentamicin and amikacin-resistant Mycobacterium tuberculosis Praha 131 after 21 days",Other,24369840.0,
4637,1063969,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifamycin, streptomycin, ethambutol, clofazimine, ofloxacin, gentamicin and amikacin-resistant Mycobacterium tuberculosis Praha 131 after 14 days",Other,24369840.0,
4638,1063970,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifamycin, streptomycin, ethambutol and clofazimine-resistant Mycobacterium tuberculosis Praha 1 after 21 days",Other,24369840.0,
4639,1063971,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifamycin, streptomycin, ethambutol and clofazimine-resistant Mycobacterium tuberculosis Praha 1 after 14 days",Other,24369840.0,
4640,1063972,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifamycin and streptomycin-resistant Mycobacterium tuberculosis 9449/2006 after 21 days",Other,24369840.0,
4641,1063973,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifamycin and streptomycin-resistant Mycobacterium tuberculosis 9449/2006 after 14 days",Other,24369840.0,
4642,1063974,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifampicin, rifabutin, streptomycin and ethambutol-resistant Mycobacterium tuberculosis 234/2005 after 21 days",Other,24369840.0,
4643,1063975,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifampicin, rifabutin, streptomycin and ethambutol-resistant Mycobacterium tuberculosis 234/2005 after 14 days",Other,24369840.0,
4644,1063976,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days,Other,24369840.0,
4645,1063977,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days,Other,24369840.0,
4646,1063978,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days,Other,24369840.0,
4647,1063979,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 21 days,Other,24369840.0,
4648,1063980,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 14 days,Other,24369840.0,
4649,1063981,1,3,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter assay,Confirmatory,24369840.0,
4650,1063982,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 7 days,Other,24369840.0,
4651,1063983,1,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampicin, ethambutol and ofloxacin-resistant Mycobacterium avium My 330/88 after 21 days",Other,24369840.0,
4652,1063984,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampicin, ethambutol and ofloxacin-resistant Mycobacterium avium My 330/88 after 14 days",Other,24369840.0,
4653,1063985,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 after 21 days,Other,24369840.0,
4654,1063986,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 after 14 days,Other,24369840.0,
4655,1064516,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pyrazinamide-resistant Mycobacterium avium CNCTC My 152/73 after 5 days by microplate alamar blue assay,Other,24388809.0,
4656,1064521,1,1,,103168230,3767,Unspecified,,,,,"Lipophilicity, log K of the compound by HPLC analysis",Other,24388809.0,
4657,1064523,3,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against pyrazinamide-resistant Mycobacterium avium CNCTC My 80/72 after 5 days by microplate alamar blue assay,Other,24388809.0,
4658,1064524,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against pyrazinamide-resistant Mycobacterium kansasii CNCTC My 235/80 after 5 days by microplate alamar blue assay,Other,24388809.0,
4659,1064525,3,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv CNCTC My 331/88 after 5 days by microplate alamar blue assay,Other,24388809.0,
4660,1067041,3,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate Alamar Blue assay,Other,24486416.0,
4661,1068890,1,1,,103168230,3767,Unspecified,,,,,"Antitubercular activity against Mycobacterium tuberculosis in acute mouse infection model assessed as reduction of bacterial load in lung at 3 mg/kg, po qd administered on day 3 to 10 measured every day of compound dosing (Rvb = 1.7)",Other,24405701.0,
4662,1069168,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against rifampin-resistant Mycobacterium tuberculosis H37Rv SRI 1367 assessed as growth inhibition at MIC after 7 days by broth microdilution assay relative to control,Other,24412719.0,
4663,1069169,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against rifampin-resistant Mycobacterium tuberculosis H37Rv SRI 1367 assessed as growth inhibition after 7 days by broth microdilution assay,Other,24412719.0,
4664,1069174,1,1,,103168230,3767,Active,,,,IC50,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by BacTiter-Glo assay,Confirmatory,24412719.0,
4665,1069665,1,1,,103168230,3767,Inactive,,,,,Antituberculosis activity against multidrug-resistant Mycobacterium tuberculosis LAM1 assessed as growth inhibition at 0.1 ug/ml measured everyday by BACTEC assay,Other,24448419.0,
4666,1069683,1,1,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of IC50 for mouse J774A1 cells to IC50 for Mycobacterium tuberculosis H37Rv expressing pSMT1",Other,24448419.0,
4667,1069684,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse J774A1 cells after 24 hrs by neutral red uptake assay,Other,24448419.0,
4668,1069685,1,1,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as inhibition of bacterial replication after 6 days by luminometry analysis,Other,24448419.0,
4669,1070190,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium intracellulare MNT1408 clinical isolate by MTT assay,Other,24463437.0,
4670,1070191,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium scrofulaceum MNT1193 clinical isolate by MTT assay,Other,24463437.0,
4671,1070192,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium szulgai MNT1100 clinical isolate by MTT assay,Other,24463437.0,
4672,1070193,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium fortuitum MNT1073 clinical isolate by MTT assay,Other,24463437.0,
4673,1070194,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium chelonae MNT1407 clinical isolate by MTT assay,Other,24463437.0,
4674,1070195,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid and rifampicin-resistant Mycobacterium tuberculosis MTB985 clinical isolate by MTT assay,Other,24463437.0,
4675,1070196,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid and rifampicin-resistant Mycobacterium tuberculosis MTB411 clinical isolate by MTT assay,Other,24463437.0,
4676,1070197,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid and rifampicin-resistant Mycobacterium tuberculosis UT544 clinical isolate by MTT assay,Other,24463437.0,
4677,1070198,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid and rifampicin-resistant Mycobacterium tuberculosis MTB4000 clinical isolate by MTT assay,Other,24463437.0,
4678,1070199,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid and rifampicin-resistant Mycobacterium tuberculosis MTB2556 clinical isolate by MTT assay,Other,24463437.0,
4679,1070200,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis H37Rv ATCC 35820 by MTT assay,Other,24463437.0,
4680,1070201,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv ATCC 35822 by MTT assay,Other,24463437.0,
4681,1070202,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampicin-resistant Mycobacterium tuberculosis H37Rv ATCC 35838 by MTT assay,Other,24463437.0,
4682,1070203,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against ethambutol-resistant Mycobacterium tuberculosis H37Rv ATCC 35837 by MTT assay,Other,24463437.0,
4683,1070204,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against streptomycin, isoniazid, rifampicin, ethambutol and pirazynamide-susceptible Mycobacterium tuberculosis H37Rv ATCC 27294 by MTT assay",Other,24463437.0,
4684,1071095,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis H37Rv SRI 1367 at MIC after 7 days by broth microdilution assay relative to control,Other,24268596.0,
4685,1071096,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis H37Rv SRI 1367 after 7 days by broth microdilution assay,Other,24268596.0,
4686,1071102,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by broth microdilution assay,Other,24268596.0,
4687,1071104,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate Alamar blue assay,Other,24268596.0,
4688,1071109,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 0.31 ug/ml after 7 days by microplate Alamar blue assay relative to control,Other,24268596.0,
4689,1071112,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 0.63 ug/ml after 7 days by microplate Alamar blue assay relative to control,Other,24268596.0,
4690,1071113,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 1.25 to 5 ug/ml after 7 days by microplate Alamar blue assay relative to control,Other,24268596.0,
4691,1071659,1,1,,103168230,3767,Active,,,,EC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by Alamar Blue staining-based broth microdilution assay,Confirmatory,24472146.0,
4692,1072704,1,2,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells at 50 uM after 72 hrs by MTT assay,Other,24565972.0,
4693,1072705,2,3,,103168230,3767,Unspecified,614101224.0,885459.0,25.0,IC50,Inhibition of Mycobacterium tuberculosis pantothenate synthetase expressed in Escherichia coli BL21 (DE3),Confirmatory,24565972.0,
4694,1072706,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,24565972.0,
4695,1073489,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis W210 clinical isolate assessed as parasite growth inhibition after 6 days by microplate Alamar Blue assay,Other,24266862.0,
4696,1073490,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis TN587 clinical isolate harboring Kat G 3315T mutant assessed as parasite growth inhibition after 6 days by microplate Alamar Blue assay,Other,24266862.0,
4697,1073491,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis NHN382 clinical isolate harboring Kat G S315t mutant assessed as parasite growth inhibition after 6 days by microplate Alamar Blue assay,Other,24266862.0,
4698,1073493,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as parasite growth inhibition after 6 days by microplate Alamar Blue assay,Other,24266862.0,
4699,1076098,3,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin microtitre assay,Other,24530490.0,
4700,1076818,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against extensive drug-resistant Mycobacterium tuberculosis clinical isolate 7 assessed as growth inhibition by microdilution method,Other,24582981.0,
4701,1076819,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against extensive drug-resistant Mycobacterium tuberculosis clinical isolate 6 assessed as growth inhibition by microdilution method,Other,24582981.0,
4702,1076820,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against extensive drug-resistant Mycobacterium tuberculosis clinical isolate 5 assessed as growth inhibition by microdilution method,Other,24582981.0,
4703,1076821,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against extensive drug-resistant Mycobacterium tuberculosis clinical isolate 4 assessed as growth inhibition by microdilution method,Other,24582981.0,
4704,1076822,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate 3 assessed as growth inhibition by microdilution method,Other,24582981.0,
4705,1076823,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate 2 assessed as growth inhibition by microdilution method,Other,24582981.0,
4706,1076824,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis H37RV clinical isolate 1 assessed as growth inhibition by microdilution method,Other,24582981.0,
4707,1076825,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37RV ATCC 27294 assessed as growth inhibition after 3 to 11 days by microdilution method,Other,24582981.0,
4708,1076828,3,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis assessed as growth inhibition after 18 hrs by broth microdilution method,Other,24582981.0,
4709,1076840,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for African green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv",Other,24582983.0,
4710,1076841,1,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells,Other,24582983.0,
4711,1076842,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by 2-fold dilution assay,Other,24582983.0,
4712,1076894,1,2,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition at 50 uM after 72 hrs by MTT assay,Other,24583350.0,
4713,1076895,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution method in presence of efflux pump inhibitor verapamil,Other,24583350.0,
4714,1076896,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution method,Other,24583350.0,
4715,1077008,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 2 to 3 weeks by broth microdilution assay,Other,24589483.0,
4716,1077231,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 155 ATCC 14468 after 32 hrs by broth microdilution method,Other,24607876.0,
4717,1078029,1,2,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of GI50 for mouse RAW264.7 cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 27294",Other,,
4718,1078030,1,2,,103168230,3767,Unspecified,,,21900.0,GI50,Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay,Confirmatory,,
4719,1078031,3,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium bovis BCG ATCC 35734 after 2 weeks by spot culture growth inhibition assay,Other,,
4720,1078032,3,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 2 weeks by spot culture growth inhibition assay,Other,,
4721,1079614,1,2,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis clinical isolates by broth dilution method,Other,,
4722,1079615,1,3,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis clinical isolates by broth dilution method,Other,,
4723,1079616,1,3,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against rifampicin-resistant Mycobacterium tuberculosis clinical isolates by broth dilution method,Other,,
4724,1079931,1,1,,103168230,3767,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
4725,1079932,1,1,,103168230,3767,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
4726,1079933,1,1,,103168230,3767,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
4727,1079934,1,1,,103168230,3767,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
4728,1079935,1,1,,103168230,3767,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
4729,1079936,1,1,,103168230,3767,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
4730,1079937,1,1,,103168230,3767,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
4731,1079938,1,1,,103168230,3767,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
4732,1079939,1,1,,103168230,3767,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
4733,1079940,1,1,,103168230,3767,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
4734,1079941,1,1,,103168230,3767,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
4735,1079942,1,1,,103168230,3767,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
4736,1079943,1,1,,103168230,3767,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
4737,1079944,1,1,,103168230,3767,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
4738,1079945,1,1,,103168230,3767,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
4739,1079946,1,1,,103168230,3767,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
4740,1079947,1,1,,103168230,3767,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
4741,1079948,1,1,,103168230,3767,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
4742,1079949,1,1,,103168230,3767,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
4743,1083723,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 30 days by agar microdilution method,Other,,
4744,1083727,1,2,,103168230,3767,Unspecified,,,,,Toxicity in Homo sapiens (human) HepG2 cells assessed as change in cell morphology at 1 mM after 24 hr by phase contrast microscopic analysis,Other,,
4745,1083728,1,2,,103168230,3767,Unspecified,,,,,Toxicity in pyrazinamide pretreated Homo sapiens (human) HepG2 cells assessed as cell viability at 200 mM after 24 hr by MTT assay,Other,,
4746,1083733,1,2,,103168230,3767,Unspecified,,,,,Toxicity in Homo sapiens (human) HepG2 cells assessed as cell viability at 50 mM after 24 hr by MTT assay,Other,,
4747,1083734,1,2,,103168230,3767,Unspecified,,,,,Toxicity in Homo sapiens (human) HepG2 cells assessed as cell viability at 5 mM after 24 hr by MTT assay,Other,,
4748,1083735,1,2,,103168230,3767,Unspecified,,,,,Toxicity in Homo sapiens (human) HepG2 cells assessed as cell viability at 10 mM after 24 hr by MTT assay,Other,,
4749,1083736,1,2,,103168230,3767,Unspecified,,,,,Toxicity in Homo sapiens (human) HepG2 cells assessed as cell viability at 1 mM after 24 hr by MTT assay,Other,,
4750,1084402,1,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 21 days by BACTEC based radiometric respiratory technique,Other,,
4751,1084878,1,2,,103168230,3767,Active,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis by NCCLS agar dilution method,Other,,
4752,1084879,1,2,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by NCCLS agar dilution method,Other,,
4753,1084880,1,2,,103168230,3767,Unspecified,,,455.8,CC50,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 72 hr by MTT assay,Confirmatory,,
4754,1084922,1,2,,103168230,3767,Unspecified,,,450.0,IC50,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr by MTT assay,Confirmatory,,
4755,1084923,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by Alamar blue assay,Other,,
4756,1085023,1,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,,
4757,1085024,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Aspergillus niger after 7 days by serial dilution method,Other,,
4758,1085025,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Candida albicans after 48 hr by serial dilution method,Other,,
4759,1085026,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Escherichia coli after 24 hr by serial dilution method,Other,,
4760,1085027,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus after 24 hr by serial dilution method,Other,,
4761,1085028,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis after 24 hr by serial dilution method,Other,,
4762,1085355,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by broth dilution method,Other,,
4763,1085575,1,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis by agar dilution method,Other,,
4764,1085649,1,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis by Bactec TB-460 assay,Other,,
4765,1085882,1,2,,103168230,3767,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv MTCC 200 at 0.2 ug/ml after 28 days by Lowenstein-Jensen method,Other,,
4766,1085963,1,2,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate alamar blue assay,Other,,
4767,1087207,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by BACTEC MGIT method,Other,,
4768,1087291,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by MABA,Other,,
4769,1093781,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 using alamar blue staining by broth microdilution assay,Other,,
4770,1094019,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 30 days by agar microdilution method,Other,,
4771,1094228,1,2,,103168230,3767,Unspecified,,,128.0,IC50,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells,Confirmatory,,
4772,1094229,1,2,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC90 for Mycobacterium tuberculosis H37Rv",Other,,
4773,1094230,1,2,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay,Other,,
4774,1096863,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis by agar dilution method,Other,,
4775,1096927,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Aspergillus niger after 7 days by tube dilution method,Other,,
4776,1096928,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Candida albicans after 48 hr by tube dilution method,Other,,
4777,1096929,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Escherichia coli after 24 hr by tube dilution method,Other,,
4778,1096930,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus after 24 hr by tube dilution method,Other,,
4779,1096931,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis after 24 hr by tube dilution method,Other,,
4780,1096932,1,2,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,,
4781,1096988,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by MABA method,Other,,
4782,1097161,3,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 10 days by BACTEC MGIT method,Other,,
4783,1097199,1,2,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis,Other,,
4784,1105832,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition at MIC by BACTEC MGIT method,Other,,
4785,1105833,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by BACTEC MGIT method,Other,,
4786,1105981,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition at MIC measured within 10 days by BACTEC MGIT method,Other,,
4787,1105982,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition measured within 10 days by BACTEC MGIT method,Other,,
4788,1106020,1,2,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero C1008 cells to MIC for Mycobacterium tuberculosis H37Rv",Other,,
4789,1106021,1,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero C1008 cells assessed as cell viability after 72 hr by MTT assay,Other,,
4790,1106022,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 7 days by resazurin microplate assay,Other,,
4791,1106154,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by BACTEC MGIT method,Other,,
4792,1106278,1,2,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 12 to 28 days by L-J MIC method,Other,,
4793,1106304,1,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as inhibition of cell viability after 96 hr by MTT assay,Other,,
4794,1106305,1,2,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv",Other,,
4795,1106306,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 21 days by broth dilution assay,Other,,
4796,1106439,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 21 days by broth dilution assay method,Other,,
4797,1106483,1,2,,103168230,3767,Unspecified,,,,,Elimination half life in healthy Homo sapiens (human),Other,,
4798,1106590,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 21 days by broth dilution method,Other,,
4799,1106591,1,2,,103168230,3767,Unspecified,,,450.0,IC50,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr by MTT assay,Confirmatory,,
4800,1106592,1,2,,103168230,3767,Unspecified,,,450.0,IC50,Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay,Confirmatory,,
4801,1107015,1,2,,103168230,3767,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv at MIC after 28 days by Lowenstein-Jensen agar method,Other,,
4802,1107016,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 28 days by Lowenstein-Jensen agar method,Other,,
4803,1107276,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 6 days by resazurin MIC assay,Other,,
4804,1114492,3,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv MTCC 200 assessed as growth inhibition measured within 10 days by BACTEC MGIT method,Other,,
4805,1114854,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 28 days by Lowenstein-Jensen method,Other,,
4806,1114855,1,2,,103168230,3767,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv at 6.25 ug/ml after 28 days by Lowenstein-Jensen method,Other,,
4807,1115236,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv MTCC 300 after 7 days by Alamar blue assay,Other,,
4808,1115321,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by secondary screen assay,Other,,
4809,1115322,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by primary screen assay,Other,,
4810,1115324,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition at <6.25 ug/ml by primary screen assay,Other,,
4811,1115558,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 28 days by agar dilution method,Other,,
4812,1116222,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 21 days by broth microdilution method,Other,,
4813,1116372,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis assessed as growth inhibition at 0.3125 to 5 ug/mL after 7 days by resazurin reduction test,Other,,
4814,1116373,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium fortuitum ATCC 19542 assessed as growth inhibition at 0.3125 to 5 ug/mL after 7 days by resazurin reduction test,Other,,
4815,1116374,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis ATCC 19420 assessed as growth inhibition at 0.3125 to 5 ug/mL after 7 days by resazurin reduction test,Other,,
4816,1116375,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 0.3125 to 5 ug/mL after 7 days by resazurin reduction test,Other,,
4817,1116376,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis ATCC 19420 assessed as growth inhibition at 1 to 100 ug/mL after 7 days by resazurin reduction test,Other,,
4818,1116377,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium fortuitum ATCC 19542 assessed as growth inhibition at 1 to 100 ug/mL after 7 days by resazurin reduction test,Other,,
4819,1116378,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 1 to 100 ug/mL after 7 days by resazurin reduction test,Other,,
4820,1116431,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis ATCC 35797 assessed as growth inhibition after 48 hr by NCCLS agar dilution method,Other,,
4821,1116432,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium chelonae ATCC 35751 assessed as growth inhibition after 48 hr by NCCLS agar dilution method,Other,,
4822,1116433,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium xenopi ATCC 14470 assessed as growth inhibition after 48 hr by NCCLS agar dilution method,Other,,
4823,1116434,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium intracellulare ATCC 35743 assessed as growth inhibition after 48 hr by NCCLS agar dilution method,Other,,
4824,1116563,1,2,,103168230,3767,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv MTCC 200 assessed as growth inhibition at MIC by L.J. MIC method,Other,,
4825,1116564,1,2,,103168230,3767,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv MTCC 200 assessed as growth inhibition by L.J. MIC method,Other,,
4826,1116565,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv MTCC 200 assessed as growth inhibition at 6.25 ug/ml by BACTEC MGIT method,Other,,
4827,1116566,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv MTCC 200 assessed as growth inhibition by BACTEC MGIT method,Other,,
4828,1116647,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv grown on Lowenstein-Jensen solid medium assessed as growth inhibition measured after 4 weeks,Other,,
4829,1116648,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against MDR Mycobacterium tuberculosis grown in MGIT liquid medium assessed as growth inhibition measured after 4 weeks by BACTEC method,Other,,
4830,1116649,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv grown in MGIT liquid medium assessed as growth inhibition measured after 4 weeks by BACTEC method,Other,,
4831,1116697,1,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Klebsiella sp. after 24 hr by agar cup assay,Other,,
4832,1116698,1,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Shigella sp. after 24 hr by agar cup assay,Other,,
4833,1116699,1,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Arthrobacter sp. after 24 hr by agar cup assay,Other,,
4834,1116700,1,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Proteus mirabilis after 24 hr by agar cup assay,Other,,
4835,1116701,1,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Escherichia coli after 24 hr by agar cup assay,Other,,
4836,1116702,1,2,,103168230,3767,Unspecified,,,,,Antibacterial activity against Bacillus subtilis after 24 hr by agar cup assay,Other,,
4837,1117255,1,2,,103168230,3767,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv MTCC 200 at MIC after 28 days by micro dilution anti-microbial susceptibility test,Other,,
4838,1117257,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv MTCC 200 after 28 days by micro dilution anti-microbial susceptibility test,Other,,
4839,1117298,1,2,,170466877,3767,Inactive,,,0.7079,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
4840,1117304,1,2,,170466877,3767,Inactive,,,3.1623,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
4841,1117305,1,2,,170466877,3767,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
4842,1117310,1,1,,170466877,3767,Inactive,,,0.707946,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
4843,1117312,1,1,,170466877,3767,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
4844,1117314,1,1,,170466877,3767,Inactive,,,3.16228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
4845,1117319,1,2,,855769,3767,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
4846,1117319,1,2,,855769,3767,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
4847,1117326,1,1,,170466877,3767,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
4848,1117329,1,1,,170466877,3767,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
4849,1117336,1,1,,170466877,3767,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
4850,1117340,1,1,,170466877,3767,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
4851,1117341,1,1,,170466877,3767,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
4852,1117342,1,1,,170466877,3767,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
4853,1117343,1,1,,170466877,3767,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
4854,1117346,1,1,,170466877,3767,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
4855,1117995,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,,
4856,1118025,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 30 days by agar microdilution method,Other,,
4857,1121524,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 155 under hypoxic condition after 96 hrs,Other,,
4858,1121525,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis MC2 155 under aerobic condition after 48 hrs by MTT assay,Other,,
4859,1124850,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay,Other,24631185.0,
4860,1125147,1,1,,103168230,3767,Active,,,,IC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by luciferase reporter gene assay,Confirmatory,24631899.0,
4861,1125149,1,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against mouse J774A1 cells after 24 hrs by neutral red dye uptake assay,Confirmatory,24631899.0,
4862,1125150,1,1,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of I50 for mouse J774A1 cells to IC50 for Mycobacterium tuberculosis H37Rv",Other,24631899.0,
4863,1125169,1,1,,103168230,3767,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis LAM-1 at 0.73 uM after 4 to 6 days by BACTEC MGIT 960 assay,Other,24631899.0,
4864,1126498,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,24679703.0,
4865,1126674,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of colony formation at 250 ug/mL after 2 to 4 weeks by Lowensteine-Jensen method relative to control,Other,24681985.0,
4866,1126675,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of colony formation at 100 ug/mL after 2 to 4 weeks by Lowensteine-Jensen method relative to control,Other,24681985.0,
4867,1127155,1,2,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 24 hrs by Lowenstein-Jensen agar dilution method,Other,24721315.0,
4868,1127156,1,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay,Other,24721315.0,
4869,1129649,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv expressing luciferase assessed as growth inhibition after 6 days by luminometry,Other,24611928.0,
4870,1129650,1,1,,103168230,3767,Unspecified,,,100.0,IC50,Cytotoxicity against mouse J774A1 cells assessed as cell viability after 24 hrs by Trypan blue exclusion assay,Confirmatory,24611928.0,
4871,1129651,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse J774A1 cells to MIC for Mycobacterium tuberculosis H37Rv expressing luciferase",Other,24611928.0,
4872,1129654,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis Beijing 17919 expressing luciferase assessed as growth inhibition after 6 days by luminometry,Other,24611928.0,
4873,1129655,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium bovis AN5 expressing luciferase assessed as growth inhibition after 6 days by luminometry,Other,24611928.0,
4874,1129656,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium avium subsp. paratuberculosis ATCC 19698 expressing luciferase assessed as growth inhibition after 6 days by luminometry,Other,24611928.0,
4875,1129657,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium avium subsp. avium ATCC 15769 expressing luciferase assessed as growth inhibition after 6 days by luminometry,Other,24611928.0,
4876,1132595,1,1,,103168230,3767,Unspecified,,,,,Antitubercular against Mycobacterium smegmatis ATCC 607 by agar dilution method,Other,650670.0,
4877,1132599,1,1,,103168230,3767,Active,,,,,Antitubercular against Mycobacterium tuberculosis H37Rv infected in mouse assessed as host survival at 9 mg/kg/day administered with food for 19 days measured on day 30,Other,650670.0,
4878,1132600,1,1,,103168230,3767,Inactive,,,,,Antitubercular against Mycobacterium tuberculosis H37Rv infected in mouse assessed as host survival at 2.5 mg/kg/day administered with food for 19 days measured on day 30,Other,650670.0,
4879,1137526,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition by standard microdilution method,Other,24088190.0,
4880,1137531,1,1,,103168230,3767,Active,,,,,"Antitubercular activity against 1-ethyl-3-(6-(pyrimidin-5-yl)-5-((tetrahydrofuran-3-yl)methoxy)thiazolo[5,4-b]pyridin-2-yl)urea-resistant Mycobacterium tuberculosis H37Rv clone 8.1 harboring DNA gyraseB ATP domain Ala92Ser mutant assessed as growth inhibition by standard microdilution method",Other,24088190.0,
4881,1137532,1,1,,103168230,3767,Active,,,,,"Antitubercular activity against 1-ethyl-3-(6-(pyrimidin-5-yl)-5-((tetrahydrofuran-3-yl)methoxy)thiazolo[5,4-b]pyridin-2-yl)urea-resistant Mycobacterium tuberculosis H37Rv clone 8.2 harboring DNA gyraseB ATP domain Ala92Ser mutant assessed as growth inhibition by standard microdilution method",Other,24088190.0,
4882,1143263,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis Beijing (E-47/94) assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
4883,1143264,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
4884,1143265,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis D-211 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
4885,1143266,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis 136570 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
4886,1143267,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis 912253 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
4887,1143268,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis 19000 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
4888,1143269,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against ethambutol-resistant Mycobacterium tuberculosis 17003 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
4889,1143270,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against ofloxacin-resistant Mycobacterium tuberculosis 12119 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
4890,1143271,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against wild type Mycobacterium tuberculosis H37Rv assessed as growth inhibition by resazurin assay,Other,24818517.0,
4891,1143272,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis overexpressing DprE1 assessed as growth inhibition by resazurin assay,Other,24818517.0,
4892,1143273,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against BTZ043-resistant Mycobacterium tuberculosis harboring DprE1 C-G mutant assessed as growth inhibition by resazurin assay,Other,24818517.0,
4893,1143274,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against BTZ043-resistant Mycobacterium tuberculosis harboring DprE1 C-S mutant assessed as growth inhibition by resazurin assay,Other,24818517.0,
4894,1143275,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against 3-cyclopropyl-1-phenyl-5-((3-(trifluoromethyl)benzylamino)-methyl)-1H-pyrazolo[3,4-b]pyridin-6(7H)-one-resistant Mycobacterium tuberculosis clone 8.1 assessed as growth inhibition by resazurin assay",Other,24818517.0,
4895,1143276,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against 3-cyclopropyl-1-phenyl-5-((3-(trifluoromethyl)benzylamino)-methyl)-1H-pyrazolo[3,4-b]pyridin-6(7H)-one-resistant Mycobacterium tuberculosis clone 8.2 assessed as growth inhibition by resazurin assay",Other,24818517.0,
4896,1143277,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against 3-cyclopropyl-1-phenyl-5-((3-(trifluoromethyl)benzylamino)-methyl)-1H-pyrazolo[3,4-b]pyridin-6(7H)-one-resistant Mycobacterium tuberculosis clone 8.3 assessed as growth inhibition by resazurin assay",Other,24818517.0,
4897,1143483,1,2,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by BACTEC 960 assay,Other,24836065.0,
4898,1143484,1,2,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv clinical isolate harboring katG S315T mutant by BACTEC 960 assay,Other,24836065.0,
4899,1143485,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against katG-deficient isoniazid-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 by BACTEC 960 assay,Other,24836065.0,
4900,1143486,2,1,,103168230,3767,Unspecified,,,,,"Octanol-water partition co-efficient, log P of the compound by shake-flask method",Other,24836065.0,
4901,1143488,1,2,,103168230,3767,Unspecified,,,200.0,IC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay,Confirmatory,24836065.0,
4902,1143489,1,2,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 27294",Other,24836065.0,
4903,1143683,1,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 infected in Balb/c mouse assessed as reduction in bacterial load in spleen at 100 mg/kg, po qd administered five days in a week starting 2 weeks post challenge measured after 6 weeks relative to untreated control",Other,24852277.0,
4904,1143690,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 infected in Balb/c mouse assessed as reduction in bacterial load in lung at 100 mg/kg, po qd administered five days in a week starting 2 weeks post challenge measured after 10 weeks relative to untreated control",Other,24852277.0,
4905,1143691,1,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 infected in Balb/c mouse assessed as reduction in bacterial load in spleen at 100 mg/kg, po qd administered five days in a week starting 2 weeks post challenge measured after 10 weeks relative to untreated control",Other,24852277.0,
4906,1143693,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 14 days by microscopy,Other,24852277.0,
4907,1143702,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 infected in Balb/c mouse assessed as reduction in bacterial load in lung at 100 mg/kg, po qd administered five days in a week starting 2 weeks post challenge measured after 3 weeks relative to untreated control",Other,24852277.0,
4908,1143703,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 infected in Balb/c mouse assessed as reduction in bacterial load in lung at 100 mg/kg, po qd administered five days in a week starting 2 weeks post challenge measured after 6 weeks relative to untreated control",Other,24852277.0,
4909,1143704,1,2,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 infected in Balb/c mouse assessed as reduction in bacterial load in spleen at 100 mg/kg, po qd administered five days in a week starting 2 weeks post challenge measured after 3 weeks relative to untreated control",Other,24852277.0,
4910,1145282,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv,Other,1263204.0,
4911,1149229,1,1,,103168230,3767,Unspecified,,,,,"Retardation factor, Rm of the compound in acetone-water-silica gel layer",Other,817022.0,
4912,1149231,1,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis assessed as growth inhibition,Other,817022.0,
4913,1149232,1,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis assessed as growth inhibition in absence of 16 uM nicotinic acid hydrazide,Other,817022.0,
4914,1149233,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis assessed as growth inhibition in presence of 16 uM nicotinic acid hydrazide,Other,817022.0,
4915,1149236,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by two-fold serial dilution method,Other,817022.0,
4916,1149237,2,1,,103168230,3767,Unspecified,,,,,"1-octanol-phosphate buffer partition coefficient, log P of the compound at pH 7.4",Other,817022.0,
4917,1152758,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against wild-type Mycobacterium tuberculosis H37Rv ATCC 27294 after 16 to 18 days by BACTEC 7H12B microdilution method,Other,24809953.0,
4918,1152776,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against 2-oxo-1-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-1,2-dihydroquinoline-7-carbonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA A74V mutant",Other,24809953.0,
4919,1152777,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant",Other,24809953.0,
4920,1152778,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis harboring DNA gyraseA G88N mutant,Other,24809953.0,
4921,1154327,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 5 days by standard microdilution method,Other,24871036.0,
4922,1154347,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis over expressing DprE1 after 5 days by standard microdilution method,Other,24871036.0,
4923,1154348,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis over expressing InhA after 5 days by standard microdilution method,Other,24871036.0,
4924,1154349,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis over expressing TopA after 5 days by standard microdilution method,Other,24871036.0,
4925,1154350,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis over expressing PimA after 5 days by standard microdilution method,Other,24871036.0,
4926,1154351,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against BTZ043-resistant Mycobacterium tuberculosis over expressing DprE1 C387S mutant after 5 days by standard microdilution method,Other,24871036.0,
4927,1154352,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against TMC207R-resistant Mycobacterium tuberculosis clone 8.1 over expressing DprE1 mutant after 5 days by standard microdilution method,Other,24871036.0,
4928,1154353,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis clone 4.1 over expressing DprE1 mutant after 5 days by standard microdilution method,Other,24871036.0,
4929,1154542,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 5 days by microdilution method,Other,24874895.0,
4930,1154543,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 OE mutant assessed as growth inhibition after 5 days by microdilution method,Other,24874895.0,
4931,1154544,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 C387S mutant assessed as growth inhibition after 5 days by microdilution method,Other,24874895.0,
4932,1154545,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 C387G mutant assessed as growth inhibition after 5 days by microdilution method,Other,24874895.0,
4933,1154546,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 Y314H mutant assessed as growth inhibition after 5 days by microdilution method,Other,24874895.0,
4934,1154547,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 Rv1937/F426C mutant assessed as growth inhibition after 5 days by microdilution method,Other,24874895.0,
4935,1155865,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 to 8 days by BACTEC 12B method,Other,24934572.0,
4936,1158009,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by Lowenstein-Jensen slope method,Other,24856067.0,
4937,1158102,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv in liquid broth culture medium,Other,24870926.0,
4938,1158103,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv in macrophages,Other,24870926.0,
4939,1158121,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in BALB/c mouse assessed as lung bacterial load at 15 mg/kg administered 3 weeks after infection via oral gavage for 28 days, five times per week measured per lung (Rvb = 7.24 +/- 0.17 log10 CFU)",Other,24870926.0,
4940,1158125,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in BALB/c mouse assessed as lung bacterial load administered 3 weeks after infection via oral gavage for 28 days, five times per week measured per lung",Other,24870926.0,
4941,1159302,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 in GAST/Fe medium after 1 week by broth microdilution method,Other,24972340.0,
4942,1159303,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 in GAST/Fe medium after 2 weeks by broth microdilution method,Other,24972340.0,
4943,1159304,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 in 7H9/ADC/Tween medium after 1 week by broth microdilution method,Other,24972340.0,
4944,1159305,1,2,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 in 7H9/ADC/Tween medium after 2 weeks by broth microdilution method,Other,24972340.0,
4945,1159306,1,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells assessed as survival at 50 ug/ml after 48 hrs by Cell-Titre Blue assay,Other,24972340.0,
4946,1159307,1,2,,103168230,3767,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells assessed as survival at 25 ug/ml after 48 hrs by Cell-Titre Blue assay,Other,24972340.0,
4947,1159387,1,2,,103168230,3767,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
4948,1159509,1,1,,144208565,3767,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4949,1159509,1,1,,144210513,3767,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4950,1159509,1,1,,170466877,3767,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4951,1159515,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4952,1159515,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4953,1159515,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4954,1159516,1,1,,144208565,3767,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4955,1159516,1,1,,144210513,3767,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4956,1159516,1,1,,170466877,3767,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4957,1159517,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4958,1159517,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4959,1159517,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4960,1159518,1,1,,144208565,3767,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4961,1159518,1,1,,144210513,3767,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4962,1159518,1,1,,170466877,3767,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4963,1159519,1,1,,144208565,3767,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4964,1159519,1,1,,144210513,3767,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4965,1159519,1,1,,170466877,3767,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4966,1159520,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4967,1159520,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4968,1159520,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4969,1159521,1,1,,144208565,3767,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4970,1159521,1,1,,144210513,3767,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4971,1159521,1,1,,170466877,3767,Inactive,15928672.0,19885.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4972,1159523,1,1,,144208565,3767,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4973,1159523,1,1,,144210513,3767,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4974,1159523,1,1,,170466877,3767,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4975,1159524,1,1,,49718175,3767,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4976,1159524,1,1,,124881930,3767,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4977,1159524,1,1,,124881932,3767,Inactive,,,19.9526,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4978,1159525,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4979,1159525,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4980,1159525,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4981,1159526,1,1,,144208565,3767,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4982,1159526,1,1,,144210513,3767,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4983,1159526,1,1,,170466877,3767,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4984,1159527,1,1,,144208565,3767,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4985,1159527,1,1,,144210513,3767,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4986,1159527,1,1,,170466877,3767,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4987,1159528,1,1,,144208565,3767,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4988,1159528,1,1,,144210513,3767,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4989,1159528,1,1,,170466877,3767,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4990,1159529,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4991,1159529,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4992,1159529,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4993,1159531,1,1,,144208565,3767,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4994,1159531,1,1,,144210513,3767,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4995,1159531,1,1,,170466877,3767,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4996,1159550,3,1,,252402253,3767,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
4997,1159551,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4998,1159551,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4999,1159551,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
5000,1159552,1,1,,144208565,3767,Inactive,325495463.0,5914.0,30.7314,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5001,1159552,1,1,,144210513,3767,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5002,1159552,1,1,,170466877,3767,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5003,1159553,2,1,,144208565,3767,Inconclusive,325495463.0,5914.0,10.9039,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5004,1159553,2,1,,144210513,3767,Active,325495463.0,5914.0,22.8192,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5005,1159553,2,1,,170466877,3767,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5006,1159555,1,1,,144208565,3767,Inconclusive,325495463.0,5914.0,20.1488,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
5007,1159555,1,1,,144210513,3767,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
5008,1159555,1,1,,170466877,3767,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
5009,1159580,2,1,,268734588,3767,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
5010,1159583,2,1,,178127225,3767,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
5011,1159606,1,1,,49718175,3767,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
5012,1159607,2,1,,312309668,3767,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
5013,1159614,1,2,,170466877,3767,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
5014,1159620,1,1,,103168230,3767,Active,,,,,Summary of drug indications.,Other,,
5015,1162181,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis assessed as intracellular bacterial killing,Other,25173852.0,
5016,1163978,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution assay,Other,25218910.0,
5017,1163979,1,1,,103168230,3767,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution assay in presence of 8 mg/mL piperine efflux pump inhibitor,Other,25218910.0,
5018,1163980,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against isoniazid, rifampicin, ofloxacin and kanamycin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 clinical isolate after 28 days by two-fold serial dilution assay in presence of 8 mg/mL piperine efflux pump inhibitor",Other,25218910.0,
5019,1163981,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells at 100 uM after 72 hrs by MTT assay,Other,25218910.0,
5020,1163982,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells at 50 uM after 72 hrs by MTT assay,Other,25218910.0,
5021,1163983,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by MABA method,Other,25218911.0,
5022,1163984,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid and rifampicin resistant Mycobacterium tuberculosis 6133 by MABA method,Other,25218911.0,
5023,1163985,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against isoniazid and rifampicin resistant Mycobacterium tuberculosis 11277 by MABA method,Other,25218911.0,
5024,1164281,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against wild-type Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 5 days by microdilution method,Other,25221657.0,
5025,1164294,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis assessed as growth inhibition after 5 days by microdilution method,Other,25221657.0,
5026,1164295,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis overexpressing DprE1 assessed as growth inhibition after 5 days by microdilution method,Other,25221657.0,
5027,1164305,1,1,,103168230,3767,Unspecified,,,,,Selectivity ratio of MIC for Mycobacterium tuberculosis overexpressing InhA to MIC for wild-type Mycobacterium tuberculosis H37Rv,Other,25221657.0,
5028,1164940,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by microbroth dilution method,Other,25238443.0,
5029,1165081,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by MABA method,Other,25240097.0,
5030,1166351,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 assessed as microbial growth inhibition incubated for 14 days,Other,25259627.0,
5031,1166623,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis ATCC 27294 in 7H9 medium after 5 days by Alamar blue assay,Other,25264074.0,
5032,1166624,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis ATCC 27294 in high iron condition after 5 days by Alamar blue assay,Other,25264074.0,
5033,1166625,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis ATCC 27294 in low iron condition after 5 days by Alamar blue assay,Other,25264074.0,
5034,1167605,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold agar dilution method,Other,25282650.0,
5035,1167608,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis XDR-TB after 28 days by two-fold agar dilution method,Other,25282650.0,
5036,1170646,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by MABA assay,Other,25372601.0,
5037,1172296,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv CNCTC My 331/88 after 10 to 14 days by AlamarBlue assay,Other,25438883.0,
5038,1172297,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 5 to 7 days by AlamarBlue assay,Other,25438883.0,
5039,1172298,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium subsp. avium Chester CNCTC My 80/72 after 5 days by AlamarBlue assay,Other,25438883.0,
5040,1172690,1,1,,103168230,3767,Unspecified,,,,,Anti-tubercular activity against Mycobacterium tuberculosis H37Rv by resazurin microtitre assay,Other,25442308.0,
5041,1173783,1,2,,103168230,3767,Inconclusive,152032507.0,,,IC50,Inhibition of purified Mycobacterium smegmatis GyrB at 50 to 100 uM after 100 mins by ATPase assay,Confirmatory,25456076.0,
5042,1173784,1,1,,103168230,3767,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase using relaxed pBR322 as substrate after 30 mins by supercoiling assay,Confirmatory,25456076.0,
5043,1173785,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by MABA assay,Other,25456076.0,
5044,1173786,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by MTT assay,Other,25456076.0,
5045,1174106,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol, streptomycin, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
5046,1174107,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, streptomycin, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
5047,1174108,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
5048,1174109,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol, streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
5049,1174110,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
5050,1174111,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
5051,1174112,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
5052,1174120,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv by two-fold serial dilution method,Other,25462221.0,
5053,1174121,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis Spec. 192 by two-fold serial dilution method,Other,25462221.0,
5054,1174122,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis Spec. 210 by two-fold serial dilution method,Other,25462221.0,
5055,1174678,1,1,,103168230,3767,Unspecified,,,,MIC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by MABA method,Confirmatory,25462270.0,
5056,1174920,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by REMA resazurin microtiter assay,Other,25464882.0,
5057,1174923,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate 29/10 after 7 days by REMA resazurin microtiter assay,Other,25464882.0,
5058,1174924,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate 439/11 after 7 days by REMA resazurin microtiter assay,Other,25464882.0,
5059,1174925,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate 756/10 after 7 days by REMA resazurin microtiter assay,Other,25464882.0,
5060,1174926,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate 778/10 after 7 days by REMA resazurin microtiter assay,Other,25464882.0,
5061,1174927,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis isolate 917/10 after 7 days by REMA resazurin microtiter assay,Other,25464882.0,
5062,1177944,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition,Other,24583357.0,
5063,1178139,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv transformed with pSMT1 luciferase reporter plasmid assessed as growth inhibition after 6 days by luminometry,Other,24681334.0,
5064,1178140,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse J774A1 cells after 24 hrs by neutral red dye uptake assay,Other,24681334.0,
5065,1178141,1,1,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of I50 for mouse J774A1 cells to GI50 for Mycobacterium tuberculosis H37Rv",Other,24681334.0,
5066,1178148,1,1,,103168230,3767,Inactive,,,,,Antimicrobial activity against multi-drug resistant Mycobacterium tuberculosis LAM-1 strain clinical isolate assessed as growth reduction at 0.1 ug/mL by BACTEC_MGIT_960-TB detection system,Other,24681334.0,
5067,1178727,1,1,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against Escherichia coli ATCC 25922 after 48 hrs by broth dilution technique,Other,24878195.0,
5068,1178728,1,1,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against Klebsiella pneumoniae after 48 hrs by broth dilution technique,Other,24878195.0,
5069,1178729,1,1,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 35556 after 48 hrs by broth dilution technique,Other,24878195.0,
5070,1178730,1,1,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43866 after 48 hrs by broth dilution technique,Other,24878195.0,
5071,1178731,1,1,,103168230,3767,Inconclusive,,,,,Antimicrobial activity against Candida albicans after 48 hrs by agar dilution method,Other,24878195.0,
5072,1178732,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by Resazurin micro titer assay,Other,24878195.0,
5073,1178733,1,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay,Confirmatory,24878195.0,
5074,1179478,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium abscessus ATCC 19977 in 7H9 medium after 3 days and 4 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay,Other,24909079.0,
5075,1179479,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium chelonae ATCC 35752 in 7H9 medium after 3 days and 4 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay,Other,24909079.0,
5076,1179480,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium marinum ATCC 927 in 7H9 medium after 5 days and 6 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay,Other,24909079.0,
5077,1179481,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium ATCC 15769 in 7H9 medium after 6 days and 18 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay,Other,24909079.0,
5078,1179482,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii ATCC 12478 in 7H9 medium after 6 days and 18 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay,Other,24909079.0,
5079,1179483,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium bovis BCG ATCC 35734 in 7H12 medium after 6 days and 18 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay,Other,24909079.0,
5080,1180390,1,1,,103168230,3767,Unspecified,,,25.0,IC50,Inhibition of Mycobacterium tuberculosis pantothenate synthetase expressed in Escherichia coli BL21 (DE3) by spectrophotometry,Confirmatory,24953948.0,
5081,1180391,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 28 days by agar dilution method,Other,24953948.0,
5082,1180392,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 50 uM after 72 hrs by MTT assay,Other,24953948.0,
5083,1180434,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 assessed as complete growth inhibition after 14 days,Other,24953953.0,
5084,1180435,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 assessed as complete growth inhibition after 21 days,Other,24953953.0,
5085,1180436,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Isoniazid, rifampicin, ofloxacin and ethambutol-resistant Mycobacterium avium 330/88 assessed as complete growth inhibition after 14 days",Other,24953953.0,
5086,1180437,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Isoniazid, rifampicin, ofloxacin and ethambutol-resistant Mycobacterium avium 330/88 assessed as complete growth inhibition after 21 days",Other,24953953.0,
5087,1180438,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 7 days,Other,24953953.0,
5088,1180439,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 14 days,Other,24953953.0,
5089,1180440,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 21 days,Other,24953953.0,
5090,1180441,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 7 days,Other,24953953.0,
5091,1180442,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 14 days,Other,24953953.0,
5092,1180443,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 21 days,Other,24953953.0,
5093,1180444,1,1,,103168230,3767,Unspecified,,,,,Inhibition of Mycobacterium tuberculosis H37Rv isocitrate lyase assessed as glyoxylate phenyl hydrazone formation at 10 uM,Other,24953953.0,
5094,1180455,1,1,,103168230,3767,Unspecified,,,250.0,IC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay,Confirmatory,24953953.0,
5095,1180457,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium kansasii 6509/96",Other,24953953.0,
5096,1180460,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis H37Rv",Other,24953953.0,
5097,1181078,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate Alamar Blue assay,Other,24964393.0,
5098,1181154,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5099,1181155,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis ATCC25618 assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5100,1181156,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis Erdman assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5101,1181157,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis Beijing assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5102,1181158,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis Harlingen assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5103,1181159,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis ATCC35811 assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5104,1181160,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis DKU76 assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5105,1181161,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis DKU97A assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5106,1181162,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis DKU211 assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5107,1181163,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis DKU220 assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5108,1181164,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Mycobacterium tuberculosis JAL assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5109,1181165,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Isoniazid-resistant Mycobacterium tuberculosis assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5110,1181166,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against clinical isolate Rifampin-resistant Mycobacterium tuberculosis assessed as growth inhibition after 7 days by turbidometry,Other,24967731.0,
5111,1181167,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against first mutant generation Mycobacterium tuberculosis 1024_1 assessed as fold shift in MIC relative to parent strain,Other,24967731.0,
5112,1181168,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against first mutant generation Mycobacterium tuberculosis 1024_18 assessed as fold shift in MIC relative to parent strain,Other,24967731.0,
5113,1181169,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_18 assessed as fold shift in MIC relative to parent strain,Other,24967731.0,
5114,1181170,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_8.12 assessed as fold shift in MIC relative to parent strain,Other,24967731.0,
5115,1181171,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_16.5 assessed as fold shift in MIC relative to parent strain,Other,24967731.0,
5116,1181172,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_16.6 assessed as fold shift in MIC relative to parent strain,Other,24967731.0,
5117,1181176,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv over-expressing InhA cells assessed as upshift of MIC relative to wild type,Other,24967731.0,
5118,1183263,1,1,,103168230,3767,Unspecified,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of colony formation at 250 ug/ml after 4 weeks of incubation,Other,25016227.0,
5119,1183298,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,25016370.0,
5120,1183300,1,1,,103168230,3767,Active,,,41.63,GI50,Antimycobacterial activity against Mycobacterium smegmatis assessed as growth inhibition after 32 hrs by spectrophotometry,Confirmatory,25016370.0,
5121,1185138,1,1,,103168230,3767,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis H37Rv DNA gyrase A2B2 holoenzyme supercoiling activity using relaxed pBR322 substrate incubated for 90 mins by ethidium bromide staining based gel electrophoresis method,Confirmatory,25050172.0,
5122,1185139,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294,Other,25050172.0,
5123,1185144,1,1,,103168230,3767,Active,,,,,"Antimicrobial activity against 2-oxo-1-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-1,2-dihydroquinoline-7-carbonitrile resistant Mycobacterium tuberculosis H37Rv ATCC 27294 containing DNA gyrase A74V mutant",Other,25050172.0,
5124,1185145,1,1,,103168230,3767,Active,,,,,"Antimicrobial activity against 5-(((3S,4R)-3-fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile resistant Mycobacterium tuberculosis H37Rv ATCC 27294 containing DNA gyrase D89N mutant",Other,25050172.0,
5125,1185146,1,1,,103168230,3767,Active,,,,,Antimicrobial activity against moxicillin resistant Mycobacterium tuberculosis H37Rv ATCC 27294 containing DNA gyrase G88N mutant,Other,25050172.0,
5126,1185308,1,1,,103168230,3767,Active,,,,,Antitubercular activity Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 5 days by MABA method,Other,25055342.0,
5127,1185309,1,1,,103168230,3767,Active,,,,,Antitubercular activity Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 30 days by agar microdilution method,Other,25055342.0,
5128,1185314,1,1,,103168230,3767,Inconclusive,,,,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,25055342.0,
5129,1185315,1,1,,103168230,3767,Inconclusive,,,,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,25055342.0,
5130,1185554,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 5 days by MABA method,Other,25062011.0,
5131,1186605,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv strain at 6.25 ug/ml by microplate alamar blue assay,Other,25089809.0,
5132,1186606,1,1,,103168230,3767,Unspecified,,,,IC50,Antitubercular activity against Mycobacterium tuberculosis H37Rv strain by BACTEC 460 radiometric assay,Confirmatory,25089809.0,
5133,1187928,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 4 weeks,Other,25127167.0,
5134,1188153,1,2,,103168230,3767,Inconclusive,152032507.0,,,IC50,Inhibition of 6-His-tagged Mycobacterium smegmatis GyrB expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 100 mins in presence of ATP by malachite green dye based ATP assay,Confirmatory,25129171.0,
5135,1188154,1,1,,103168230,3767,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase supercoiling activity using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining method,Confirmatory,25129171.0,
5136,1188155,1,1,,103168230,3767,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay method,Other,25129171.0,
5137,1188156,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM after 48 hrs by MTT assay,Other,25129171.0,
5138,1188166,1,1,,103168230,3767,Active,,,,IC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by microdilution AlamarBlue broth assay,Confirmatory,25129868.0,
5139,1189129,1,1,,103168230,3767,Unspecified,,,656.26,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
5140,1189130,1,1,,103168230,3767,Unspecified,,,656.26,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
5141,1189131,1,1,,103168230,3767,Unspecified,,,218.75,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
5142,1189133,1,1,,103168230,3767,Unspecified,,,656.26,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
5143,1189134,1,1,,103168230,3767,Unspecified,,,656.26,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
5144,1189135,1,1,,103168230,3767,Unspecified,,,218.75,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
5145,1189136,1,1,,103168230,3767,Unspecified,,,36.46,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
5146,1191013,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as reduction in bacterial growth incubated for 7 days under 7H12 medium by MABA method,Other,25699139.0,
5147,1191014,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as reduction in bacterial growth incubated for 7 days under GAS medium by MABA method,Other,25699139.0,
5148,1191015,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium marinum ATCC 927 assessed as reduction in bacterial growth incubated for 5 days by MABA method,Other,25699139.0,
5149,1191016,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium bovis BCG ATCC 35734 assessed as reduction in bacterial growth incubated for 6 days by MABA method,Other,25699139.0,
5150,1191017,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii ATCC 12478 assessed as reduction in bacterial growth incubated for 6 days by MABA method,Other,25699139.0,
5151,1191489,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days by microdilution method,Other,25593095.0,
5152,1191490,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days by microdilution method,Other,25593095.0,
5153,1191491,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against INH,RIF,OFX,EMB-resistant Mycobacterium avium 330/88 after 14 days by microdilution method",Other,25593095.0,
5154,1191492,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against INH,RIF,OFX,EMB-resistant Mycobacterium avium 330/88 after 21 days by microdilution method",Other,25593095.0,
5155,1191493,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days by microdilution method,Other,25593095.0,
5156,1191494,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days by microdilution method,Other,25593095.0,
5157,1191495,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days by microdilution method,Other,25593095.0,
5158,1191496,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days by microdilution method,Other,25593095.0,
5159,1191497,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by microdilution method,Other,25593095.0,
5160,1191498,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by microdilution method,Other,25593095.0,
5161,1191521,1,1,,103168230,3767,Inconclusive,,,,IC50,Cytostatic activity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,25593095.0,
5162,1191522,1,1,,103168230,3767,Unspecified,,,250.0,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,25593095.0,
5163,1191523,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis",Other,25593095.0,
5164,1191526,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium kansasii 6509/96",Other,25593095.0,
5165,1192646,1,1,,103168230,3767,Inactive,,,,IC50,Inhibition of Mycobacterium smegmatis TMC 607 ATP synthase incubated for 10 mins prior to NADH addition measured after 1 hr by luminescence assay,Confirmatory,25614114.0,
5166,1192648,1,1,,103168230,3767,Unspecified,,,,,Inhibition of Mycobacterium smegmatis TMC 607 ATP synthase at 0.3 uM incubated for 10 mins prior to NADH addition measured after 1 hr by luminescence assay,Other,25614114.0,
5167,1192649,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 4 weeks by agar dilution assay,Other,25614114.0,
5168,1192650,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against African green monkey Vero cells after 72 hrs yb resazurin assay,Other,25614114.0,
5169,1192651,1,1,,103168230,3767,Inconclusive,,,,,"Selectivity index, ratio of CC50 for African green monkey Vero cells to MIC100 for Mycobacterium tuberculosis H37Rv",Other,25614114.0,
5170,1192652,1,1,,103168230,3767,Unspecified,,,,,Inhibition of Mycobacterium tuberculosis H37Rv ATP synthase assessed as reduction in total ATP content at 0.5 ug/ml after 18 hrs by bead-vortexing settling method,Other,25614114.0,
5171,1192659,1,1,,103168230,3767,Unspecified,,,,,Bactericidal activity against non-replicating Mycobacterium tuberculosis H37Rv Wayne model under hypoxic/oxygen depleted conditions assessed as log reduction after 4 days by serial dilution assay,Other,25614114.0,
5172,1192662,1,1,,103168230,3767,Unspecified,,,,,Bactericidal activity against non-replicating Mycobacterium tuberculosis H37Rv Wayne model under hypoxic/oxygen depleted conditions assessed as log reduction at 5 ug/ml after 4 days by serial dilution assay,Other,25614114.0,
5173,1193492,1,1,,103168230,3767,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method",Other,25740159.0,
5174,1193493,1,1,,103168230,3767,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
5175,1193494,1,1,,103168230,3767,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
5176,1193495,1,1,,103168230,3767,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
5177,1193496,1,1,,103168230,3767,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method",Other,25740159.0,
5178,1193497,1,1,,103168230,3767,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method",Other,25740159.0,
5179,1193498,1,1,,103168230,3767,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method",Other,25740159.0,
5180,1193499,1,1,,103168230,3767,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method",Other,25740159.0,
5181,1193576,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 assessed as inhibition of bacterial growth after 72 hrs by MTT dye based microbroth dilution assay,Other,25746816.0,
5182,1193868,1,1,,103168230,3767,Active,,,16.0,IC50,Anti-tubercular activity against Mycobacterium smegmatis str. MC2 155,Confirmatory,25765907.0,
5183,1193920,1,1,,103168230,3767,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis DNA GyrA/B heterotetramer assessed as inhibition of pBR322 supercoiling after 30 mins by gel electrophoresis,Confirmatory,25766629.0,
5184,1193921,1,2,,103168230,3767,Inconclusive,152032507.0,,,IC50,Inhibition of Mycobacterium smegmatis DNA GyrB domain assessed as inhibition of inorganic phosphate release after 100 mins at room temperature by ATPase assay,Confirmatory,25766629.0,
5185,1193922,1,1,,103168230,3767,Active,,,,,Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,25766629.0,
5186,1193923,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay,Other,25766629.0,
5187,1194222,1,1,,103168230,3767,Unspecified,,,,,Tuberculostatic activity against Mycobacterium tuberculosis H37Rv by two-fold classical test-tube method,Other,25797161.0,
5188,1194223,1,1,,103168230,3767,Unspecified,,,,,Tuberculostatic activity against Mycobacterium tuberculosis Spec. 192 by two-fold classical test-tube method,Other,25797161.0,
5189,1194224,1,1,,103168230,3767,Unspecified,,,,,Tuberculostatic activity against Mycobacterium tuberculosis Spec. 210 by two-fold classical test-tube method,Other,25797161.0,
5190,1194330,1,2,,103168230,3767,Inconclusive,152032507.0,,,IC50,Inhibition of Mycobacterium smegmatis GyrB ATPase activity expressed in Escherichia coli BL21 (DE3) pLysS cells after 100 mins by inorganic phosphate release detection based malachite green reagent assay,Confirmatory,25801151.0,
5191,1194333,1,1,,103168230,3767,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis GyrA/GyrB using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining and electrophoresis based DNA supercoiling assay,Confirmatory,25801151.0,
5192,1194334,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by microplate alamar blue assay method,Other,25801151.0,
5193,1194335,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth at 50 uM after 48 hrs by MTT assay,Other,25801151.0,
5194,1194561,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv expressing Lux assessed as reduction in growth measured at 5 uM after 3 weeks by bioluminescence assay,Other,25818768.0,
5195,1194570,1,1,,103168230,3767,Active,,,0.33,IC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv expressing Lux assessed as reduction in growth measured after 3 weeks by bioluminescence assay,Confirmatory,25818768.0,
5196,1194621,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 incubated for 7 days by alamar blue assay,Other,25819330.0,
5197,1194622,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium complex isolate CIT19/06 incubated for 5 days by alamar blue assay,Other,25819330.0,
5198,1194623,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium subsp. paratuberculosis isolate CIT03 incubated for 11 days by alamar blue assay,Other,25819330.0,
5199,1196883,1,1,,103168230,3767,Inactive,,,,IC50,Inhibition of Mycobacterium tuberculosis AlaDH using L-alanine as substrate after 20 mins by spectrophotometry,Confirmatory,25585006.0,
5200,1196884,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against dormant Mycobacterium tuberculosis H37Rv model assessed as log reduction at 10 ug/ml incubated for 7 days measured after 28 days in presence of nutrient deprived condition,Other,25585006.0,
5201,1196885,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,25585006.0,
5202,1196886,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells at 50 uM after 48 hrs by MTT assay,Other,25585006.0,
5203,1198805,1,1,,103168230,3767,Unspecified,,,,IC50,Anti-tuberculosis activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of microbial growth by MABA method,Confirmatory,25747550.0,
5204,1201573,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294/XDR-TB incubated for 28 days by agar dilution method,Other,25794789.0,
5205,1201995,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in mouse bone-marrow derived macrophages assessed as reduction in intracellular colony forming units at 4 times antimycobacterial MIC measured during 3 hrs infection period,Other,25828928.0,
5206,1201996,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in human blood monocyte derived macrophages assessed as reduction in intracellular colony forming units at 4 times antimycobacterial MIC measured during 3 hrs infection period,Other,25828928.0,
5207,1201997,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in mouse bone-marrow derived macrophages assessed as reduction in intracellular colony forming units at 4 times antimycobacterial MIC measured during 3 hrs infection period relative to control,Other,25828928.0,
5208,1201998,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in human blood monocyte derived macrophages assessed as reduction in intracellular colony forming units at 4 times antimycobacterial MIC measured during 3 hrs infection period relative to control,Other,25828928.0,
5209,1202228,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by broth microdilution method,Other,25874329.0,
5210,1204021,1,1,,103168230,3767,Active,,,,,Anti-mycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as inhibition of microbial growth incubated for 5 days by MABA method,Other,25908515.0,
5211,1204022,1,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against PBMC (unknown origin) assessed as reduction in cell viability after 72 hrs by MTT assay,Other,25908515.0,
5212,1204023,1,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 72 hrs by MTT assay,Other,25908515.0,
5213,1204426,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 10 days by microbroth dilution method,Other,25982331.0,
5214,1204427,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium avium after 10 days by microbroth dilution method,Other,25982331.0,
5215,1204428,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium terrae after 10 days by microbroth dilution method,Other,25982331.0,
5216,1204431,1,1,,103168230,3767,Unspecified,,,,,Toxicity in po dosed mouse after 14 days,Other,25982331.0,
5217,1204432,1,1,,103168230,3767,Unspecified,,,,,Toxicity in ip dosed mouse after 14 days,Other,25982331.0,
5218,1204849,1,1,,103168230,3767,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as parasite growth inhibition after 7 days by broth microdilution assay,Other,26005918.0,
5219,1204850,1,1,,103168230,3767,Inconclusive,,,,,Antitubercular activity against Rifampicin-resistant Mycobacterium tuberculosis assessed as parasite growth inhibition by REMA method,Other,26005918.0,
5220,1204851,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Isoniazid-resistant Mycobacterium tuberculosis assessed as parasite growth inhibition by REMA method,Other,26005918.0,
5221,1204852,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis assessed as parasite growth inhibition by REMA method,Other,26005918.0,
5222,1205458,1,1,,103168230,3767,Unspecified,,,,,"Antitubercular activity against isoniazid, rifampin, streptomycin, ethambutol, amikacin, ofloxacin, kanamycin-susceptible Mycobacterium tuberculosis assessed as inhibition of bacterial growth after 4 weeks by two-fold dilution technique",Other,25771108.0,
5223,1205459,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis assessed as inhibition of bacterial growth after 4 weeks by two-fold dilution technique,Other,25771108.0,
5224,1205460,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against rifampin and isoniazid-resistant Mycobacterium tuberculosis assessed as inhibition of bacterial growth after 4 weeks by two-fold dilution technique,Other,25771108.0,
5225,1205461,1,1,,103168230,3767,Unspecified,,,,,"Antitubercular activity against rifampin, isoniazid and streptomycin-resistant Mycobacterium tuberculosis assessed as inhibition of bacterial growth after 4 weeks by two-fold dilution technique",Other,25771108.0,
5226,1205462,1,1,,103168230,3767,Unspecified,,,,,"Antitubercular activity against rifampin, isoniazid and ethambutol-resistant Mycobacterium tuberculosis assessed as inhibition of bacterial growth after 4 weeks by two-fold dilution technique",Other,25771108.0,
5227,1205463,1,1,,103168230,3767,Unspecified,,,,,"Antitubercular activity against rifampin, isoniazid, amikacin and ofloxacin-resistant Mycobacterium tuberculosis assessed as inhibition of bacterial growth after 4 weeks by two-fold dilution technique",Other,25771108.0,
5228,1205464,1,1,,103168230,3767,Unspecified,,,,,"Antitubercular activity against rifampin, isoniazid, kanamycin and ofloxacin-resistant Mycobacterium tuberculosis assessed as inhibition of bacterial growth after 4 weeks by two-fold dilution technique",Other,25771108.0,
5229,1209455,1,2,,103168230,3767,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
5230,1209456,1,2,,103168230,3767,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
5231,1209457,1,1,,103168230,3767,Unspecified,,,,,Unbound Cmax in human plasma,Other,21965623.0,
5232,1224127,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 10 days by microbroth dilution method,Other,24856062.0,
5233,1224128,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium after 10 days by microbroth dilution method,Other,24856062.0,
5234,1224129,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium terrae after 10 days by microbroth dilution method,Other,24856062.0,
5235,1224131,1,1,,103168230,3767,Unspecified,,,,,Acute toxicity in mouse administered as single po dose,Other,24856062.0,
5236,1224132,1,1,,103168230,3767,Unspecified,,,,,Acute toxicity in mouse administered as single ip dose,Other,24856062.0,
5237,1224507,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 14 days by micromethod,Other,24927053.0,
5238,1224508,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 21 days by micromethod,Other,24927053.0,
5239,1224509,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 14 days by micromethod,Other,24927053.0,
5240,1224510,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 21 days by micromethod,Other,24927053.0,
5241,1224511,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 7 days by micromethod,Other,24927053.0,
5242,1224512,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 14 days by micromethod,Other,24927053.0,
5243,1224514,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days by micromethod,Other,24927053.0,
5244,1224515,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by micromethod,Other,24927053.0,
5245,1224516,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by micromethod,Other,24927053.0,
5246,1224517,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 7 days by micromethod,Other,24927053.0,
5247,1224519,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 7 days by micromethod,Other,24927053.0,
5248,1224521,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 7 days by micromethod,Other,24927053.0,
5249,1224523,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 7 days by micromethod,Other,24927053.0,
5250,1224525,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 7 days by micromethod,Other,24927053.0,
5251,1224527,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 7 days by micromethod,Other,24927053.0,
5252,1224744,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at 250 ug/ml,Other,25010936.0,
5253,1224745,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv,Other,25010936.0,
5254,1224824,1,1,,174006260,3767,Inactive,,,0.003,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
5255,1224825,1,1,,174006260,3767,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
5256,1224834,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5257,1224834,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5258,1224834,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5259,1224835,1,1,,144208565,3767,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5260,1224835,1,1,,144210513,3767,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5261,1224835,1,1,,170466877,3767,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5262,1224836,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5263,1224836,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5264,1224836,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5265,1224837,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5266,1224837,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5267,1224837,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5268,1224838,1,1,,144208565,3767,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5269,1224838,1,1,,144210513,3767,Inactive,66775687.0,9970.0,0.2282,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5270,1224838,1,1,,170466877,3767,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5271,1224839,1,1,,144208565,3767,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5272,1224839,1,1,,144210513,3767,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5273,1224839,1,1,,170466877,3767,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5274,1224840,3,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5275,1224840,3,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5276,1224840,3,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5277,1224841,3,1,,144208565,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5278,1224841,3,1,,144210513,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5279,1224841,3,1,,170466877,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5280,1224842,3,1,,144208565,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5281,1224842,3,1,,144210513,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5282,1224842,3,1,,170466877,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5283,1224843,1,1,,144208565,3767,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5284,1224843,1,1,,144210513,3767,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5285,1224843,1,1,,170466877,3767,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5286,1224844,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5287,1224844,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5288,1224844,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5289,1224845,1,1,,144208565,3767,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5290,1224845,1,1,,144210513,3767,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5291,1224845,1,1,,170466877,3767,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5292,1224846,1,1,,144208565,3767,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5293,1224846,1,1,,144210513,3767,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5294,1224846,1,1,,170466877,3767,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5295,1224847,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5296,1224847,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5297,1224847,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5298,1224848,3,1,,144208565,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5299,1224848,3,1,,144210513,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5300,1224848,3,1,,170466877,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5301,1224849,3,1,,144208565,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5302,1224849,3,1,,144210513,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5303,1224849,3,1,,170466877,3767,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5304,1224857,2,1,,170466877,3767,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5305,1224857,2,1,,174006260,3767,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5306,1224859,2,1,,170466877,3767,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5307,1224859,2,1,,174006260,3767,Inactive,,,37.2212,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5308,1224863,1,1,,176484051,3767,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5309,1224863,1,1,,176484751,3767,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5310,1224863,1,1,,316919952,3767,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5311,1224863,1,1,,316920372,3767,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5312,1224864,1,2,,316933997,3767,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
5313,1224865,1,2,,49718175,3767,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
5314,1224867,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5315,1224867,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5316,1224867,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5317,1224868,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5318,1224868,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5319,1224868,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5320,1224869,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5321,1224869,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5322,1224869,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5323,1224870,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5324,1224870,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5325,1224870,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5326,1224871,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5327,1224871,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5328,1224871,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5329,1224872,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5330,1224872,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5331,1224872,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5332,1224873,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5333,1224873,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5334,1224873,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5335,1224874,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5336,1224874,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5337,1224874,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5338,1224875,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5339,1224875,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5340,1224875,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5341,1224876,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5342,1224876,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5343,1224876,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5344,1224877,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5345,1224877,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5346,1224877,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5347,1224878,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5348,1224878,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5349,1224878,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5350,1224879,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5351,1224879,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5352,1224879,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5353,1224880,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5354,1224880,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5355,1224880,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5356,1224881,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5357,1224881,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5358,1224881,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5359,1224882,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5360,1224882,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5361,1224882,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5362,1224883,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5363,1224883,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5364,1224883,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5365,1224884,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5366,1224884,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5367,1224884,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5368,1224885,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5369,1224885,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5370,1224885,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5371,1224886,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5372,1224886,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5373,1224886,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5374,1224887,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5375,1224887,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5376,1224887,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5377,1224888,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5378,1224888,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5379,1224888,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5380,1224889,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5381,1224889,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5382,1224889,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5383,1224890,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5384,1224890,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5385,1224890,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5386,1224892,1,1,,144208565,3767,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5387,1224892,1,1,,144210513,3767,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5388,1224892,1,1,,170466877,3767,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5389,1224893,1,1,,144208565,3767,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5390,1224893,1,1,,144210513,3767,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5391,1224893,1,1,,170466877,3767,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5392,1224894,1,1,,144208565,3767,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5393,1224894,1,1,,144210513,3767,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5394,1224894,1,1,,170466877,3767,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5395,1224895,1,1,,144208565,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5396,1224895,1,1,,144210513,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5397,1224895,1,1,,170466877,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5398,1224896,1,1,,144208565,3767,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5399,1224896,1,1,,144210513,3767,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5400,1224896,1,1,,170466877,3767,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5401,1224905,2,1,,92308852,3767,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5402,1224905,2,1,,92308852,3767,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5403,1225686,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth after 5 days by Microplate Alamar Blue Assay,Other,25771110.0,
5404,1225687,1,1,,103168230,3767,Unspecified,,,450.0,IC50,Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation by MTT assay,Confirmatory,25771110.0,
5405,1225688,1,1,,103168230,3767,Unspecified,,,450.0,IC50,Cytotoxicity against human A549 assessed as inhibition of cell proliferation by MTT assay,Confirmatory,25771110.0,
5406,1225720,1,1,,103168230,3767,Active,,,9.8,IC50,Anti-mycobacterial activity against Mycobacterium smegmatis assessed as bacterial growth inhibition after 24 hrs by microplate reader analysis,Confirmatory,25778993.0,
5407,1227981,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against GFP expressing Mycobacterium tuberculosis H37Ra assessed as microbial growth inhibition incubated at 37 degC for 7 days by fluorescence based assay,Other,25734623.0,
5408,1231578,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis MC2 155 under aerobic condition after 36 hrs by MTT assay,Other,25934225.0,
5409,1231579,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis MC2 155 under hypoxic condition after 96 hrs by MTT assay,Other,25934225.0,
5410,1231580,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG under aerobic condition after 7 days by MTT assay,Other,25934225.0,
5411,1231581,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG under hypoxic condition after 14 days by MTT assay,Other,25934225.0,
5412,1231597,1,1,,103168230,3767,Inactive,,,,,Inhibition of nybomycin probe (2) binding to pMV206 DNA (unknown origin) with cloned 700476 to 702854 bp of Mycobacterium bovis BCG genome overexpressed in Mycobacterium smegmatis ICHO1036 at 60 uM after 1 hr by agarose gel electrophoresis,Other,25934225.0,
5413,1232405,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days,Other,25921267.0,
5414,1232406,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium bovis BCG after 7 days,Other,25921267.0,
5415,1232407,1,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells,Other,25921267.0,
5416,1232411,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of GIC50 for mouse RAW264.7 cells to MIC for Mycobacterium tuberculosis H37Rv",Other,25921267.0,
5417,1233774,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis str. MC2 155 assessed as inhibition of microbial growth incubated for 24 hrs by REMA method,Other,26092447.0,
5418,1234134,1,1,,103168230,3767,Unspecified,,,,,"Terminal half life in Sprague-Dawley rat at 2.5 mg/kg, iv by LC-MS/MS method",Other,26110337.0,
5419,1234135,1,1,,103168230,3767,Unspecified,,,,,"Cmax in Sprague-Dawley rat at 25 mg/kg, po by LC-MS/MS method",Other,26110337.0,
5420,1234137,1,1,,103168230,3767,Unspecified,,,,,Oral bioavailability in Sprague-Dawley rat at 25 mg/kg by LC-MS/MS method,Other,26110337.0,
5421,1234656,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated up to 7 days measured on day 7 by microplate Alamar Blue assay,Other,26071857.0,
5422,1236138,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis after 6 days by resazurin dye reduction method,Other,26213786.0,
5423,1236139,1,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human THP1 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method,Confirmatory,26213786.0,
5424,1236140,1,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method,Confirmatory,26213786.0,
5425,1236378,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution method,Other,,
5426,1237430,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis str. MC2 155 incubated for 30 hrs by turbidometric assay,Other,26048808.0,
5427,1240997,1,1,,103168230,3767,Active,,,,IC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by MTT assay,Confirmatory,26254828.0,
5428,1240998,1,1,,103168230,3767,Active,,,,IC50,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis MYC5165 after 6 days by MTT assay,Confirmatory,26254828.0,
5429,1241002,1,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against human MRC5 cells after 24 hrs,Other,26254828.0,
5430,1241003,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MRC5 cells to MIC for Mycobacterium tuberculosis H37Rv",Other,26254828.0,
5431,1241004,1,1,,103168230,3767,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MRC5 cells to MIC for isoniazid-resistant Mycobacterium tuberculosis MYC5165",Other,26254828.0,
5432,1241967,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 21 days by microbroth dilution method,Other,26142487.0,
5433,1242341,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by microdilution method,Other,26191359.0,
5434,1242343,1,1,,103168230,3767,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis H37Rv DNA gyrase assessed as supercoiling of pBR322 DNA after 90 mins by agarose gel electrophoresis method,Confirmatory,26191359.0,
5435,1242344,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against 6-((1-(2-(7-chloro-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one resistant Mycobacterium tuberculosis H37Rv harboring DNA gyraseA A74V mutant incubated for 7 days by microdilution method",Other,26191359.0,
5436,1242345,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against 1-(2-(4-((5-chloro-6-methylpyridin-3-yl)methylamino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-one resistant Mycobacterium tuberculosis H37Rv harboring DNA gyraseA D89N mutant incubated for 7 days by microdilution method",Other,26191359.0,
5437,1242346,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against moxifloxacin resistant Mycobacterium tuberculosis H37Rv harboring DNA gyraseA G88N mutant incubated for 7 days by microdilution method,Other,26191359.0,
5438,1243392,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis,Other,26253635.0,
5439,1244176,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay,Other,26191372.0,
5440,1244177,1,1,,103168230,3767,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Ra after 7 days by microplate alamar blue assay,Other,26191372.0,
5441,1244178,1,1,,103168230,3767,Inconclusive,,,,IC50,Cytotoxicity against African green monkey Vero cells after 72 hrs by CCK8 assay,Confirmatory,26191372.0,
5442,1244382,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium abscessus ATCC 19977 after 7 days by serial dilution method,Other,26210507.0,
5443,1244383,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by serial dilution method,Other,26210507.0,
5444,1244384,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistance Mycobacterium tuberculosis A8 after 28 days by serial dilution method,Other,26210507.0,
5445,1244408,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 6.25 ug/ml after 5 days by microplate Alamar Blue assay,Other,26210508.0,
5446,1244409,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by microplate Alamar Blue assay,Other,26210508.0,
5447,1244410,1,1,,103168230,3767,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells assessed as cell survival at 10 times MIC after 72 hrs by MTT assay,Other,26210508.0,
5448,1244806,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 6538 after 18 hrs by serial microdilution method,Other,26254943.0,
5449,1244813,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 4163 after 18 hrs by serial microdilution method,Other,26254943.0,
5450,1244820,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by serial microdilution method,Other,26254943.0,
5451,1244827,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by serial microdilution method,Other,26254943.0,
5452,1244834,1,1,,103168230,3767,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 49134 after 18 hrs by serial microdilution method,Other,26254943.0,
5453,1246165,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 25618,Other,26119992.0,
5454,1246166,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against p-aminosalicylic acid/isonicotinic acid hydrazide/etambutol/rifampicin-resistant Mycobacterium tuberculosis Spec. 210,Other,26119992.0,
5455,1246167,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against drug-sensitive Mycobacterium tuberculosis Spec. 192,Other,26119992.0,
5456,1246490,1,1,,103168230,3767,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis incubated for 18 hrs by Alamar blue assay,Other,26263247.0,
5457,1246787,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by micro alamar blue assay,Other,26277407.0,
5458,1246800,1,1,,103168230,3767,Unspecified,,,,MIC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by spectrophotometry,Confirmatory,26280920.0,
5459,1246801,1,1,,103168230,3767,Inconclusive,,,,CC50,Cytotoxicity against human HepG2 cells after 3 days,Confirmatory,26280920.0,
5460,1246802,1,1,,103168230,3767,Inconclusive,,,,CC50,Cytotoxicity against hamster BHK21 cells after 3 days,Confirmatory,26280920.0,
5461,1246803,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN675 after 5 days by spectrophotometry,Other,26280920.0,
5462,1246804,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN913 after 5 days by spectrophotometry,Other,26280920.0,
5463,1246805,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN994 after 5 days by spectrophotometry,Other,26280920.0,
5464,1246806,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1008 after 5 days by spectrophotometry,Other,26280920.0,
5465,1246807,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1037 after 5 days by spectrophotometry,Other,26280920.0,
5466,1246808,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1040 after 5 days by spectrophotometry,Other,26280920.0,
5467,1246809,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1051 after 5 days by spectrophotometry,Other,26280920.0,
5468,1246810,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN1082 after 5 days by spectrophotometry,Other,26280920.0,
5469,1246811,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN2351 after 5 days by spectrophotometry,Other,26280920.0,
5470,1246812,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN2524 after 5 days by spectrophotometry,Other,26280920.0,
5471,1246813,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN3183 after 5 days by spectrophotometry,Other,26280920.0,
5472,1246814,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN3979 after 5 days by spectrophotometry,Other,26280920.0,
5473,1246815,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis TN4259 after 5 days by spectrophotometry,Other,26280920.0,
5474,1246816,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis AH9584 after 5 days by spectrophotometry,Other,26280920.0,
5475,1246817,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis BE11677 after 5 days by spectrophotometry,Other,26280920.0,
5476,1246818,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis E8133 after 5 days by spectrophotometry,Other,26280920.0,
5477,1246819,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis W4 after 5 days by spectrophotometry,Other,26280920.0,
5478,1246831,1,1,,103168230,3767,Inconclusive,,,,,Bactericidal activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by spectrophotometry,Other,26280920.0,
5479,1247162,1,1,,103168230,3767,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,26298500.0,
5480,1247197,1,1,,103168230,3767,Unspecified,,,,,"Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive dormant phage of Mycobacterium tuberculosis H37Ra ATCC 25177 by serial dilution method",Other,26299346.0,
5481,1247198,1,1,,103168230,3767,Unspecified,,,,,"Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive active phage of Mycobacterium tuberculosis H37Ra ATCC 25177 by serial dilution method",Other,26299346.0,
5482,1247199,1,1,,103168230,3767,Unspecified,,,,,"Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive dormant phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay",Other,26299346.0,
5483,1247200,1,1,,103168230,3767,Unspecified,,,,,"Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive active phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay",Other,26299346.0,
5484,1249031,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as inhibition of bacterial growth incubated for 14 days by inverted plate reader based macroscopy,Other,,
5485,1249033,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in Balb/c mouse assessed as reduction in lung bacterial load at 25 mg/kg, po dosed once daily 5 days per week for 3 weeks",Other,,
5486,1249034,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in Balb/c mouse assessed as reduction in lung bacterial load at 25 mg/kg, po dosed once daily 5 days per week for 6 weeks",Other,,
5487,1249035,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in Balb/c mouse assessed as reduction in lung bacterial load at 25 mg/kg, po dosed once daily 5 days per week for 10 weeks",Other,,
5488,1249036,1,1,,103168230,3767,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in Balb/c mouse assessed as reduction in spleen bacterial load at 25 mg/kg, po dosed once daily 5 days per week for 3 weeks",Other,,
5489,1249037,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in Balb/c mouse assessed as reduction in spleen bacterial load at 25 mg/kg, po dosed once daily 5 days per week for 6 weeks",Other,,
5490,1249038,1,1,,103168230,3767,Active,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in Balb/c mouse assessed as reduction in spleen bacterial load at 25 mg/kg, po dosed once daily 5 days per week for 10 weeks",Other,,
5491,1249070,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 after 14 days by micromethod,Other,,
5492,1249071,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium My 330/88 after 14 days by micromethod,Other,,
5493,1249072,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 after 21 days by micromethod,Other,,
5494,1249073,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium My 330/88 after 21 days by micromethod,Other,,
5495,1249074,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 7 days by micromethod,Other,,
5496,1249075,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 14 days by micromethod,Other,,
5497,1249076,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 21 days by micromethod,Other,,
5498,1249077,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days by micromethod,Other,,
5499,1249078,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by micromethod,Other,,
5500,1249079,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by micromethod,Other,,
5501,1249103,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium bovis BCG after 14 days by inverted microscopic analysis,Other,,
5502,1249104,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis str. MC2 155 after 2 days by inverted microscopic analysis,Other,,
5503,1249105,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 14 days by inverted microscopic analysis,Other,,
5504,1249106,1,1,,103168230,3767,Inconclusive,,,,,Hemolytic activity in chicken RBC after 1 hr,Other,,
5505,1249107,1,1,,103168230,3767,Inconclusive,,,,,Hemolytic activity in sheep RBC after 1 hr,Other,,
5506,1249108,1,1,,103168230,3767,Inconclusive,,,,,"Therapeutic index, ratio of MHC50 for chicken RBC to MIC99 for Mycobacterium tuberculosis H37Rv",Other,,
5507,1249109,1,1,,103168230,3767,Inconclusive,,,,,"Therapeutic index, ratio of MHC50 for sheep RBC to MIC99 for Mycobacterium tuberculosis H37Rv",Other,,
5508,1250472,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 7 days by alamar blue dye assay,Other,26316467.0,
5509,1252459,1,1,,103168230,3767,Inconclusive,152032507.0,,,IC50,Inhibition of Mycobacterium smegmatis DNA gyrase B expressed in Escherichia coli BL21 (DE3) pLysS cells assessed as reduction in ATPase activity incubated for 100 mins by inorganic phosphate detection assay,Confirmatory,26318054.0,
5510,1252462,1,1,,103168230,3767,Inconclusive,,,,IC50,Inhibition of DNA gyrase GyrA/GyrB in Mycobacterium tuberculosis incubated for 30 mins assessed as reduction in supercoiling of relaxed relaxed pBR322 DNA by ethidium bromide staining based agarose gel electrophoresis method,Confirmatory,26318054.0,
5511,1252463,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition incubated for 7 days by microplate alamar blue assay,Other,26318054.0,
5512,1252464,1,1,,103168230,3767,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 50 uM incubated for 48 hrs at 37 degC by MTT assay relative to control,Other,26318054.0,
5513,1253865,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by microplate alamar blue assay,Other,26459210.0,
5514,1253866,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis FJ05120 after 3 to 4 weeks by microplate alamar blue assay,Other,26459210.0,
5515,1253867,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis FJ05195 after 3 to 4 weeks by microplate alamar blue assay,Other,26459210.0,
5516,1254288,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days,Other,26526729.0,
5517,1254289,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days,Other,26526729.0,
5518,1254290,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium 330/80 after 14 days,Other,26526729.0,
5519,1254291,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium avium 330/80 after 21 days,Other,26526729.0,
5520,1254292,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days,Other,26526729.0,
5521,1254293,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days,Other,26526729.0,
5522,1254294,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days,Other,26526729.0,
5523,1254295,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days,Other,26526729.0,
5524,1254296,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days,Other,26526729.0,
5525,1254297,1,1,,103168230,3767,Active,,,,,Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days,Other,26526729.0,
5526,1255800,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate alamar blue assay,Other,26421992.0,
5527,1256530,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by alamar blue assay,Other,26476970.0,
5528,1256531,1,1,,103168230,3767,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 6133 by alamar blue assay,Other,26476970.0,
5529,1259241,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5530,1259241,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5531,1259241,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5532,1259242,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5533,1259242,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5534,1259242,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5535,1259243,1,1,,144208565,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5536,1259243,1,1,,144210513,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5537,1259243,1,1,,170466877,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5538,1259244,1,1,,144208565,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5539,1259244,1,1,,144210513,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5540,1259244,1,1,,170466877,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5541,1259247,1,1,,144208565,3767,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5542,1259247,1,1,,144210513,3767,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5543,1259247,1,1,,170466877,3767,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5544,1259248,1,1,,144208565,3767,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5545,1259248,1,1,,144210513,3767,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5546,1259248,1,1,,170466877,3767,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5547,1259252,1,1,,174006260,3767,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
5548,1259253,1,1,,174006260,3767,Inactive,169655958.0,,0.001,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
5549,1259255,1,1,,174006260,3767,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
5550,1259256,1,1,,174006260,3767,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
5551,1259309,1,1,,178127225,3767,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
5552,1259310,1,1,,104170011,3767,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5553,1259310,1,1,,321942825,3767,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5554,1259310,1,1,,332877328,3767,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5555,1259311,1,1,,178127225,3767,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
5556,1259313,1,1,,49718175,3767,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
5557,1259318,1,1,,49718175,3767,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
5558,1259325,1,2,,336954285,3767,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
5559,1259344,1,1,,144207189,3767,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
5560,1259364,1,1,,144208565,3767,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5561,1259364,1,1,,144210513,3767,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5562,1259364,1,1,,170466877,3767,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5563,1259365,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5564,1259365,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5565,1259365,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5566,1259366,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5567,1259366,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5568,1259366,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5569,1259367,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5570,1259367,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5571,1259367,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5572,1259368,1,1,,144208565,3767,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5573,1259368,1,1,,144210513,3767,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5574,1259368,1,1,,170466877,3767,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5575,1259369,1,1,,144208565,3767,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5576,1259369,1,1,,144210513,3767,Inconclusive,109731339.0,2737.0,28.7277,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5577,1259369,1,1,,170466877,3767,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5578,1259377,1,1,,144208565,3767,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5579,1259377,1,1,,144210513,3767,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5580,1259377,1,1,,170466877,3767,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5581,1259378,1,1,,144208565,3767,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5582,1259378,1,1,,144210513,3767,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5583,1259378,1,1,,170466877,3767,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5584,1259379,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5585,1259379,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5586,1259379,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5587,1259380,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5588,1259380,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5589,1259380,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5590,1259381,1,1,,144208565,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5591,1259381,1,1,,144210513,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5592,1259381,1,1,,170466877,3767,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5593,1259382,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5594,1259382,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5595,1259382,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5596,1259383,1,1,,144208565,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5597,1259383,1,1,,144210513,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5598,1259383,1,1,,170466877,3767,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5599,1259384,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5600,1259384,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5601,1259384,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5602,1259385,1,1,,144208565,3767,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5603,1259385,1,1,,144210513,3767,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5604,1259385,1,1,,170466877,3767,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5605,1259386,1,1,,144208565,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5606,1259386,1,1,,144210513,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5607,1259386,1,1,,170466877,3767,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5608,1259387,1,1,,144208565,3767,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5609,1259387,1,1,,144210513,3767,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5610,1259387,1,1,,170466877,3767,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5611,1259388,1,1,,144208565,3767,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5612,1259388,1,1,,144210513,3767,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5613,1259388,1,1,,170466877,3767,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5614,1259389,1,1,,124637543,3767,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
5615,1259390,1,1,,144208565,3767,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5616,1259390,1,1,,144210513,3767,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5617,1259390,1,1,,170466877,3767,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5618,1259391,1,1,,144208565,3767,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5619,1259391,1,1,,144210513,3767,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5620,1259391,1,1,,170466877,3767,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5621,1259392,1,1,,144208565,3767,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5622,1259392,1,1,,144210513,3767,Inconclusive,109731339.0,2737.0,25.6036,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5623,1259392,1,1,,170466877,3767,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5624,1259393,1,1,,144208565,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5625,1259393,1,1,,144210513,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5626,1259393,1,1,,170466877,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5627,1259394,1,1,,144208565,3767,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5628,1259394,1,1,,144210513,3767,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5629,1259394,1,1,,170466877,3767,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5630,1259395,1,1,,144208565,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5631,1259395,1,1,,144210513,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5632,1259395,1,1,,170466877,3767,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5633,1259396,1,1,,144208565,3767,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5634,1259396,1,1,,144210513,3767,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5635,1259396,1,1,,170466877,3767,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5636,1259400,1,1,,170466877,3767,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
5637,1259401,1,1,,144208565,3767,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5638,1259401,1,1,,144210513,3767,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5639,1259401,1,1,,170466877,3767,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5640,1259402,1,1,,144208565,3767,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5641,1259402,1,1,,144210513,3767,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5642,1259402,1,1,,170466877,3767,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5643,1259403,1,1,,144208565,3767,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5644,1259403,1,1,,144210513,3767,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5645,1259403,1,1,,170466877,3767,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5646,1259404,1,1,,144208565,3767,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5647,1259404,1,1,,144210513,3767,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5648,1259404,1,1,,170466877,3767,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5649,1259406,1,1,,363920282,3767,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
5650,1259406,1,1,1.0,363920282,3767,Inactive,26638650.0,3778.0,0.00908529,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
5651,1259406,1,1,2.0,363920282,3767,Inactive,4758626.0,3779.0,0.013772299999999998,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5652,1259406,1,1,3.0,363920282,3767,Inactive,5031823.0,10242.0,0.00987988,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
5653,1259406,1,1,4.0,363920282,3767,Inactive,26051275.0,27345.0,0.0512645,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
5654,1259406,1,1,5.0,363920282,3767,Inactive,160410009.0,389816.0,0.0221891,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5655,1259406,1,1,6.0,363920282,3767,Inactive,26638650.0,3778.0,0.00764538,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
5656,1259406,1,1,7.0,363920282,3767,Inactive,4758626.0,3779.0,-0.00352948,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5657,1259406,1,1,8.0,363920282,3767,Inactive,5031823.0,10242.0,0.033886,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
5658,1259406,1,1,9.0,363920282,3767,Inactive,26051275.0,27345.0,0.00390408,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
5659,1259406,1,1,10.0,363920282,3767,Inactive,5031823.0,10242.0,-0.0323299,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
5660,1259407,1,1,,363898301,3767,Inactive,,,,,CCRIS mutagenicity studies,Other,,
5661,1259408,1,1,,363894821,3767,Active,,,,,GENE-TOX mutagenicity studies,Other,,
5662,1259411,1,1,,363898301,3767,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
5663,1259413,1,2,,104170011,3767,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
5664,1259415,1,1,,49718175,3767,Inconclusive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
5665,1259416,1,2,,855769,3767,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5666,1259416,1,2,,340080096,3767,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5667,1259416,1,2,,340080097,3767,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5668,1259416,1,2,,375178412,3767,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5669,1259421,1,1,,340080096,3767,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5670,1259421,1,1,,340080097,3767,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5671,1259421,1,1,,375178412,3767,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5672,1259423,1,2,,354800708,3767,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5673,1259423,1,2,,354936296,3767,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5674,1259423,1,2,,354950570,3767,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5675,1259423,1,2,,354955230,3767,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5676,1259423,1,2,,355021982,3767,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
